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ABSTRACT 
The application of immunotherapeutic approaches to target tumour cells by harnessing the 
body’s most important defence the immune system, could provide opportunities to oppose 
cancer. A prerequisite of tumour immunotherapy lies in the identification of antigens that 
are distinctively expressed in cancer and can elicit immune responses in the tumour-
bearing host. Testis clone 21 (T21) was first identified as a promising prostate-associated 
tumour antigen identified using modified SEREX expression cloning showing restricted 
protein expression to normal testis and prostate, breast, kidney, ovary, melanoma, colon 
and stomach cancer among others. More recently, T21 was found to share significant 
sequence similarity with a centrosomal protein called CEP290. This study proposed to 
address the current understanding of T21 through analysis of gene sequence similarities 
observed with CEP290 and begin to extrapolate possible functional attributes of T21 and 
the role it may play in cancer progression. Furthermore this investigation aimed to 
evaluate T21 as a prospective prognostic indicator of prostate cancer and in addition, 
investigate T21 as a potential target for immunotherapy. In silico sequence analysis 
revealed that T21 contained a 93bp region, a consequence of an alternative splicing event 
resulting in the retention of a CEP290 intronic region making its translation to protein 
unique. This finding was supported by experimental observations using PCR and northern 
blotting. Using this T21 “unique region” sequence, T21 mRNA and protein was shown to 
be expressed in some normal tissues including prostate, stomach and spinal cord when 
compared to testis therefore T21 cannot be considered a cancer testis antigen as previously 
suggested. Evidence of T21 protein expression was shown in a number of cancer tissues, 
however a histological study demonstrated no significant discrimination between benign 
and prostate cancer patients. In vitro assessment of cell proliferation following T21 gene 
knockdown indicated an association between T21 and increased tumour cell proliferation. 
Expression profiling of data obtained from Next Generation Sequencing (NGS) indicated 
T21 function was related to cell proliferation and survival, modulation of immune 
responses and suppression of regulatory processes involved in tumourigenesis. Collective 
evidences suggest T21 activity to be independent of that of CEP290. Finally, this study 
identified a novel immunogenic and naturally processed peptide target using a transgenic 
murine model, further verified using human cancer patient PBMCs. Future studies to 
determine the immunotherapeutic potential of T21 would focus on providing evidence of 
peptide-specific tumour killing targeting this novel antigenic sequence in the first instance.  
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Cancer  
 
Cancer has remained one of the leading causes of morbidity and mortality worldwide. The 
latest global figures published by the World Health Organisation (WHO), state that an 
estimated one in eight deaths are attributed to cancer, second only to cardiovascular disease 
as the leading cause of death across the world. In 2008, there were an estimated 12.7 
million new cancer cases with an estimated 7.6 million cancer-related deaths worldwide, 
making cancer responsible for more deaths than AIDS, tuberculosis and malaria combined. 
Current figures estimate that cancer is responsible for almost one in four (28%) of total 
deaths in the UK. Cancer Research UK statistics for 2010 reported a total of 157,275 
deaths from cancer of which lung, colorectal, breast and prostate cancers accounting for 
almost half (46%). Decades of research towards earlier detection and improved treatments 
supported by public cancer awareness campaigns regarding risk factors and promoting 
healthier lifestyles have meant that cancer is no longer viewed as an inevitable death 
sentence. With projections for a burgeoning world population that continues to live longer 
than before have meant considerable investment to find more refined diagnostic aids and 
effective treatments to tackle the expected economical and social impact of cancer 
morbidities over the coming years.  
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1.1.1 Cancer is a multi-factorial disease 
 
Cancer is a term broadly used to describe many diseases characterised by uncontrolled cell 
division arising from the sequential acquisition of key mutations in genes which enable the 
cell to break free of the regulatory control mechanisms that maintain homeostatic balance 
(Bertram, 2000). In normal cells, a stringent command over each cell proliferation, 
differentiation and programmed cell death event is achieved by the action of complex 
networks of molecular mechanisms responding to strict signalling instruction from other 
cells in their vicinity. This constantly dynamic interaction ensures that all tissues are 
proportionally and architecturally maintained in a manner suited to the body’s 
requirements. Disturbances in these interactions which undermine the homeostatic balance 
are evident during the development of successful tumours through their defining features 
which are self-sufficiency in regard to growth signals and insensitivity to inhibitory ones, 
an infinite capacity for self-renewal, a resistance to apoptosis, sustained angiogenesis and 
invasion of tissue and metastasis. Four more recent concepts emerging as key to facilitating 
cancer are the tumours capability to reprogramme the cells energy metabolism, promote 
genomic stress, evade immune destruction and to promote inflammation, together these ten 
features typify the characteristic “hallmarks” of cancer illustrated in Figure 1.1 (Hanahan 
& Weinberg, 2011). 
 
Once beyond the control of intrinsic and external control mechanisms, cancers can 
continually transform over many divisions accumulating further genetic mutations and gain 
novel functions that confer selective growth advantages over neighbouring normal cells. 
Crucially, tumours continue to survive and thrive due to their rapid clonal expansion 
acquiring random mutations and adapting to selective pressures of the surrounding 
microenvironment much in the fashion of Darwinian evolution (Bertram, 2000).  
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 Figure 1.1 – The hallmarks of cancer. (Adapted from Hanahan & Weinberg, 2011). 
 
It is thought that DNA could be exposed to tens of thousands events per day capable of 
causing damage as a consequence of normal metabolic processes and external 
environmental factors (carcinogens) (Fortini et al., 2003; Lodish et al., 2004). Continual or 
frequent exposure of DNA to carcinogens allow further mutations to accumulate, 
increasing the possibility of developing cancer, a notion supported by the observation 
between increasing incidences of most cancers and advancing age. The onset of tumour 
growth can be initiated by exposure to external causative agents that inflict damage to the 
cell genome which fall into the following categories of carcinogens: 
 
Exposure to environmental carcinogens: Humans frequently encounter an abundance of 
initiating agents in their surrounding environment that are able to alter the physical 
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structure of genes, these agents originate from both chemical and physical sources. 
Chemical carcinogens encompass a wide range of agents including industrial chemicals 
associated with occupational cancers such as asbestos (lung cancer) and arsenic (skin and 
lung cancers), to more commonly known example, the by-products of tobacco smoke 
containing 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and benzo[a]pyrene 
(BaP), have been shown a causative agent to induce lung cancer (Hecht et al., 1994). 
Prolonged exposure to physical carcinogens such as those that emit ionising radiation such 
as solar (UV) radiation and sources of radioactive decay (radon, radium and X-rays) have 
been shown to induce malignancy (Belpomme et al., 2007).  
 
Exposure to infectious pathogens: Oncogenic viruses are influencing factors in 
approximately 18% of neoplasia (Parkin, 2006). Two viral infections most frequently 
associated with cancer are human papillomavirus (HPV) which is strongly associated with 
cervical cancer and head and neck cancers and secondly, hepatitis B viruses (HBV) with 
hepatocellular carcinoma. Each of these viruses contributes differently to the initiation of 
the cell. HPV acts directly by inducing viral gene products E6 and E7 that inhibit the host 
cell signalling cascade of p53 and retinoblastoma (Rb) enhancing proliferation signals and 
inhibiting apoptotic signals (Song et al., 1999). HBV on the other hand, indirectly induces 
chronic inflammation which consequently generates reactive oxygen species (ROS), a 
contributor to tumourigenesis (Jackson & Loeb, 2001). In addition to viruses, certain 
bacteria have been associated with cancer attributing to their induction of chronic 
inflammation, an example being Helicobacter pylori known to establish chronic ulceration 
in the stomach and has been linked to gastric cancer (Eslick et al., 1999).   
 
Epigenetic aberrations: Whilst mutations by factors previously mentioned are localised to 
the nucleotide sequence of genes, an aberration of processes involved in structural 
modifications that span whole chromatin can contribute to the transformation to cancer. 
Expression modifying events from which cancer arises include DNA methylation, covalent 
modification of histones and microRNA gene silencing often impacts on the activation of 
oncogenes and the silencing of tumour suppressor genes (discussed in sections 1.1.2.1 and 
1.1.2.2). Unlike genetic changes, epigenetically altered gene expression can be restored 
and in some instances can be utilised for diagnostic and prognostic purposes. Reversing 
inversed methylation patterns in leukaemias and lymphoma using 5-azacytidine and 5-aza-
2’-deoxycytidine (Kantarjian et al., 2006) has been shown, and similarly in Food and Drug 
Chapter 1: Introduction  1.1 
 
6 
 
Administration (FDA) approved histone deacetylase inhibitors, Vorinostat and Romidepsin 
in cutaneous T cell lymphoma (CTCL) and acute myloid leukemia (AML) (Marks & 
Breslow, 2007; Klimek et al., 2008).  
 
Pathways for DNA repair exist to counterbalance the onslaught of DNA damage in order to 
maintain the integrity of the genome. The inherent instability of DNA molecules 
themselves mean spontaneous DNA mutations can occur from within the cell by direct 
errors during replication, or indirectly following chemical damage most frequently due to 
ROS capable of inducing mutations in critical DNA stability genes (Jackson & Loeb, 
2001). Cells are left highly vulnerable to further mutations evident in those carrying 
germline mutations in DNA repair genes having higher then normal genetic predisposition 
to cancer. The most well-known examples include defects in BRCA genes (Hall et al., 1990) 
associated with an increased susceptibility to breast, ovarian, prostate, stomach and 
pancreas and colon cancer (Friedenson, 2005). Similarly, mutations in mismatch repair 
genes in hereditary non-polyposis colorectal cancer (Lui et al., 1996).  
 
Studies on common mechanisms between the processes involved in ageing and the 
initiation of cancer have implicated the decline in co-ordinated responses to oxidative 
stress and chronic inflammation as key elements toward cellular decline and with possible 
roles as mediators in tumourigenesis (Reuter et al., 2010; Finkel et al., 2007). Many of the 
carcinogens mentioned previously are termed as much due to their indirect induction of 
ROS creating an imbalance between oxidative stress and antioxidant defences in cells. 
Epidemiological studies correlating ethnic and geographical variations in the incidence and 
mortality across many cancers indicate toward the beneficial actions of certain dietary 
components. A number of dietary antioxidants, including β-carotene, lycopene and 
vitamins A, C and E have been shown to limit or prevent tumour growth in both in vitro 
and in animal studies; however large-scale epidemiology studies have proven far less 
conclusive. For example, several experimental studies demonstrated the individual anti-
cancer actions of vitamin E and selenium in prostate cancer (Gunawardena et al., 2000; 
Menter et al., 2000). However, subsequent results in clinical trials such as the Selenium 
and Vitamin E Cancer Prevention Trial (SELECT) was stopped early due to the lack of 
efficacy for risk reduction (Lippman et al., 2009) and the Physicians Health Study II (PHS 
II) also found no effect on the incidence of prostate cancer using combinations of vitamins 
E and C (Gaziano et al., 2009) or vitamin E, selenium and soy protein on the progression 
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from high grade PIN (carcinoma in situ) to malignant disease (Fleshner et al., 2011). 
Interestingly, data from a number of prospective studies supported the association of 
dietary supplements of vitamin E (Peters et al., 2008) and intake of lycopene (Key et al., 
2007) reducing the risk of advanced prostate cancer among smokers. This difference could 
account for later trials designed to include screening for serum levels of prostate specific 
antigen (PSA), which would include biologically indolent cancers that would have gone 
undiagnosed in earlier investigation.  
 
1.1.2 Genetic alteration: The underlying cause of cancer 
 
Despite cells undergoing numerous divisions and under constant threat of potentially 
mutagenic events throughout life, the progression to cancer remains a relatively rare event. 
In normal cells, the process of cell division is tightly regulated by checkpoints during each 
of the four phases of the cell cycle (G1, S, G2 and M) ensuring that the genetic material is 
faithfully copied to each descendent cell. Following damage, these checkpoint controls 
either allow the cell passage through the cell cycle pending the repair of genetic damage or 
initiate the processes leading to programmed cell death (apoptosis) if the damage is too 
great. Central to maintaining tissue integrity is a turnover of viable cells byway of the 
retirement of those that have exhausted their replication limit (cellular senescence). This is 
a consequence of shortening of non-coding DNA sequences that cap chromosomes called 
telomeres which undergo a partial degradation following each round of genetic replication. 
This irreversible process serves to keep cellular proliferation in check. Tumour cells 
overcome these barriers to proliferation by disrupting control elements in the cell cycle 
leading to uncontrolled and unregulated cell division, jeopardising genomic integrity and 
inviting further mutations on each subsequent division. In this way, cancer is generally 
accepted to be clonal in nature expanded from a primary mutated cell which acquires an 
increasing number of mutations through an increasingly unstable genome (Stratton et al., 
2009). As illustrated in Figure 1.2, successful tumour cells balance subsequent 
proliferation and accumulative mutations to overcome barriers that restrict growth through 
gradual and increasing genomic instability without surpassing the threshold for cell 
viability (Cahill et al., 1999).  
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Figure 1.2 – The pathways to cancer. An overview of the events involved during the 
progression of a cell to a malignant state. Cells accumulate mutations which must promote cell 
survival and overcome control mechanisms in place to eliminate the mutated cell. (Adapted 
from Bertram, 2000). 
  
For a cell to successfully reach the stage of exhibiting the classical hallmarks of cancer it 
must over time obtain mutations in at least five genes with each mutation enhancing the 
cells capability to adapt and grow in the host organism modelled in the development of 
colon carcinoma (Fearon & Vogelstein, 1990). Since this time, other solid-tumour cancers 
have been extensively scrutinised to identify early initiating molecular events involved in 
tumour progression. For example in prostate cancer, down regulation of NKX3.1 
homeobox gene through promoter methylation (Asatiani et al., 2005) is an early initiation 
event that demonstrates roles in responses to oxidative stress and DNA damage (Ouyang 
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et al., 2005; Bowen & Gelmann, 2010). Somatic amplification of MYC oncogene has also 
been associated as a contributing factor to in the early onset of disease (Jenkins et al., 
1997) along with TMPRSS2-ERG fusions, a product of 21q chromosomal rearrangement 
resulting in a truncated ERG protein driven by androgen-responsive promotor elements of 
TMPRSS2 (Tomlins et al., 2005). The loss or reduction of cell cycle associated PTEN 
tumour suppression in prostate cancer has been shown to precede the gradual progression 
to an androgen independent phenotype (Mulholland et al., 2006). Finally, up regulation of 
a histone-lysine N-methyltransferase encoded by EZH2 gene due to loss of miR-101 has 
been frequently associated with late stage metastatic disease promoting cellular pathways 
such as Ras and NF-κB which are often deregulated in various cancers (Chiaradonna et al., 
2008; Sun & Xiao, 2003) (Figure 1.3). The development of prostate cancer is a 
predominantly slow and often asymptomatic process. Once symptoms are observed, the 
cancer usually signifies the onset of advanced stage disease and spread to distant organs 
(bone, lymph nodes, colorectal regions and brain).  
 
 
          
 
 
 
 
 
 
 
 
Figure 1.3 – The multistep progression of prostate cancer. Commonly acquired gene 
mutations during the progression of disease from a high grade PIN to localised 
adenocarcinoma after breaching of the basal lamina, to progression into the lumen on the 
gland and the surrounding connective tissue. Finally, the progression to a malignant phenotype 
capable of distant metastases (Adapted from Abate-Shen & Shen, 2000).  
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As alluded to previously, the progression of a healthy cell to a malignant phenotype 
exhibiting the cancerous hallmarks is essentially due to genetic mutations in cancer-related 
genes that aid initiation and stimulate growth (proto-oncogenes) and the silencing of those 
genes that inhibit cell proliferation and transformation (tumour suppressor genes).  
 
1.1.2.1 The activation of proto-oncogenes 
 
Oncogenes are derived from altered normal genes (proto-oncogenes) which encode for 
proteins that are involved in regulating growth and cellular differentiation in response 
from external signals. They are activated through interpretation of external growth signals 
resulting in changes in gene expression, and consequently, serve to promote cell 
proliferation, cytoskeletal remodelling, cell-to-cell adhesion, angiogenesis, cellular 
metabolism and inhibit differentiation and cell death. Mutations in locations where proto-
oncogenes reside invariably lead to the deregulated activation of pathways that control cell 
growth, which under normal physiological conditions would remain silent. The excessive 
activity of oncogenic proteins can impact cell functions in a number of ways contributing 
significantly towards tumourigenesis. The activation of growth factors and their receptors, 
for example, the overproduction of platelet-derived growth factor B (PDGF-B) has been 
associated with tumour progression (Barnhill et al., 1996). Erb-B family of growth 
receptor tyrosine kinases, in particular ERBB2 gene (Her2/neu) have been implicated in 
the development several types of cancer due to genetic changes resulting in gene 
amplification leading to the overexpression of the receptor (Ross & Fletcher, 1999). 
Further downstream from growth receptors, the constitutive activation of intra-cellular 
signalling transduction kinases of the RAS/RAF/ERK families lead to self-sufficient cell 
growth and proliferation. H-RAS was the first oncogene to be discovered to induce 
neoplastic transformation of cells when present in its mutated form (Parada et al., 1982). 
Since this time, mutations in RAS family oncogenes have appeared in various tumour 
types and have been extensively investigated in cancer (Bos, 1989). The direct activation 
of nuclear transcription factors which regulate gene expression of proteins involved in the 
cell cycle circumvent many of the control regulators further upstream in signalling 
pathways. Inappropriate activation of transcription factors through excessive expression or 
altered protein function drives continual cell proliferation. The most notable example 
being the overexpression MYC family oncogenes regulating in the accumulation of cyclin 
A and cyclin E proteins driving forward cell division (Dang, 1999).  
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1.1.2.2 The inhibition of tumour suppressor genes  
 
In opposition to oncogenic signals, several safeguard mechanisms operate to prevent cells 
entering a state of uncontrolled cell division. These mechanisms contain within a group of 
cancer-related genes identified as tumour suppressor genes (TSG), which as the name 
suggests, are essential in averting cellular transformation and tumour expansion. The 
activities of their protein products are intrinsic to the cell cycle checkpoint responses, 
DNA damage and repair, promotion of apoptosis and the prevention of tumour progression 
(Sherr, 2004). Importantly, the realisation that most, if not all, pathways that promote cell 
proliferation also operate within an intrinsic growth inhibitory pathway networked to at 
least one TSG has placed further significance on their role in events leading to malignant 
transformation.  
 
In contrast to proto-oncogenes, genetic mutations in both alleles of a tumour suppressor 
genes result in a loss of normal protein function through processes such as loss of 
hetrozygosity, methylation, cytogenic aberrations, and polymorphisms (Teh et al., 1999). 
In 1971, the “two-hit” mutation theory proposed by Knudson stating that a germline 
mutation of one allele of a gene predisposes an individual to cancer following somatic 
mutation in the second allele still holds true for most TSGs (Knudson, 1971). Fifteen years 
later, the discovery of the first TSG isolated from retinoblastoma, and termed the RB gene 
(Friend et al., 1986) is commonly found to be defective in multiple cancers through its role 
as a checkpoint control during transition to S phase of the cell cycle. In hereditary cancer 
syndromes, defective TSG expression predisposes individuals to further mutation and the 
development of cancer. For example patients with familial adenomatous polyposis have an 
increased risk of developing colorectal cancer due to mutations that reduce the activity of 
the adenomatous polyposis coli (APC) gene. This TSG operates within the Wnt signalling 
pathway, targeting free β-catenin for ubiquitination preventing the transcription of cyclin 
D1 and MYC genes which drive progression of the cell cycle to S phase (Vogelstein & 
Kinzler, 2004). Germline mutations in stability genes BRCA1 and BRCA2 also predispose 
individuals to breast and ovarian cancer (King et al., 2003).   
 
Gene mutations that lead to the loss or functional impairment of p53 protein are perhaps 
the most frequent genetic alteration event observed in cancer. The p53 gene acts as a 
transcription factor controlling the activation and inhibition of many genes and functions 
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and sits at the nexus of all cell cycle signalling pathways. It is activated in response to 
diverse cellular stress signals including nucleotide deprivation, oncogene activation and 
hypoxia following which p53 orchestrates stress-specific pathways. Most significantly p53 
is instrumental in preserving cell function by activating proteins required for DNA repair 
by initiating cell cycle arrest in the event of DNA damage or triggering programmed cell 
death if the damage is too great (Bertram, 2000; Horn & Vousden, 2007). The importance 
of p53 and Rb and their network of associated proteins are further underscored by the fact 
that they are both are commonly defective across several types of cancer and virtually all 
oncoviruses directly or indirectly inactivate both p53 and RB TSG pathways leading to 
tumour formation (Vogelstein & Kinzler, 2004).  
 
1.1.3 Tumour associated antigens 
 
Through successive divisions, tumour cells evolve to activate (proto-oncogenes) and 
inactivate (TSG) mutated genes providing selective advantages that support continual 
tumour growth and metastasis. The activation and inactivation of oncogene-TGS pathways 
expose the cell to further genome wide mutations as a combined effect of undue growth 
and the loss of genomic preservation. As a consequence, these events trigger signalling 
cascades affecting the expression of other gene products. The aberrant expression of these 
proteins seen to be restricted to tumour cells are called tumour associated antigens (TAAs). 
For this reason, identifying new TAAs have been the subject of intense investigation not 
only for their diagnostic utility but also for their application as tumour specific targets in 
treatment therapies. There has been particular focus on identifying short peptide regions 
(epitopes) derived from TAAs which are presented by major histocompatability complex 
(MHC) molecules that are recognised by T cells and are able to generate a tumour-specific 
T cell response. The first TAA identified from a melanoma patient (MAGE-1) using 
molecular cloning (van der Bruggen et al., 1991) also provided the first tumour-specific T 
cell reactive MAGE-1 epitope by the same group the following year (Traversari et al., 
1992). Since then, techniques to identify TAA and their immunogenic epitopes have 
ranged from using genetic approaches (van der Bruggen et al., 1991), modified serological 
analysis of recombinant cDNA libraries (SEREX) (Sahin et al., 1995) and representational 
difference analysis (RDA) (Lisitsyn et al., 1993) are discussed later. 
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Unsurprisingly, given the wide range of genomic mutations and epigenetic alterations that 
occur, a whole spectrum of altered TAAs have been identified which can be broadly 
classified into one of the following categories (Table 1.1).  
 
Oncofetal antigens: Genes that are typically only activated during fetal development may 
also be re-expressed in tumour cells. Due to their restricted expression, oncofetal antigens 
have been investigated for their use as both serum biomarkers and for immunotherapy. For 
example, carcinoembryonic antigen (CEA), a glycoprotein produced in the gastrointestinal 
tissue during embryogenesis and is involved in cellular adhesion which may aid metastatic 
spread in colorectal carcinoma (Greiner et al., 2002). Similar studies have been performed 
targeting of alpha-fetal protein (AFP) in patients with hepatocellular carcinoma (HCC) 
(Butterfield et al., 2007).  
 
Oncoviral antigens: Viruses associated with malignant transformation of infected cells are 
also a source of TAAs. Importantly, they invite considerable interest as targetable tumour 
antigens due to their involvement in tumour transformation and their expression being 
restricted to infected cells which encompass the tumour cell population. In addition, by 
virtue of being foreign (non-self antigen) to their infected host, T cell receptors specific to 
their viral molecules would not undergo deletion during early T cell selection processes 
and they would not induce autoimmunity. For example, antigens derived from human 
papillomavirus (HPV) namely E6 and E7 products act as oncogenes to inactivate TSGs 
p53 and pRb respectively (Münger & Howley, 2002) and have led to the development of 
two prophylactic vaccines against HPV (Cervarix and Gardasil) to prevent virally induced 
cervical carcinoma. Other targetable viral antigens originating from hepatitis B virus 
(HBV) in HCC and Epstein-Barr virus (EBV) in Burkitt’s and Hodgkin’s lymphomas have 
also demonstrated encouraging results (Gehring et al., 2011; Kennedy-Nasser et al., 2009). 
 
Tumour-specific unique antigens: Tumour antigens arising from genes that undergo 
mutation can also provide a source of neo-antigens due to their newly exposed and 
possibly immunogenic epitopes that may potentially be recognised by T cells to engage in 
tumour rejection. So far, evidence of the immunogenic potential of some proteins involved 
in tumour progression has generated great interest. For example gene alterations in 
BCR/ABL in CML (Cai et al., 2012) as a result of chromosomal translocation, point 
mutation in CDK4 in melanoma (Wӧlfel et al., 1995) and in immunoglobulin (Ig) idiotype 
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a gene fusion product in Non-Hodgkin’s lymphoma (Redfern et al., 2006). A notable 
feature of tumour cells is the deregulation of pre-mRNA splicing processes which may 
lead to the expression of protein variants that are specific to tumour cells. The 
advancement of genome-wide analysis technologies have allowed for the identification of 
cancer-specific variants as a result of deregulated alternative splicing and post-transitional 
modifications (Thorsen et al., 2008; Eswaran et al., 2013). Although questions remain as 
to whether these unique antigens accumulate as random by-products in tumour cells or 
whether they play an active role in tumourigenesis (Ghigna et al., 2008). Examples of 
targeting variants assessed for their use in therapy include CD44v6 in head and neck 
cancer (Bӧrjesson et al., 2003) and Bcr/Abl in CML (Volpe et al., 2007).   
 
Cancer testis antigens: Similar to oncofetal antigens, the re-expression of normally silent 
cancer/testis (CT) antigens is restricted to tumour cells, male germline cells in the testis 
and placental tissue. As germline cells lack the expression of MHC molecules, they are 
considered to be immunoprivileged. The main appeal for therapy therefore lies in the 
ability to generate T cells that recognise CT antigens expressed on the surface of tumour 
cells in the context of their MHC allowing for immune responses elicited against tumour 
cells alone. These antigens are the best-characterised of the TAA classes and have been 
identified in multiple cancer types including the first CT antigen from melanoma, MAGE 
(van der Bruggen et al., 1991) and later BAGE, GAGE (Boon & van der Bruggen, 1996) 
and NY-ESO-1 (Chen et al., 1997) in multiple cancers.   
 
Overexpressed antigens: These antigens are derived from a wide range of genes that are 
found to have higher expression in multiple malignant tissues compared to their generally 
lower expression in normal tissues. Examples include epidermal growth receptor 2 (Her-2) 
and mucin-1 (Muc-1) in breast and ovarian cancer and Wilm’s tumour-1 (WT-1) in 
multiple cancers such as gastric, lung and HCC. Mutated and wild-type forms of p53 have 
been associated with multiple cancers as has survivin. Despite their low level ubiquitous 
expression in normal tissues, these antigens invite the opportunity to target tumours that 
overexpress these antigens via their HLA complex. Challenges still remain in identifying 
T cells that recognise these unaltered self-antigens which have avoided clonal deletion and 
are capable in generating a tumour-specific immune response.  
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Differentiation antigens: Differentially expressed antigen expression is characterised by 
their restriction to the tumour and the tissue from which it arose. To date, most of these 
antigens have been identified in melanoma sharing their expression in normal melanocytes 
and are involved in the production of melanin. Those that demonstrated immunogenicity 
and have advanced toward clinical assessments include Melan-A/Mart-1, gp100 and 
tyrosinase (Romero et al., 2002; Schwartzentruber et al., 2011; Valmori et al., 2003). 
Other reported antigens include those from prostate tissue such as prostate acid 
phosphatase (PAP), prostate specific antigen (PSA) and prostate specific membrane 
antigen (PSMA) (Kantoff et al., 2010; Corman et al., 1998; Murphy et al., 1996) 
respectively.   
 
Tumour antigen Expression in tumour 
Normal tissue 
distribution 
Oncofetal antigens: 
  AFP 
  CEA 
 
Hepatocellular carcinoma  
Colorectal carcinoma 
 
 
None 
None 
Oncoviral antigens: 
  EBV  
  HPV(E6/E7) 
  HBV 
 
 
Burkitt’s and Hodgkin’s lymphoma 
Cervical cancer, head and neck 
Hepatocellular carcinoma  
 
- 
- 
- 
 
Tumour-specific unique antigens: 
  Bcr/Abl 
  Ig idiotype 
 
 
Chronic myeloid leukaemia 
B cell non-Hodgkin’s lymphoma 
 
None 
None 
 
Cancer-Testis antigens: 
  MAGE, BAGE,GAGE families 
  NY-ESO-1 
 
 
Multiple 
Multiple 
 
Testis 
Testis 
Overexpressed antigens: 
  Her-2 
  Muc-1 
  p53 (mutated) 
  p53 (wild type) 
  Survivin  
  WT-1 
 
Breast, ovarian, lung 
Breast, ovarian 
Pancreatic, colon, lung 
Multiple 
Multiple 
Gastric, lung, HCC, leukaemia 
 
 
Ubiquitous (low) 
Breast 
None  
Ubiquitous (low) 
Ubiquitous (low) 
None 
 
Differentiation antigens: 
  Melan-A/Mart-1 
  gp100 
  Tyrosinase 
  PAP, PSA, PSMA 
 
 
Melanoma 
Melanoma 
Melanoma 
Prostate 
 
Melanocytes 
Melanocytes 
Melanocytes 
Prostate 
 
 
Table 1.1 – Tumour associated antigens. A list of the major classes of TAAs found in cancer 
with examples showing the types of malignancies in which they can be found and their 
expression in normal tissue. References to each TAA are detailed in the main text.   
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1.1.4 The tumour microenvironment 
 
Tumour cells engage in dynamic signalling interactions with their surrounding tumour 
microenvironment (TME) to further promote their growth and metastasis. The TME is a 
collective term referring to stromal tissues and local cells surrounding tumours, composed 
of tumour endothelial cells, pericytes, adipocytes, fibroblasts, dendritic cells, macrophages, 
T and B lymphocytes, natural killer (NK) cells and other inflammatory cells. Signalling 
components of the TME include chemokines and cytokines as well as danger signals from 
heat-shock proteins (HSPs), nucleic acids, stress induced proteins and other damage-
associated molecular patterns (DAMPs) (Wilson & Balkwill 2002; Balkwill, 2012; 
Calderwood et al., 2006; Lotze et al., 2007). The crosstalk between tumour and the 
surrounding cells, particularly with macrophages and stromal fibroblasts, can be 
conditioned to aid growth, support angiogenesis and facilitate tumour invasion and distant 
metastasis through a number of mechanisms which are ordinarily intended to regulate cell 
behaviour and co-ordinate responses to danger or tissue damage. Malignancy occurs from 
tumour cells that have successfully achieved i) cell transformation and sustained 
accelerated growth ii) tumour survival iii) invasion of surrounding tissues iv) escape from 
detection and elimination v) dissemination and adaption to distant organs. It is becoming 
increasing apparent that the immune system plays a complex role in both the regression 
and progression of tumour (Hanahan & Coussens, 2012; de Visser et al., 2006). 
Immunosuppressive components that further compound tumour progression are discussed 
later in section 1.3.2.2. The relationship between the TME, macrophages, fibroblast cells 
and their impact on events leading to the promotion of tumourigenesis, namely 
angiogenesis and metastasis are highlighted below.  
 
1.1.4.1 Role of inflammation in tumourigenesis 
 
Inflammation and the initiation of cancer: The causal relationship between inflammation 
and cancer was first theorised in 1863 by Dr Rudolf Virchow, in which he suggested that 
the presence of leukocytes in neoplastic tissue indicated that chronic inflammation 
contributes to tumour progression (Virchow 1863-67; reviewed in Balkwill & Mantovani, 
2001). As exemplified in the increased incidence of colon cancer arising in individuals 
with autoimmune diseases such as inflammatory bowel diseases (chronic ulcerative colitis 
and Crohn’s disease) (Triantafillidis et al., 2009), and persistent infections and 
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inflammatory conditions such as H. pylori linked to stomach cancer (Eslick et al., 1999) 
and in cases of prostatitis proceeding prostate carcinogenesis (Platz & De Marzo, 2004). 
Many environmental carcinogens are associated with chronic infections or inflammation 
such as tobacco smoke. In mice, obesity has been demonstrated to promote liver 
inflammation and hepatocellular carcinoma (HCC) through elevation of tumour promoting 
cytokines (interleukin 6 and tumour necrosis factors) activating oncogenic transcription 
factor STAT3 (Park et al., 2010). Leukocytes are essential during infection and injury as 
the first line of defence, however they may indirectly mediate cellular transformation. For 
example, during acute inflammation, phagocytic leukocytes infiltrating to the affected site 
engulf and destroy invading micro-organisms through the release cytotoxic mediators such 
as ROS, eradicating pathogens and neighbouring healthy cells alike. In chronic 
inflammation, persistent release of phagocyte-derived ROS may in fact contribute to the 
initiation of cancer (Azad et al., 2008).       
 
In response to tumour, infiltrating monocytes differentiate into immature dendritic cells 
(DC) under the influence of interferon gamma (IFNγ), tumour necrosis factor alpha (TNFα) 
and granulocyte macrophage colony factor (GM-CSF), which can then capture antigens 
and migrate to lymph nodes to prime T cells, termed the M1 phenotype. However the 
production of interleukins; IL-4, IL-6, IL-10, IL-13 and colony-stimulating factor 1 (CSF-
1) by tumour cells can cause precursors to assume a macrophage-like phenotype (M2 
phenotype) (Sica & Mantovani, 2012). The presence of macrophages with the M2 
phenotype in the TME have been shown to correlate with poor prognosis for many cancers 
such as in breast, prostate and bladder cancer (Leek et al., 1999; Lissbrant et al., 2000; 
Hanada et al., 2000). Unlike T helper subtypes (discussed later), an important feature of 
macrophage M1/M2 differentiation is the high degree of plasticity in their phenotype 
enabling them to switch between polarities depending on the stage of tumour development. 
Thus, the predominantly M2-like phenotype contributes to neoplastic formation in early 
stages of growth and later switches to tumour growth, angiogenesis and metastasis in 
established tumours (Biswas et al., 2008). 
 
Sustaining tumourigenesis: Once recruited to the TME, tumour-associated macrophages 
(TAMs) play a significant role in tumour progression producing a number of potent 
growth factors that accelerate angiogenesis primarily through their production of VEGF-A. 
Similarly, TAMs support other tumour related activities in the TME such as 
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lymphangiogenesis (basic fibroblast growth factor 2 (bFGF-2), TNFα), matrix remodelling 
(matrix metalloproteinases (MMPs)) and invasion/metastasis (plasminogen activators, 
macrophage colony stimulating factor (M-CSF), CSF-1, TNFα) (Ono, 2008). Furthermore, 
they can secrete mitogenic growth mediators (epidermal growth factor (EGF, TGFα) to 
stimulate tumour growth and also surrounding cancer associated fibroblasts (CAF). Like 
TAMs, CAFs can activate wound repair programmes which induce cell proliferation and 
neovascularisation (Hanahan & Coussens, 2012). Finally, TAMs produce growth factors 
and cytokines to promote anti-apoptosis (hepatocyte growth factor (HGF), IL-8), 
immunosupression (IL-10, TGFβ) and recruitment of other macrophages and neutrophils 
(monocyte chemoattractant protein 1 (MCP-1), chemokine ligand 5 (CCL5), M-CSF, 
VEGF-A) (Ono, 2008). Collaborative interactions between tumour cells, TAMs and CAFs 
produce a perpetual pro-inflammatory environment that fosters malignant growth in a 
scenario that represents tumours as “wounds that do not heal” (Dvorak, 1986). 
 
Promotion of neovascularisation in established tumours: The delicate homeostasis 
between angiogenic inducers and regulators secreted by tumour cells and the cells of the 
TME is disturbed during tumourigenesis, which lead to the formation of new and often 
highly disorganised, networks of blood vessels. Increasing the activity of pro-angiogenic 
factors or a decrease of inhibitors, skew the “angiogenic switch” to favour vascular 
expansion, a critical step in tumour progression (Bergers & Benjamin, 2003). The VEGF 
family and in particular VEGF-A, are prominent stimulators of angiogenesis triggered 
through oncogenes and TSGs for example by K-RAS, BCR/ABL, SRC, STAT3 and p53 
(Ikeda et al., 2001; Ebos et al., 2002; Ellis et al., 1998; Niu et al., 2002; Fujisawa et al., 
2003) as well as through cytokine-induced signalling during hypoxia (HIF1α and -β) and 
cell receptors and growth factors (EGFR, cyclooxgenase-2 (COX2) and platelet derived 
growth factor (PDGF)) (Bergers & Benjamin, 2003).  
 
Tumours can successfully stimulate angiogenesis through the release of cellular stress 
signals. Growing tumours (>2.0 mm) require an increasing intra-tumoural blood supply to 
provide oxygen and nutrients whilst removing waste products. When this demand is not 
met, hypoxic tumour cells trigger the induction of hypoxia-inducible factor 1 alpha, 
transcriptional factor (HIF-1α) which activates a cascade of genes involved in the 
induction of angiogenesis such as VEGF and inducible nitric oxide synthase (iNOS) (Pugh 
& Ratcliffe, 2003). In addition, hypoxic tumours release a number of growth factors 
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including (CSF-1 and GM-CSF), transforming growth factor beta (TGF-β), cytokines and 
chemokines that recruit monocytes and macrophages. This can further cultivate an 
environment suited to tumour growth and vascularisation (Coussens & Werb, 2002). More 
recently, Lin and colleagues (2006) demonstrated that the presence of TAMs in pre-
malignant mammary cells aided transition to a malignant phenotype through increased 
neoangiogenesis.  
 
Many anti-angiogenic drugs (for example bevacizumab, sunitinib, and sorafenib) designed 
to target tumour-infrastructure have proven effective in halting tumour progression (Yang 
et al., 2003, Motzer et al., 2009, Llovet et al., 2008). Although, a major consequence is 
that often only a transient affect is observed using these treatments resulting in the 
eventual selection of drug resistant tumour cells. Resistant cells are not dependent on 
angiogenic factors such as VEGR and circumvent hypoxia-induced apoptosis which 
restores tumour growth with an increasingly aggressive malignant phenotype (Bergers & 
Hanahan, 2008).    
  
Promotion of metastasis: The production of various matrix metalloproteases (MMPs) 
released by infiltrating TAMs may also support escape and migration through ECM and 
further facilitate migration of tumours into blood and lymphatic circulation (intravasation). 
Firstly, the degradation of the endothelial basement membrane during inflammation is 
associated with TAMs which increase the mobility of metastatic cells (Kessenbrock et al., 
2010). Furthermore, the release of TAM-derived TNFα activates signalling cascades 
leading to the increased expression of pro-invasive factors such as extracellular matrix 
metalloprotease inducer (EMMPRIN). This activation is mediated by the activation of the 
nuclear factor kappa B (NFκB) pathway which is involved in the activation of other 
mechanisms that are favourable to tumour cells. These include the induction of pro-
inflammatory cytokines and molecules which promote tumourigenesis (IL-6, TNFα, 
MMP’s, COX-2 and iNOS and ROS). A consequence of NFκB activation is that it can 
inhibit TNFα-induced apoptosis through the activation of caspase-8 and BCL-2 family 
(Karin et al., 2002). During metastasis, detached tumour cells may be eliminated through 
anoikis, apoptosis trigger by the loss of adhesion. A recent study demonstrated that α4-
integrin expressing TAMs engage with breast cancer cells by binding to vascular cell 
adhesion molecule-1 (VCAM-1) on the tumour surface, which in turn lead to a cascade of 
signalling events leading to the suppression of apoptosis (Chen et al., 2011).  
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1.1.4.2 Immunoediting and tumour escape 
  
The policing of the microenvironment by immune cells can be effective in detecting and 
eliminating nascent transformed cells through a process described as immunosurveillance. 
The basis of this theory was first put forward by Burnet and Thomas (1957) and was later 
supported following observations that transplanted tumours could be repressed by the 
immune system in mice. Earlier observations demonstrating the rejection of tumours in 
athymic nude mice were later attributed to the actions of NK cells in response to tumour. 
Together with the observation that tumour-specific protection was generated in genetically 
identical mice suggested toward the existence of TAAs which formed the notion of 
immunosurveillance (Dunn et al., 2002; Dunn et al., 2004; Kim et al., 2007). It is now 
broadly accepted that immunosurveillance forms part of a wider process in immune 
responses to cancer, in which some tumours are able to avoid elimination by immune cells 
through a process termed immunoediting (Dunn et al., 2004). This concept proposes that 
certain tumour cells are successfully eliminated by both innate (NK cells and macrophages) 
and adaptive (CD4+ and CD8+ T lymphocyte cells) immune responses. As a consequence, 
this leads to either total eradication of tumour cells and restoration of normal tissue or the 
removal of those cells highly susceptible to immune attack, leaving a subgroup of immune 
resistant tumour cells. For the latter, continuous phases of cell elimination of the tumour 
leads to the development of tumour cells capable of avoiding immune destruction. This 
phase of immunoselection may occur over a long period of time in which the immense 
selective pressures maintain tumours whilst they acquire further mutation as a 
consequence of their increasingly unstable genomes. Those mutations that confer a 
selective advantage whilst clonally inheriting resistance from immune onslaught proceed 
to proliferate and metastasise unopposed by immune restraints (Dunn et al., 2004). This 
process is illustrated in Figure 1.4.  
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Figure 1.4 – Overview of the three phases of cancer immunoediting. After transformation 
through genetic alterations, various immune events may occur. First, tumour cell elimination 
by cells of innate (NK=Natural killer cell, MØ=Macrophage) and adaptive immunity (CD4+ 
and CD8+ T lymphocyte populations) leading to the restoration of normal tissues (A). However, 
if unsuccessful, cells may enter a phase of equilibrium (B) in which they are maintained 
through selective pressures until acute immune reactions lead to tumour eradication or to a 
newly formed population of immunosculpted tumour cells which are resistant to immune 
elimination and displaying aggressive phenotype (C). This population may escape immune 
recognition through any number of tumour driven evasion mechanisms (e.g. up regulation of 
Fas-L) and immunosuppressive cell populations may also contribute to immune evasion (e.g 
regulatory T cells) (Adapted from Dunn et al., 2004).  
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1.1.5 The cancer stem cell hypothesis 
 
The origins of cancer have in the past, and continue to be, the source of intense debate. For 
many years the understanding that cancer arises from a single cell that is subject to 
mutational change leading to the gradual selection of clones remained the most widely 
accepted hypothesis, termed the clonal evolution theory. Accordingly, the majority of 
conventional therapies aim to target tumours based on this principle. The fact that current 
therapies often fall short of eliminating all tumour cells suggest that tumours contain a 
population of cells that are not only resistant to treatments, but are also responsible for 
reoccurrence and metastasis. The notion that only a rare subpopulation (cancer stem 
population) of cells holds the capacity to initiate and maintain tumour growth has formed 
the foundation for what is now referred to as the cancer stem cell model. In 1997, the first 
major breakthrough in providing evidence for the cancer stem cell model was the 
existence of leukaemic stem cell populations that were capable of generating tumours 
(Bonnet & Dick, 1997). The study demonstrated that injection of a rare stem cell 
population isolated from leukaemic cells with a specific surface expression (CD34+/CD38-) 
into non-obese diabetic mice with severe combined immunodeficiency disease 
(NOD/SCID) mice were capable of generating tumours that were phenotypically identical 
to that of the donor tumour. This finding prompted several investigations which identified 
tumour–initiating cancer stem cell populations in many tumour types including in breast, 
brain, prostate, colon and ovary (Al-Hajj et al., 2003; Singh et al., 2003; Collins et al., 
2005; O’Brien et al., 2007; Zhang et al., 2008).  
 
Despite their discovery, many questions still remain as to the events that lead to their entry 
into tumourigenesis. The biological characteristics of these cells such as their ability to 
self-renew and also generate differentiated cell populations from CSC-derived progenitor-
like cells, may possibly explain the unique features of some cancers such as 
teratocarcinomas (Andrews, 2002). Additionally, CSC possess more resistance to cell 
death then tumour cells when challenged with drug treatments, radiotherapy, apoptosis and 
their lack of surface MHC expression suggest that they may escape immune attention. The 
similarities shared between CSC and the stem cells from which they are named after give 
credibility to the proposal in which a self-replenishing population may indeed, drive 
tumourogenesis and could possibly initiate tissue invasion and cell dissemination through 
the generation of a metastatic CSC population (Brabletz et al., 2005).  
Chapter 1: Introduction  1.1 
 
23 
 
 1.1.6 Current treatment strategies 
 
There are more than 100 classified types of cancer that are distinguished according to their 
tissue and cell of origin. Genetic, environmental and lifestyle factor interactions can 
culminate to produce a given malignancy in a particular individual. It is therefore 
unsurprising that, given these layers of complexity, a varying degree of success is achieved 
across cancers and within subtypes with the current selection of treatments despite their 
refinement over time.   
 
At present, first line treatments still largely depend on established traditional approaches 
which include surgery, radiotherapy, chemotherapy and hormone therapy. Surgical 
intervention is the mainstay in treating localised primary solid tumours and alone can be 
curative. However in the majority of cases, surgical removal of cancers that have 
metastasised beyond the primary site is ineffective and therefore require additional 
radiotherapy and/or chemotherapy treatments. Radiotherapy and chemotherapy can be used 
to target and destroy rapidly proliferating cancer cells. Due to their genomic instability, 
cancer cells are more susceptible to irreversible DNA damage as a consequence of their 
loss of damage repair mechanisms making them more vulnerable than normal cells to 
targeted radiation. Meanwhile chemotherapy using cytotoxic agents inhibits cell 
proliferation particularly in rapidly dividing cells leading to cell death. However, a major 
drawback to these treatments is that they also damage highly proliferative normal cells 
leading to the adverse and often severe toxicity. In addition, these two approaches are 
mostly effective in tumours which are well oxygenated making hypoxic areas within then 
resistant to radiation and poorly perfused by chemotherapeutic agents to be effective. 
Furthermore, chemotherapy and radiotherapy can, in some instances, also promote 
tumourigenesis through their impact on cells of the immune system. Finally, hormone 
therapy can be utilised block hormone-dependent tumour growth. Existing hormone 
therapies such as testosterone in prostate cancer are often only partially effective leading 
patients to relapse due to the generation of hormone-resistant tumours. In more recent 
times, approaches using monoclonal antibody technology and targeting cancer specific 
molecules using drugs have proven useful but are limited to those patients that sufficiently 
express the appropriate molecular target.  
Chapter 1: Introduction  1.2 
 
24 
 
Often with these treatments, even when combined, fail to prevent cancer–related mortality. 
In the UK, for patients diagnosed with cancer in 2007, the predicted overall 5 year survival 
rates were 46% men and 56% for women (Cancer Research UK). These statistics, in part 
reflect on the limitations of the current treatment modalities, in particular their lack of 
specificity to cancer cells, damaging (and potentially initiating) surrounding normal cells 
and their severe toxic side-effects. Finally, current therapies that lead to the accumulation 
of treatment resistant tumour cells can arguably lead to a more invasive tumour phenotype 
and poorer survival outlooks. Thus, alternative curative approaches are required that limit 
their therapeutic action specifically toward tumours sparing normal cells. The concept of 
instructing the body’s own immune system to specifically target and destroy tumour cells 
to avoid more invasive treatments which carry higher mortality risk and unwelcome side 
effects poses an attractive alternative approach. The current status of cancer 
immunotherapy is discussed further in section 1.4.   
 
1.2  The Immune System and Cancer 
 
The association between infection and the regression of cancer dates back to the late 18th 
century when Dr William Coley devised the first anti-cancer vaccine which involved 
triggering the immune system using bacterial toxins. Later in 1909, the concept of 
immunosurveillance was first formulated by Dr Paul Ehrlich who suggested that 
transformed cells are frequent occurrences in humans however they are recognised and 
eliminated by the immune system before they become clinically apparent. In more recent 
times, several investigations have added further weight to the notion that both the innate 
and adaptive immune system plays an influential role on tumours. In particular, the 
identification of natural tumour-specific circulating T lymphocytes as well as tumour 
reactive antibodies in the bloodstream of cancer patients (Valmori et al., 2000; 
Schlichtholz et al., 1992). Similarly, the release of cellular stress induced signals and the 
loss of surface MHC class I expression can activate NK cell mediated tumour cell lysis 
(Long & Rajagopalan, 2002). Over the years, as the knowledge of the intricate processes 
that orchestrate the anti-tumour response has expanded, it has also prompted virtually 
every facet of the immune system to be examined as a therapeutic strategy against cancer. 
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1.2.1  Innate immunity 
 
The innate immune system is consider to be the “non-specific” arm of the immune system 
which includes defences that are constitutively present and prepared to mobilise 
immediately upon infection of a foreign pathogen. The innate system operates a rapid, 
inflexible first line response to quickly eliminate any invading pathogens that the body 
encounters. There are several effector cells that have been identified as important 
mediators of this response, including NK cells, NKT cells and γδ T cells originating from 
lymphoid progenitor cells, and phagocytic cells such as macrophages and DCs derived 
from myeloid lineage. These cells perform their function through cell-surface pattern 
recognition receptors (PRR) in order to identify pathogen-associated molecular patterns 
(PAMPs) which are associated with a wide range of conserved surface molecules found on 
microbial pathogens or are cellular stress signals. Similarly, damage-associated molecular 
patterns (DAMPs) have also been suggested to be recognised by PRRs during cellular 
damage (Seong & Matzinger, 2004). Following recognition of these molecules, phagocytic 
cells commence ingestion of pathogens in a process known as phagocytosis, in which 
phagocytes generate toxins (e.g. O2
-, H2O2 and NOS) that assist in killing engulfed 
microorganisms. Likewise, NK cells release cytotoxic granules to induce either apoptotic 
or osmotic lysis of target cells. At this stage, activated cells are able to activate the 
adaptive immune response through cross-talk with antigen- presenting cells (APCs). A 
family of transmembrane protein structures referred to as toll-like receptors (TLR) are 
considered the most important type of PRR’s. TLRs are common among vertebrates and 
invertebrate and to date in mammalian species, ten functional members and have been 
classified according to their known agonists. These include TLR recognition of 
peptidogylans (TLR2), double stranded RNA (TLR3), lipopolysaccharide and viral 
proteins (TLR4), flagellin (TLR5) and unmethylated CpG DNA motifs (TLR9) (Akira & 
Takeda, 2004). TLR mediated-activation of signalling pathways including NFκB and 
mitogen-activated protein kinases (MAPK) can induce pro-inflammatory cytokines and 
chemokines and the expression of co-stimulatory molecules which are essential for the 
induction of adaptive immunity via APCs (Medzhitov, 2001).  
 
Although much attention to the role of the adaptive immune response has been given in 
tumour immunosurveillance, more recently it has been suggested that cells of the innate 
immune system are also capable of detecting tumour cells. It has been suggested that 
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endogenous danger signals released by damaged cells, principally uric acid (Shi et al., 
2003) or through exposure to certain inherent biological signals of the tumour itself 
(Seong & Matzinger., 2004) are sufficient to induce innate immune responses. The 
ensuing pro-inflammatory responses may be induced through the activation of TLRs by 
agonists such as heat-shock proteins (HSP’s), high-mobility group protein B1 (HMGB1) 
and ECM derivatives (hyaluronic acid and heparin sulphates) (Dunn et al., 2004). To date, 
a number of danger signals have been identified to be produced by tumours, which in turn 
allows for the recruitment of specific cells of the innate immune system. Taking the earlier 
example, tumours cells under hypoxic conditions induce molecules associated with stress 
called major histocompatability complex class I chain-related proteins A and B (MICA/B) 
and UL16-binding proteins. These molecules are cellular ligands of NK cell activating 
receptor (NKG2D) found on NK and NKT cells, cytotoxic T lymphocytes (CTL) and γδ T 
cells (Pende et al., 2001). In NK cells, NKG2D acts as an activation receptor capable of 
triggering NK mediated tumour cell lysis and induce NK cells to secrete IFNγ, a potent 
pro-inflammatory stimulator, which among other activities is capable of direct cell killing 
through the inhibition of angiogenesis and metastasis and the recruitment of lymphocytes. 
In addition, IFNγ activates the adaptive response through the maturation of macrophages 
and DCs which in turn release IL-12 which enhances CD8+ CTL and further promotes NK 
cytotoxic activity. In CTL, NKG2D serves as a co-stimulatory receptor of TCR-activated 
cells (González et al., 2008). NK cells have also been found to recognise MHC class I 
molecules via specific surface receptors (Killer Ig-like receptors (KIRs), lectin-like 
receptor 1 (LIR-1) and CD94-NKG2A) that act to inhibit NK cytotoxic activity. The 
absence or insufficient concentration of MHC class I expression on the cell surface, a 
frequent immune evasion strategy used by tumour cells, fulfil the “the missing-self” 
criteria required for NK mediated cell lysis (Moretta & Moretta, 2004).  
 
More recently, “unconventional” T cell populations have been studied for their role in 
bridging innate and adaptive immune responses. NKT cells represent a subset of CD3+ T 
lymphocyte cells that express a CD1d-restricted TCR on their surface. These TCR differ 
from their conventional αβ T cells in their TCRs in that they are typically limited to 
recognising glycolipid antigens via PRR from bacterial microbes rather than peptide/MHC. 
Phenotypically, NKT cells more closely resemble cells of the innate immune system with 
NK-like features such as the rapid production of IFNγ, IL-4 and GM-CSF upon activation 
as well as exhibiting NK-like killing, however fail to generate immunological memory 
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(Berzofsky & Terabe, 2009; van Kaer et al., 2011). Similarly, mature γδ T cells form 
functionally distinct subgroups that places them in both innate and adaptive divisions of 
the immune system. These cells are capable of recognising microbial invaders (Vδ2 T 
cells) and transformed cells (Vδ1 T cells) independently of antigen presenting and MHC 
molecules, can eliciting both NK cell and CTL anti-tumour effector responses, and can 
directly induce effector CD4+ and CD8+ T cell responses through APC-like activity and 
appear to have immunological memory (Holtmeier & Kabelitz, 2005; Kalyan & Kabelitz, 
2013). These two populations provide evidence of the overlapping components that span 
over both the innate and adaptive arms of the immune system. Taken together the 
emerging evidence suggests that these populations have several influential roles from 
detecting “early danger” signals to immunosurveillance to switching from innate to 
regulating adaptive responses in cancer (Kim et al., 2007).  
 
The most effective cross-talk between the innate and adaptive immune systems occurs 
through three populations of cells that are responsible for antigen capture, processing and 
presentation via the MHC complexes termed professional antigen presenting cells (APCs). 
Through this process, B lymphocytes, macrophages and DCs are able to present effector 
cells of the adaptive immune response with specific antigens against which a targeted 
immune response can be initiated. Of these populations, DCs are considered the most 
potent and important of the APCs and sit centrally in the body’s immune system, 
transmitting from innate to adaptive responses. DCs have been intensely researched to 
discover their various subsets and their role in order to determine how they could be 
harnessed for use in clinical therapy.  
 
As previously mentioned DCs are derived from bone-marrow progenitor cells and are 
designated as sentinels of the immune system that are mostly positioned at the antigen 
entry points of the body. DCs reside in the periphery in an immature state, following an 
encounter with damaged or infected cells, DCs begin to engulf cellular debris through 
phagocytic mechanisms. Following antigen uptake, DCs begin to migrate into draining 
lymph nodes via the afferent lymphatics, during which time the cell undergoes various 
stages of maturation which culminate in the up regulation of surface MHC molecules and 
co-stimulatory molecules CD40 and B7. In addition, DCs process captured proteins into 
short peptides which are then displayed onto MHC molecules bound to the surface of the 
cell. Upon arrival at the lymph nodes, DCs activate naive CD4+ and CD8+ T cells that then 
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differentiate into antigen-specific effectors T cells. The maturation status of DCs is 
important in generating functional effector T cells, immature DCs that fail to present 
appropriate co-stimulation can lead to antigen-specific T cell anergy (Steinbrink et al., 
2009; Palucka & Banchereau, 2012).  
 
1.2.2  Adaptive immunity 
 
Unlike the innate immune response, the adaptive arm of the immune system consists of a 
sophisticated network of cellular components that co-ordinate measured responses through 
antigen-specific receptors. These responses can be classed under two headings, namely as 
humoral immunity consisting of B cell and antibody responses and/or cell mediated 
immunity relaying on T cell activity. The latter can be considered to be the chief instigator 
in the immune response against cancer through CD4+ and CD8+ T cell recognition of 
tumour associated antigens. 
 
1.2.2.1 The humoral response 
 
Humoral immunity is generated through antigen-dependent activation of B lymphocytes 
by DCs leading to either memory B cells or their clonal proliferation and terminal 
differentiation into antibody-secreting plasma cells. Circulating antibodies (Ab) can 
facilitate the ingestion of cells by phagocytic macrophages through antibody opsonisation, 
a process involving FAb mediated binding of antigen and activation of Fc receptors on the 
surface of macrophages. Similarly antigen bound antibodies can attract complement 
molecules to induce cell clearance via macrophages. Critically, B lymphocytes are 
themselves able to recognise and engulf soluble forms of their cognate antigen and display 
processed antigens bound to MHC class II molecules on their surface to T lymphocytes. 
Following B lymphocyte and CD4+ T cell interactions, a further co-stimulation signal (via 
CD40/CD40L) activate B cell proliferation. Meanwhile CD4+ T cell begin secreting 
cytokines to drive the development of the Th2 response. Without the assistance of cognate 
CD4+ T cells, plasma cells are unable to generate high-titre of antibodies. This has led to 
the identification of numerous TAA through SEREX suggesting that humoral responses 
are capable of inducing antibody mediated anti-tumour responses. During their 
development, B lymphocytes undergo negative selection to antigens in the bone marrow, a 
process that is less stringent than the selection mechanisms involved in T lymphocyte 
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development and therefore may be readily activated against tumour cells. Despite this, the 
role B lymphocytes play in anti-tumour immunity has remained debatable. Studies have 
demonstrated that an increase in B cell tumour infiltrates correlate with a poor prognosis 
in patients with metastatic disease (Dong et al., 2006), contrary to other findings which 
associate them with improved survival (Nzula et al., 2003; Kotlan et al., 2005). The 
adoptive transfer of B lymphocytes into HPV16 mice lacking T and B cells restored the 
capacity of pre-malignant tissue to progress to full malignancy via the reinstatement of a 
chronically inflamed microenvironment (de Visser et al., 2005). The down regulation of 
MHC class I molecules by tumour cells and their secretion of cytokines (IL-4 and IL-13) 
may preferentially skew the adaptive response to favour a Th2 response in which case the 
use of therapeutic monoclonal antibodies may be beneficial either alone or in conjunction 
with Th1 effectors to induce the rejection of tumours. Although it is evident that in 
isolation, the humoral response is detrimental to the effectiveness of the anti-tumour 
responses, it is becoming increasing clear that striking the correct Th1/Th2 balance 
between CD4+, CD8+ and B cells are critical to promote tumour rejection (Kao et al., 2006; 
DiLillo et al., 2010).    
 
1.2.2.2 The cell mediated response 
 
The cell mediated response is comprised for three functional classes of T lymphocytes 
which are capable orchestrating antigen-specific responses following their activation by 
APCs. Cytotoxic T lymphocytes or CD8+ T cells recognise and eliminate infected or 
transformed cells. T helper lymphocytes (Th) or CD4+ can differentiate into two further 
subtypes of effector cells namely, T helper 1 lymphocytes (Th1 cells) which are involved 
in promoting CTL responses through APC signalling and drives the activation of 
macrophages. In contrast T helper 2 lymphocytes (Th2 cells) promote the development of 
a humoral response via their B cell interaction.  
 
Typically, DCs that are recruited to the tumour site and begin to internalise apoptotic and 
necrotic tumour cell debris and migrate to neighbouring lymph nodes where they interact 
with CD4+ and CD8+ T cells. During this migration period DC maturation occurs and as a 
consequence, they lose their ability to phagocytose further cellular material and instead, 
increase their ability to present processed antigens on their surface to effector T cell 
populations (Garrett et al., 2000). Once receptor interactions with CD4+ T cells occur, 
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DCs undergo further maturation which allow for exchanges between DCs and CD8+ T 
cells to take place. This in turn leads to the differentiation and expansion of CD8+ T cells 
into antigen specific CTL. This licences activated CTL and T helper cells to migrate to the 
site of the tumour and exercise antigen-specific killing of tumour cells bearing the same 
antigen through the release of cytolytic toxins or through the activation of death-inducing 
signal receptors on the cell-surface of target cells. This simplified overview describes the 
mobilisation of cellular components involved during the adaptive response. This response 
occurs as a consequence of the co-ordinated release of many cytokines that not only drive 
the induction of an adaptive immune response but are also central to the recruitment of 
immune cells that can either, depending on the cytokine profile, promote an anti-tumour 
offensive or dampen the response altogether.  
 
(a)   Major histocompatibility complex: structure and function 
 
The major histocompatibility complex (MHC) molecules are transport complexes present 
on the surface membrane of cells. They provide the appropriate platform for the 
presentation of antigen fragments to T cells in order for them to initiate and regulate 
antigen-specific immune responses. The MHC molecules are encoded by a cluster of 
closely linked genes situated on chromosome 6 in humans and chromosome 17 in mice. 
Historically, human MHC molecules are known as human leukocyte antigen (HLA) and 
the mouse equivalent as H2 (histocompatibility 2). The HLA genes are organised into three 
classes: the HLA class I, class II and class III genes. The former two classes encode for 
molecules that are important for the presentation of antigenic peptides to T cells. Both 
MHC class I and class II consist of a variation of an α and β chain which form unique 
peptide binding grooves in order to tether peptides at specified amino acid anchor residues 
on the peptide. MHC molecules are highly polymorphic and allow promiscuous binding of 
a diverse variety of peptides by a given MHC molecule (Reche & Reinherz, 2003). Once 
bound to membranous MHC molecules, peptides are recognised by T cell receptors (TCR) 
on the surface of T lymphocytes.   
 
The TCR complex is heterodimer composed of two glycoprotein chains (α and β or γ and 
δ). The majority of T cells express the α and β subunits which each form a highly variable 
region (vα and vβ) and a constant region (cα and cβ). TCR share a similar structural 
composition to that of immunoglobulin (Ig) molecules. The variable region of TCR’s are 
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encoded by “random” combinations of multiple variable (V), diversity (D), and joining (J) 
gene segments during early T cell development creating a vast and diverse pool of T cells 
which together are able to recognise a vast array of antigenic peptides. This pool is 
condensed down through the deletion of self-recognising T cells during thymic selection 
(discussed later in section 1.3.2.1). Unlike Ig, activation of T cells cannot be achieved 
through the recognition of free form antigens as they require presentation in the context of 
MHC molecules. TCR’s are expressed alongside the CD3 protein complex consisting of γ 
δ and two ε chains and two intracellular ζ chains forming the immunoreceptor tyrosine-
based activation motif (ITAM). Recognition of MHC-peptide complex by TCR, alongside 
binding of the respective MHC class I (CD8) or MHC class II (CD4) molecules and co-
stimulation signals, triggers downstream signalling and T cell activation (Figure 1.5A). 
The interaction between MHC-peptide-TCR and the appropriate co-stimulatory signalling 
are crucial for T cells to become fully activated (Smith-Garvin et al., 2009).  
 
The human HLA genes encode for three class I variable α chain subunits (HLA-A, -B and -
C) and three class II variable α and β chain subunits (HLA-DR, -DP and -DQ). The mouse 
H2 equivalent consists of three class I α chain subunits (H2-K, -L and -D) and two class II 
α and β chain subunits (IE and IA). Genes associated with class II molecules namely β2-
microglobulin (B2M) and the invariant chain (CD74) are situated away from the HLA 
locus on chromosomes 15 and 5 respectively. MHC class I and class II are the most 
polymorphic genes in the human genome. In addition, the expression of the HLA alleles is 
co-dominant, meaning that both sets of the principle 6 alleles are expressed simultaneously 
in heterozygous individuals. This introduces extensive diversity to the possible MHC 
binding groove; in fact each allele differs by up to 20 amino acids in this region of the 
MHC, allowing for a broad range of peptides that can be presented to TCR (Janeway, 
2001).   
 
In humans, the α chain region of the MHC class I molecule, also referred to as the heavy 
chain, consists of α1, α2 and α3 domains. This chain forms a non-covalent interaction 
between β2m and α3 domain to form the MHC class I complex. The α1 and α2 domains 
conform to create a deep pocketed binding groove which restricts the size of peptides 
suitable to bind to 8 to 10 amino acids in length. MHC class I molecules are constitutively 
expressed on nearly all somatic nucleated cells of the body with exceptions such as testis. 
Their biological function is to present intracellular proteins, to the CD8+ T cells (Figure 
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1.5B). The presentation of “self-antigens” by healthy cells are surveyed by the immune 
system and are recognised as “normal” requiring no further exchange. However, in 
instances of virally infected cells, the profile of antigens presented on the cell surface 
change to include virally derived antigens leading to the recognition of “non-self” antigens. 
As a consequence, the immune system responds by destroying the infected cells. This 
mechanism is also crucial in monitoring “altered-self antigens” during cell transfection 
(Janeway, 2001). MHC class II complex is composed of two α and β chains (α1, α2 and β1, 
β2), which fold to create an open ended peptide binding groove between the α1 and 
β1domains capable of anchoring peptides between 10 – 16 amino acids in length (Figure 
1.5C). These MHC molecules are constitutively expressed on the surface of professional 
APCs and present to CD4+ T cells. As the peptides presented are predominantly of 
extracellular origin, this mechanism is plays a prominent role in evoking an adaptive 
immune response through the interactions with CD4+ T cells (Janeway, 2001). 
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Figure 1.5 – Schematic representation of TCR and MHC class I and class II molecule 
structure. The TCR consists of one α and one β chain which are themselves divided into one 
variable (v) and one constant (c) region. The variable regions form the binding domain for 
MHC bound peptides. The accompanying CD3 complex consisting of γ, δ, ε and ζ subunits and 
the ITAM mediate T cell activation and the ensuing intracellular signalling cascade (A). MHC 
class I consists of three α chain domains (α1, α2, α3) and β2m molecule. The α1 and α2 
domains fold to form a cleft for peptides to bind (B). MHC class II consists of one α chain and 
one β chain domain (α1, α2 and β1, β2). Here the α1 and β1 domains fold to form the groove 
for peptides to binding (C) (Adapted from Wange & Samelson, 1996). 
 
(b)  Antigen presentation pathways 
 
As explained previously, the components of the immune system continuously assess the 
intra- and extracellular proteins for indications of infection or transformed cells. This 
process is mediated through MHC class I and class II molecules which present peptide 
fragments to T cells. These MHC-peptide complexes are generated with APCs and 
presented to T cells. The peptides and MHC molecules are generated in one of two 
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classical antigen presentation pathways. Typically, MHC class I molecules bind peptide 
fragments from intracellular sources (e.g. viral and altered self proteins) presented to CD8+ 
T cell whereas MHC class II molecules present proteins arising from extracellular sources 
as a consequence of phagocytic activity by the APCs. The processing and presentation of 
antigens via MHC class I and class II pathways are illustrated in Figure 1.6. 
 
Endogenous peptides destined for surface presentation by MHC class I molecules are 
derived from cytoplasmic proteins which undergo degradation by a multi-catalytic 
complex called the proteasome. Proteasomes are responsible for the disassembly of all 
miss-folded, damaged or foreign cytoplasmic proteins that have been covalently tagged 
with ubiquitin molecules regardless of whether they are transported to the endoplasmic 
reticulum (ER) (Michalek et al., 1993). Proteasomes contain three IFNγ-inducible 
immunoproteasome subunits, LMP2, LMP7 and MECL-1 which induce proteasomal 
proteases that lead to a change in the nature of the peptides utilised for antigen 
presentation. Specifically, LMP2 and LMP7 enhance specific cleavage after hydrophobic 
and basic to create peptides with carboxyl ends which allow for easier transportation of 
peptide fragments and more suitable entry into peptide binding groove on the MHC 
molecule. The peptide fragments are transported to the ER via transporters associated with 
antigen processing (TAP) molecules, TAP 1 and TAP 2. MHC class I molecules are 
assembled within the ER lumen through the co-ordination of the peptide loading complex 
which consists of tapasin, ERp57, calreticulin and TAP molecules. The MHC heavy chain 
(α1, α2 and α3 components) and are stabilized by the glycoprotein binding chaperon 
protein called calnexin before binding with β2m. Tapasin also mediates the editing and 
loading of high affinity peptides onto the MHC class I molecule (Praveen et al., 2010). 
TAP has also been shown to have a bias toward transporting amino acid sequences with 
hydrophobic side chains as this allows a stronger binding affinity between peptide and 
MHC (Momburg et al., 1994). The binding of peptides enhance the structural stability of 
the MHC molecule and the complex is exported out of the ER to the Golgi complex and 
exocytosed to the cell surface via transporter vesicles for presentation to CD8+ T cells 
(Figure 1.6).  
 
Although MHC class I and II molecules share a similar structure and role in the cell, the 
assembly of the MHC class II molecules differs considerably to the mechanism described 
above. Exogenous proteins enter the cell via intracellular endosomal vesicles. As 
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endosomes advance further into the cell the pH environment within falls, which activates 
acid proteases (such as cathepsins) to degrade antigens into short peptide fragments. These 
fragments undergo lysosomal protease mediated degradation into smaller peptide 
fragments which remain within the endosomal vesicles. In the ER lumen, MHC class II α 
and β chain are synthesised and assembled in a dimer formation along the ER internal 
membrane. During this stage, an additional chaperon chain molecule associates to form a 
hetrodimer. This chain is termed the invariant chain (Ii) and is required to prevent binding 
of polypeptides to the peptide binding groove. The hetrodimer complexes are exported to 
the Golgi complex and trafficked through the cytoplasm via exocytic vesicles where 
proteases and cathepsins partially degrade the Ii so that only a small region inside the 
binding groove remains. This shorten region termed class II-associated Ii peptide (CLIP) 
ensures that no inappropriate binding to the MHC occurs. Endosomal and exocytic 
vesicles containing the peptide fragments and the MHC fuse to form late endosomes, 
CLIP then detaches from the MHC class II allowing dominant peptides with high affinity 
for the peptide binding groove on the MHC to load onto the complex. The vesicle 
containing the MHC class II-peptide complex shuttles towards the plasma membrane for 
presentation to CD4+ T cells (Figure 1.6).  
 
Although the two pathways mediate extracellular (exogenous route) and intracellular 
(endogenous route) these divisions are not strictly adhered to. Indeed, endogenous 
antigens internalised by DCs can generate peptide-MHC class I complexes that are cross-
presented to CD8+ T cells (Bevan, 1976; Shen & Rock, 2006). Similarly, endogenous 
proteins which are independent of the proteosome and TAP complexes may lead to 
peptide-MHC class II complexes recognised by CD4+ T cells in a process known as cell 
autophagy (Li et al., 2008). Mechanisms for cross-presentation are still to be determined 
although evidence suggests that exogenous antigens from phagosomes escape through 
channels or translocators into the cytostol or through phagosome-ER fusion leading to 
MHC class I presentation (Shen & Rock, 2006). Importantly, these overlapping 
mechanisms of cross-presentation can be exploited to induce antigen-specific immune 
responses. Whereby preparations of antigens are taken up by APCs and presented by 
MHC class I and class II molecules stimulating both CD4+ and CD8+ responses (discussed 
further in section 1.4).  
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Figure 1.6 - Antigen processing and presentation on MHC class I and class II molecules. 
(Left panel) Endogenous peptides generated in the cystol by the proteosome and cystolic 
proteases and are transported through the transporter associated with antigen (TAP) complex 
into the RER. Here MHC class I molecules are synthesised and are assembled along with the 
now processed 8-10 amino acid long peptides by the peptide loading complex (tapasin, ERp57, 
calreticulin and TAP molecules). The MHC-peptide complexes are trafficked via vesicles 
through the Golgi complex and to the cell surface to be presented to CD8+ T cells. (Right panel) 
After MHC class II molecules are assembled in the RER with invariant chain they are 
transported via vesicles through the Golgi complex following which, the Ii undergoes 
proteolytic degradation leaving the class II-associated Ii peptide (CLIP). Exogenous antigens 
digested in endocytic compartments incorporate with vesicles transporting MHC class I 
molecules, CLIP is released from the peptide binding groove and peptides processed to the 
appropriate length (~10-16 amino acids) are loaded onto the MHC complex and shuttled to the 
cell surface to be presented to CD4+ T cells and B cells.(Adapted from Kuby, 1997). 
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(c)   T cell effector functions 
 
Naive lymphocytes cells require two specific signals to induce activation. The first is 
mediated through TCR recognition of cognate antigen bound to MHC molecules on the 
surface of DCs, in addition to the CD4 or CD8 co-receptor molecules binding to the MHC 
molecule. The second signal arises from the interactions of co-stimulatory receptor CD28 
along with either CD80/CD86 surface proteins on APCs. The absence of either one of 
these signals during activation leads to the T cell undergoing apoptosis or left in a state of 
anergy (Harding et al., 1992). This interaction between DCs and CD4+ T cells promotes 
CD40/CD40L mediated cross talk which licences DCs to activate CD8+ T cells and induce 
CD4+ T cell differentiation or memory T cells. As a consequence, CD4+ T cells are 
polarised towards either a Th1 or Th2 phenotype which produce cytokine profiles that 
orientate the immune response by either promoting CTL activation from CD8+ T cells or 
promoting B lymphocyte production. Cytokine signalling from DCs constitute a third 
activation signal which determines the differentiation fate of T cells through the induction 
of T cell transcription factors. The secretion of IL-12 and IFNγ are key cytokines that are 
critical in the progression of Th1 CD4
+ T cells leading to the production of their signature 
cytokines: IFNγ, IL-2 and IL-12 which promote CD8+ mediated cytolytic activity. On the 
other hand, the secretion of IL-4 and IL-2 by DCs induce the development of Th2 CD4
+ T 
cells leading to the release of cytokines (IL-4, IL-5, IL-10 and IL-13) which promote 
antibody responses towards the antigen. Therein, CD4+ T cells sit centrally in the 
development and regulation of nearly all antigen-specific immune responses mediated 
through the function of their downstream subset of effector cell populations.  
 
In regards to anti-tumour immunity, many in vitro and in vivo studies have now firmly 
established that CD4+ T cell help is required to support the induction of strong CTL 
responses (Bennett et al., 1997; Ossendorp et al., 1998; Wang & Livingstone, 2003). The 
release of IFNγ and TNFα by CD4+ T cells promotes cytotoxic effects towards tumour 
cells (Corthay et al., 2005). In addition, IFNγ enhances tumour recognition and cell lysis 
by CTL by up regulating the cell surface expression of MHC class I and class II 
complexes on both immune cells and tumour cells (Dighe et al., 1994). Activated tumour-
specific CD4+ T cells are also associated with the accumulation of increased frequency of 
activated CD8+ T cells that infiltrate tumours (Wong et al., 2008). Cognate memory CD4+ 
T cells also assist in the expansion of cognate memory CD8+ T cell population leading to 
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an increased elimination of tumour cells (Hwang et al., 2007). The importance of CD4+ T 
cell populations and their functions in the control of tumour are underlined by the use of 
adoptive therapies which engage tumour-reactive CTL. These early studies demonstrated 
that using CTL does not always promote effective tumour regression and that the lack of 
CD4+ T cell help is an important factor owing towards the poor anti-tumour responses 
observed (Rosenberg & Dudley, 2004). Indeed in instances where CD4+ T cells were 
either therapeutically depleted or were absent in knockout mice, the immune responses 
generated by CD8+ T cells were reduced significantly (Hung et al., 1998). It was proposed 
that in order to elicit strong and long lasting anti-tumour responses, DCs must engage both 
CD4+ and CD8+ T cells which recognise the same cognate antigen. Aside from promoting 
the expansion and maintenance of CTL for direct tumour killing, CD4+ T cells have many 
diverse signalling functions which further contribute towards anti-tumour immunity. In 
fact, CD4+ T cells have also demonstrated a capacity to recognise tumour antigens and 
induce direct tumour killing on their own (Daniel et al., 2005). Several studies have 
demonstrated CD4+ T cell direct tumour killing through a number of mechanisms 
including the use of perforins, Fas-FasL and TRAIL pathways (Porakishvili et al., 2004; 
Stalder et al., 1994; Thomas & Hersey, 1998). Moreover, CD4+ T cell release of cytokines 
such as IFNγ recruit other immune effector cells to the tumour site which are able to 
engage in tumour killing (macrophages and eosinophils) (Hung et al., 1998).  
 
As a consequence, CD4+ T cells can orchestrate anti-tumour immune activity through the 
release of IFNγ creating a pro-apoptotic and anti-proliferative tumour environment that 
encourages the immune cells present to activity seek and eliminate tumour cells (Ikeda et 
al., 2002). Although CD4+ T cells perform many roles in mediating indirect tumour killing, 
the induction of CD4+ T cell specific direct tumour lysis is consisted to be a minor 
function of CD4+ T cells as few tumours express MHC class II molecules on their cell 
surface. Therefore initial therapeutic approaches relied solely on priming CD8+ T cells due 
to their primary function as cytotoxic effector T cells that directly destroy tumour cells.  
 
CD8+ T cells only recognise antigen in the context of presentation by MHC class I 
molecules and upon activation with secondary stimulatory signals result in their 
differentiation and proliferate to form a population of cytotoxic T cells (CTL). In the 
absence of the co-stimulatory signals, CD8+ T cells generally produce a weakened, short-
lived immune response causing these cells to be either be deleted or become anergic and 
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unresponsive to further stimulation. The extent of this response is variable from one T cell 
to another due largely to TCR affinity which dictates the antigen threshold required to 
stimulate a response in the absence of co-stimulation. In the presence of the appropriate 
co-stimulation signals and the presence of stimulatory cytokines (IL-2 and IFNγ) CTL 
proceed to elicit strong cytotoxic effect on tumour cells. The kinetics of TCR activation 
and sustained T cell functions are the focus of rigorous investigation with the intention of 
boosting anti-tumour immunity by isolating or engineering TCR’s that demonstrate high 
avidity and affinity for their cognate antigen (Johnson et al., 2009; Porter et al., 2011; 
Curran et al., 2012). Following tumour antigen recognition CTL mediated cell death 
occurs through one of two cell-cell lysis pathways. The first is through the targeted release 
of perforins and granzymes by CTL. Secretory lysosomes containing cytolytic toxins 
mobilise at a specific cleft that forms between CTL and target cell membranes releasing 
the contents into target cells causing apoptosis (Andersen et al., 2006). The second 
mechanism is based on the activation of apoptosis via death receptors such as triggering 
Fas-FasL and TRAIL (TNF-related apoptosis inducing ligand) on the surface of target 
cells. The Fas ligand (FasL) is present on the surface of CTL and can trigger tumour cell 
apoptosis through its interaction with Fas receptor (CD95) on tumour cells. This 
interaction brings about the formation of a death inducing signalling complex (DISC) and 
subsequent initiation of downstream signalling of the caspase cascade resulting in 
programmed cell death. A similar response occurs following the engagement of death 
receptors on tumours via TRAIL. A third indirect pathway is mediated by the secretion of 
cytokines (TNFα and IFNγ) during CTL stimulation that bind to their respective receptors 
on target cells and lead to the direct triggering of caspase cascades (TNFα) and the 
induction of transcription factors that increase MHC class I presentation and FasL on the 
surface of tumours (IFNγ).  
 
1.3  Tumour Immune Evasion 
 
As discussed previously, the dynamic interactions between tumours and the immune 
system play an important role in tumourigenesis. The escape of tumours from the control 
of the immune system is a consequence of an amalgamation of multiple signalling 
mechanisms arising from the tumour and its influence on the surrounding TME and the 
immune response thereafter. Malignant cells expertly exploit the immune systems failsafe 
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mechanisms in place, which are intended to prevent autoimmunity and use those that 
promote wound healing following infection/injury to help facilitate tumour survival 
through the resistance of cell lysis, and promotion of cell proliferation and dissemination. 
A brief summary of these mechanisms have been described earlier in respect to 
immunosurveillance, “danger signals” and inflammation however for escape to occur, 
contributing factors from both the tumour cells and immune cells must be considered.    
 
1.3.1  Tumour cells: Evading immune destruction 
  
Several mechanisms employed by tumour cells have been identified which result in 
immunosuppression. As described earlier, the presentation of antigens in the context of 
MHC class I and class II molecules is essential in early activation phases during 
lymphocyte priming and during the effector phase of an immune response. Absence of 
antigen presentation through the loss or down regulation of genes that encode MHC 
complex associated proteins is a frequent occurrence in metastatic legions compared to 
primary tumour (Maeurer et al., 1996; Hicklin et al., 1999). The absence of MHC class I is 
often a consequence of mutations of the β2m subunit leading defective assembly which 
prevent immune recognition of tumours. Loss of MHC class I presentation may also be a 
consequence of defects in the tumour antigen processing machinery. More specifically, 
mutations leading to the loss or down regulation of immunoproteasomal subunits LMP2 
and LMP7 (PSMB9 and PSMB8 genes) and peptide transporter genes TAP1 and TAP2 
(Seliger et al., 2003; Chen et al., 1996; Agrawal et al., 2004) have been associated with 
several tumour types such as melanoma, colorectal carcinoma, renal cell carcinoma 
pancreatic cancer and prostate cancer (Kageshita et al., 1999; Cabrera et al., 2003; Dovhey 
et al., 2000; Pandha et al., 2007; Sanda et al., 1995). The loss of MHC class I leave 
tumours more susceptible to NK cell lysis via NKG2A/MICA/B interactions and 
suppression of the inhibitory KIR molecules, however one further strategy that the 
tumours may employ is the deletion or down regulation of surface expression of MICA/B 
(Khong & Restifo, 2002). The effective destruction of tumour cells presenting 
immunogenic antigens on the other hand, present the problem of epitope 
immunodominance leading to the loss of antigen variants to target. As a consequence this 
phenomenon it thought to have occurred in patients with recurrent metastasis following 
immunotherapy with a specific TAA epitope (Yee et al., 2002; Jäger et al., 1996). Thus, 
the adoption of simultaneous targeting of multiple TAAs, particularly those that are 
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essential for tumour growth may help avert the emergence of tumour variants that immune 
cells fail to recognise. 
 
Many studies have drawn attention to the down-regulation of co-stimulatory molecules 
such as B7.1 and B7.2 by tumours as a factor leading to suboptimal immune cell activity 
and are seen as a contributor to T cell anergy (Koyama et al., 1998; Harding et al., 1992). 
In studies which transfect and restore the expression of B7 co-stimulatory molecules on 
tumours have demonstrated an increased induction of CTL mediated rejection in in vitro 
and in animal models (Hodge et al., 1994; Townsend & Allison, 1993; Li et al., 1994). 
Aside from mechanisms that impair surface MHC molecule expression, tumours may also 
alter the expression of surface receptors in order to avoid immune targeting. For example, 
the expression of non-classical HLA genes such as HLA-G and HLA-E protect MHC class 
I negative tumours from NK cell mediated lysis (Paul et al., 1998; Marín et al., 2003, de 
Kruijf et al., 2010). To a similar end, tumours can down regulate or delete the surface 
expression of Fas and TRAIL receptors in order to prevent T cells activating cellular 
apoptosis through these death signalling pathways. The inhibition of these pathways are 
also a consequence of gene mutations of molecules involved in downstream signalling 
(Park et al., 2001; Shin et al., 2001). Besides avoiding death through apoptotic signalling, 
tumour can also prevent cytotoxin induced cell lysis by CTL and NK cells through their 
overexpression of a serine protease inhibitor, PI-9/SPI-6 which inhibits granzyme 
B/perforins pathways (Medema et al., 2001).  
 
In addition to resisting T cell mediated destruction, tumours may also instigate a “counter-
attack” through their own expression of FasL observed on the surface of several tumour 
types leading to T cell apoptosis. To date, the role of tumour FasL in mediating tumour 
escape has remained controversial due to it pro- and anti-inflammatory activities (Ryan et 
al., 2005). Finally, tumours may also employ contact independent mechanisms as a means 
of immune escape. As discussed earlier, tumour cells can modulate the TME by secreting 
immunosuppressive cytokines and other factors such as VEGF, IL-10 and TGFβ which 
inhibit DC maturation, trafficking to lymph nodes and antigen presentation (Gabrilovich et 
al., 2004). Other immunosuppressive molecules released by tumours such as ICAM-1, 
prostaglandin E2, gangliosides, and indoleamine 2,3-dioxygenase (IDO) can also hinder 
anti-tumour responses (Liu et al., 2005; Greenhough et al., 2009; Birklé et al., 2003; 
Munn & Mellor, 2007).  
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1.3.2  Tumour evasion mechanisms associated with the immune response 
 
Without doubt the one crucial trait that tumours possess that gives them the advantage to 
succeed in populating the body is that they are derived from self. The immune system has 
in place a tightly regulated system of tolerance towards self to prevent T cells from 
reacting to self cells, meanwhile retaining the functions to survey and eliminate damaged 
or altered cells. The current knowledge of T cell development and tolerance to self and the 
more recent understanding of immune regulators and suppressive cell populations and 
their relevance in cancer must be considered as they present a major obstacle in generating 
anti-tumour responses through cancer immunotherapy.  
 
1.3.2.1 Immunological tolerance and cancer 
 
During their development, lymphoid progenitor cells emerging from the bone marrow are 
classed as double negative (CD4-/CD8-). Upon reaching the thymus, they undergo stages 
of development and selection and become single positive for either CD8+ or CD4+ 
depending on whether they recognise MHC class I or class II respectively. Following this, 
thymocytes enter the medulla where they undergo negative and positive selection 
processes through central tolerance mechanisms. During selection thymocytes are exposed 
to epithelial cells of the thymic cortex (cTECs) which present them with MHC molecules. 
Thymocytes that form any MHC-peptide complexes are maintained as this interaction also 
provides them with a survival signal; those that fail to form complexes are deprived of the 
survival signal and undergo death by neglect. Thymocytes that exhibit too high affinity 
TCR for self-antigen are eliminated by negative selection as a measure to prevent 
autoimmune reaction. Alternatively, these cells may avoid deletion by undergoing gene 
rearrangement at the TCRα loci, which consequently alters the specificity of the TCR in a 
process known as receptor editing (Santori et al., 2002). Despite these processes, auto-
reactive T cells may still escape into the periphery (Anderton et al., 2002). The surviving 
population of thymocytes bear TCR which are capable of forming MHC-peptide 
complexes that are of medium affinities which are now of a committed linage. Next, 
thymocytes meet medullary thymic epithelial cells (mTECs) which express a diverse range 
of tissue specific self-antigens (TSA) promoted through the expression of a nuclear 
regulatory protein known as autoimmune regulator (AIRE). Once again high affinity auto-
reactive thymocytes are deleted. Following rigorous selection, the selected pool of CD4+ 
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and CD8+ T lymphocytes migrate to the periphery to begin to assess antigens presented by 
APCs in order detect pathogenic threats or infected and transformed cells. Following 
maturation, T lymphocytes pools are maintained through constant apoptosis which ensures 
homeostatic balance of the immune system. For example, following antigen recognition, 
reactive T cells trigger T cell expansion and engage and eliminate antigen bearing cells. 
Once the antigen is no longer detected, the presence of activated T cells reduces, returning 
back to a state of equilibrium. This winding down process relies on the elimination of 
surplus T cells leaving a small contingent to form a pool of memory T cells.  
 
1.3.2.2 Immune regulators and suppressor cells 
 
As alluded to earlier, macrophages are classed in accordance to their response to tumour in 
a similar manner as is designation for CD4+ Th cells (Th1 and Th2). Macrophages that are 
“classically activated” in response to TME stimuli such as IFNγ and microbial molecules 
(such as LPS) are polarised towards the M1 phenotype. These cells are characterised by 
their production of IL-12 and IL-23 and subsequent activation of Th1, anti-tumour 
cytotoxicity, production of iNOS and proficiency as APCs for T lymphocytes. In contrast, 
macrophages that are “alternatively activated” in response to IL-4 and IL-13 revert to a M2 
phenotype. The distinguishing features of these cells are their promotion of ECM 
remodelling, secretion of growth factors which support tumourigenesis and high levels of 
IL-10 production promoting Treg cells (Sica & Mantovani, 2012). Like Th1/Th2 balance, 
the loss of homeostasis between M1/M2 populations could induce chronic inflammatory 
environments (excess M1) or induction of immune suppression (excess of M2). Tumour 
associated macrophages (TAM) recruited to the site of tumour share resemblance to M2 
macrophages and as a consequence their cytokine profile helps to shape a Th2 immune 
response whilst down regulating a Th1-mediated adaptive response (Martinez et al., 2009).   
 
Myeloid derived suppressor cells (MDSCs) are inflammatory monocytes composed of 
incomplete inactivated granulocytes, macrophages and dendritic cells and are defined with 
a CD11b+/CD33+/CD14- phenotype (Peranzoni et al., 2010). High levels of MDSCs have 
been detected during chronic inflammation and tumourigenesis (Almand et al., 2001; 
Ostrand-Rosenberg & Sinha, 2009). MDSCs are capable of direct suppression of both 
CD4+ and CD8+ T cell activity through a number of mechanisms. Firstly, through their 
surface expression of CD28L (B7.1) which bind with high affinity to T cell surface 
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molecule cytotoxicity T lymphocyte antigen 4 (CTLA-4) which brings about negative 
control and inhibits activity of T cells. It has also been shown that MDSCs can also induce 
Treg cells by their release of IL-10, increase production of arinase and depletion of 
cysteine reduce the activation and function of T cells and up regulate COX/PGE2 
(Ostrand-Rosenberg & Sinha, 2009).   
 
To date, the most well studied population of immunosuppressive cells are 
CD4+/CD25+/FoxP3+ regulatory T (Treg cells). These cells can be broadly divided into 
two distinct classes; the first are naturally occurring Treg cells selected on their high 
avidity interactions in the thymus and the others are antigen-induced Treg cells generated 
the peripheral tissues in order to enforce peripheral tolerance to self-antigens (Curotto et 
al., 2009). The latter originate from CD4+/CD25- T lymphocytes which acquire CD25+ 
expression induced by suppressive cytokines such as IL-10 and TGF-β (Chen et al., 2003). 
Treg cells are able to suppress anti-tumour activity by inhibiting T cells via their surface 
expression of CTLA-4, a major inhibitory signal for activated T cells which subsequently 
dampens the adaptive immune response. Treg cells may present the most formidable 
immunosuppressive huddle to be overcome in order to generate strong, long lasting anti-
tumour responses using immunotherapy. In 2004, Chakraborty and colleagues monitored 
antigen-specific CTL following immunisation of melanoma patients with APC-loaded 
with peptide or autologous tumour lysates. They observed a peak in CTL response by day 
7 post-vaccine, followed by a return to pre-vaccine levels by day 28. The decline showed 
an inverted correlation to the expansion of CD4+/CD25+ Treg cells and increased level of 
IL-10-secretion Treg cells in post-vaccine peripheral blood lymphocytes (Chakraborty et 
al., 2004). Many studies have since demonstrated the therapeutic benefit of depleting or 
inhibiting Treg cells prior to vaccination can lead to enhanced and prolonged CTL-
mediated responses (Dannull et al., 2005; Quezada et al., 2008). The more recently 
identified Th17 are generated under the influence of TGF-β and IL-6 released from 
activated CD4+ T cells. Th17 cells are credited with the augmentation of anti-tumour 
effects through the secretion of IL-17 (Martin-Orozco et al., 2009) however some studies 
suggest that their inflammatory activities may stimulate Treg cells and promote 
tumourigenesis (Charles et al., 2009; Wu et al., 2009). 
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1.4  Cancer Immunotherapy 
 
Although forms of immunisation therapies against cancer have been attempted for well 
over a hundred years, it is only during the last fifty years that have seen the identification 
of antigens, TCRs and molecular modulators that are responsible for immune recognition 
of tumour cells. The emergence of new technologies, bring further insight into the inner 
workings of the immune system and how it could be harnessed to destroy tumours without 
targeting healthy self tissue. Immunotherapy can be broadly divided into three major 
categories; passive immunotherapy which utilise immune-effector molecules mostly 
through the administration of immunoglobulins active immunotherapy which attempt to 
activate immune responses directly within the patient, whereas the final approach, 
adoptive immunotherapy is built on ex vivo T cells which are stimulated prior to reinfusion 
back into the patient.   
 
1.4.1  Passive cancer immunotherapy 
 
One of the most effective therapeutic strategies to date can be found in the form of 
exogenously produced monoclonal antibodies (mAb) which are immunoglobulins 
designed to target TAAs and cell receptor molecules that are important for tumour growth. 
Treatment with mAbs attempts to mimic the existing mechanism of immunoglobulin 
mediated immune responses within the body. Immunoglobulins that have been generated 
to bind previously identified TAAs or other molecules expressed by tumour cells can 
trigger antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent 
cytotoxicity (CDC). In effect, this action allows tumours to become more visible to NK 
cells which secrete Th1 promoting cytokines such as IFNγ, helping to potentiate an 
adaptive immune response (Weiner, 2010). One of the most widely used mAb therapies is 
an anti-CD20 mAb (Rituximab) for B cell non-Hodgkin’s lymphoma (Scott, 1998; Dotan 
et al., 2010). Alternatively, mAbs may act as receptor blockade mechanisms which can be 
used to prevent access of growth factors or inhibit the transduction of signals. Perhaps the 
most well-known drug trastuzumab (Herceptin), specifically targets a tyrosinase kinase 
receptor molecule HER2 found to be over-expressed on the cell surface in certain breast 
carcinomas. The mAb inhibits the signalling cascade that normally activates following 
receptor interaction with HER and the tumour cells undergo apoptosis (Hudis et al., 2007). 
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In addition to targeting antigens involved in tumourigenesis, mAbs can be utilised against 
immunological targets that are critical to the anti-tumour response. For example, a mAb 
known as Ipilimumab acts as a CTLA-4 blockade mAb which potentiates T cell activation 
by preventing inhibitory receptor signalling (CTLA-4) from occurring allowing antigen-
specific activated CTL to destroy metastatic melanoma when used in combination with 
peptide vaccines (Hodi et al., 2010). The therapeutic success of Ipilimumab has drawn 
attention on other immunological targets such as PD-1 blockade (PD-L1/B7.1) which has 
demonstrated durable anti-tumour activity in colorectal cancer, castrate resistant prostate 
cancer and renal cell carcinoma (RCC) (Brahmer et al., 2010). Further mAb therapies 
have been developed to utilise mAbs as vehicles to deliver potent cytocidal payloads to the 
site of tumours. This has included engineering of Fc regions of mAbs using cytocidal 
agents such as toxin (Mylotarg) or radionuclide (Zevalin) or pro-drug conjugates which 
home to tumour cells and exert their effects (Ducry & Stump, 2010; Scott et al., 2012).  
 
1.4.2  Active cancer immunotherapy 
 
Whole cell vaccines: Whole cell vaccines consist of genetically modified autologous or 
allogeneic tumour cells that are irradiated before injection into the patient. These in vitro 
cell modifications can facilitate the cells to secrete immunostimulatory cytokines (GM-
CSF, IL-7 IFNγ and IL-2) and express co-stimulatory molecules (ODN, TLR ligands, 
OX40) in order to present antigen to T cells via APC (Parmiani et al., 2000; Ali et al., 
2000). The use of autologous material ensures that patients are vaccinated with antigen 
that are relevant to their tumour and the approach does not require elucidation of 
individual antigen. Alternatively the use of allogeneic tumour cells can bypass time 
consuming therapy with patient tumour cells. Moreover, cross priming of CD8+ T cells by 
APCs does not require HLA-matching between the tumour cell vaccine and the recipient 
(Nemunaitis et al., 2006). The results from clinical trials have proven to be only partially 
effective in generating clinically relevant responses. Clinical trials have reported complete 
or partial responses in only a small proportion of patients treated with autologous tumour 
cells expressing cytokines in melanoma and kidney cancer (Parmiani et al., 2000). More 
recent efforts to further stimulate immune responses of whole cell vaccines are begin 
pursued by combining other treatment modalities such as administering mAbs that target 
cognate antigen found on injected tumour cells and using immune blockade (CTLA-4) 
(Kim et al., 2008; Schoenfeld et al., 2010). Despite their limited successes to date, whole 
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cells vaccines have provided an important stepping stone towards antigen specific 
vaccines. 
 
Heat shock proteins: Heat shock proteins (HSPs) consist as part of a large family of 
ubiquitously expressed inducible proteins that are responsible for transportation of 
intracellular peptides to APCs. These molecular chaperons are also responsible for the 
induction of both cellular (CTL and antibody generated) and innate (activation of DC and 
NK cell activity) immune response via HSP receptors such as Lox-1, SR-A, TLR2 and 
TLR4 present on APCs (Srivastava, 2002; Tsan & Gao, 2009). Most HSP clinical trial 
vaccines followed the removal and purification of HSP-peptide complexes (HSP-PC) from 
the primary site of the tumour and were reinfused back into the patient. In a phase I trial 
conducted using autologous HSP96-PC derived from various malignancies, it was shown 
that 6/12 patients developed CTL and 8/13 patients showed increased NK cell populations 
after immunisation (Janetzki et al., 2000). Several clinical trials have been conducted 
using an autologous tumour gp96-PC preparation commercially known as Vitespen and 
have so far demonstrated safety and feasibility colorectal cancer, melanoma, non-
Hodgkin’s lymphoma, pancreatic adenocarcinoma and RCC (Randazzo et al., 2012). 
Approaches have been taken to enhance the potency of HSP-PC in therapeutic settings 
such as extracting HSP-PC from DCs fused to tumour cells which would contain more 
immunogenic antigens compared to with HSP-PC derived from tumour (Gong et al., 
2010). Studies to induce tumour killing using ex vivo preparations of IL-2 activated NK 
cells pulsed with an HSP70-derived peptide (TKD) demonstrated NK cell mediated 
cytolytic responses in a phase I trial of colon and lung cancer patients (Krause et al., 2004). 
Moreover, the 14mer TKD peptide was used to generate a mAb (cmHsp70.1) which was 
shown to recognise membrane bound HSP in human tumours and is capable of 
significantly inhibiting tumour growth in mice bearing CT26 tumours through ADCC, an 
effect that could be further enhanced with the addition of IL-2 (Stangl et al., 2011). The 
major advantage of this approach in cancer immunotherapy is that it relies primarily on 
NK cell activity and other macrophages to mediate tumour killing and therefore not 
restrained to targeting only MHC-positive tumour cells or face the challenges of 
overcoming tolerance to self-antigens. Although, increased NK cell activity and 
consequently their secretion of IFNγ may in turn promote CTL mediated tumour 
destruction and help skew CD4+ T cells to perpetuate Th1 responses (Cheng et al., 2013).  
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Peptide vaccines: The identification of many proteins that are associated with cancer has 
subsequently led to the identification of short epitopes that are presented and recognised 
by CTL in the context of MHC class I molecules. Peptide vaccines were formed on the 
basic principle that antigens specific to tumours could be made targets of the immune 
system. The discovery that some patients expressed T cells specific for CT and differential 
antigens in their tumours instigated the development of peptide vaccines. To date, 
hundreds of TAA peptide sequences have been reported 
(http://cancerimmunity.org/peptide/) leading to the design of peptide vaccines (Table 1.1). 
First generation peptide vaccines consisted of one or multiple HLA class I restricted 
peptide epitopes which were emulsified with Freund’s incomplete adjuvant or Montanide 
or transfected into DCs prior to vaccination. Later, findings that indicated towards the 
pivotal role of CD4+ T helper cells in the induction of CTL and memory responses lead to 
their inclusion alongside MHC class I epitopes (Toes et al., 1999; Overwijk et al., 1999). 
These earlier trials highlighted many issues need to be overcome in order to reap 
therapeutic benefits, not least the need to enhance the immunogenicity of peptides. The 
binding affinities of peptides to the cognate MHC molecules vary from one peptide to 
another leading to competition during peptide editing when loading onto MHC molecules 
during processing. One novel method of increasing the potential for MHC presentation is 
using TAA derived peptides linked to (LRMK) Ii-Key, which offers the associated peptide 
preferential binding to MHC class II molecules. Studies using HER2-derived peptide 
vaccine (Ii-Key/Her2/neu), reported that the linkage helped increase the potency 
immunological responses (Voutsas et al., 2007; Sotiriadou et al., 2007) and have 
demonstrated safety and high immunogenicity in two phase I trials on HER2+ breast and 
prostate cancer patients (Sears et al., 2011; Perez et al., 2010b). The combined use of IL-2 
and a gp100 derived peptide was recently shown to enhance anti-tumour response and 
prolong progression-free survival compared with IL-2 therapy alone in melanoma patients 
demonstrated the need to stimulate the immune system in order to generate more durable 
responses (Schwartzentruber et al., 2011). Some of the more recent promising agents to 
partner peptide vaccines include blockade of immune checkpoints using anti-CTLA-4 and 
anti-PD-1 Ab which are expected to improve tumour reactivity in T cells and enhance 
anti-tumour immunity (Pardoll, 2012). Programmed cell death 1 (PD-1) is an inhibitory 
surface membrane molecule expressed on T and B cells, its ligand is expressed in some 
peripheral tissues and in tumours and has been assessed in cancer patients with PD-1+ 
tumours demonstrating objective responses in 9/25 (36%) cases (Topalian et al., 2012).  
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There are several advantages of synthetic peptide vaccines have over other 
immunotherapy approaches. In addition to their ease of manufacture and modification, 
stability, and safety demonstrated for clinical use they have the benefit of personalising 
vaccines to individual patients based on their tumour antigen fingerprint in feasible time 
and financial scale. Although, short peptide vaccines have the limitation of potentially 
binding to non-professional APCs (e.g. fibroblasts) on administration and thus inducing 
tolerance to the antigen. Moreover, prior knowledge of immunogenic epitopes that have 
been assessed for HLA-compatibility before use reduces the number of patients that can be 
treated with the same peptide. Finally successful elimination of tumours bearing cognate 
antigens may give raise to tumours capable of immune evasion due to their lack of antigen 
expression. Therefore current peptide vaccines have shifted to multi-epitope (HLA class I 
and class II) and multi-valent approaches. Longer peptide sequences (ranging from 12 – 
50 amino acids in length) circumvent many of the issues raised above. Long peptides are 
also more likely to contain multiple HLA class I and HLA class II epitopes, which 
increases their application to all patients irrespective of HLA type. A number of recent 
studies in clinical trials have demonstrated their ability to induce cytokine responses 
attributed to the activation of immune responses (Speetjens et al., 2009; Welters et al., 
2008; Leffers et al., 2009; Bijker et al., 2008). Peptide cocktail vaccines administered to 
induce responses using multiple antigen targets can help combat the generation of antigen-
loss variant tumours. Two phase II clinical studies consisting of multiple TAA (IMA901) 
plus pre-treatment with cyclophosphamide to reduced Treg cell populations have 
demonstrated immune responses and longer overall survival in HLA.A2+ renal cell cancer 
(Walter et al., 2012) and colorectal cell cancer patients (Walter, PIVAC conference 2011) 
with further phase III studies currently underway (Walter et al., 2012).   
   
Dendritic cell vaccines: As reiterated throughout, the actions of DCs are essential in 
determining the fate of the immune response to cancer. Therefore it is unsurprising that 
DCs are the topic of extensive investigation for immunotherapeutic intervention due to 
their unique function in orchestrating both innate and adaptive immune responses. This 
approach has also lead to the first active cancer immunotherapy meeting FDA approval in 
2010 for the vaccine Provenge (Sipuleucel-T) for use in castration resistant prostate cancer 
(Kantoff et al., 2010a). Sipuleucel-T consists of ex vivo generated DCs cultured with a 
recombinant fusion protein composed of TAA prostatic acid phosphatase (PAP) linked to 
GM-CSF with results demonstrating a four month-prolonged median survival in phase III 
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trials (Higano et al., 2009; Kantoff et al., 2010b). The using of ex vivo generated DCs hold 
some key advantages in that they are capable of priming both CD4+ and CD8+ T cells. 
Studies have demonstrated that anti-tumour responses can be improved by targeting 
specific sub populations of DCs that favour the induction of Th1 cell mediated immune 
responses (Bonifaz et al., 2004). DCs that express CD205(Ly-75) on their cell surface 
present antigens to both MHC class I and class II molecules whereas, DCs that are positive 
for 33D1 antigens present only on MHC class II (Dudziak et al., 2007). Several DC 
vaccine trials have been conducted using ex vivo cultured DCs and loaded with GM-CSF 
and/or IL-4 and tumour specific targets including HLA-restricted peptides in metastatic 
prostate cancer and melanoma (Murphy et al., 1999; Thurner et al., 1999), tumour eluted 
peptides or lysates in melanoma, RCC, and glioma (Nestle et al., 1998; Hӧltl et al., 1999; 
Yu et al., 2001), autologous or allogeneic RNA in colon and prostate cancer (Nair et al., 
2002; Mu et al., 2005) and using DC co-stimulation molecules such as NKT cell ligand α-
Galactoslceramide (αGalCer) in advanced cancers (Chang et al., 2005). Taken together, 
these studies all demonstrated that DC-based vaccines are safe, are capable of inducing 
antigen-specific T cell expansion with clinically significant responses in some patients. 
These studies also highlighted that clinical responses are gradual however patients can 
undergo long lasting remission.  
 
DNA vaccines: DNA constructs consist of DNA coding sequences derived from a TAA 
inserted into a bacterial plasmid which can be delivered to patients via liposomes, nano-
particles, bacteria and viruses. An advantage of using such an approach is that CTL’s the 
presentation of antigens to APCs may be generated against multiple epitopes of both MHC 
classes and can be designed to encode co-stimulatory molecules, cytokines, CpG 
oligonucleotide sequences to enhance the immunological effectiveness of targeted APCs. 
One vaccine strategy uses a DNA vector encoding an antibody and T cell epitopes (termed 
ImmunoBody) can directly present or cross present epitopes via the high affinity Fcγ 
(CD64) receptor in APCs that can consequently activate high avidity T cells capable of  
recognising and destroying tumours (Pudney et al., 2010). A phase I/II using a DNA 
vaccine (SCIB1) using the ImmunoBody approach is currently underway in patients with 
melanoma (ClinicalTrial.gov Identifier: NCT01138410/completion 2017). DNA vaccines 
are administered through a number of routes including intramuscular, intranasal, 
intramucosal or intradermally by coating DNA constructs onto gold micro-particles and 
administering them using gene gun immunisation (Stoitzner et al., 2006). The constructs 
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are taken up by surrounding cells or residing langerhans cells which allow APCs to cross 
present and initiation of the immune response. Previous studies using animal models have 
demonstrated that the mode of administration seem to be a determining factor in the type 
of response generated. For example, intramuscular immunisation predominantly favours a 
Th1 response whereas gene gun assisted delivery favours a Th2 response (Weiss et al., 
2002). A recent study has challenged this notion suggesting that gene gun immunisations 
can polarise T cell to Th1 responses demonstrated the induction of antigen-specific CTL 
capable of in vivo and in vitro tumour cell killing (Nguyen-Hoai et al., 2012). To date, 
studies conducted in numerous phase I clinical setting confirm DNA vaccines and their 
various routes of administration mentioned above to be safe and capable of eliciting 
clinically relevant antigen-specific immune responses (Senovilla et al., 2013).  
 
Viral vector vaccines: Vectors encoding TAAs attempt to exploit the potent immune 
responses directed towards viral components to potentiate immune reactivity against the 
TAA. Retrovirus, poxvirus, adenovirus and HPV have all been investigated in pre-clinical 
models with human trials currently underway. In a recent phase II trial, 125 castrate-
resistant prostate cancer patients receiving PSA-targeted poxviral vaccine (PROSTVAC-
VF) which included co-stimulatory molecules (B7.1, ICAM-1 and LFA-3) demonstrated 
an overall survival benefit of 25.1 months over the control cohort (16.6 months) 
immunised with empty vector (Kantoff et al., 2010b). Many recombinant bacterial 
vaccines derived from strains of Salmonella choleraesuis, Bacillus Calmette-Guerin (BCG) 
and Listeria monocytogenes are currently under evaluation for their potential use in 
immunotherapy (Avogadri et al., 2005; Yuk et al., 2010; Wood et al., 2009).  
 
1.4.3  Adoptive cancer immunotherapy 
 
In contrast to active immunotherapy, adoptive therapies achieve tumour reactive T 
lymphocyte ex vivo through the activation and expansion of autologous tumour specific T 
cell populations which are then transferred back into the patient. The principle behind 
adoptive T cell therapy (ACT) is on the observation that certain lymphocytes migrate to 
tumour sites and may promote some form of anti-tumour response. This cells referred to as 
tumour infiltrating lymphocytes (TILs) are extraction from tumour lesions and clonally 
expanded in vitro under the influence of a cocktail of cytokine modulators including IL-2. 
Prior to ACT therapy, patients may undergo pre-conditional lymphodepletion using non-
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myeloablative chemotherapy, total body irradiation (TBI) and cytokine therapy to remove 
the patients host immune system. Although this may seem counter-intuitive, studies have 
demonstrated that the depletion of immune cells prior to transfer of reactive TILs augment 
anti-tumour efficacy (Rosenberg et al., 2011). This may be a consequence of the 
elimination of immunosuppressive immune components such as Treg cells and MDSCs 
(using cyclophosphamide and fludarabine), the depletion of endogenous immune cells that 
compete for activating cytokines and the increased activation and availability of APCs 
(Gattinoni et al., 2006). ACT therapy has been used in several clinical trials conducted by 
Rosenberg and colleagues in the treatment of late-stage melanoma where it has 
demonstrated impressive results in achieving significant regression of tumour lesions 
(Dudley et al., 2005; Rosenberg et al., 2008). This approach does highlight the over-
represented role of regulatory cells and other negative immune modulators (TGF-β) that 
exist in tumours. Indeed, selective depletion of Treg cells through CTLA-4 and PD-1 
blockade or TGF-β prior to ACT therapy many enhance tumour regression (Phan et al., 
2003). In mice, T cells pulsed with a NKT cell ligand known as α-Galactoslceramide 
(αGalCer) prior to infusion potential enhanced anti-tumour responses through the 
maturation DCs and activation of NK, T and B cells (Choi et al., 2011). Further 
investigation of the differentiation features of effector T cells concluded that the later 
effector T cells differentiate in long term culture, the less effective they were in generating 
in vivo responses. This challenged the clonal expansion principle that the methodology 
using long term culture relied upon (Gattinoni et al., 2005). Recently, the same group 
identified a stem cell-like memory T cell population which have phenotypic characteristics 
similar to that of naive T cells, however also expressed (CD95, IL-2Rβ, CXCR3 and LFA-
1) and compared to naive T cells, they had increased proliferative capacity and elicited 
stronger anti-tumour responses in animal models (Gattinoni et al., 2011). New findings 
such as these which appear to single out T cell subset populations could significantly 
improve the efficacy of ACT therapy in the future. A limitation of this strategy is often 
deriving large populations of reactive T cells specific to each individual is problematic.  
 
ACT therapy has been further refined to activate autologous T cells that recognise 
identified TAAs such as gp100 and MART-1 which are prevalent in melanoma (Powell et 
al., 2006; Duval et al., 2006). Genes that encode for α/β TCR’s isolated from T 
lymphocytes that demonstrate high avidity for a selected TAA can be delivered to 
lymphocytes using viral vectors in order to generate a whole population of T cells with the 
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same high avidity specificity for a particular antigen. Despite initially achieving successful 
regression of metastatic melanoma, there have been reports of adverse toxicity in which 
patients experienced including severe transient colitis and evidence of autoimmunity 
against normal tissues expressing rare cognate antigen (Parkhurst et al., 2011; Johnson et 
al., 2009). This autoimmune response may be attributed to a TCR cross-pairing 
phenomenon occurring, in which an endogenous α/β TCR may recombine with the 
respective α/β chains of a transgenic TCR forming a third hybrid TCR. The new hybrid 
TCR may in turn lose specificity for the antigen of interest in favour for another, self-
antigen expressed on normal cells (Brenner, 2010). As described earlier, tumour may 
evade immune recognition by down regulating their expression of MHC class I molecules 
which renders the application of engineered α/β TCRs redundant in some cases.  
 
One approach that may help target MHC-negative tumours is using engineered T cells to 
express chimeric antigen receptors (CARs) designed to induce high avidity antigen-
specific immune responses against surface antigens found on tumour cells, bypassing the 
need of MHC-peptide presentation (Bridgeman et al., 2010). The CARs are constructed as 
a hybrid between a TCR and an immunoglobulin in that the light and heavy chain of 
variable region of Ig’s, or single chain Fc (scFv), with a flexible hinge or spacer, 
transmembrane domain and endodomain (for intracellular signalling) upon scFv 
recognition of antigen. The current generation of CARs also include one or more T cell 
co-stimulatory molecules in the endodomain to circumvent T cell activation through APC 
interaction (Jena et al., 2010).  
 
Studies that combine immunotherapies with conventional modalities such as 
chemotherapy suggest valuable synergistic effects that could be utilised to circumvent 
tumour immune evasion and tolerance issues (Andersen et al., 2008). The future of cancer 
treatment may indeed lie in the use of multiple approaches such as debulking tumour 
masses (chemotherapy, radiotherapy, surgery), in combination with immunotherapeutic 
treatments that enhance tumour specific T cell responses (peptide vaccines plus agonistic 
mAbs cytokines, TLR ligand adjuvants) whilst counteracting immunosupressive 
components (depletion of Treg cells and MDSCs and immune blockade of CTLA-4/PD-1).   
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1.5  T21: A Potential Tumour Associated Antigen and Target for Cancer 
 
 1.5.1  Serological identification of T21 
 
To date, among the multitude of identified and characterised human tumour-associated 
antigens, research continues towards determining the most effective candidate antigens to 
incorporate into antigen-specific immunotherapeutic vaccines. Several tumour associated 
antigens identified by T cell responses such as Her2/neu and MAGE-1 have demonstrated 
that CD4+ and CD8+ T cells and B cells form an integrate immune response against tumour, 
having also been defined using serological analysis of cDNA expression (SEREX) (Sahin 
et al., 1997). Since the specificity of B cell responses are regulated by negative selection in 
the bone marrow, the induction of high-titre antibody responses require cognate CD4+ T 
cell help indicating towards the capability of both the adaptive and humoral systems to 
elicit an orchestrated response against tumours. SEREX technology was first devised in 
1995 (Sahin et al., 1995), and combines serological analysis with antigen expression and 
cloning approaches to identify, in this instance, human tumour antigens which elicit 
antibody responses in cancer patients. This method involves extraction of mRNA from 
tumour derived tissue which is then expressed in λ-phage display vectors to create cDNA 
expression libraries, these libraries are screened with patient sera, the positive colonies are 
isolated and cloned and sequenced and are finally put forward for DNA databank search.  
 
By applying this principle in a modified SEREX approach, cDNA expression libraries 
were constructed from normal human testicular mRNA and were used to screen pooled 
allogeneic sera from prostate cancer patients in order to identify novel tumour associated 
antigens (Figure 1.7). Following this, positive clones underwent databank searches, 
analysis of gene anomalies, and assessment of mRNA expression in normal and malignant 
tissue. A panel of serologically defined antigens expressed human prostate cancer cells 
were identified, included T21 and the findings published in 2007 (Miles et al., 2007). 
Further examination of T21 serological reactivity using recombinantly expressed protein 
showed T21 reactivity with sera from 5/10 prostate patients whereas no reactivity was 
observed in 10 healthy individuals with benign prostatic hyperplasia (BPH). RT-PCR using 
cDNA reverse transcribed from whole tissues also supported the notion of a potentially 
good immunotherapeutic target with expression restricted to normal testis, kidney, gastric 
and prostate cancer, mild expression in BPH and little or no mRNA expression observed in 
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normal essential tissues examined. Later, T21 was found to share significant sequence 
similarity with a centrosomal protein called CEP290 to which the presence of CEP290 
antibodies has been previous reported in a number of malignancies (Eichmuller et al., 2001; 
Chen & Shou, 2001).  
 
 
 
 
 
 
 
 
 
Figure 1.7 – Modified SEREX approach used to identify T21. A normal testicular cDNA 
library was screened with allogeneic sera from prostate cancer patient, from which positive 
clones were isolated and analysed.   
 
 
1.5.2  Proposed study rationale 
 
The identification of T21 and initial molecular characterisation has warranted further study 
to determine if it has the potential to be a tumour biomarker and/or be utilised as a target 
antigen for immunotherapy. This project proposed to achieve this within the scope of 
prostate cancer by advancing the current understanding of T21 through analysis of gene 
sequence similarities observed with CEP290 and begin to extrapolate possible functional 
attributes of T21 and the role it may play in cancer. In order to validate the use of T21 as a 
target for immunotherapy, this study aims to complete a comprehensive mRNA and 
protein expression profile on various human prostate cancer cell lines (and other 
malignancies) and normal tissues. Evaluation of T21 as a potential prognostic indicator of 
prostate cancer using and both prostate cancer and benign tumours will be sought. Finally, 
this study aimed to evaluate the immunological potential of T21 derived overlapping 
15mer peptides to generate immune responses in a pre-clinical transgenic mouse model as 
a pre-requisite for the development of a T21 directed cancer vaccine. In addition, 
positively identified peptides will be taken forward to assess their utility for 
immunotherapy and immunomonitoring using human prostate cancer patient PBMCs.  
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CHAPTER 2 
 
MATERIALS AND METHODS 
 
2.1 Materials 
 
2.1.1 Reagents and a list of suppliers 
 
All chemicals and reagents were stored as according to manufacturer’s instructions and 
used within the expiry date. 
 
 Culture media Supplier 
 C.T.L-Test media Cellular Technology Ltd 
 KSFM, Opti-MEM media (w/o phenol) Invitrogen 
 DMEM, HAMS-F12, McCoy’s, RPMI media Lonza  
 
 Culture media supplements Supplier 
 2-mercaptoethanol (2-ME) Sigma  
 Blasticidin Invitrogen  
 Fetal calf serum (FCS) Perbio Thermo Fisher 
 Fungizone Lonza 
 HEPES buffer Lonza 
 Human AB serum Sigma 
 L-glutamine, Pyruvate Lonza 
 Non-essential amino acids (NEAAs) Lonza 
 Penicillin/Streptomycin (PenStrep) Lonza 
  
 Additional culture reagents Supplier 
 Acetic Acid Fisher Scientific 
 Dimehyl Sulphoxide Hybri-Max (DMSO) Sigma  
 IL-2, GM-CSF (murine) R&D Systems 
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 Incomplete Freund’s Adjuvant (IFA) Sigma 
 INTERFERin transfection reagent Polyplus Transfection 
 Lipofectamine-2000 Invitrogen 
 Lipopolysaccharide (LPS) Sigma 
 Phosphate buffer saline (dPBS)  Lonza  
 Polyinosinic Polycytideylic acid (Poly I.C) Sigma 
 Staphylococcal exterotoxin B (SEB) Sigma 
 Trypan blue Sigma 
 Trypsin/Versene Lonza 
 Vitamin E Calbiochem 
 
 Chemical reagents Supplier 
 2-methylbutane (Isopentane) and Acetone Acros Organics  
 Acetonitrile  Sigma 
 Acrylamide (30%) National Diagnostics 
 Agarose Bioline 
 Ammonium sulphate  National Diagnostics 
 Boric acid and Calcium chloride (CaCl2) Sigma 
 Bovine Serum Albumin (BSA) Calbiochem 
 Chloroform Sigma 
 Coomassie Brilliant Blue PhiBio Systems 
 Decon 90 Decon Laboratory Ltd  
 Dextran Sulphate Sigma 
 Dithiothreitol (DTT) Apollo Scientific 
 dNTPs Promega  
 DNA ladders (1kb and 100bp) Promega 
 Dried marvel skimmed milk Premier Brands  
 Dry Anhydrous Ethanol Sigma  
 Ethanol BDH Merck 
 Ethylenediaminetetraacetic acid (EDTA) Sigma 
 GelRed Nucleic Acid Gel Stain Biotium 
 Glycerol Sigma 
 Gold microcarriers (1.0µm) Bio-Rad 
 Hydrochloric acid (HCl) Fisher Scientific 
 Isopropanol Fisher 
 iQ SYBR Green SuperMix Bio-Rad  
 Magnesium chloride (MgCl2) Promega  
 Microscint-O Scintillation media Perkin Elmer 
 M-MLV RT and 5X Reaction Buffer Promega 
 Nuclease-Free water  Ambion 
 Octyl β-D-glucopyranoside (OGP) Apollo Scientific  
 Oligo(dT)15 Primer Promega  
 Orange G powder Sigma 
 Paraformaldehyde Sigma 
 Polyinosinic-polycytidylic acid (Poly-IC) Sigma 
 Polyvinylpolypyrolidone (PVP) Sigma 
 Presept Johnson and Johnson 
 RapidStep ECL Reagent Calbiochem  
 RNasin Ribonuclease Inhibitor Promega 
 RNA STAT-60 AMS Biotechnology 
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 Spermidine Sigma 
 Sodium dodecyl sulphate (SDS) Sigma 
 Sodium chloride (NaCl) Fisher Scientific 
 Sulphuric Acid Fisher Scientific 
 TEMED National Diagnostics 
 Tepol Johnson and Johnson  
 [6-3H]-Thymidine (3Thy), 1 mCi (37 Mbq) Amersham  
 Tris and Tris HCl Fisher Scientific 
 Trifluroacetic acid (TFA) Fisher Scientific 
 Tris glycine transfer and SDS running solutions National Diagnostics 
 Trizma base and Tween-20 Sigma 
 Trypsin gold MS grade Promega 
 Ultima Gold Packard Instrument Co. 
 Urea Sigma 
 VectorShield with DAPI VectorLabs 
 Xylene Acros Organics 
   
2.1.2 Equipment and a list of suppliers 
 
 Equipment Supplier 
 4°C Refrigerators   Lec  
 4°C Refrigerated centrifuges  Eppendorf/Sanyo 
 -20°C Freezers Lec 
 -80°C Freezers Revco/Sanyo 
 96-well plate reader  Tecan 
 Autoclave  Rodwell 
 Autostainer XL Leica 
 Bench top vortex mixers Scientific Industries 
 Cell Harvester, Filtermate Harvester Packard 
 Centrifuges (MSE Mistral 2000R) Sanyo 
 Class II safety cabinets, Microflow biological 
 safety cabinet Walker 
 Cryostore, Cryo 200 Forma Scientific 
 Drying cabinet  SLS 
 Electrophoresis gel tanks and apparatus Bio-Rad/Geneflow  
 EliSpot Reader, Immunospot analyzer Cellular Technology Ltd 
 Fluorescence microscope Olympus BX51 
 Fujifilm intelligent dark box Fujifilm Life Sciences Products 
 Gallios Flow Cytometer  Beckman Coulter 
 Gamma counter – Topcount scintillation  
 counter Packard 
 Gel documentation system InGenius Syngene  
 Haemocytometers Weber 
 Hairdryer Fransen 
 Helios Gene-Gun System Bio-Rad 
 Helium gas and cylinder  BOC 
 Incubators CO2 water jacked incubators Forma Scientific/Galaxy 
 Light microscope Nikon/Olympus 
 Light microscope camera Nikon 
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 Liquid Nitrogen and canister British Oxygen Company 
 MACSMix Tube Rotator Miltenyi Biotech 
 Microcentrifuge, Microcentraur MSE 
 Microwave Matsui  
 MoFlo XDP High-Speed Cell Sorter  Beckman Coulter 
 Nanodrop 8000 Spectrophotometer Thermo Scientific 
 Nitrogen gas and cylinder BOC 
 Orbital plate shaker VWR  
 PCR workstation cabinet Grant Instruments 
 pH meters Metler Toledo 
 Pipettes and multichannel pipettes Gilson, Star labs, Eppendorf 
 Pipette guns SLS, Eppendorf, Star labs 
 Plate rocker VWR 
 Powerpacks Bio-Rad  
 Real Time qPCR Thermal Cycler Qiagen 
 Tecan ULTRA Tecan Group Ltd. 
 Thermo cycler TC-5000 Techne 
 Transfer apparatus, (wet transfer) Bio-Rad 
 Transfer apparatus, Trans-blot cell (semi-dry) Bio-Rad  
 Tube prep station Bio-Rad  
 Ultra sonicator  VWR 
 Ultrapure water dispenser  Barnstead 
 Ultraflextreme MALDI-TOFTOF MS  Bruker Daltonics 
 UNO-Thermoblock Biometra 
 UV transilluminator Ultra Violet Products 
 Water baths Grant Instruments 
 Weighing scale Fisherbrand 
 Whirlmixers Scientific Industries 
    
2.1.3 Consumables and a list of suppliers 
 
 Disposable equipment and plastic-ware Supplier 
 0.2 µm filters Sartorius  
 8-well chamber culture slide BD 
 10 ml syringes  Becton Dickenson  
 24-well plate round coverslips SLS  
 25 cm2, 75 cm2, 175 cm2 tissue culture flasks Sarstedt  
 90 mm petri dishes Phillip Harris Scientific 
 96-well plate covers Star Labs 
 96-well plate harvester filters Perkin Elmer  
 96 Uni/Filter scintillin-coated plates Perkin Elmer  
 96-well ELISA plates NUNC  
 Bijou tubes (5 ml) Sterilin 
 Blotting paper SLS  
 Cell scrapers 12 mm blade TTP  
 Coverslips Fisher 
 Cryovials TTP 
 Dry ice pellets BOC 
 EliSpot plate 96-well, multiscreen HA filter Millipore  
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 Eppendorf tubes (0.5 ml, 1.5 ml) Sarstedt 
 Filter tips (10 µl, 100 µl, 200 µl, 1000 µl) Sarstedt 
 Flat bottom culture dishes (6-, 12-, 24-, 96-well) Sarstedt 
 Flow cytometry tubes  Tyco Healthcare Group 
 Gel cutting tips Alpha Laboratories 
 Microscope glass slides SLS/Menzel-Glaser 
 Needles and syringes (0.5 ml, 1 ml) Becton Dickinson 
 Nitrocellulose membrane Amersham  
Nylon Membranes, positively charged Roache 
 Pasteur pipettes Sarstedt 
 PCR tubes Qiagen/Micronic Systems 
 Polypropylene screw top tubes (15 ml, 50 ml) Sarstedt 
 Round bottom culture dishes (96-well) Sarstedt 
 Scalpels Swan Morton 
 Serological pipettes (2 ml, 5 ml, 10 ml, 25 ml) Sarstedt 
 Sequenza slide racks and coverslips Thermo Fisher 
 Sterile hypodermic needles 25 G Becton Dickinson 
 Syringes (5 ml) Stem Cell Technology 
 Pipette tips (20 µl, 200 µl, 1000 µl) Sarstedt 
 Tefzel tubing Bio-Rad 
 Universal tubes (25 ml) Sterilin 
 Weigh boats  SLS 
 Whatman 3 MM filter paper  Whatman 
 ZipTipC18 pipette tips Millipore 
 
2.1.4 Cell lines and media compositions 
   
Cell culture media was prepared and used within the expiry date and maintained at 4°C 
when not in use. Complete BM-DC media was prepared fresh immediately prior to use. 
All serum was heat inactivated at 56°C for 30 minutes prior to use.  
 
 T cell media BM-DC media  
 RPMI RPMI 
 10% (v/v) FCS 5% (v/v) FCS 
 2 mM L-glutamine 2 mM L-glutamine 
 20 mM HEPES buffer 20 mM HEPES buffer 
 50 µM 2-ME 50 µM 2-ME 
 50 U/ml Penicillin/Steptomycin 50 U/ml Penicillin/Steptomycin 
 0.25 µg/ml Fungizone 0.25 µg/ml Fungizone 
  
Complete BM-DC media  Complete PBMC media 
BM-DC media + 1 ng/ml mGM-CSF  RPMI  
 5% (v/v) AB serum 
 2 mM L-glutamine 
Complete C.T.L media     
C.T.L media + 2 mM L-glutamine  
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Human prostate derived cell lines: All grow as a monolayer 
Human breast derived cell lines: All grow as a monolayer 
 
 Table 2.1 - Cell lines used for in vitro studies, descriptions and propagation conditions 
 
 
 
 
 
Cell Line / 
Source 
Tumour origin and 
cell line features 
Tumour-
igenicity 
Androgen 
receptor 
Prostate 
Specific 
Antigen 
(PSA) 
Prostatic 
acid phos-
phatase 
(PAP) 
Culture media 
DU145 / 
ATCC  
Prostate carcinoma 
derived from brain 
moderate + (low) no no 
DMEM + 10% 
FCS, 1% pyruvate 
LNCaP / 
ATCC 
Androgen 
dependent prostate 
carcinoma derived 
from lymph node 
low + yes yes 
RPMI 1640 + 10% 
FCS + 1% L-
glutamine 
PC3 / 
ATCC 
Prostate 
adenocarcinoma 
derived from bone 
high + (low) no no 
HAM-F-12K + 
10% FCS 
OPCT-1 / 
Onyvax 
Derived from 
prostate tumour 
epithelium 
moderate
/low 
- + (low) - KSFM + 2% FCS 
PNT1a / 
ECACC 
Benign prostatic 
epithelial 
non - - - 
RPMI 1640 + 10% 
FCS + 1% L-
glutamine 
PNT2 / 
ECACC 
Benign prostatic 
epithelial 
non - - - 
RPMI 1640 + 10% 
FCS + 1% L-
glutamine 
Cell Line / Source 
Tumour origin 
and cell line 
features 
Estrogen/ 
Progesterone 
receptor 
Luminal / 
Basal Type 
Her2 over-
expression 
Culture media 
T47D / ATCC 
Breast invasive 
ductal 
carcinoma 
+/+ Luminal A - 
RPMI1640 + 
10% FCS + 1% 
L-glutamine 
MCF7 / ATCC 
Breast invasive 
ductal 
carcinoma 
+/+ Luminal A - 
DMEM + 10% 
FCS  
MDA468 / ATCC 
Breast 
adenocarcinoma 
-/- Basal B - 
RPMI1640 + 
10% FCS + 1% 
L-glutamine 
MDA231 / Dr de 
Gremoux, Institut 
Paris, (gift) 
Breast 
adenocarcinoma 
-/- Basal B + 
RPMI1640 + 
10% FCS + 1% 
L-glutamine 
SkBr3 / Sheffield 
Medical School (gift) 
Breast 
adenocarcinoma 
-/- - 
Her2/c-
erb-2 
McCoys + 10% 
FCS  
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2.1.5 Antibodies and kits 
 
All antibodies and kits were prepared and stored in accordance to manufacturer’s 
instructions and used within the expiry date. Optimum antibody dilutions and assay 
conditions were determined for ELISA, Immunofluorescence (IF), Western blotting (WB), 
Immunohistochemistry (IHC) and Northern blotting (NB). 
 
 Custom Primary Antibodies Dilution/application Supplier  
 Anti T21/CEP290 pAb (Rb) (3 mg/ml) 1:300 (IF) Pacific Immunology 
 Seq: (VELERQLRKENEKQKNEL) 1:500 (WB) 
     
 Anti T21u pAb (Rb) (0.4 mg/ml) 1:50 (IF) Pacific Immunology 
 Seq: (ADIELEHHRSQAEQ) 1:50 (IHC)  
  1:100 (WB) 
  1:1000 (ELISA) 
 
 
 Primary Antibodies Dilution/application Supplier   
 Anti CEP290 pAb (Gt) 1:100 (IF) Everest Biotech 
 Seq: (RNSKHLKQQQYRAEN) 1:200 (WB) 
 
 Anti Pericentrin (Mu) 1:100 (IF) Abcam 
 Anti Ki67 (Mu) 1:50 (IF) Serotec 
 IgG Rabbit Isotype control As applicable Serotec 
 IgG Mouse Isotype control As applicable Invitrogen 
 Anti b-actin (Rb) 1:1000 (WB) Cell Signalling 
 Precision Plus Protein Ladder  5 µl (WB) Bio-Rad 
 RiboReady™ Color RNA Ladder 5 or 6 µl (NB)  Amresco 
 
 
 Secondary Antibodies Dilution/application Supplier 
 Alexafluor 488 – goat anti-rabbit IgG 1:1500 (IF)  Invitrogen 
 Alexafluor 488 – chick anti-rabbit IgG 1:1200 (IF)  Invitrogen  
 Alexafluor 488 – goat anti-mouse IgG 1:1500 (IF)  Invitrogen  
 Alexafluor 568 – goat anti-rabbit IgG 1:1000 (IF)  Invitrogen 
 Alexafluor 568 – goat anti-mouse IgG 1:1000 (IF)  Invitrogen 
 Anti-rabbit IgG HRP – conjugate 1:1000 (WB)  Cell Signalling 
 Anti-mouse IgG HRP – conjugate 1:1000 (WB)  Cell Signalling 
 Precision StrepTactin HRP – conjugate 1:5000 (WB)  Bio-Rad 
 Biotinylated – rabbit anti-goat 1:1000 (WB)  Dako 
 Biotinylated – goat anti-rabbit  1:500 (ELISA)  Dako 
 
 
 Kits   Supplier 
 Bio-Rad protein assay   Bio-Rad 
 Chemiluminescent nucleic acid detection module    Thermo Scientific 
 Click-iT EdU Alexafluor 647 Flow cytometry kit   Invitrogen 
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 Colour blue developing reagent kit   R and D Systems 
 ELISA Substrate Reagent Pack & ELISA Streptavidin-HRP R and D Systems 
GeneRacer® Kit with SuperScript® III RT and TOPO   Invitrogen 
 GoTaq   Promega 
Human Total RNA Master Panel II    Clontech 
Immunoprecipitation Kit - Dynabeads® Protein G  Invitrogen 
LIVE/DEAD Cell Stain Kit, 405 nm excitation   Invitrogen  
hIFNγ and mIFNγ EliSpot development modules   R and D Systems 
 Novolink Polymer Detection System   Leica 
 Pierce 3’ end biotinylation kit   Thermo Scientific 
Phusion High-Fidelity DNA Polymerase    NEB 
 QIAquick PCR purification kit & RNAeasy Mini Prep kit Qiagen 
 Wizard SV gel & PCR clean up system   Promega 
   
 
 Oligonucleotides and plasmids and peptides   Supplier 
 DNA oligonucleotide primers for PCR   Eurofins 
 siRNA oligonucleotides   Eurogentec  
 RNA molecular probes   Sigma 
 T21 shRNA and negative control shRNA plasmids  Origene Technologies 
 Recombinant T21 protein    GTP Technology 
 Overlapping long peptide library    ProImmune 
  
 
2.1.6 Buffers and solutions 
 
All buffers and solutions were prepared in sterile duran glass bottles or glass vials and 
maintained at recommended temperature when not in use with some solutions prepared 
fresh immediately prior to use. 
 
 Cell counting solutions: 
 
 Trypan blue solution: White cell counting solution: 
 0.1% (v/v) trypan blue solution in dPBS 0.6% (v/v) acetic acid in dPBS 
  
 Buffers used for DNA or protein analysis and Polymerase Chain Reaction (PCR): 
 
 50X TAE: 1% agarose gel electrophoresis:  
 242 g Tris 1 g agarose powder 
 57.1 ml glacial acetic acid 100 ml 1X TAE 
 100 ml 0.5 M EDTA (pH 8.0) 8 µl GelRed 
 Completed to 1 L ddH2O 
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 Orange G DNA loading buffer: Cell lysis buffer: 
 0.25% (w/v) orange G powder 9.5% (w/v) urea 
 30% (v/v) glycerol 2% (w/v) DTT 
 Complete to final volume with ddH2O 1% (w/v) OGP 
  Complete to final volume with ddH2O 
 
 Protein assay working dye reagent: Sample reducing buffer: 
 1 parts Dye reagent concentrate 0.5 M tris-HCl, pH 6.8 
 4 part ddH2O 2% (w/v) SDS 
  10% (w/v) DTT 
  Complete to final volume with ddH2O 
 
 Tris buffer saline (TBS): TBS-Tween-20 (Marvel):  
 50 mM tris 0.05% Tween-20 
 150 mM NaCl 5% (w/v) marvel milk 
 pH adjusted to 7.5 with HCl Complete to final volume with TBS 
 Completed to 1L dH2O  
  
 Resolving gel: Stacking gel:  
 30% acrylamide 30% acrylamide 
 1.5 M tris-HCl (pH 8.8) 0.5 M tris-HCl (pH 6.8) 
 dH2O dH2O 
 10% (w/v) SDS 10% (w/v) SDS 
 10% (w/v) APS 10% (w/v) APS 
 TEMED  TEMED  
 
 Running buffer: Transfer buffer:  
 0.25 M trizma base 48 M tris 
 2 M glycine 39 mM glycine 
 1% (w/v) SDS 20% (v/v) methanol 
 Complete to 1 L with dH2O  Complete to 1 L with dH2O 
 
 De-staining solution:  
 10% (v/v) acetic acid   
 30% (v/v) methanol 
 Complete to 1 L with dH2O   
 
 Buffers and solutions for Northern blotting:  
 
 5X TBE buffer: Resolving gel:  
 0.44 M tris base 30% acrylamide  
 0.44 M boric acid 5X TBE buffer 
 10m M EDTA dH2O  
 Complete to 1 L with DEPC treated dH2O 10% (w/v) APS 
  TEMED 
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 Buffers and solutions for immunohistochemistry and for immunofluorescence:  
 
 Novolink Polymer Detection System: 
 
 Citrate solution: TBS: 
 10 mM citric acid (anhydrous) 50 mM tris  
 0.05% (v/v) Tween-20 150 mM NaCl  
 pH adjusted to 6.0 with NaOH pH adjusted to 7.5 with HCl  
 Complete to 1 L with dH2O Completed to 1 L with dH2O   
  
 Fixing solution: PBST wash buffer: 
 4% (w/v) paraformaldehyde  0.1% (v/v) Tween-20 
 Dissolved in 1X dPBS  Complete to final  
 pH adjusted to 7.2 with HCl  volume with 1X PBS 
  
 Blocking solution: 
 10% (w/v) BSA 
 Complete to final volume using 
 1X PBST wash buffer 
 
 Buffers and solutions for ELISA and EliSpot assay:  
  
 Wash buffer (TTBS): Coating solution: 
 50 mM tris HCL (pH7.4) 15 mM Na2CO3   
 150 mM NaCl 30 mM NaHCO3 
 0.05% (v/v) tween-20 in ddH20 0.02% (w/v) azide 
  pH adjusted to 9.6 with HCl 
 
 Blocking buffer:  Dilution buffer:  
 4% (w/v) BSA in TTBS 2% (w/v) BSA in TTBS  
  
 Substrate solution: Stop solution: 
 1 volume colour reagent A  2 N H2SO4 
 1 volume colour reagent B 
      
 Wash buffer: Reagent diluent solution:  
 0.05% (v/v) Tween-20 in dPBS 1% (w/v) BSA  
  Complete to final volume with dPBS 
 
 Buffer for flow cytometry:  
  
 Wash buffer:  
 1% (w/v) BSA in 1X dPBS  
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2.2 Methods  
 
2.2.1  Cell culture 
 
2.2.1.1 Tissue culture cell line propagation 
 
Cell line storage conditions: Cell lines and culture conditions are described in Table 2.1. 
All cell culture work was performed in class II safety cabinets. All cell lines were frozen in 
1 ml cryovials using freezing media comprising of 50% FCS, 40% culture media and 10% 
DMSO. Cells were frozen at -80oC for one day prior to transfer into liquid nitrogen for 
long term storage. Cell lines were maintained in a humidified incubator at 37oC, 5% CO2 
culture flasks or plates.  
 
Culture of adherent cells: Confluent monolayer cells were washed 3 times with an 
appropriate volume of dPBS to remove residual media, and dislodged at 37°C using 1X 
TrypsinVersene stopped by the addition of complete growth media, centrifuged at 400 g, 
4oC for 3 minutes, counted using trypan blue exclusion method and seeded at the 
appropriate density into cell culture flasks or plates. Seeded DCs were harvested from 
culture plates by scraping using a pipette tip. Seeded PBMCs and cells for lysate or RNA 
extraction were removed by gentle mechanical scrapping.  
 
Culture of suspension cells: Suspension cell lines were passaged by centrifuging cell 
suspension as above and splitting the resuspend pellet into flasks, which were replenished 
with fresh culture media and antibiotics as required.  
 
2.2.2  Genomic expression analysis 
 
Studies involving investigation of genomic expression were performed by analysing RNA 
expression in samples. For these studies, RNA was routinely extracted from cell lines and 
reverse transcribed into complementary DNA (cDNA) which was then used in quantitative 
real time PCR (RT-Q-PCR) and semi-quantitative PCR reactions. Semi-quantitative PCR 
products underwent size separation using agarose gels, DNA purification and clean up and 
finally DNA sequencing.        
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2.2.2.1 RNA extraction and cDNA synthesis 
 
RNA extraction by RNA spin columns: RNA was extracted using RNAeasy mini kit 
(Qiagen) according to the manufacturer’s instructions. In brief, adherent cells (up to x107 
cells) were collected (as described in section 2.2.1.1) into universal tubes and washed once 
using dPBS by centrifugation at 86 g, 21°C for 3 minutes and the supernatant pipetted off. 
To the tubes, 350 µl of RTL lysis buffer followed by 350 µl of 70% ethanol were added 
and the pellet dispersed through pipetting up and down several times. The cells were then 
transferred onto an RNAeasy spin column and centrifuged at 8600 g for 15 seconds and the 
flow through discarded. To remove DNA and other contaminants 500 µl of RW1 wash 
buffer was applied to each column, which was then centrifuged and the flow through 
discarded as before. Following this, 500 µl of Buffer RPE was added to the column and 
centrifuged as before. After discarding the flow through, 500 µl of Buffer RPE was again 
added to the column and centrifuged 8600 g for 2 minutes to wash the membrane and 
ensure removal of ethanol prior to the elution steps. The column was then transferred to a 
fresh collection tube and between 10 and 25 µl of RNAase free water was added directly to 
the column membrane and centrifuged 8600 g for 60 seconds to elute the purified RNA 
into the collection tube. RNA concentration was measured using a Nanodrop 
spectrophotometer and resuspended to a concentration of 1 µg/µl in ddH2O ready for 
reverse transcription or stored at -80°C for up to 6 months for future use. 
 
RNA extraction by isopropanol precipitation method: RNA was extracted using RNA 
STAT-60 according to manufacturer’s instruction. Briefly, tissues were ground to a 
powder in liquid nitrogen. The powder was collected into 1.5 ml eppendorfs and 1 ml of 
RNA STAT-60 added. Cell lines were homogenised using 500 µl per 2x106 cells of RNA 
STAT-60 in 1.5 ml eppendorf tubes and left at room temperature (RT) for 3 minutes. To 
this, 100 µl of chloroform per 500 µl of RNA STAT-60 was added and mixed by shaking 
vigorously for 60 seconds and again tubes were left for 3 minutes at RT. Tubes were then 
centrifuged at 17000 g, 4°C for 15 minutes and the colourless upper aqueous phase 
containing RNA was carefully removed into a fresh 1.5 ml eppendorf and the phenol red 
phase discarded. To this, 250 µl of isopropanol per 500 µl of RNA STAT-60 was added 
and the solution left at RT for 8 minutes in order to precipitate out RNA before again 
centrifuging at 12000 g, 4°C for 10 minutes. The supernatant was removed and discarded 
leaving a white pellet, and the RNA washed using 1 ml of 75% ethanol followed by 
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centrifugation at 4800 g, 4°C for 5 minutes. The supernatant was again removed and 
discarded and the white pellet left to air dry completely until clear. The pellet was 
resuspended in an appropriate volume (between 10-30 µl) of ddH2O and stored at 
-80°C 
and used within 6 months. RNA concentration was measured using a Nanodrop 
spectrophotometer and resuspended to a concentration of 1 µg/µl in ddH2O ready for 
reverse transcription. 
 
Reverse transcription: First-strand cDNA synthesis from RNA was prepared following the 
manufacturers protocol described below per sample. Into a 0.5 ml eppendorf, 2 µg of 
RNA, 0.5 µg of the Oligo(dT)15 primer and ddH2O were added to give a final volume of  
15 µl. The samples were then heated using UNO-Thermoblock to 70°C for 5 minutes to 
melt secondary structures. Samples were then immediately put on ice before the following 
were added to each sample: 5 µl of M-MLV 5X reaction buffer, 1 µl of 40 mM dNTP’s, 
0.7 µl of RNasin ribonuclease inhibitor, 1 µl M-MLV RT and 2.3 µl ddH2O. Samples were 
mixed gently and incubated for 60 minutes at 42°C in a water bath. After incubation, 
samples were finally heated using an UNO-Thermoblock to 95°C for 5 minutes and 
immediately stored at -20°C ready for PCR.  
 
2.2.2.2 Semi-quantitative PCR amplification 
 
Primer design and optimisation: PCR was performed on a 96 well automated DNA 
thermal cycler using oligo-primers designed using online primer designing tools 
(http://eu.idtdna.com/analyzer/Applications/OligoAnalyzer/), (http://frodo.wi.mit.edu/) and 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) purchased from MWG Eurofins. Primers 
were optimised in accordance to protocols described elsewhere (Roux, 2009; Bustin et al., 
2009). PCR tubes were prepared following manufacturer’s protocols specific to the Taq 
DNA polymerase used.  
 
PCR set-up conditions: For product amplification using GoTaq DNA polymerase, each 
tube was prepared using 5 µl of 5X Reaction Buffer, 13.3 µl of ddH20, 1.5 µl of 25 mM 
MgCl2, 1 µl of 10 mM dNTP mix, 1 µl of each primer and 0.2 µl of 5 U/µl GoTaq DNA 
polymerase and 2 µl of template cDNA. Gradient PCR was performed under the following 
program conditions; Initial denaturation at 95°C for 2 minutes (1 cycle), denaturation 95°C 
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for 60 seconds, annealing 60°C at 12 gradient for 60 seconds, extension 75°C for 60 
seconds/kb (35 cycles), final extension 75°C for 5 minutes (1 cycle) and final hold at 4°C.  
 
2.2.2.3 DNA isolation and purification for sequencing analysis 
 
Gel electrophoresis and visualisation: PCR products were separated using agarose gel 
electrophoresis and visualised with 1:10,000 GelRed stain using a UV transilluminator. To 
achieve good separation and resolution, percentage agarose gels were prepared in 
accordance to expected product size. Gels trays were loaded into the electrophoresis tank 
and samples were loaded with 3 µl orange G onto the gel wells and ran at 70-110 V for 30-
60 minutes. Gels were then removed from trays and visualised using a UV transilluminator 
and images captured using GeneSnap (Syngene) software.  
 
DNA clean-up of post PCR product: Following PCR, DNA clean-up was performed using 
QIAquick PCR purification kit (Qiagen) following manufacturer’s instructions. The PCR 
product was transferred to a 1.5 ml eppendorf tube and diluted in 5 volumes of buffer PB 
before adding to the QIAquick column assembly. Tubes were centrifuged at 14500 g for 40 
seconds and the flow through discarded from the collection tube. A further 750 µl of buffer 
PE was applied to the column and tubes were centrifuged as before, discarding the flow 
though. The column was further centrifuged as before for 60 seconds to remove residual 
wash buffer before being transferred to fresh 1.5 ml eppendorf tube and 50 µl of buffer EB 
was applied directly to the column membrane to elute DNA. After 60 seconds incubation 
at room temperature (RT), the column assembly was centrifuged for 60 seconds at 14500 g 
and the eluted DNA collected and quantified using a nanodrop and stored at between 4°C 
and   -20°C for future use.  
 
Gel band extraction and DNA purification: Following electrophoresis gel bands were 
excised under ultraviolet (UV) light using GelX tips and placed in 1.5 ml eppendorf tubes. 
Purification of DNA was performed using a Wizard SV gel and PCR clean up system 
(Promega) following the manufacturer’s instructions. Briefly, gel slices were weighed and 
10 µl of membrane binding solution was added per 10 mg of gel. Tubes were then vortex 
mixed and incubated at 50°C until the gel slices were completely dissolved. Following 
incubation, an equal volume of membrane binding solution was added to the tubes before 
the dissolved gel mixture was transferred to the column assembly and incubated at RT for 
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60 seconds. Tubes were centrifuged at 17000 g for 60 seconds and the flow through 
discarded from the collection tube. A further 700 µl of membrane wash solution was 
applied to the column and tubes were centrifuged as before, discarding the flow though. 
Columns were washed and centrifuged at 17000 g for 5 minutes with 500 µl of membrane 
wash solution with the flow through discarded. The column was further centrifuged as 
before for 60 seconds to remove residual ethanol before being transferred to fresh 1.5 ml 
eppendorf tube and 50 µl of nuclease-free water added to elute DNA. After 60 seconds 
incubation at RT, the column assembly was centrifuged for 60 seconds at 17000 g and the 
eluted DNA collected and quantified using a nanodrop and stored at between 4°C and -
20°C for future use.  
 
2.2.2.4 Quantitative real time PCR (RT-Q-PCR) 
 
PCR set-up conditions: A panel of normal tissue mRNA’s were purchased from Clontech 
and subjected to reverse transcription (as described in section 2.2.2.1). All oligo-primers 
were designed to be between 15 – 30 bases in length and would generate products no 
greater then 250bp for RT-Q-PCR. All oligo-primers were purchased from Eurofins MWG 
Operon and diluted to a working concentration of 10 pg/µl using ddH2O and stored at         
-20°C. Real time quantitative PCR was performed on a Real Time qPCR Thermal Cycler 
using iQ SYBR Green fluorescence dye. PCR tubes prepared for each reaction were 
prepared in 12.5 µl volume containing 6.25 µl of iQ SYBR Green SuperMix, 4.75 µl of 
ddH2O, 0.5 µl of each primer and 0.5 µl of template cDNA. In cases of Non-Template 
Control (NTC), cDNA template was substituted with ddH2O. PCR was performed under 
the following program conditions; Initial melt step at 95°C for 5 minutes, followed by 40 
cycles of denaturation 95°C for 30 seconds, primer specific annealing (detailed in Table 
2.2) for 30 seconds, extension 72°C for 30 seconds and a final extension at 98°C for 60 
seconds. Samples were run in duplicate and repeated at least 3 times to ensure validity of 
results which were then analysed using the ΔCt calculation (Bustin et al., 2009). 
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Table 2.2 – Primers used for PCR, descriptions and amplification conditions. Abbreviations: 
bp – base pairs; Tm. - annealing temperature; Ext. – extension time; HKG - House Keeping 
Gene. 
 
 
 2.2.3  Rapid Amplification of 5’ and 3’ cDNA Ends (RACE) 
 
 Rapid Amplification of cDNA Ends (RACE) technique allows for the identification of the 
5’ and 3’ untranslated regions of a gene using known partial sequences obtained by library 
screening methodologies such as SEREX. Preparation of RNA was performed using 
GeneRacer kit (Invitrogen) which is based on RNA ligase-mediated and oligo-capping 
RACE methods resulting in selective ligation of primers to the 5’ ends of decapped mRNA 
using T4 RNA ligase. 
 
 
Amplicon Primer Sequence (5’ – 3’) 
Product 
size 
Tm. Ext. 
CEP290 
CEP290 F4 GCTTCGATTGCCTGCCACTGC 
214bp 62°C 30sec 
CEP290 R4 GCAGTGGCAGGCAATCGAAGC 
T21 unique  
region 
T21 qPCR F CAAAGAATGAAATCATAGCACAGG 
100bp 55°C 30sec 
T21 qPCR R TTCTGTTCTGCCTGGCTTCT 
HKG:  
Transferase 
hHPRT1 F TGACACTGGCAAAACAATGCA 
94bp 57°C 30sec 
hHPRT1 R GGTCCTTTTCACCAGCAAGCT 
HKG: TATA  
box binding  
hTBP F TGCACAGGAGCCAAGAGTGAA 
132bp 57°C 30sec 
hTBP R CACATCACAGCTCCCCACCA 
OAS1:  
induced by IFN 
OAS1 F CAAGCTCAAGAGCCTCATCC 
150bp 59°C 30sec 
OAS1 R TGGGCTGTGTTGAAATGTGT 
STAT1:  
activated by IFN 
STAT1 F AAATTCCTGGAGCAGGTTCA 
166bp 59°C 30sec 
STAT1 R TGGCCCCAAGTCACTTAATC 
HKG: β-actin  
β-actin F CTCTTCCAGCCTTCCTTCCT 
116bp 57°C 30sec 
β-actin R AGCACTGTGTTGGCGTACAG 
CEP290/T21 
T21 – F1 ATGCCACCTAATATAAACTGGAAAG 
1829bp 62.5°C 2min 
T21 – R1 TTTCATTCTTTGATTGTGCTTCA 
CEP290/T21 
T21 – F3 AGAAGCCAGGCAGAACAGAA 
1508bp 59.4°C 2min 
T21 – R3 CAAACCTCAGCAAATTTGGTTTC 
CEP290/T21 
CEP290/T21 F ATGAGTGAAGCACAATCAAAG 194/ 
287bp 
60°C 30sec 
CEP290/T21 R TCAGGATCTTTCTGCATTTCC 
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2.2.3.1 Preparation of total RNA to full length mRNA   
 
To commence preparation of 5’ RACE, total RNA was required to be processed for full 
length capping which was performed by dephosphorylation of non mRNA and truncated 
mRNA, removal of the mRNA cap structure and ligation with GeneRacer RNA Oligo to 
full length mRNA. 
 
Dephosphorylation: First, dephosphorylation reaction was performed in a 0.5 ml 
eppendorf tube using 3 µg of prostate total RNA (Clontech) to which 1 µl of 10X CIP 
buffer, 1 µl RNaseOut (40 U/µl), 1 µl CIP (10 U/µl) and 4 µl DEPC water was added. 
Tubes were gently mixed and briefly centrifuged before being incubated at 50oC for 60 
minutes. Following incubation, tubes were again briefly centrifuged and placed on ice. 
Next, RNA was precipitated out by adding 90 µl of DEPC water and 100 µl 
phenol:chloroform with the mixture then vortex mixed for 30 seconds before 
centrifugation for 5 minutes at 14500 g in order to separate the phases. The top layer 
aqueous phase was carefully removed and transferred into a fresh eppendorf before 
proceeding with RNA precipitation. Next, 2 µl of mussel glycogen (10 mg/ml) and 10 µl 
of 3 M NaOAc (pH 5.2) was added followed by 220 µl of 95% ethanol taking care to 
vortex mix the tubes well after each addition. Tubes were then super-chilled on dry ice for 
10 minutes. Following incubation, tubes were spun at 4oC for 20 minutes at 17000 g and 
the supernatant carefully removed and discarded so not to disturb the pellet. The remaining 
pellet was washed with 500 µl of 70% ethanol and centrifuged at 17000 g for 2 minutes at 
4oC. After discarding the supernatant, the pellet was allowed to air dry for 2 minutes at RT 
before being resuspended in 7 µl of DEPC water. 
 
Decapping of 5’ structure: Upon dephosphorylation and precipitation of the RNA, 
decapping of the 5’ structure was performed in a 0.5 ml eppendorf tube on ice by gently 
mixing 1 µl 10X TAP buffer, 1 µl RNaseOut (40 U/µl), 1 µl TAP (0.5 U/µl), followed by 
briefly centrifuging the tubes to collect liquid and incubated at 37oC of 60 minutes. 
Following incubation tubes were again briefly centrifuged and placed on ice. Subsequent 
mRNA precipitation was performed as described previously. Following the decapping 
procedure, the precipitated mRNA was ready for ligation with the Generacer RNA Oligo, 
specifically to the 5’ end of the decapped mRNA. First, 7 µl of dephosphorolated, 
decapped mRNA was added to the lyophilised pre-aliquoted GeneRacer RNA Oligo     
Chapter 2: Materials and Methods  2.2 
 
73 
 
(0.25 µg), mixed well and briefly centrifuged to collect the liquid at the bottom of the tube 
prior to incubation at 65°C for 5 minutes followed by incubation on ice for 2 minutes. 
Tubes were briefly centrifuged and the following components added to each tube: 1 µl of 
10 Ligase buffer, 1 µl ATP (10mM), 1 µl RNaseOut (40 U/µl), 1 µl T4 RNA ligase          
(5 U/µl) before being incubated at 37°C for 60 minutes. After incubation, tubes were 
briefly centrifuged and placed on ice and the RNA was precipitated as described 
previously and the resulting pellet resuspended in 10 µl of DEPC treated water. 
 
2.2.3.2 Reverse transcription of mRNA for 5’ and 3’ ends   
 
Reverse transcription: Reverse transcription was performed on the unprocessed RNA for 
3’ RACE and processed RNA for 5’RACE described in the previous section. Briefly, 3 µl 
of unprocessed total RNA from prostate and 7 µl of DEPC for 3’RACE or 10 µl of 
processed RNA processed for 5’RACE were prepared in 0.5 ml eppendorfs to which 1 µl 
of GeneRacer Oligo dT primer (50 µM) and 1 µl of dNTP mix 25 mM) was added. Next, 
RNA secondary structures were removed by incubating for 5 minutes at 65°C followed by 
incubation on ice for a further 2 minutes. Tubes where then briefly centrifuged and the 
following components were added to the primer mixture and ligated RNA: 4 µl of 5X RT 
buffer, 1 µl of cloned AMV RT (15 U/µl), 2 µl sterile water and 1 µl RNaseOut (40 U/µl). 
Tubes were mixed well and incubated at 45°C for 60 minutes followed by incubation at 
85°C for 15 minutes to inactivate Cloned AMV RT. Tubes were once again briefly 
centrifuged and the cDNA stored at -20oC for future use. 
 
2.2.3.3 Rapid Amplification of 5’ and 3’ ends of T21 
 
Semi quantitative RT PCR together with Phusion High-Fidelity DNA Polymerase was 
used to amplify the previously untranslated region 5’ and 3’ ends of T21 from prostate 
tissue cDNA. For amplification of 5’ and 3’ ends, T21 unique region specific sequence 
reverse and forward primers were used respectively along with the GeneRacer primers 
provided. 
T21 specific primer T21 specific primer sequence Tm. 
T21 specific 5’ RACE primer reverse GAATTCCTGTGCTATGATTT 65.2°C 
T21 specific 3’ RACE primer forward AAATCATAGCACAGGAATTC 61.5°C 
  Table 2.3 – Primers used for RACE PCR 
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PCR set-up conditions: For amplification using Phusion High-Fidelity DNA Polymerase, 
each PCR tube was prepared to a total reaction volume of 50 µl using 10 µl of 5X Hi-
Fidelity Buffer, 32.5 µl of nuclease-free water, 1 µl of dNTPS (10 mM), 3 µl of GeneRacer 
5’ Primer (10 µmole/µl) for 5’end amplification or 1 µl of T21 sequence specific forward 
primer (10 µmole/µl) for 3’ end amplification, 1 µl of T21 sequence specific reverse 
primer (10 µmole/µl) for 5’end amplification or 3 µl of GeneRacer 3’ Primer                   
(10 µmole/µl) for 3’ end amplification, 0.5 µl of Phusion Hi-Fidelity Taq polymerase and    
2 µl of template cDNA.  
 
PCR was performed under the following program conditions; hotstart at 98°C, initial 
denaturation at 98°C for 30 seconds (1 cycle), denaturation 98°C for 10 seconds, annealing 
(as indicated in the table above) for 30 seconds, extension 72°C for 30 seconds (35 cycles), 
final extension 72°C for 10 minutes (1 cycle) and final hold at 4°C. Upon completion, PCR 
products were loaded onto 1.2% agarose gel and underwent visualisation, band extraction 
and purification using methods described in section 2.2.2.3.    
  
2.2.4  Northern Blotting 
 
Northern blotting allows for the detection of specific RNA transcripts using 
complementary sequence probes that are labelled using either radioactive isotopes such as 
(32P) or with chemiluminescence using enzyme substrates directly or indirectly attached to 
probes labelled with chemiluminescent molecules such as biotin. This technique allows for 
identification of novel gene transcripts and determining transcription variants in relation to 
specific binding and transcript size as well as observations of gene expression patterns and 
transcript abundance from tissue to tissue.   
   
2.2.4.1 RNA 3’ end biotinylation of probes and RNA/probe hybridisation   
 
RNA 3’ end biotinylation of probes: RNA probes purchased from Sigma were 
resuspended at a concentration of 100 µM using dH20 to prepare a working stock of          
10 µM. For the RNA ligation reaction, 5 µl of RNA probe were transferred into a 0.5 ml 
eppendorf tube and heated for 5 minutes at 85°C before being placed on ice. Next, the 
labelling reaction mix was prepared and the components added as follows: 3 µl nuclease-
free water, 3 µl 10X RNA ligase reaction buffer, 1 µl RNase inhibitor (40 U), 5 µl RNA,  
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1 µl of biotinylated cytidine (Bis)phosphate (1 nmol), 2 µl T4 RNA ligase (40 U) and      
15 µl of 30% PEG. The labelling reaction mix was pipette mixed and incubated at 16°C 
overnight for approximately 18 hours. Following ligation, 70 µl of nuclease-free water 
was added to the reaction followed by 100 µl of chloroform:isoamyl alcohol used to 
extract the RNA ligase. The mixture was vortex mixed before centrifugation for 3 minutes 
at 17000 g in order to separate the phases. The top layer aqueous phase was carefully 
removed and transferred into a fresh eppendorf before proceeding with RNA precipitation. 
Next, 10 µl of 5 M NaCl, 1 µl of glycogen and 300 µl of cold 100% ethanol was added to 
each tube and centrifuged for 15 minutes at 17000 g at 4°C. The supernatant was 
discarded and the pellet washed with a further 300 µl of cold 70% ethanol before being 
discarded and the pellet left to air dry for 5 minutes. The dried pellet was then resuspended 
in 20 µl of nuclease-free water ready for hybridisation with RNA.  
 
Probe No. Target gene RNA sequence 
1 T21 AUAGCACAGGAAUUCUUGAUCA 
2 CEP290 UCCCUGACCCUAGUUUGCCCCU 
3 CEP290/T21 GAAAACGAUCAUUAUCAACUUCAAG 
4 T21 CAAACCUCAGCAAAUUUGGUUUC 
 
 Table 2.4 - RNA probes used for northern blotting  
 
RNA/probe hybridisation: Following labelling, 1 µl of RNA probe was mixed with 4 µl of 
a 250 ng/µl stock of total RNA derived from various tissue in a 0.5 ml eppendorf tube and 
incubated at 95°C for 5 minutes. Tubes were then place immediately on to ice for 30 
minutes to avoid formation of secondary structures. Tubes were then incubated at RT for 
30 minutes before commencing to polyacrylamide gel electrophoresis (PAGE).      
   
2.2.4.2 Northern blotting 
 
PAGE, membrane transfer and cross-linking of RNA/probe: Polyacrylamide gels were 
made with the constituents listed below and cast between two glass plate gel casters and 
with a spacer comb inserted between the glass plates. After a minimum of 30 minutes 
following gel polymerisation, the glass plates were removed from caster apparatus and 
transferred to a running tank and covered with 0.5X TBE buffer and the spacer comb 
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carefully removed and the gel was pre-run for 30 minutes a 130 V to equilibrate the gel 
and remove any traces of ammonium persulphate and any other trace contaminants that 
may interfere with the running of RNA. 
   
Polyacrylamide Gel 12%  
30% Acrylamide  3.300 
5X TBE 2.000 
dH2O 4.700 
10% Ammonium persulphate 0.100 
TEMED 0.010 
 
 Table 2.5 - Polyacrylamide gel formulation used for northern blotting. Values given in (ml)  
 
Next, 15 µl of RNA/probe was mixed with 5 µl Orange G (used for sample tracking) and 
was carefully loaded into the wells and the tank was then run for 30 minutes at 130 V. Gels 
were then removed from the apparatus and placed in 0.5X TBE buffer to equilibrate before 
transfer onto positively charged nylon membranes. Following electrophoresis, a stack was 
constructed were 3 gel sized pieces of blotting paper, the nylon membrane, the gel and 
again 3 pieces blotting paper all soaked in 0.5X TBE buffer were placed onto the semi-dry 
transfer unit and run at 200 mA for 30 minutes. After transfer, nylon membranes were 
removed from the transfer apparatus and placed onto an A5-sized sheet of blotting paper 
soaked with 0.5X TBE buffer before being completely covered by a sheet of Whatman 
3MM paper also soaked in 0.5X TBE buffer to prevent the nylon membrane from drying 
out. This stack containing the membrane was incubated at 80°C for 15 minutes in a pre-
heated drying cabinet in order to cross-link RNA to the membrane, which was then placed 
in a container ready for detection. 
 
Detection of immobilised RNA/probe: The detection of RNA/probes was performed using 
a chemiluminescent nucleic acid detection module (Thermo Scientific) as per the 
recommended instructions. Briefly, for a 10 x 10 cm membrane 16 ml of pre-warmed 
blocking buffer was added to the membrane and left to incubate at RT for 15 minutes with 
gently rocking before being removed. Next, 50 µl of streptavidin-horseradish peroxidase 
conjugate diluted in 16 mls of blocking buffer was added to the membrane and was left to 
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incubate as described above. Meanwhile, a working concentration of 1X wash solution was 
prepared using 40 mls of pre-warmed X4 wash buffer and 120 ml ddH20. Membranes 
were transferred into a fresh container and rinsed with 20 mls of 1X wash buffer prior to 
washing 4 times for 5 minutes whilst gently rocking. Following the final wash, membranes 
were transferred to a fresh container and incubated with 30 mls of substrate equilibrium 
buffer for 5 minutes under gentle rocking. Meanwhile, the chemiluminescent substrate 
working solution was prepared by mixing 6 mls of luminol/enhancer solution to 6 ml of 
stable peroxide solution in a tube concealed from light. Following incubation, membrane 
edges were carefully blotted onto absorbent paper to remove excess buffer before being 
transferred into a polythene bag containing 12 mls of chemiluminescent substrate solution 
and was left to incubate for 5 minutes on a flat surface without shaking. Membranes were 
then removed from the bag and the excess liquid removed by blotting using absorbent 
paper and membranes subjected to luminescence detection.  
 
2.2.5  Protein expression analysis 
 
Protein expression and localisation studies were performed by employing methods 
involving immunoblotting and immunosorbent assays, immunohistochemistry and 
immunocytochemistry. For each assay, antibody concentrations were used were from 
manufacturers suggested recommendations. Optimal assay conditions and antibody 
concentrations were determined prior to the use of customised antibodies, all of which are 
detailed in section 2.1.5. 
 
2.2.5.1 Indirect immunofluorescence 
 
Cell preparation: A day prior to immunofluorescent staining, cells were seeded into 24 
well culture plates at a concentration of between 2-10x104 cells/ml at 1 ml per well each 
containing one sterile round glass cover slip. For LNCaP cells (low adhesive properties), 
fluorescence was performed in 8 well chamber slides and all solution volumes were scaled 
down 5-fold. Cells were then incubated for at least 24 hours at 37oC, 5% CO2 so that cells 
would be between 85-95% confluent at the time of staining.  
 
Immunofluorescence staining: The following day, media was removed from the wells and 
200 µl of cold 4% paraformaldehyde solution was added to each well for 15 minutes at 4oC 
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in order to fix cells. Wells were then washed once for 10 minutes using dPBS whilst on a 
plate rocker followed by blocking for 60 minutes using blocking buffer. After blocking, 
primary antibodies and isotype controls were prepared in blocking buffer at optimal 
dilutions optimised in house or suggested by manufacturers and added to appropriate wells 
and left to incubate overnight at 4°C on a plate rocker. Following incubation, wells were 
washed using wash buffer x3 times for 10 minutes and the secondary Alexafluor antibodies 
prepared using blocking buffer and added to appropriate wells. Plates were then wrapped 
in foil and incubated at RT whilst rocking for 60 minutes. Following washing with wash 
buffer as before round glass cover slips were removed from the base of the wells and 
placed cell side down onto mounting fluid containing DAPI on microscope slides. Slides 
were placed in slide holders and wrapped in foil and kept at 4oC until ready to view using a 
fluorescence microscope. 
 
2.2.5.2 Immunohistochemistry staining of paraffin-embedded sections 
 
Pre-staining procedure: Slides purchased from US Biomax were stained using the 
following procedure. For paraffin embedded tissue microarray sections (TMA) slides were 
initially heated on a hotplate for 10 minutes at 60°C to melt the paraffin wax before 
beginning automated deparaffinisation/hydration process using an Autostainer XL (Leica) 
programmed automation as follows: emersion of slides in xylene bath for 5 minutes, 
second xylene bath 5 minutes, three consecutive graded alcohol baths (100%, 100% and 
70% ethanol) each for 2 minutes and a final dH20 bath for 5 minutes. Slides were then 
placed in antigen retrieval buffer (0.01 M citrate solution pH 6) and microwaved for 20 
minutes from boiling after which, slides were then allowed to cool under cool tap water for 
5 minutes. Whilst underwater, slides were loaded onto sequenza coverslips and carefully 
inserted into sequenza racks. Slides were washed using TBS which was applied between 
the slide and to the coverslip creating a reservoir allowing liquids to run down the slide and 
out of the bottom via capillary action.   
 
Tissue staining: Staining was performed using a Novolink kit following the 
manufacturer’s instructions (all kit solutions were applied in 100 µl volume each time 
followed by x2 wash stages using TBS for 5 minutes). Initial peroxidase block was applied 
to the slide and following washes, protein block was added and again left for 5 minutes 
followed by washing as before. Next primary antibody prepared in antibody diluent was 
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applied to the slide and incubated overnight at 4°C followed by washing. Next, post 
primary block was added and washed after 30 minutes followed by addition of polymer for 
30 minutes and subsequent wash. Finally, DAB working solution was added for 5 minutes 
followed by wash and counterstained using haematoxylin for 6 minutes after which dH20 
was added to rinse of excess haematoxylin and slides were removed from the sequenza 
apparatus and placed into racks to begin automated dehydration process using Autostainer 
XL programmed as follows: immersion of slides in three consecutive graded alcohol baths 
(70%, 100% and 100% ethanol) each for 2 minutes, xylene bath for 5 minutes, second 
xylene bath 5 minutes, and a final dH20 bath for 5 minutes. Coverslips were then mounted 
on to slides using DPX mounting medium.       
 
2.2.5.3 Cell protein preparation and quantification for SDS-PAGE 
 
Cell protein preparation: Protein lysates were prepared from adherent cultures grown to 
70 – 80% confluency in culture flasks. Cells were then washed twice with dPBS to remove 
residual calf serum, and homogenised with a cell scraper and transferred into a 15 ml 
universal tube. Lysed cells were then centrifuged at 8600 g for 5 minutes at 4°C following 
which the supernatant discarded and the pellet resuspended in dPBS and centrifuged once 
again. Supernatant was then removed leaving a dry pellet which was suspended in 2x106 
cells/100µl of cell lysis buffer. Cell pellets were sonicated to disrupt the pellet for 5 
minutes followed by 5 minutes of cooling on ice. Following this, 2x106 cells/100µl of cell 
lysis buffer containing 0.1% TFA at ratio of 1:3 was added and the solution was then 
subjected to a further 2 cycles of 5 minutes under sonication followed by 5 minutes on ice. 
The samples were centrifuged at 17000 g for 60 seconds at 4°C to pellet cell debris and 
stored at -20°C for one month or at -80°C for long term storage. 
 
Protein quantification: All protein concentrations were determined using Bradford assay. 
This assay utilises coomassie brilliant blue G-250, an acidic detection dye used to bind to 
aromatic amino acid residues present on proteins. This results in differential colour change 
forming a blue complex measurable at wavelength of 590 nm. 
 
First a standard calibration curve was determined following the manufacturers protocol by 
preparing serial dilutions of BSA using lysate buffer and 40 µl of duplicates of BSA 
standard or protein lysate sample added to a 96 well round bottom plate. Next, 200 µl of 
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working dye reagent was added to each well and the plate was sealed with film and 
incubated at 37°C for 10 minutes with shaking. The absorbance was then measured at 
590nm wavelength using a Tecan plate reader, enabling a standard curve to be constructed 
from the BSA serial dilutions following which the sample protein concentration could be 
derived based on the absorbance values obtained. 
 
2.2.5.4 SDS-PAGE and transfer 
 
Gel preparation and electrophoresis: The western blotting method was utilised to assess 
protein expression derived from cell lines. Gels were cast between two glass plate gel 
casters. Firstly the resolving gel made with the constituents listed on Table 2.6 depending 
on the protein molecular weight was added using a 1 ml pipette into the gel casters up to 
3cm from the top of the glass plates. A thin layer of distilled water was added to the top of 
the gel for gel levelling and to stop evaporation. After a minimum of 45 minutes following 
complete gel polymerisation, the water was removed from the gel using blotting paper and 
the stacking gel added to the top of the gel followed by insertion of the spacer comb. The 
stacking gel allows for packing of the protein bands after loading and the resolving gel 
then allows for good protein band separation.  
 
Following polymerisation of the stacking gel, glass plates were removed from the caster 
apparatus and transferred to a running tank and covered with running buffer and the spacer 
combs carefully removed. Next, 30-60 µg of protein lysate were heated to 95°C for 5 
minutes with x3 sample reducing buffer (3:1 sample:buffer) in order to break disulphide 
bonds, after which samples and a biotinylated protein ladder were carefully loaded into the 
wells. The tank was then run for 15 minutes at 70 V allowing protein to travel through the 
stacking gel followed by another 60 – 90 minutes at 140 V until bands were approximately 
1cm from the bottom of the gel. Gels were then removed from the apparatus, the stacking 
gel cut off and discarded and the gel placed in cold transfer buffer to equilibrate for up to 5 
minutes before staining or nitrocellulose transfer. Alternatively, gels could be stained for 
protein using coomassie staining.  
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Resolving Gel 6% 10% 
30% acrylamide   1.000 3.300 
1.5M tris HCl (pH 8.8) 1.300 2.500 
dH2O 5.300 4.000 
10% SDS 0.050 0.100 
10% ammonium persulphate 0.050 0.100 
TEMED 0.004 0.004 
Stacking Gel 5%  
30% acrylamide   0.330  
1M tris HCl (pH 6.8) 1.250  
dH2O 1.400  
10% SDS 0.020  
10% ammonium persulphate 0.020  
TEMED 0.002  
   
Table 2.6 – Polyacrylamide gel formulations used for western blotting. Formulations are 
given for 2 gels with volume in ml, lower molecular weight proteins require high percentage 
gels whereas lower percentage gels can give better resolution for larger proteins. 
 
Protein transfer from SDS-PAGE to nitrocellulose membrane: After band separation 
using SDS-PAGE, a stack was constructed were two gel sized pieces of blotting paper, the 
nitrocellulose membrane, the gel and again two pieces blotting paper all soaked in transfer 
buffer were placed onto the transfer unit and run at 30 V overnight at 4°C. 
 
Ponceau red staining: To assess for successful transfer of proteins, membranes were 
rinsed in TBST and placed in Ponceau Red solution and agitated for 5–10 minutes. 
Membranes were washed extensively using dH2O to reveal defined red/pink stained 
protein bands. Membranes were then destained completely using TBST before proceeding 
to western blotting.  
 
Coomassie staining: Gels were stained to determine if proteins have migrated uniformly 
and show equal protein loading or to extract bands using a coomassie blue staining 
method. To allow band extraction, the proteins are fixed in the gel in 50% methanol, 40% 
dH2O and 10% glacial acetic acid for 60 minutes with shaking, the solution discarded and 
replaced with fresh solution and left overnight with gentle agitation. Gels were then stained 
with coomassie blue solution overnight with gentle shaking followed by several destaining 
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washes using 50% dH2O, 40% methanol and 10% glacial acetic acid until the gel was fully 
destained leaving well-defined blue protein bands. 
 
2.2.5.5 Western blotting 
 
Membrane probing: Membranes were blocked to prevent non-specific binding of 
antibodies using TBST-5% marvel milk solution for 60 minutes followed by 5 minutes x2 
washes using TBST and the addition of the primary antibody diluted at a working 
concentration in TBST-3% marvel milk solution and incubated at 4°C overnight under 
gentle rocking.  
 
Chemioluminescent detection: In order to remove excess and non-specifically bound 
primary antibody, membranes were washed for 10 minutes x5 washes with TBST before 
the addition of the secondary HRP-conjugated antibodies diluted using TBST-3% marvel 
milk solution for 2 hours at RT under agitation. The membranes were washed as before 
and developed using 3 – 4 sprays of RapidStep ECL to wet the membrane with 
chemioluminescence solution and left to stand without agitation for 60 seconds and the 
excess blotted off using absorbent paper and membranes subjected to luminescence 
detection using Fujifilm intelligent dark box.  
 
2.2.5.6 Protein immunoprecipitation using Dynal magnetic beads 
  
Preparation of antigen sample and Dynabeads: Before commencing 
immunoprecipitation, protein lysates were obtained from individual cell lines, quantified 
and frozen at -80°C (refer to section 2.2.5.3). For each sample, 50 µl of Dynabeads protein 
G was transferred into a 1.5 ml eppendorf tube and magnetically separated into beads and 
supernatant.  
 
Binding of antibody: Following separation, the now clear supernatant was removed from 
the tube and replaced with 1-10 µg of appropriate antibody diluted in 200 µl of antibody 
binding and washing buffer (anti-T21u antibody at 10 µg and IgG controls 5 µg). Tubes 
were incubated with rotation for 10 minutes at RT before the unbound antibody was 
removed by placing tubes in a magnetic separator and the supernatants carefully removed. 
The tube containing the Dynabead-antibody complexes were removed from the magnet 
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and gently washed using 200 µl of antibody binding and washing buffer before being 
placed on the magnet to remove the clear supernatant.  
 
Immunoprecipitation of target antigen: Protein lysates containing antigen were added to 
the Dynabeads-antibody complexes and thoroughly mixed by flicking the tube. Tubes were 
then incubated with rotation for 30 minutes at RT. Following incubation tubes were again 
transferred to the magnet and the supernatants removed. Dynabead-antibody-antigen 
complexes were then removed from the magnet and washed using 200 µl of washing 
buffer before being replaced onto the magnet to remove the supernatants. This wash step 
was repeated a further three times. After the removal of the final supernatant wash, 
Dynabead-antibody-antigen were resuspended with 100 µl of washing buffer and 
transferred to a fresh eppendorf tube. 
 
Elution of target antigen: Tubes were placed on the magnet and the supernatants were 
completely removed, before the addition of 30 µl the elution mix (20 µl elution buffer 
containing 10 µl of sample reducing buffer used for western blotting). Tubes were heated 
to 70°C for 10 minutes and replaced on the magnet and the eluted antibody and antigen 
collected in the resulting supernatant. Samples were then loaded onto SDS-PAGE gels for 
western blotting. 
 
2.2.5.7 In-gel band digestion using trypsin for MALDI MS analysis 
 
Gel preparation - Protein staining and de-staining: Following electrophoresis of 
immunoprecipitated samples, SDS-PAGE gels were stained overnight with coomassie blue 
and then washed using de-staining solution for 4 hours under agitation changing the de-
staining solution every 30 minutes. The protein bands observed at the desired mass were 
carefully excised and placed into 1.5 ml eppendorf tubes were gel pieces were 
homogenised into roughly 1 x 1 mm pieces using a scalpel. Tubes were then stored at the 
4°C until further use.    
 
Protein in-gel digestion with trypsin: The gel pieces were washed using ddH2O ensuring 
all liquid was carefully removed prior to re-hydration with an equal volume of 50 nM 
(NH4)HCO3 added along with 100% acetonitrile (ACN) and left to partially dissolve in an 
oven at 37°C. Following incubation approximately 50 µl of (NH4)HCO3/ACN solution, at 
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a ratio of 1:1, was added to the tubes and left to incubate at RT under agitation for 15 
minutes. Following incubation, the liquid was carefully discarded and gel pieces 
underwent dehydration by addition of enough 100% ACN to fully immerse the gel pieces 
which were again left to incubate under agitation until the pieces were observed to have 
reduced in size. The ACN was removed and 200 µl of 50 nM (NH4)HCO3 was added to 
hydrate the gel pieces for 5 minutes. Next, 200 µl of 100% ACN was added to the tubes 
and left under agitation for 15 minutes. The liquid was then fully removed and 100% ACN 
was once again added to dehydrate the gel pieces before being removed and the gel pieces 
left to dry for 5 minutes. Finally dH2O was added to hydrate the gel pieces and then 
immediately removed. Proteins underwent typsination by addition of 7.6 µl of ddH2O,   
16.6 µl of (NH4)HCO3 and 1 µl of mass spectrometry grade trypsin to tubes and were left 
to incubate at 37°C in an oven overnight.   
 
Sample preparation using ZIP-TIP and analysis using LC-MALDI: Following digestion, 
protein fragments were purified and concentrated using ZipTipC18 pipette tips. Briefly, 
80% ACN was applied to pre-wet the ZipTip before equilibrating using 0.1% trifluroacetic 
acid (TFA). Next, 1 µl of 1% TFA was added to the overnight sample in order to halt the 
trypsin reaction and the sample was taken up into the ZipTip by pipetting up and down five 
times followed by immersion of the ZipTip with bound peptide fragments into 80% ACN 
and the pippetting action repeated three times. Next the ZipTip was immersed in 0.1% 
TFA and the pippetting action repeated once more. The same ZipTip was again immersed 
in the sample and pipetted up and down 15 times followed by two cycles of pippeting 
using 10 µl of 0.1% TFA which were discarded from the ZipTip. Finally bound peptide 
fragments were eluted from the ZipTip by pipetting up and down 15 times using 4 µl of 
80% ACN into a fresh tube containing 18 µl of 0.1% TFA. Samples were then spotted onto 
an MS target plate which was loaded in the ultrafleXtreme MALDI-TOFTOF Mass 
Spectrometer (Bruker Daltonics). Results were observed as spectral peaks of the masses of 
the trypsin-digested peptides. The data was searched against a database made against 
CEP290 and the T21 hypothetical protein and using MASCOT 2.2 (Perkins et al., 1999).  
 
2.2.5.8 Enzyme Linked Immunosorbent Assay (ELISA) 
  
Plate preparation: Indirect ELISA was utilised to detect binding of specific peptide or 
protein in samples and was performed as follows. One day prior to assay, samples were 
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diluted in coating buffer and applied at 50 µl/well to 96 well NUNC plates and sealed with 
an adhesive plate cover. In this instance, diluted samples consisted of either, cell line or 
protein lysates isolated from patient tumour sections at 1mg/ml, recombinant T21 protein 
at 0.3 µg/ml or T21 antibody specific peptide serially diluted from 10 ng/ml to 0.01 pg/ml.  
 
ELISA and detection: Following overnight incubation at 4°C, wells were aspirated, 
blotted and washed with wash buffer x3 and wells were then incubated with 100µl/well of 
chilled blocking buffer at RT for 2 hours. Wells were washed as previously described and 
primary antibodies were prepared in chilled dilution buffer and seeded at 50µl/well into the 
appropriate wells. Plates were incubated at RT for 60 minutes followed by aspiration and 
washing as described above. Wells were then incubated for 2 hours with biotinylated 
secondary antibody prepared as described previously. Following incubation, wells were 
again washed as previously described and wells were incubated 100µl/well of HRP 
Strepavidin diluted to a working stock of 1:200 in dilution buffer. Plates were again 
incubated at RT for 20 minutes before a final wash as described previously. To each well, 
substrate reagent solution was added at 100µl/well comprising of 1 part colour reagent-A 
(stabilised hydrogen peroxide) and 1 part colour reagent-B (stabilised 
tetramethylbenzidine) and allowed to develop concealed from light at RT for 15 minutes. 
Finally 50 µl of acid stop solution (H2SO4) was added to each well and the optical density 
was measured at 450 nm wavelength using a Tecan microplate reader. 
 
 2.2.5.9 Cell cycle analysis 
  
Cell preparation and staining: Cell cycle analysis was performed using the Click-iT EdU 
ALEXAfluor 647 flow cytometry kit following the manufacturers guidelines. Briefly, 5-
ethynyl-2´-deoxyuridine (EdU) was added to 24 well plate cell cultures at a concentration 
of 10 µM/well 2 hours prior to harvesting into flow cytometry tubes. Following this, cells 
were centrifuged at 400 g for 3 minutes at 4°C, supernatants were discarded and the cell 
pellet resuspended in dPBS and centrifuged as before. The supernatants were discarded 
and the pellet resuspended in 500 µl of 4% paraformaldehyde fixative solution (PFA) for 
15 minutes at RT. Cells were then centrifuged as before and washed with 1% BSA in 
dPBS wash buffer to remove any residue PFA (In the cases of time-point studies, cell 
pellets were stored at 4°C for up to 5 days before continuing the procedure). Following 
washing, 500 µl of the following mixture was prepared from the kit components provided 
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and added to each tube and incubated in the dark at RT for 30 minutes, 438 µl of Click-iT 
1X reaction buffer, 10 µl of CuSO4, 2.5 µl of fluorescent azide (CellCycle 647-red 7-
AAD) and 50 µl 1X reaction buffer additive. Following incubation, cells were washed 
using 1:10 dilution of saponin buffer and centrifuged as before. The supernatants were 
discarded and the cell pellet resuspended in 500 µl of 1:10 dilution of saponin buffer. To 
measure the DNA content of the cells 1 µl of cell cycle dye 405-violet along with 2 µl of 
RNAse was added to the resuspended cells and incubated in dark for 15 minutes. DNA/cell 
cycle analysis was performed using a Gallios flow cytometer and data obtained analysed 
using the Kaluza Flow Analysis Software (version 1.0) from Beckman Coulter. Cell 
analysis was performed by plotting DNA content (x-axis) against EdU (y-axis) measured 
in linear mode (LIN).  
 
2.2.6  Cell transfection for gene silencing studies   
 
Targeted suppression of gene expression using interfering RNA (iRNA) is a widely utilised 
tool for the investigation of gene function. Cell transfection of small interfering RNA 
(siRNAs) specifically designed to target the RNA sequence of a gene enable initiation of 
gene silencing via the degradation of the mRNA sequence. To induce long-lived stable 
gene suppression, an alternative short hairpin RNA (shRNAs), employing the use of an 
expression vector can be used.  
 
2.2.6.1 Small interfering RNA (siRNA) transfection 
 
Transfection of cell lines using siRNA was done using INTERFERin transfection reagent 
according to the manufacturers protocol.  
 
Cell preparation: Briefly a day prior to transfection, cells were seeded into a 24 well flat 
bottom plate at a concentration of 5x104 cells/ml and left to incubated overnight at 37oC, 
5% CO2 so that cells would be between 30-50% confluent at the time of transfection. 
 
Cell transfection: The following day, siRNA stocks were prepared at 40 µM/well in 
100µl/well of serum free Opti-MEM media and mixed. To these mixtures 2 µl/well of 
INTERFERin reagent was added and vortexed for 10 seconds. Further wells containing 
commercially available control siRNA (Eurogentec), INTERFERin only and Opti-MEM 
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media alone were prepared and all mixtures were incubated at RT for 10 minutes to allow 
complexes to form. These complexes were then added dropwise whilst on a plate rocker at 
a volume of 100µl/well to appropriate cells containing 100µl/well of complete media. All 
plates were left to rock for 10 minutes before incubating at 37oC, 5% CO2 for 6 hours after 
which 500 µl of pre-warmed complete media was added to each well and incubated (time 
dependent on the assay performed).   
 
Target gene siRNA duplexes Sequence (5’ – 3’) 
T21 1 
GUGUAGAAAUGCAGAUAUA 
UAUAUCUGCAUUUCUACAC 
T21 2 
AGAUAUAGAGCUUGAACAU 
AUGUUCAAGCUCUAUAUCU 
T21 3 
GCACAGGAAUUCUUGAUCA 
UGAUCAAGAAUUCCUGUGC 
 
 Table 2.7 – RNA duplexes designed for siRNA transfection. 
 
2.2.6.2 Short hairpin RNA (shRNA) transfection 
 
Stable transfection of cell lines using a pGFP-B-RS vector with blasticidin resistance gene 
(see appendix Figure Ia for vector map) and containing T21 shRNA designed as follows: 
(sense:5’GCACAGGAATTCTTGATCA3’ TCAAGAG antisense:5’TGATCAAGAATTCCTGTGC3') 
(purchased from Origene Technologies) was performed using Lipofectamine-2000 
transfection reagent according to the manufacturers protocol.  
 
Cell preparation: Briefly a day prior to transfection, cells were seeded into a 24 well flat 
bottom plate at a concentration of 5x105 cells/ml and left to incubated overnight at 37oC, 
5% CO2 so that cells would be between 85-95% confluent at the time of transfection. 
 
Cell transfection: The following day, shRNA stock was prepared in HAMS-F12 media at 
a concentration of 1.2 µg per 50 µl per well and mixed gently. Alongside to this,                      
2 µg per 50 µl per well of Lipofectamine-2000 was also prepared in HAMS-F12 and both 
preparations were left to incubate at RT for 5 minutes before combining the diluted DNA 
and Lipofectamine-2000 allowing complexes to form at RT for 30 minutes. During which, 
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media from the wells of the overnight cultures were removed and replaced with 100 µl of 
the complexes containing the DNA/Lipofectamine-2000 solutions which were added 
dropwise to the wells whilst on a rocking platform and then incubated at 37oC, 5% CO2 for 
6 hours, after which a further 900 µl of pre-warmed complete media was added and left to 
incubate. Following 48 hours of transfection, media from the wells was removed and fresh 
media containing 25 µg/ml of blasticidin selective antibiotic was added. The cells were 
then observed over the following days to monitor cell viability.  
 
Clonal selection: Following 3-4 days post-transfection, cells were trypsinised and removed 
from wells and centrifuged at 400 g, RT for 3 minutes and resuspended in complete culture 
media. The cells were counted using trypan blue exclusion method and seeded into 96-well 
flat bottom plates at concentrations of 10 cells, 1 cell and 0.33 cells/well with the addition 
of 25 µg/ml blasticidin. Plates were observed over the following weeks and growing clones 
tested for T21 gene expression using RT-Q-PCR and immunofluorescent staining over 
several passages to ensure stable transfection.  
 
Cell Sorting: Following culture of clones positively expressing GFP post-transfection, 
cells were trypsinised and removed from wells and centrifuged at 400 g, RT for 3 minutes 
and resuspended in culture media. Cells then underwent cell sorting using a MoFlo XDP 
High-Speed Cell Sorter under sterile conditions to enable re-culture of GFP positive cells. 
Following sorting, cells were gently centrifuged 300 g, RT for 3 minutes and seeded into 
flasks. Cells were supplemented with antibiotics 2 days post-cell sorting. 
 
2.2.7  Animals and peptides 
 
2.2.7.1 Animals 
 
C57B/6 HLA-A2.1/DR1 transgenic mice (HLA-A2/DR1) used were murine class I 
knockout, but express chimeric HLA-A2.1 molecule with human α1, 2α and β2-
microglobulin and 3α domain murine and were received as a gift from Dr. Lemonnier, 
Institut Pasteur, Paris. Mice were bred and all work was carried out under Home Office 
approved project licence number 40/3563 and in accordance to Home Office regulations at 
the Nottingham University Animal facility and the Nottingham Trent University Animal 
facility.   
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2.2.7.2 Peptides 
 
Overlapping 15mer peptides were either purchased (ProImmune Ltd) or obtained through 
collaboration (Dr Cave and Dr Mundell, Nottingham Trent University) and used for 
immunisation experiments. All peptides for injection were resolubilised in 100% DMSO at 
a final concentration of 10 mg/ml and stored at -80°C. Peptide received from Pacific 
Immunology was resolubilised following manufacturer’s instruction in 50% ACN and 50% 
ddH20. 
 
2.2.8  Immunisations and procedures 
 
2.2.8.1 Peptide immunisations 
 
Double transgenic HLA-A2/DR1 mice used between 6 – 12 weeks were given a bolus 
injection of 100 µl of test peptide(s) (100 or 110 µg) in PBS emulsified in Incomplete 
Freund’s Adjuvant (IFA) in a ratio of 1:1 subcutaneously at the base of the tail. In 
accordance with experimental requirements, mice could be given a further 2 rounds of 
weekly immunisations 7 days following initial immunisation. Between 7-10 days post final 
immunisation, spleens were harvested for in vitro assays.   
 
2.2.8.2 DNA bullet preparation and DNA immunisation  
 
DNA bullet preparation - Gold microcarrier solution preparation: Gold “bullets” 
containing the gold labelled DNA were produced according to kit manufacturers protocol 
with the following adjustments. DNA (see appendix Figure Ib for vector map) to be 
labelled was made up to a working concentration of 1 µg/µl in ddH2O in a final volume of 
36 µl. This gave a dose of 1 µg of DNA/bullet/animal. To the measured gold, 200 µl of 
0.05 M spermidine was added and vortex mixed, then sonicated to break up gold clumps. 
The DNA was then added to the gold and spermidine mixture and briefly vortexed, then 
whilst sonicating 200 µl of 1 M CaCl2 was added dropwise to the mixture. The mixture 
was left precipitate at RT for 10 minutes. The microcarrier solution was centrifuged at 
14500 g for 30 seconds and the supernatant discarded. Following this, the pellet was 
washed three times using 1 ml of 100% anhydrous ethanol briefly vortexing between each 
wash. Following the final wash step the supernatant was discarded and the pellet once 
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again vortexed briefly. To the microcarrier solution, 1 ml of 0.025 mg/ml of PVP 
(Polyvinylpolypyrrolidone) was added and the solution was transferred to a 15 ml 
polypropylene centrifuge tube. The tube previously containing the microcarrier solution 
was then used to rinse using again 1 ml of 0.025 mg/ml of PVP and transferred into the 
same polypropylene tube giving a final volume of 2 ml.     
 
Loading onto the Prep Station: Prior to loading the microcarrier solution, the gold-coating 
tubing was completely dried by purging with nitrogen gas for 15 minutes at flow set to 0.3-
0.4 LMP on the Tubing Prep Station. The dried tubing was then removed, the adaptor 
tubing fitted with a 10 ml syringe was fixed at one end. The other end of the tubing was 
placed into the gold suspension, then whilst sonicating, the suspension was quickly drawn 
into the gold-coating tubing. The tubing was then loaded onto the Tubing Prep Station with 
the gas turned off. The microcarriers were left to settle for 3-5 minutes before the ethanol 
was removed using the 10 ml syringe. The tubing was then turned 180° for 5 minutes to 
allow the gold to begin coating the inside surface of the tubing. Following this the tubing 
was set to rotate for a further 30 minutes before the nitrogen gas was switched on for 5 
minutes at flow set to 0.3-0.4 LMP to completely dry the gold microcarriers. The Tubing 
Prep Station was then switched off and the gold-coated tubing removed and placed into the 
tubing cutter to cut the gold coated areas of the tubing into 1.0 cm pieces. These “bullets” 
were stored in a tube at 4°C for DNA immunisations.      
 
DNA immunisation: Mice aged between 6 – 12 weeks were administered with DNA 
encoding whole T21 protein coated onto 1.0 µm gold particles which were then 
administered intradermally by the Helios Gene Gun as per manufacturer’s instructions, 
with each mouse receiving 1 µg of DNA per immunisation. This was repeated at weekly 
intervals for a total of three immunisations. Between 7 – 10 days post final immunisation, 
spleens were harvested for in vitro assays.   
 
2.2.9  In vitro generation of CTL and murine IFNγ EliSpot assay 
  
2.2.9.1 LPS blast cell generation  
 
Preparation of LPS blast cells: Splenocytes from naïve animals were used as APCs during 
in vitro restimulation of immunised splenocytes and were therefore harvested 2 days prior 
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to spleens of immunised animals were collected. Spleens were excised post-mortem and 
transported in dPBS, then using a Petri dish and sterile scissors and forceps the spleens 
were prepared firstly by carefully cut away and removing fatty tissue deposits followed by 
gentle massage of the spleen to break down internal compartments. Next, a 10 ml syringe 
containing 10 ml of T cell media was used to inject media into the ends of the spleen and 
the forceps used to gently flush the contents until the splenic sack became translucent. The 
splenic sack was then homogenised using scissors and both spleen and the flush were 
collected and placed in a 15 ml polypropylene tube and further broken down using a 
pasteur pipette. After allowing the debris to settle the supernatant was collected and 
centrifuged at 400 g, 4oC for 3 minutes. The cellular pellet was resuspended in T cell 
media and cells were counted using 0.06% acetic acid, and then trypan blue, to exclude red 
blood cells and dead cells which appear blue under the microscope. The cell suspension 
was then seeded into a T75 flask at a concentration of 1.5x106 cells/ml with 25 µg/ml of 
lipopolysaccharide (LPS) and 7 µg/ml of dextran sulphate, used to mature cells (Firat et 
al., 1999), and 1.6 µg/ml of Vitamin E, used to minimise cell death. These cells were then 
incubated at 37oC, 5% CO2 for 48 hours. Following incubation, cells were then harvested 
and irradiated with 21.35 Gy for 15 minutes, washed twice and resuspended using T cell 
media at 20x106 cells/ml in universal tubes with 10 µg/ml of relevant peptide(s) and 
incubated with a slightly loosened lid to allow sufficient ventilation at 37oC, 5% CO2 for 
60 minutes. Following incubation, cells were once again washed, counted and the 
concentration adjusted to 0.5x106 cells per 500 µl per well and were seeded into flat bottom 
24 well plates alongside splenocytes from immunised animals. 
 
2.2.9.2 In vitro restimulation with peptide 
 
Spleens from immunised animals were harvested 7 days after final immunisation from 
which splenocytes were flushed and processed from the spleen as mentioned above. The 
cellular pellet was resuspended at 2.5x106 cells per 500 µl per well alongside peptide-
pulsed LPS blast splenocytes into flat bottom 24 well plates and placed at 37°C, 5% CO2 
for 6 days. 
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2.2.9.3 Bone marrow-derived dendritic cell generation 
 
Processing and culture of BM-DC: Bone marrow-derived dendritic cells (BM-DCs) were 
generated by taking bone marrow from mouse hind limbs 8 days prior to carrying out the 
proliferation assay. Limbs were placed in a petri dish and surrounding muscle and tissue 
was carefully removed using sterile scissors and forceps to expose the hind leg bones. The 
bones were then separated from the knee joint and placed in a petri dish containing BM-
DC media. The ends of the femur, and tibia were cut and using a 10 ml syringe containing 
10 ml of BM-DC media, bones were injected with media, in turn, from each end flushing 
the marrow into the petri dish. The marrow cells were further broken down using a pasteur 
pipette and passed through a cell strainer into a universal tube. The suspension was 
centrifuged at 400 g, 4oC for 3 minutes. The cellular pellet was resuspended in BM-DC 
media and cells were counted using 0.06% acetic acid and trypan blue. The cell 
concentration was adjusted to 1x106 cells/ml with 1 pg/ml of GM-CSF and seeded into 24 
well flat bottom plates at 1ml per well. These cells were then incubated at 37oC, 5% CO2. 
 
Washing DC cultures: After 2 and 4 days, non-adherent cells were removed by gentle 
wash with 700 µl of BM-DC media contained in the well. Wells were then replenished 
with 750 µl of fresh media containing 1 pg/ml of GM-CSF.  
 
2.2.9.4 Dendritic cell maturation for antigen presentation 
 
DC maturation: After 7 days of culture, DCs were harvested from wells and centrifuged at 
400 g, 4oC for 3 minutes and the cellular pellet resuspended in BM-DC media and cells 
were counted using trypan blue. Cell concentration was adjusted to 0.5x106 per ml 
containing 1 pg/ml of GM-CSF and 1 µg/ml peptide(s). Plates were then left for incubation 
at 37oC, 5% CO2 for 4 hours after which, 2.5 µg/well of LPS in 100 µl per well of BM-DC 
media was added to induce maturation and left to incubate overnight. The following day, 
the mature DCs were harvested from wells and centrifuged at 400 g, 4oC for 3 minutes and 
the cellular pellet, resuspended in 1 ml of BM-DC media into universal tubes and pulsed 
with 1 µg/ml of relevant peptide(s). An additional 12.5 µg/ml of Poly-IC, used to induce 
full maturation of cells, was added and incubated at 37oC, 5% CO2 for 2 hours with the lids 
screwed loosely on to allow cells sufficient ventilation.  
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After incubation, centrifuged as before and the cellular pellet resuspended in 1 ml of T cell 
media and counted using trypan blue. The cell concentration was adjusted to 5x103 cells 
per 50 µl in T cell media and used as antigen presenting cells in the proliferation assay.    
 
2.2.9.5 Murine interferon gamma EliSpot assay 
 
Plate preparation: EliSpot assays were performed using manufacturer’s procedure 
guidelines. Microplates were pre-wet using 100 µl of 75% ethanol for 5 minutes. 
Meanwhile, capture antibody was used at a 1:60 dilution from the stock using dPBS 
allowing for 10 mls per plate. The ethanol from the wells was aspirated off and the plate 
blotted onto tissue paper to remove residual liquid. Immediately 100 µl of the diluted 
capture antibody was added to wells, covered with the lid and incubated overnight at 4°C.    
 
EliSpot assay: The following day, the unbound capture antibody was aspirated off the 
wells and blotted, and 200 µl of C.T.L media was added and plates were placed at 37oC, 
5% CO2 in order for wells to reach optimal pH and conditions before addition of cells. 
Prior to addition of cells wells were aspirated and plates blotted. Both effector and target 
cells were prepared and resuspended in C.T.L media and seeded into appropriate wells. 
Plates were incubated at 37oC, 5% CO2 for 48 hours after which cells were aspirated off 
and washed 3 times with 200 µl of wash buffer finally removing any remaining liquid by 
blotting against tissue paper. Detection antibody was also used at a 1:60 dilution from the 
stock using reagent diluent allowing for 10 mls per plate. The diluted detection antibody 
was added at a volume of 100 µl to wells, covered with the lid and incubated overnight at 
4°C.    
 
EliSpot detection: The following day, plates were washed as described as above using 
wash buffer. Strepavidin-AP was used at a 1:60 dilution from the stock using reagent 
diluent and seeded at 100 µl into each well and incubated for 2 hours at RT. Plates were 
again washed and 100 µl of BCI/NBT solution was added to each well and the plates 
wrapped in foil to allow colour development for 20-30 minutes. The colour development 
was then stopped by rinsing wells using ddH2O and blotting plate to remove any excess 
liquid, and the plastic backing of the plate removed. Plates were then left to dry at RT for 
at least 2 hours before spots could be quantified using an EliSpot reader.   
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2.2.9.6 3H thymidine incorporation assay for murine T cells 
 
Plate preparation: Splenocytes from the immunised mice were harvested and centrifuged 
at 400 g, 4oC for 3 minutes resuspended in T cell media counted using trypan blue. Cell 
concentration was adjusted to 5x104 cells per 100 µl per well using T cell media and 
seeded into appropriate wells of a 96 well round bottom plate. DCs pulsed with relevant 
peptide(s) were then added at 5x103cells per 50 µl per well alongside plated T cells in 
quadruplicate sets of wells.  
 
3H thymidine incorporation and detection: Cultures were incubated for approximately 60 
hours at 37oC, 5% CO2, and [
3H]-Thymidine was added at 37 MBq/well in the last 18 
hours of incubation. Plates were harvested using a cell harvester onto 96 Uni/Filter 
scintillation plates and were counted using a Top-Count counter. Results are expressed in 
counts per minute (cpm) and as means of the quadruplicate wells. Data analysed using the 
unpaired student’s t test. Significance levels were assigned as p≤0.05, p≤0.01 and p≤0.001.   
 
2.2.10 In vitro restimulation of patient PBMCs and human IFNγ EliSpot assay  
 
2.2.10.1 Preparation of lymphocytes from frozen PBMCs 
 
Frozen vials containing patient PBMCs were thawed rapidly using a hairdryer before being 
transferred into a 25 ml tube containing pre-warmed complete PBMC media and washed 
twice by centrifugation at 300 g for 5 minutes. Cell pellets were resuspended in      4 ml of 
media and incubated for 30 minutes with loosened lid at 37oC, 5% CO2. Peptides were 
prepared in complete C.T.L media at a concentration of 1 µg/ml and 10 µg/ml and added to 
appropriate wells at 100 µl volume. Cells were then centrifuged as before and the pellet 
resuspended in complete C.T.L media, counted and seeded into a 96 well EliSpot plate at 
concentrations between 1-50x104 cells per well. Following 48 hour incubation at 37oC, 5% 
CO2, cell supernatants were carefully collected and stored at 
-20°C for further analysis and 
wells were subsequently washed with x3 times with wash buffer before addition of 
detection antibody and following EliSpot performed (refer to in section 2.2.9.5). Following 
development, plates were air dried, scanned and spots counted using an Immunospot 
analyzer, EliSpot Reader (Cellular Technology Ltd). 
 
 
 
 
 
 
 
CHAPTER 3 
 
GENE AND TRANSCRIPT ANALYSIS AND PROTEIN 
VERIFICATION OF T21 
 
3.1 Introduction 
 
Biomarkers have been defined by the National Cancer Institute as “a biological molecule 
found in blood, other body fluids, or tissue that is a sign of a normal or abnormal process 
or of a condition or disease.” Molecular biomarkers are widely utilised as inexpensive and 
non-invasive tools to evaluate biological changes indicative of cancer, leading to early and 
rapid clinical intervention. Biomarkers have been introduced in early prevention 
population screening and diagnosis in order to reliably detect the presence and classify the 
type of cancer. Biomarkers can also further determine patient outcome prior to treatment 
by identifying aggressive and indolent forms of cancer and also in risk stratification to 
evaluate occurrence or reoccurrence in populations. In addition to their use as prognostic 
markers, they can be used as predictive markers to anticipate patient responses following 
specific treatment. This enables a more informed decision to be made on the most 
effective treatment options available and in post-treatment monitoring as early predictors 
of relapse.      
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Molecular biomarkers such as Her-2 in breast cancer (Sjӧgren et al., 1998) and the 
Philadelphia chromosome (Ph) in certain leukaemias (Shtivelman et al., 1985) have 
unquestionably had a major impact on combating cancer. Despite breakthroughs like 
these, no other non-hereditary cancer biomarker has emerged demonstrating the same 
degree of success or has been approved for clinical use in the last 25 years. Often, 
shortcomings in molecular markers have been attributed to their lack of overall sensitivity 
and/or specificity, the most common example being prostate-specific antigen (PSA) 
presently used in screening for prostate cancer.      
 
Molecular biomarkers have provided great opportunities as biological targets for cancer 
therapies and have paved the first steps towards the development of personalised cancer 
treatments. For instance the use of anti-cancer drugs such as Herceptin in Her2 positive 
breast cancer and Imatinib in CML patients carrying BCR/ABL gene fusion have translated 
into powerful tools used to take advantage of the molecular traits exhibited by an 
individual’s tumour. Over the last three decades, a better understanding of the immune 
system’s response to cancer has encouraged the emergence of personalised cancer 
vaccines as a promising treatment strategy for patients with cancer. This approach has 
been aided significantly by the identification of tumour associated biomarkers and 
exploiting their apparent dual role as biomarkers of disease and as targetable tumour 
antigens due to their aberrant expression in cancer. The appeal of this approach is the use 
of pre-selected biomarkers as tumour-specific targetable antigens by the tumour-bearers 
own immune system, bypassing various forms of toxicity associated with many current 
treatment strategies. Approaches for the serological identification of biomarkers using 
tumour-specific CTL cloning and SEREX has allowed for the discovery of antigens that 
are both immunogenic tumour proteins and in the case of SEREX, screen for antigens that 
elicit high-titre IgG TAA-specific antibody responses, which in turn help identify CD4+ T 
cells reactive to the antigen in question (Jäger et al., 2000). This has provided the platform 
for assessment of newly identified antigens for their utility to become part of 
immunotherapeutic intervention strategies and to this end, in the early 2000’s, this 
laboratory sought to identify prostate cancer specific antigens with relevance as 
immunotherapeutic targets. During this period, T21 (testis clone 21) was identified as a 
promising candidate tumour associated antigen as a result of modified SEREX screening 
of a normal testicular cDNA library expressed in E.coli and probed with allogeneic 
prostate cancer patient serum (Miles et al., 2007). Briefly, sera from prostate cancer 
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patients was used to screen an allogeneic testicular cDNA library (purchased from 
Clontech, USA) whereby plaque-forming units (PFU) were screened with pooled sera 
from four patients with prostate cancer. Reactive clones underwent secondary and tertiary 
screening to reach monoclonality, in vivo excised and converted to plasmid forms. The 
subsequent cDNA were analysed using restriction mapping and sequencing. The 
identification and initial screening of T21 using the method described warranted further 
genomic study to determine its function and investigate its immunological potential. 
Following sequencing of the T21 clone, rapid amplification of 5’ and 3’ cDNA ends 
(RACE) and nested PCR experiments using testicular cDNA were performed to identify 
the extension of the cDNA sequence in both directions including the un-translated regions. 
The identified transcript resulted in a 2797bp length nucleotide sequence and subsequent 3 
frame translation of this sequence lead to the confirmation of a novel protein consisting of 
534 amino acids (Figures 3.2 and 3.3). In silico analysis performed in 2001 sited the T21 
sequence to chromosome 12q21.33 and was found to be composed of 19 exons with 12 
exons covering the coding region of the gene with numerous transcript similarities.  
 
Following the identification of T21, work was undertaken to determine T21 mRNA and 
protein expression in a panel of healthy, benign and cancerous tissues as well as in 
characterised cell lines (Dr Alistair Rogers, PhD Thesis 2009). This work demonstrated 
mRNA expression present at a low level in essential tissues and strongly localised to 
malignant glands compared to control and BPH when the prostate cohort was interrogated. 
Further investigation using a custom designed mono-specific polyclonal antibody raised in 
rabbit designed in coding exon 9 of T21 with the peptide sequence: 
(VELERQLRKENEKQKNEL) showed protein expression to be restricted in normal 
stomach, ovary, breast and prostate with greater expression demonstrated in numerous 
cancer tissues. Protein expression has been extensively studied in prostate cancer in which 
this laboratory reported significant over expression of T21 in prostate cancer glands 
compared with those derived from benign tissue. Additionally, expression was positively 
associated with pathological stage of tumours and suggested a correlation with increasing 
Gleason grade and PSA recurrence (Miles et al., 2012). Further in vitro gene knockdown 
experiments in prostate cancer cell lines performed using siRNA transfection with the 
oligonucleotide sequence CTAGTGCCAGTATCATTAA designed in exon 6 of T21, 
suggested towards the involvement of T21 in cellular proliferation.  
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Later in silico analysis using sequence NCBI-BLAST and alignment tools revealed that 
T21 shared significant sequence similarity with a centrosomal protein called CEP290. This 
gene is also known as nephrocystin-6, 3H11Ag, KIAA0373, tumour antigen Se2-2 and 
cancer/testis antigen-87 (CT87). The CEP290 gene encodes for a centrosomal protein (290 
kDa) which is present in the cell centrosomes of dividing cells and has a role in tissue 
specific cillogenesis (Coppieters et al., 2010). CEP290 was initially identified by Nagase 
and colleagues in 1997 as a partial clone corresponding to CEP290 which they called 
KIAA0373 derived from sequencing of human brain cDNA libraries. In 2001, Chen and 
Shou independently identified a partial sequence demonstrating homology to the same 
gene (which they termed 3H11Ag) from a gastric cancer cell line expression library. They 
determined that the sequence generated a transcript approximately 2.3kb in size and 
encoded for a 70 kDa protein. Two years later, Andersen and colleagues (2003) performed 
mass spectrometry-based proteomic analysis of centrosomal fractions during interphase 
(G1/S phase) (derived from human lymphoblastic KE37 cells) acquired through successive 
centrifugation. By correlating known centrosomal proteins and fluorescence-tagged 
localisation in a human osteosarcoma (U2OS cells) they identified a protein with an 
approximate relative molecular mass of 290 kDa and subsequently named the protein 
CEP290. Further analysis determined that the CEP290 gene consisted of 93.2kb, spanning 
54 exons and encoded for a putative protein consisting of 2479 amino acid residues from a 
full-length 7.9kb mRNA transcript sequence. From the deduced CEP290 protein sequence 
Sayer and colleagues described 13 putative coiled-coil domains, a region with homology 
to SMC (structural maintenance of chromosomes) chromosome segregation ATPases, a 
bipartite nuclear localisation signal, 6 RepA/Rep+ protein kinase inducible domain motifs, 
3 tropomyosin homology domains, and an ATP/GTP binding site motif A (Sayer et al., 
2006). To date, over 100 mutations of CEP290 have been identified and studied primarily 
in the context of cilia related disorders, namely Senior-Loken syndrome (Sayer et al., 
2006), Meckel syndrome (Baala et al., 2007), Leber congenital amaurosis (den Hollander 
et al., 2006), Joubert syndrome (Sayer et al., 2006; Valente et al., 2006) and Bardet-Biedl 
syndrome (Leitch et al., 2008). It is noteworthy that the presence of CEP290 antibodies 
has been reported in some cancers (Eichmuller et al., 2001; Chen & Shou, 2001).  
 
In earlier studies of T21, primers designed for PCR experiments and the custom anti-T21 
antibody used were common to both T21 and CEP290 suggesting that either of the two 
proteins could be detected in PCR and protein-based studies. As CEP290 has been found to 
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be involved in centrosomal function, it could naturally be concluded that its presence 
would be in some way linked to proliferating cells. This was evident in earlier studies 
using T21/CEP290 siRNA in prostate cancer cells; following reanalysis of affymetrix data 
for CEP290 pathway markers, genes known to be implicated in CEP290 pathways were 
significantly modified following T21/CEP290 siRNA transfection.   
 
As a consequence of the previous investigation into T21 and its more recently confirmed 
association with CEP290, it was critical to establish the link between CEP290 and T21 in 
both a genomic and transcriptional context to determine the best approach to study the role 
if any, T21 may play in cancer progression. The current study aimed to fully characterise 
the T21 mRNA sequence using both in silico and experimental investigations and 
secondly, confirm the currently hypothetical protein sequence in an effort to study T21 
independently from CEP290 and its known variants. 
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3.2 Results 
 
3.2.1 Genomic investigation into T21 
 
Prior to investigating T21, it was important to confirm how the T21 mRNA sequence 
aligned to the human genomic sequence from CEP290 situated on chromosome 12. Study 
of the extent of mRNA sequence similarity between T21, CEP290 and CEP290 variants 
was performed using publically available online curated gene repositories such as NCBI 
Human Genome Resources (http://www.ncbi.nlm.nih.gov/) and Ensembl Genome browser 
(http://www.ensembl.org/index.html). Further alignment of exon regions of CEP290 and 
its many genomic transcripts that produce putative proteins was also performed to identify 
any existing sequences that share similarity with T21.  
 
To summarise, sequence Basic Local Alignment Search Tool (BLAST) analysis 
demonstrates a 31% alignment coverage similarity between CEP290 with T21 of which 
there is 96.5% similarity between T21 and CEP290 mRNA. Further mRNA to genomic 
alignment confirmed this similarity (Figure 3.1) and also revealed a potentially unique 
protein encoding nucleotide sequence consisting of 93bp present in T21 that was absent in 
CEP290 mRNA (Figure 3.2 - highlighted in red). This sequence was subjected to focused 
searches which revealed 100% sequence homology to genomic CEP290 demonstrating 
that the short nucleotide sequence was present in an intronic portion of CEP290. After 
extensive searches of the T21 mRNA sequence, no further significant similarity to any 
other DNA or mRNA sequence in the Ensembl and NCBI databases was found, other than 
that of CEP290 and its numerous variants, and therefore it is highly likely that T21 is 
potentially a novel transcript of the CEP290 gene found on chromosome location 
12q21.32 (ch12:88442,794-88,535,993, complement strand). Moreover, the 93bp 
sequence was also found to only have homology to that of CEP290 DNA indicating that 
its inclusion in the T21 sequence to be “unique”. Further still, this 93bp insertion 
originating from intron 18 of CEP290 which, according to previous sequencing 
investigation, is encoded as part of the T21 protein product. Following nucleotide-to-
protein frame translation of T21 and alignment of this protein sequence to CEP290 a 27% 
alignment coverage similarity between CEP290 with T21 was shown. There is 96.7% 
similarity between T21 and CEP290 protein but more interestingly there is no significant 
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similarity of the “uniquely” encoded 31 amino acid T21 sequence with any other organism 
listed in the Ensembl and NCBI databases (Figure 3.3).  
 
 
 
Designation  
Name / 
Accession No. 
Function Comments  Reference  
CEP290 Centrosomal 
Protein 290 kDa 
(CEP290) / 
NM_025114.3 
Present in the cell 
centrosomes of 
dividing cells and has 
a role in tissue 
specific cillogenesis 
Well characterised at the 
genomic level used as a 
reference standard in the 
RefSeqGene project 
 
 
T21 
Prostate cancer 
antigen T21 / 
AY590151.1 
Unknown Identified by modified 
SEREX-defined screening a 
testis cDNA library using 
sera from prostate cancer 
patients 
 
Miles et al., 
(2007)  
 
3H11 Monoclonal 
antibody 
3H11antigen / 
AF317887.1  
 
Localised to the 
cytoplasm and 
nucleus 
MAb 3H11 generated from 
mice immunised with human 
gastric cancer cell lines 
 
Chen and 
Shou (2001) 
 
SE2-2 CTCL tumour 
antigen SE2-2 / 
AF273044.1 
Unknown  Identified by a SEREX-
defined screening a testis 
 cDNA library using sera 
from CTCL patients 
 
Eichmuller et 
al., (2001)  
 
KIAA0373 KIAA0373 / 
AB002371.1 
Role in centrosomes 
determined by protein 
correlation profiling 
using mass 
spectrometry 
Identified using cDNA 
libraries derived from 
human brain  
Andersen et 
al., (2003) 
   
Nagase et al., 
(1997)  
 
 
Figure 3.1 – mRNA to genomic alignment of mRNA transcripts. Above diagram compiled 
using NCBI affiliated online alignment tool http://www.ncbi.nlm.nih.gov/spidey with 
accompanying table detailing putative proteins found to have sequence similarity to CEP290. 
Blue lines illustrate genomic sequence and orange boxes are representative of exon sequence 
location and relative sequence sizes.  
 
 
5001                     98209 
Genomic 
CEP290 
T21 
3H11 
SE2-2 
KIAA0373 
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  1  CCGCGGGGAT CATTATCAAC TTCAAGTGCA GGAGCTTACA GATCTTCTGA AATCAAAAAA 
 61 TGAAGAAGAT GATCCAATTA TGGTAGCTGT CAATGCAAAA GTAGAAGAAT GGAAGCTAAT 
121  TTTGTCTTCT AAAGATGATG AAATTATTGA GTATCAGCAA ATGTTACATA ACCTAAGGGA 
181  GAAACTTAAG AATGCTCAGC TTGATGCTGA TAAAAGTAAT GTTATGGCTC TACAGCAGGG 
241  TATACAGGAA CGAGACAGTC AAATTAAGAT GCTCACCGAA CAAGTAGAAC AATATACAAA 
301  AGAAATGGAA AAGAATACTT GTATTATTGA AGATTTGAAA AATGAGCTCC AAAGAAACAA 
361  AGGTGCTTCA GCCCTTTCTC AACAGACTCA TATGAAAATT CAGTCAACGT TAGACATTTT 
421  AAAAGAGAAA ACTAAAGAGG CTGAGAGAAC AGCTGAACTG GCTGAGGCTG ATGCTAGGGA 
481  AAAGGATAAA GAATTAGTTG AGGCTCTGAA GAGGTTAAAA GATTATGAAT CGGGAGTATA 
541  TGGTTTAGAA GATGCTGTCG TTGAAATAAA GAATTGTAAA AACCAAATTA AAATAAGAGA 
601  TCGAGAGATT GAAATATTAA CAAAGGAAAT CAATAAACTT GAATTGAAGA TCAGTGATTT 
661  CCTTGATGAA AATGAGGCAC TTAGAGAGCG TGTGGGCCTT GAACCAAAGA CAATGATTGA 
721  TTTAACTGAA TTTAGAAATA GCAAACACTT AAAACAGCAG CAGTACAGAG CTGAAAACCA 
781  GATTCTTTTG AAAGAGATTG AAAGTCTAGA GGAAGAACGA CTTGATCTGA AAAAAAAAAT 
841  TCGTCAAATG GCTCAAGAAA GAGGAAAAGA AGTGCAACTT CAGGATTAAC CACTGAGGAC 
901  CTGAACCTAA CTGAAAACAT TTCTCAAGGA GATAGAATAA GTGAAAGAAA TTTGGATTTA 
961  TTGAGCCTCA AAAATATGAG TGAAGCACAA TCAAAGAATG AAATCATAGC ACAGGAATTC 
1021  TTGATCAAAG AAGCAGAGTG TAGAAATGCA GATATAGAGC TTGAACATCA CAGAAGCCAG 
1081 GCAGAACAGA ATGAATTTCT TTCAAGAGAA CTAATTGAAA AAGAAAGAGA TTTAGAAAGG 
1141 AGTAGGACAG TGATAGCCAA ATTTCAGAAT AAATTAAAAG AATTAGTTGA AGAAAATAAG 
1201 CAACTTGAAG AAGGTATGAA AGAAATATTG CAAGCAATTA AGGAAATGCA GAAAGATCCT 
1261 GATGTTAAAG GAGGAGAAAC ATCTCTAATT ATCCCTAGCC TTGAAAGACT AGTTAATGCT 
1321 ATAGAATCAA AGAATGCAGA AGGAATCTTT GATGCGAGTC TGCATTTGAA AGCCCAAGTT 
1381 GATCAGCTTA CCGGAAGAAA TGAAGAATTA AGACAGGAGC TCAGGGAATC TCGGAAAGAG 
1441  GCTATAAATT ATTCACAGCA GTTGGCAAAA GCTAATTTAA AGATAGACCA TCTTGAAAAA 
1501  GAAACTAGTC TTTTACGACA ATCAGAAGGA TCGAATGTTG TTTTTAAAGG AATTGACTTA 
1561  CCTGATGGGA TAGCACCATC TAGTGCCAGT ATCATTAATT CTCAGAATGA ATATTTAATA 
1621  CATTTGTTAC AGGAACTAGA AAATAAAGAA AAAAAGTTAA AGAATTTAGA AGATTCTCTT 
1681  GAAGATTACA ACAGAAAATT TGCTGTAATT CGTCATCAAC AAAGTTTGTT GTATAAAGAA 
1741  TACCTAAGTG AAAAGGAGAC CTGGAAAACA GAATCTAAAA CAATAAAAGA GGAAAAGAGA 
1801 AAACTTGAGG ATCAAGTCCA ACAAGATGCT ATAAAAGTAA AAGAATATAA TAATTTGCTC 
1861 AATGCTCTTC AGATGGATTC GGATGAAATG AAAAAAATAC TTGCAGAAAA TAGTAGGAAA 
1921  ATTACTGTTT TGCAAGTGAA TGAAAAATCA TTTATAAGGC AATATACAAC CTTAGTAGAA 
1981 TTGGAGCGAC AACTTAGAAA AGAAAATGAG AAGCAAAAGA ATGAATTGTT GTCAATGGAG 
2041 GCTGAAGTTT GTGAAAAAAT TGGGTGTTTG CAAAGATTTA AGGAAATGGC CATTTTCAAG 
2101  ATTGCAGCTC TCCAAAAAGT TGTAGATAAT AGTGTTTCTT TGTCTGAACT AGAACTGGCT 
2161 AATAAACAGT ACAATGAACT GACTGCTAAG TACAGGGACA TCTTGCAAAA AGATAATATG 
2221 CTTGTTCAAA GAACAAGTAA CTTGGAACAC CTGGAGTGTG AAAACATCTC CTTAAAAGAA 
2281 CAAGTGGAGT CTATAAATAA AGAACTGGAG ATTACCAAGG AAAAACTTCA CACTATTGAA 
2341 CAAGCCTGGG AACAGGAAAC TAAATTAGGT AATGAATCTA GCATGGATAA GGCAAAGAAA 
2401  TCAATAACCA ACAGTGACAT TGTTTCCATT TCAAAAAAAA TAACTATGCT GGAAATGAAG 
2461 GAATTAAATG AAAGGCAGCG GGCTGAACAT TGTCAAAAAA TGTATGAACA CTTACGGACT 
2521 TCGTTAAAGC AAATGGAGGA ACGTAATTTT GAATTGGAAA CCAAATTTGC TGAGGTTTGA 
2581  TATTATAAGT TTTATCATAC AATTATAGAA TAAAGAATTA GTTTTGGTAG ACATTGTATT 
2641  ATTGTTAAGT GGTTTGTCTG GATCTCTGAA ATATCTTATT AATATAGTGC CTATGTTTTG 
2701  TGTAATAAAT AAATAAAAGA TTTAAATCTG AATTGTTTAA AAGGAAAAAA AAAAAAAAAA 
2761  AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAA  
 
Figure 3.2 – Published T21 complete mRNA sequence. Full 2797bp T21 nucleotide sequence 
(GenBank: AY590151.1) with complete coding sequence highlighted in blue (pos.976-2580), the 
T21 unique region highlighted in red (pos.997-1089) and underlined the sequence obtained 
from the cDNA insert (pos.1101 - 1640) (Miles et al., 2007). Also a diagrammatic 
representative of Figure 3.9A.  
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  1 MSEAQSKNEI  IAQEFLIKEA  ECRNADIELE  HHRSQAEQNE  FLSRELIEKE 
 51 RDLERSRTVI  AKFQNKLKEL  VEENKQLEEG  MKEILQAIKE  MQKDPDVKGG 
101 ETSLIIPSLE  RLVNAIESKN  AEGIFDASLH  LKAQVDQLTG  RNEELRQELR 
151 ESRKEAINYS  QQLAKANLKI  DHLEKETSLL  RQSEGSNVVF  KGIDLPDGIA 
201 PSSASIINSQ  NEYLIHLLQE  LENKEKKLKN  LEDSLEDYNR  KFAVIRHQQS  
251 LLYKEYLSEK  ETWKTESKTI  KEEKRKLEDQ  VQQDAIKVKE  YNNLLNALQM 
301  DSDEMKKILA  ENSRKITVLQ  VNEKSFIRQY  TTLVELERQL  RKENEKQKNE  
351 LLSMEAEVCE  KIGCLQRFKE  MAIFKIAALQ  KVVDNSVSLS  ELELANKQYN 
401 ELTAKYRDIL  QKDNMLVQRT  SNLEHLECEN  ISLKEQVESI  NKELEITKEK 
451 LHTIEQAWEQ  ETKLGNESSM  DKAKKSITNS  DIVSISKKIT  MLEMKELNER 
501 QRAEHCQKMY  EHLRTSLKQM  EERNFELETK  FAEV 
 
Figure 3.3 – Published T21 protein sequence. (GenBank: AAT01278.1) The resulting 3 frame 
translation of T21 sequence derived from the nucleotide sequencing illustrating a 534 amino 
acid protein with a theoretical molecular mass of approximately 62 kDa. Anti-T21/CEP290 
antibody epitope region is shown underlined (pos.335-351) and the T21 unique region 
highlighted in red (pos.8-38).Translated cDNA sequence identified by SEREX in bold (pos.1-
219) 
 
The premature termination of the T21 protein is due to the splicing of intron 29 (173bp) 
from CEP20 on to the C-terminal end of T21, proceeding exon 12 (Figure 3.4). As a 
consequence, this splicing inclusion leads to the immediate encoding of a nucleotide 
triplicate “TGA” serving as a unique stop codon in T21 and resulting in a truncated protein 
which remains in-frame with the CEP290 protein sequence.  
 
Further examination of the exon 18 – exon 19 junction of CEP290 using online alternative 
splice site prediction algorithms (http://www.wangcomputing.com/assp/index and 
http://www.cbs.dtu.dk/services/NetGene2/) both predicted an alternative acceptor site 
(3’Exon-GGCAGAACAG^GTAGTGTAAA-5’Intron) and an alternative donor site 
(3’Exon-TTTCTTTAG^AATGAAATCA-5’Intron) which flanks the 93bp intronic 
sequence forming a unique alternative cassette exon (Figure 3.4). Two consensus branch 
point sequence signals were also identified further upstream of the uniquely encoded exon, 
required for effective splicing of pre-mRNA to mature RNA. 
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Figure 3.4 – Diagrammatic representation of T21 and CEP290 exon alignment. The 
theoretical alternative splicing event leading to the inclusion of the 93bp unique sequence from 
the CEP290 gene sequence at exon junction 18 (top) to T21mRNA sequence (bottom). Also 
illustrated is the generation of the unique stop codon in T21 from the splicing of intron 28 of 
CEP290.    
 
The CEP290 protein itself is highly conserved across species particularly in primates, who 
share between 96–99% sequence similarity to human CEP290. A lesser degree of 
sequence similarity is observed in other mammals for example 92% in Felix catus and 
Canis lupus familiaris, 91% in Equus caballus, 87% in Rattus norvegicus and Mus 
musculus and in the Actinopterygii subclass, Danio rerio share 58% similarity. It is of 
note that despite high conservation among species, there is no evidence indicating 
encoding of the unique sequence. Although primates (such as Pan troglodytes) maintain 
the intronic sequence in the genomic sequence, however transcription to mRNA and 
translation to protein is not observed. 
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In order to verify these new findings, primers within the 93bp “unique region” were 
designed and used in a PCR to confirm the existence of this sequence. Initially, the PCR 
was performed using cDNA derived from prostate cancer derived cell lines PC3 and 
DU145. Due to the possibility of genomic DNA contamination (leading to the likely 
amplifying intronic region of CEP290) of the RNA preparations, RNA purification 
columns were used instead of routine acid guanidinium thiocyanate-phenol-chloroform 
extraction using STAT-60. The resulting 100bp band observed established the presence of 
the unique region within T21 (Figure 3.5A) and the presence of this unique region was 
later confirmed in normal tissue samples (data not shown). In addition, amplification of the 
region flanking the T21 unique sequence using primers designed to amplify the exon 18 –
exon 19 junction containing the unique sequence showed two discreet bands corresponding 
to T21 (287bp) and CEP290 (194bp), indicating that both variants are present within a 
given sample preparation. Interestingly, the band corresponding to the T21 transcript 
appeared fainter suggesting a difference in the abundance of mRNA between the T21 and 
CEP290 transcripts (Figure 3.5B).  
 
 
Figure 3.5 – Verification of T21 unique region product amplified using qPCR. Gel image 
showing qPCR product amplification (100bp) of T21 unique region from the PC3 cell line 
derived cDNA in equalling loaded wells (A) and similarly two wells illustrating the 
amplification of both T21 (287bp) and CEP290 (194bp) PCR products using primers designed 
to flank the unique region (B) using PC3 cDNA. Non template control wells were also 
performed (data not shown).     
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3.2.2 Transcriptional evidence to establish T21 protein translation  
 
Based on the findings of T21 and its similarity to the CEP290 transcript, a number of 
questions still remained unresolved. Therefore, a more in-depth comparative study of both 
the T21 and CEP290 transcripts was deemed necessary. The alignment of the nucleotide 
sequences to the online database tools gave rise to other important differences which could 
alter the amino acid coding sequence and crucially, the expected theoretical protein length. 
Sequence alignment of the predicted 5’ untranslated region (UTR) of T21 also highlighted 
a crucial difference between the two sequences, in which there is an absent adenine residue 
at position 864 of T21 when aligned with the matching exon 17 of CEP290 (highlighted in 
yellow in Figure 3.6A). It was unclear as to whether this was indeed a real deletion or a 
sequencing error, therefore further examination using a targeted PCR approach was 
needed. To this end, primers were designed within the upstream untranslated 5’ prime 
region of T21 up to and including the unique region (highlighted in green Figure 3.6A). 
The amplified 639bp product was then excised from the PCR gel and sequenced, verifying 
the presence of the missing adenine (Figure 3.6C). The addition of this single nucleotide 
into the existing sequence and the resulting output from 6’ frame nucleotide-to-protein 
translation indicated that the previously translated sequence could be coded for as a protein 
with a theoretical size of 97 kDa, which added further urgency to investigation of the 
upstream sequencing as the protein initiation sequence remained unconfirmed.  
 
In light of the genomic alignment to CEP290, it was clear that the verification of the 3’ and 
5’ end sequences of T21 would allow for a more complete transcriptional interpretation. 
Confirmation of the completed 3’ end RACE PCR sequencing was performed when the 
sequence was first identified (Dr Amanda Miles, PhD Thesis 2004) and again in the 
current study. The presence of the unique stop codon was confirmed in a PCR experiment 
with forward primers designed within the unique region and reverse primers designed to 
include the unique stop sequence codon yielding a band at the expected 1508bp size and 
confirming the presence of the unique stop codon (Figure 3.7A).  
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Figure 3.6 – PCR showing previously missing nucleotide present in T21. Nucleotide sequence 
alignment of T21 and CEP290 illustrating the absence of a nucleotide in T21 which is present 
in CEP290 (yellow and the primers designed within the exon 14 of CEP290 to the unique region 
(green) of T21 (underlined) (A). Primers were used to perform qPCR product amplification 
(639bp) from cDNA derived from normal human prostate mRNA (B). Sequencing 
chromatography confirming the insertion of the T nucleotide not included in the first published 
sequence (C).  
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With the sequence obtained from the previous 5’ terminal RACE PCR and the knowledge 
that the sequence may now continue upstream of T21 uninterrupted, forward primers were 
designed upstream of the known T21 sequence located in exon 1 CEP290 and reverse 
primers located in the unique region of T21. The resulting PCR generated a 1931bp 
product which indicated that T21 continues further upstream suggesting that the T21 
transcript may share the same translation AUG codon to that of CEP290 (Figure 3.7B). 
Sequencing of the product band also showed the same adenine discrepancy in the sequence 
data, however despite numerous attempts full length sequencing remained incomplete due 
to the large product size meaning that further attempts at sequencing would be required to 
answer this question in its entirety.  
 
 
Figure 3.7 – PCR gel images showing amplification of T21 specific products using qPCR. Gel 
image showing qPCR product amplification (1508bp) encompassing the T21 unique region and 
the unique stop codon from cDNA derived from normal human prostate mRNA (A). PCR gel 
image demonstrating amplification of a PCR product (1931bp) using primers designed within 
the first exon of CEP290 to the unique region of T21 (B). 
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In order to perform a completed overview of the T21 mRNA analysis, it was important to 
perform a PCR that would generate (if present) the predicted full length T21 transcript 
extending from the new start region (in exon 1 of CEP290) through to the unique T21 stop 
codon. By using the appropriate primers situated at the start of CEP290 and the end of T21, 
a band corrosponding to the transcript would be apparent at 3406bp (Figure 3.8). In 
addition to the expected band, an additional band was observed at approximatly 1100bp 
therefore the gel bands were excised and purified and were used in a second round of 
amplification using primers that flanked the unique region of T21. No product bands were 
observe in the unexpected 1100bp product and was therfore considered to be non-specific 
amplicon. Interestingly, a band specific for T21 and a band specific for CEP290 were 
observed in the 3406bp sample suggesting there may be multiple amplicons of similar size 
present within the observed 3406bp band, hence explaining the difficulty in achieving full 
length sequencing experienced earlier. The opportunity to isolate one T21 specific product 
was taken by using the 3406bp band and performing a second round of PCR amplification 
using primers designed from the start of CEP290 and one within the T21 unique sequence 
resulting in a 1931bp band. Despite multiple attempts and using various sequencing 
primers, full length sequencing of the band was not achieved.   
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Figure 3.8 – PCR gel image showing amplification of extended T21 specific products. Gel 
image showing qPCR product amplification (3406bp and approx. 1100bp) from the beginning 
of CEP290 to T21 unique stop codon performed using normal human prostate mRNA derived 
cDNA. 
 
There is now accumulating evidence at the mRNA level to suggest that the T21 protein 
sequence extends in the 5’ terminus, aligning with the CEP290 start codon. It was therefore 
important to systematically examine mRNA transcript and protein variants of CEP290 
using online databases which allowed for the alignment of known (experimentally verified) 
and predicted sequences of CEP290. It was then important to verify how the protein 
sequence of T21 also aligned against these reported variants. This analysis was performed 
for two reasons, firstly to identify any previously reported instances of the 93bp unique 
region in T21 and secondly to highlight any existing partial sequences that have homology 
to the remainder of the T21 sequence and looking into the evidence for them (Figure 3.9).
  
 
Figure 3.9 – A detailed overview of published CEP290 transcripts. Online searches performed using NCBI and its affiliated sites, Ensembl and Uniprot 
were manually collated to illustrate alignment of mRNA transcripts to CEP290 detailing names and NCBI accession numbers. Additional protein 
encoding exons (blue) and non-coding exons (green) and sequence alignment to show inserts/missing exons are highlighted. In addition, the alignment of 
CEP290 and the published T21 sequence and the hypothetical alignment of T21 are illustrated in boxes (A) and (B) respectively.
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The alignments detailed in Figure 3.9 illustrated many alternative splicing events 
occurring within the CEP290 gene which in turn give rise to many transcript variants, 
some of which have been identified to have associations to various cancers. More 
specifically, the previously mentioned 311HAg sequence identified in 2001 shows an 
absence of the 93bp unique region present in T21 and therefore can be considered as an 
additional independent transcript. Similarly, Se2-2 can be considered a separate variant 
due to it sharing no sequence similarity to T21. These two examples are evidence that 
CEP290 itself may indeed be a cancer associated protein leading to anti-CEP290 antibody 
production, which has so been identified in gastric (Chen & Shou, 2001), CTCL tumours 
and also leukaemia and melanoma cell lines (Eichmuller et al., 2001).  
 
Intriguingly the discovery of a transcript containing the exact unique region was identified 
(Transcript CEP290-202). This brought to light the possibility of detecting both transcripts 
during experiments designed to be T21 mRNA or protein specific. The consequences of 
this transcript were reassessed when taking into consideration that at this time, transcript 
CEP290-202 stands as a prediction only with no experimental evidence to suggest it 
exists. Secondly, the results observed in Figures 3.7B and 3.8 suggest that T21 extends 
further upstream than that of CEP290-202. Furthermore, unlike T21, CEP290-202 
continues uninterrupted downstream to the final sequence termination signal in exon 54 of 
CEP290 suggesting they are separate variants of the same gene. Further analysis suggests 
that transcripts CEP290-202 and -005 correspond to the second reported protein isoform 
of CEP290 (UniProt Identifier O15078-2) of which functionally little is known as there is 
currently no experimental confirmation available. Importantly, the findings suggest that 
the unique region identified in T21 exists in a non-protein encoding capacity in CEP290-
202 therefore targeting the polypeptide sequence of the unique region should theoretically 
be specific to the T21 protein sequence.  
 
Not only was it necessary to consider the implications of these findings for future analysis 
of T21 but was also imperative to assess the identification of T21 retrospectively. A brief 
summary of the identification process of T21 initially by RACE PCR performed in 2004 
for the purpose of this investigation is stated below interjected with potential implications 
following the recent sequence elucidation.    
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First, 5’ end RACE PCR was performed using normal testis cDNA using the SMART-
RACE kit both purchased from Clontech, four bands were achieved which may have been 
due to the non-specific amplification of CEP290 mRNA and possibly transcript FLJ21979 
(Figures 3.9 and 3.10). Nested PCR was performed using the initial RACE PCR product 
using nested primers from the commercial kit and a gene-specific reverse primer. However 
this primer was designed well inside the unique region giving rise to two product bands 
corresponding to two of the bands observed in the initial RACE. The subsequent 
sequencing of the largest band extended to the top of the known T21 sequence to the 
unique region and overlapped with the partial sequence obtained from the cDNA insert. 
Although seemingly complete, the initiation sequence to commence protein translation was 
not identified and relied on the basis of 3-frame nucleotide-to-protein translation, therefore 
can be considered as potentially unresolved. 
  
Next, 3’ RACE was performed in the same manner in which three bands were observed. 
This time gene-specific primers were positioned within the unique region and would in 
theory extend T21 specifically. Following nested PCR using primers designed outside of 
the unique region, two bands were observed representing two bands observed on the initial 
RACE PCR (Figure 3.10). This sequence extended down from the unique region, however 
this did not include the unique stop codon and therefore translation into protein showed no 
termination sequence present. Further unsuccessful attempts in 3’ RACE prompted an in 
silico investigation using expressed sequence tag (EST) mining which identified a 
sequence in a GenBank entry (BE537521) aligning with the end of 3’ RACE sequence. 
Primers were designed within this GenBank entry sequence and using a 5’ primer which 
overlapped the unique region by 4 base pairs. Forward sequencing data of this product 
showed the T21 unique region amplification, however reverse sequencing proceeded from 
the 3’primer up through the sequence failed to show overlap with the forward sequence. 
This sequence did overlap with the sequencing data achieved from the initial 3’ RACE and 
the cDNA insert sequence. Sequencing also revealed base discrepancies meaning that the 
additional bases in T21 resulted in a non-coding sequence, and was therefore considered to 
be an incomplete sequence. Re-mining EST databases with the now extended sequence 
resulted in the identification of GenBank entry BC008641 (a clone of CEP290 which 
contains a unique stop). PCR using the BE537521 specific forward and a BC008641 
specific reverse primer which included 12 bases specific for the unique stop codon was 
performed and produced a weak band. On this occasion, sequencing demonstrated forward 
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and reverse sequencing overlap to include the unique region and confirming the stop 
sequence achieving full length protein coding of T21 (Figure 3.9). Incidentally, BC008641 
derived from human placental choriocarcinoma tissue mRNA forms a truncated portion of 
CEP290 and was noted as having a bona fide poly A tail.  
 
Figure 3.10 - Schematic showing previous RACE primer design. T21 coding region (blue) 
containing within, T21 93bp unique region (red, left) and the alternatively spliced exon 
containing the unique TGA codon (red, right). Arrows representative of primer locations for 
initial and nested RACE PCR’s performed and primers to verify sequence similarity to 
identified EST’s. 
 
Retrospectively, a number of conclusions could now be made from the previous study. 
Firstly, in both 5’ and 3’ end experiments, primers designed, were (by chance) within the 
unique region in either initial RACE or in nested PCR’s, establishing that the sequence 
amplified was T21 (or possibly CEP290-202) specific and not CEP290; moreover, the 
product sequencing also consistently showed the inclusion of the unique region. However, 
5’ terminal extension can be considered as incomplete due to the new knowledge of the 
sequencing discrepancy and therefore possible incorrect assignment of the initial AUG 
codon in the T21 mRNA. Finally, the T21 3’ end sequencing could be considered complete 
due to EST data mining and sequence alignment verified with experimental sequencing 
evidence and thus excluding CEP290-202 as a candidate. However, a question remains as 
to whether there are multiple gene transcripts within the T21 unique region which could 
terminate prior to the identified unique stop codon. An amplification of both 5’ and 3’ ends 
could i) reveal the genuine AUG codon upstream of the current transcript, ii) verify the 
known stop codon and iii) uncover multiple mRNA sequences that contain the unique 
region.  
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Preparation of RNA was performed using GeneRacer kit (Invitrogen) which is based on 
RNA ligase-mediated and oligo-capping RACE methods resulting in selective ligation of 
T21 unique region specific primers to the 5’ ends of decapped mRNA using T4 RNA 
ligase. The kit specifically amplifies mRNA that has a poly A tail and is reverse 
transcribed, therefore by eliminating truncated messages and ensuring that only full-length 
transcripts are amplified as detailed in section 2.2.3. The RACE PCR experiments were 
performed using normal prostate cDNA purchased from Clontech. Following many 
attempts, the resulting PCRs consistently produced similar sized bands to that of the RACE 
experiments performed in 2004 (Amanda Miles, PhD thesis, 2004), with both 3’ and 5’ end 
terminals failing to extend any further than the previously acquired sequences (Figure 
3.11).  
 
Figure 3.11 – 5’ and 3’ RACE PCR of T21. Figure 3.10(A) illustrates the products achieved 
following 5’RACE PCR using T21 unique region specific reverse primer. Lanes 1-3 represent 
equal loadings of the 5’RACE PCR product onto a 1% agarose gel. Two intense bands were 
obtained at approximately 880bp and 520bp (representative of three independent experiments).  
Figure 3.10(B) illustrates the products achieved following 3’RACE PCR using T21 unique 
region specific forward primer. Lanes 1 and 2 represent equal loadings of 3’RACE PCR 
product onto a 1% agarose gel. Two bands were obtained at approximately 580bp and 340bp. 
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Following inconclusive RACE PCR experiments, northern blotting was considered to be 
an appropriate approach to verify the existence of a T21 mRNA transcript. In addition, 
with the possibility of an additional transcript containing the unique region it was 
important to confirm exactly how many potential variants containing the unique sequence 
were present. Northern blotting was performed using short custom made anti-sense 
oligonucleotide RNA probes (Sigma, UK) labelled using single biotinylated cytidine 
(bis)phosphate nucleotide to the 3’ terminus using T4 RNA ligase (Thermo Scientific, 
UK). Next, labelled RNA probes were hybridised to the target total mRNA and loaded 
onto polyacrylamide gels for electrophoresis and the separated RNA blotted using semi-
dry transfer at 200 mA for 30 minutes onto positively charged nylon membranes. Next 
fixation of RNA to the membrane was performed by baking at 80°C for 15 minutes 
followed by detection using the Chemiluminescent Nucleic Acid Detection Module 
(Thermo Scientific, UK).  
 
Before commencing, optimisation experiments were performed to confirm ideal 
component concentrations, running conditions and to refine technical procedure. 
Following running of mRNA, gels were incubated with GelRed and UV light to visualise 
the quality and quantity mRNA determined by separated ribosomal RNA subunits 
observed as prominent bands representing ribosomal subunits 28S (5kb) and 18S (2kb).   
 
The experimental blots were performed using 2 µg of total normal prostate mRNA (Figure 
3.12). A single band specific to T21 was detected using a probe designed to the 93bp 
unique region (probe 1). Importantly probe 4, designed at the 3’ end of the T21 mRNA 
transcript to include the unique stop sequence also detected a band of the same size as 
observed in probe 1 indicating the existence of T21 as an actual transcript. Interesting, 
another band detected by probe 4 indicated a smaller transcript that may form part of 
another truncated CEP290 product such as BC008641. A probe designed at the 5’ end of 
the known T21 transcript was also designed with the intention of observing multiple 
separating bands allowing size confirmation of T21 and estimation of the number of 
variants CEP290 may have. However, adequate band resolution was not achieved. 
Additionally, a CEP290 specific probe designed downstream of T21 and away from many 
other mRNA variants of CEP290 (probe 2) demonstrated a single band, unexpectedly only 
slightly larger in size that that of T21 perhaps due to the variants present encoding for the 
truncated isoform of CEP290 (Figure 3.12). 
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Figure 3.12 – Detection of CEP290 and T21mRNA by northern blot analysis. Four RNA 
molecular probes designed along CEP290 and T21mRNA sequences (exon annotation referring 
to CEP290) (A). Northern blot performed using 2 µg of prostate total mRNA pre-hybridised 
with probes on 12% PAG (B), lanes 1 - 4 represent probes 1, 2, 3, and 4. (n=3). 
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3.2.3  Protein investigation to establish T21 translation 
 
Previous protein based investigations on T21 had been performed using a custom-made 
polyclonal mono-specific rabbit antibody (Pacific Immunology, USA). The epitope 
selection was based on several predicted characteristics of T21 including immunogenicity, 
hydrophobicity/hydrophilicity and protein folding. It is now known that this antibody was 
raised against a 18mer peptide sequence sharing 100% homology to CEP290 (underlined 
in Figure 3.3) and other CEP290 protein variants, therefore the antibody binding would 
not be unique to T21 (termed throughout this study as anti-T21/CEP290 antibody). In 
order to further investigate T21 at the protein level, independently from CEP290, a new 
polyclonal anti-T21 antibody (anti-T21u antibody) was produced (Pacific Immunology, 
USA). On this occasion, the mono-specific anti-T21u antibody was raised against a pre-
selected 14mer peptide sequence within the newly identified unique region of T21 
(ADIELEHHRSQAEQ), which unavoidably meant bypassing antigen prediction 
algorithms in favour of sequence specificity to T21. The procedure detailed by the 
company entailed the following; rabbits were immunised with a synthetic peptide 
sequence with 3 further boosts, and subsequently bled and the sera recovered from which 
antibodies were isolated using the same immunisation peptide sequence covalently 
coupled to affinity columns allowing for purification of mono-specific anti-T21 
antibodies. Final elutions were assessed using peptide ELISA assays ensuring antigen 
binding specificity and quantify purified antibody. Prior to antibody production, protein 
BLAST analysis revealed, as expected, 100% sequence homology to T21 only, however 
other proteins matching between 5-8 consecutive amino acid residues could unavoidably 
form potential antibody targets. With this consideration, the generation of a mono-specific 
polyclonal antibody in this way increases the probability of T21 specific binding occurring 
due to the presence of multiple T21-specific peptide binding regions. 
 
Preliminary validation assessment of the anti-T21u antibody to determine the specificity 
and reproducibility of the antibody was performed systematically using multiple 
applications. These included blocking experiments using the antibody specific peptide to 
confirm specificity of the antibody (ELISA, WB and IF), comparison of anti-T21u 
antibody to isotype control to determine levels of background IgG antibody binding (WB 
and IF) assessment of a large panel of cancer cell lines and tissues (ELISA, WB, IF and 
IHC) to optimise antibody conditions specifically for each application (detailed in section 
Chapter 3: Gene and transcript analysis and protein verification of T21 3.2 
 
119 
 
2.1.5). In addition, as a positive confirmation, immunoprobing was performed using a 
previously purchased custom recombinant T21 protein (GTP Technology) purified from 
E.coli with an N-terminal His tag (sequence shown in Figure 3.3). Band separation and 
probing of the recombinant protein with the anti-T21u antibody detected a band at 68.58 
kDa (Figure 3.13A), this finding concurred with the protein band detected by the company 
following anti-His western blot analysis (see appendix Figure II). 
     
 
 
Figure 3.13 –T21 protein detection using T21u antibody. Western blot analysis performed 
using recombinant T21 protein (RP) with anti-T21u antibody detected a discreet band at 68.58 
kDa concurring with anti-His western blot analysis supplied with the RP from GTP technology 
(A).  
Western blotting performed using 30 µg of total protein lystate derived from PC3 cells and 
probed using the anti-T21u antibody detected two prominent bands at 90 kDa and 70 kDa as 
shown in lane 1 (B). Lane 2 represents peptide blocking of antibody prior to probing PC3 cell 
lystate. An anti-β-actin  antibody was used as a protein loading control observed at 45 kDa.  
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The probing of a recombinant protein confirmed that the new T21 specific anti-T21u 
antibody was able to identify the T21 protein sequence, subsequently evidence that T21 
was indeed endogenously expressed in cells was sought. Western blot analysis was 
performed using the prostate cancer cell PC3, lead to the observation of two discreet bands 
appearing at approximately 70 kDa and more distinctly at 90 kDa (Figure 3.13B). The 
molecular weight observed did not correspond to the predicted sequence size (+100 kDa) 
and reasons for the observation of two bands instead of the anticipated one specific band 
must be considered. For example, many proteins undergo extensive modifications during 
protein synthesis resulting in mass changes in proteins when compared to their actual 
sizes. The migration of proteins may be affected by post-translational modification, post-
translational cleavage, splice variants and isoforms and the composition of amino acids 
altering the relative charge. As mentioned earlier antibodies may also bind to other linear 
epitopes present in the denatured protein lysate. 
 
These findings led to the opportunity to further investigate T21 protein in cell lines to both 
address the currently hypothetical status of this protein and thereafter investigate its 
expression in tissues and elucidate its potential function. With this said, cell lysates 
obtained from cell lines identified by immunoblotting and ELISA to express T21 protein 
using T21u antibody were chosen in order to isolate the protein by native 
immunoprecipitation (IP). Here, a Dynabead magnetic separation method was selected 
over agarose/sepharose slurry due to higher quality and specificity of recovery when 
performing small scale isolation. Additionally sepharose beads are considered unsuitable 
for downstream mass-spectrometry applications (personal communication Dr David 
Boocock). The resulting lysate elutates were subjected to western blot analysis which 
demonstrated the presence of one discreet band at approximately 90 kDa. The T21 
specificity of this band was confirmed by its absence in an IgG control probed with anti-
T21u antibody (Figure 3.14). Interestingly the previously identified band (at 
approximately 70 kDa) was not observed in the immunoprecipitated eluate suggesting that 
the presence of this band maybe due to an exposed epitope(s) occurring during protein 
denaturation which results in the appearance of a band.  
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Figure 3.14 – Western blot of T21 protein expression following immunoprecipitation. 
Western blot analysis performed using breast cancer derived cell line lysate (T47D) following 
immunoprecipitation (IP) using anti-T21u antibody. IP shows a specific band observed at 90 
kDa which was not observed using an anti-rabbit IgG antibody IP which was probed with anti-
T21 antibody during immunoblotting. Bands observed at 50 kDa represent heavy chain of 
antibody. Lane 1 = T21-IP, lane 2 = input cell lystate and lane 3 = IgG control-IP (n=3). 
 
In an attempt to confirm the presence of T21, proteins present in the IP elution underwent a 
ZipTip clean up procedure before being tryptically digested and subject to MS/MS analysis 
using an Ultraflextreme MALDI-TOFTOF (Bruker Daltonics). This procedure was 
performed using samples derived by direct elution and also by excision of the protein band 
from polyacrylamide gel following electrophoresis and coomassie brilliant blue staining. 
To determine the feasibility of this approach in respect to identifying T21, MS/MS analysis 
using mascot software 2.2 search engine (http://www.matrixscience.com/) using the 
previously mentioned recombinant T21 protein (customised by GTP Technology) lead to 
the identification of CEP290 sequences. A specifically created “in-house database” 
consisting of only the hypothetical T21 sequence identified the T21 unique region 
sequence (performed by Miss A. Yvonne Dede). This second “in-house” approach was 
used due the difficulty in identifying such a short 31 amino acid residue sequence unique 
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to T21 limiting tryptic digestion sites causing limited specific peptide sequence 
identification and in turn, reducing the overall significance of these hits. However, despite 
using the same MS/MS approach as used to identify tryptic peaks specific to the T21 
recombinant protein, T21 sequence identification using immunoprecipitated elution’s 
remained elusive with no significant identities against T21 or the homologous CEP290 
sequence being observed in the excised gel samples. Furthermore there were no 
identifiable ion peaks in the direct elution sample (data not shown).  
 
In an alternative approach also using IP, western blot analysis were performed on anti-
T21u antibody directed elutions which were then probed using either anti-CEP290 or anti-
CEP290/T21 antibodies as both of these antibodies would theoretically be directed in-
frame upstream (CEP290 antibody) or downstream (T21/CEP290 antibody) of the unique 
sequence in the T21 protein sequence (Figure 3.15). On this occasion, cross-probing in this 
manner failed to produce a T21 specific band (using anti-CEP290 antibody) and what 
remains inconclusive evidence of single 90 kDa band in the case of anti-T21/CEP290 
antibody. In addition, IP’s performed using anti-CEP290 and anti-T21/CEP290 antibodies 
which were subsequently probed using anti-T21u antibody proved equally unsuccessful 
(data not shown).    
 
Figure 3.15 – Schematic of T21 and CEP290 antibodies used for this study. Three antibodies 
specific to CEP290 and T21 proteins were used during this study (exon annotation referring to 
CEP290). 
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3.3 Discussion 
 
The identification of novel TAAs present opportunities to specifically trigger tumour-
killing mediated by TAA primed T cells, which can be incorporated into a whole host of 
immunotherapeutic treatment approaches. Many researchers have adopted the SEREX 
approach in order to identify cancer restricted, immunorelevant tumour antigens, with one 
promising sequence identified by this laboratory being T21 (Miles et al., 2007). Upon the 
discovery that this sequence may indeed have an association by virtue of significant 
sequence homology to another protein named CEP290, genomic, transcriptional and 
protein studies were undertaken in order to i) determine the genomic and transcriptional 
relationship between CEP290 and T21, ii) perform retrospective analysis to the 
identification of the T21 sequence and subsequently determine the full length 
transcriptional sequence of T21 and finally iii) to address the currently hypothetical status 
of the T21 protein sequence and establish whether it is an independent transcript to 
CEP290 and its known variants.    
 
Gene alignment to the published T21 transcript confirmed a 31% alignment coverage 
similarity between T21with CEP290 of which 96.5% similarity between T21 and CEP290 
mRNA was observed. Furthermore, no significant homology of the T21 unique region to 
any other organism in the Ensembl and NCBI databases was observed. It can therefore be 
considered that T21 is a transcript of the CEP290 gene found on chromosome 12q21.32. 
Moreover, it was concluded that a 27% alignment coverage similarity is shared between 
T21 with CEP290 of which there is 96.7% similarity between T21 and CEP290 protein 
sequences. This demonstrates that T21 shares in-frame nucleotide-to-protein translation 
with CEP290 suggesting that the antibody used in previous investigations of T21 would 
recognise peptide binding sites of both CEP290 and T21 (referred to throughout this 
investigation as CEP290/T21 antibody).  
 
In addition to in silico gene analysis, approaches were taken to investigate the 
transcriptional output of T21 centred on the primary identification, results and the sequence 
submitted to GenBank in May 2004. As a result of this study, the T21 sequence was found 
to contain a 93bp insertion proceeding exon 18 of CEP290 from CEP290 intron 18/19. 
This subsequently encodes for the incorporation of a 31 amino acid sequence which is 
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specific to T21 and not to CEP290. In silico alignment of the known transcripts of CEP290 
indicated that a transcript called CEP290-202 may indeed encode for this region, however 
it is located upstream of the protein encoding sequence. This 93bp insertion was thereafter 
referred to as “the unique region” due to its exclusive protein encoding in T21.  
 
Importantly, this was not the only difference of note, as the T21 protein prematurely 
terminates after exon 28 of CEP290. Further alignments confirmed that skipping of a 
splicing event occurs after exon 28 of CEP290 resulting in the continued transcription into 
the intronic sequence and as a consequence an immediate sequence termination signal is 
encoded for, giving rise to a truncated T21 protein sequence. These findings were also 
confirmed experimentally, giving evidence of a novel, previously unreported, CEP290 
protein variant containing an alternatively spliced exon. Interestingly, the T21 and CEP290 
mRNA were shown to be co-expressed in tissue, suggesting that T21 does not have a 
substitution affect on CEP290. Like proteins that encode point mutations, differentially 
expressed proteins and fusion proteins; alternative splicing events and intron retentions are 
a unique source of potential antigens due to their association to tumours and the sometimes 
contributing affect in malignant transformation. These factors make these proteins a 
potentially important, but often overlooked, source for immunotherapeutic targets. Early 
examples include a study which identified an intronic sequence which forms part of an 
antigenic peptide sequence for melanoma ubiquitous mutated-1 (Coulie et al., 1995); 
others that have shown intron encoded peptides include GnT-V (Guilloux et al., 1996), 
TRP-2-INT2 (Lupetti et al., 1998) and gp100-in4 (Robbins et al., 1997) capable of HLA-
restricted recognition by CD8+ T cells resulting in killing of melanoma tumour cells.  
   
Previously reported investigations of disease-related CEP290 mutations deal primarily 
with cilliopathies with little understanding as to how CEP290 mutations generate multiple 
and varying disorders and phenotypes commonly affecting brain and retina development, 
spinal cord (CNS) and kidney function (Coppieters et al., 2010). CEP290 mutations are 
frequent causes of Leber congenital amaurosis (LCA) as den Hollander and colleagues 
identified key mutations by sequencing all 53 coding exons from LCA-affected patients by 
way of RT-PCR using overlapping primer sets (den Hollander et al., 2006). One particular 
genetic defect is responsible for approximately 20% of all cases of the disease, the defect is 
caused by an intronic mutation (c.2991+1655A>G) which is responsible for creating a 
strong splice donor site and the insertion of a 128bp cryptic exon between exons 26 and 27, 
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leading to a premature stop downstream of exon 26 (p.Cys5998X). This results in the 
production of an abnormal truncated protein and consequently a complete or partial loss of 
function. Interestingly the T21 unique splicing event itself has not been identified as a 
transcriptional variant in any published allelic variants of CEP290 which have been 
associated with disease states. Other investigations demonstrated that CEP290 has been 
previously been identified as a SEREX-defined TAA (Eichmuller et al., 2001) and showed 
increased expression in several cancers (Chen & Shou, 2001), however both instances were 
shown to be independent of T21, either due to the location of the identified antigen (Se2-2) 
or the exclusion of the unique 93bp sequence indicating an alternative variant being 
identified and assessed (3H11Ag).          
 
The unexpected discovery of the unique region and a novel stop signal in T21 have proven 
invaluable in comparing T21 and CEP290 transcript expression as these differences were 
exploited to extend the 5’ end of the mRNA using RACE PCR and also used for northern 
blot analysis, both useful tools often applied to determine the presence of transcriptional 
variants and particularly in determining size and differential expression of several 
unknown or novel SEREX identified antigens (Jäger et al., 2002; Rogers et al., 2002; 
Krackhardt et al., 2002). In the case of the latter, RNA probes designed specifically at the 
unique region and at the unique stop meant T21 could be verified as an independent 
transcript confirming the presence of an alternatively encoded exon and unique stop 
sequence confirmed using both normal tissue and cancer cell line mRNA. Initially, 
northern blotting was performed using DNA templates generated using T21 or CEP290 
specific primers designed to amplify between products (sized between 200 – 800bp) from 
normal prostate total mRNA. Next, the DIG Northern Starter Kit (Roche Applied Science, 
UK) was used for in vitro transcription of the template DNA in the presence of 
digoxigenin-11-UTP (DIG), a non-radioactive label which incorporates uridine 
nucleotides, using T7 RNA polymerase to generate DIG labelled single stranded RNA 
probes. Following this, a formaldehyde agarose gel containing GelRed solution loaded 
with 2 µg of RNA was run at 3 V/cm for 2 hours and the gel briefly visualised for the two 
ribosomal bands. The separated RNA was blotted onto a positively charged nylon 
membrane by capillary transfer overnight and the RNA fixed to the membrane by UV-
crosslinking method. Membranes were then subject to overnight hybridisation of the 
labelled probe followed by a series of stringency washes followed by development using 
anti-DIG-AP antibody and CDP-star solution for signal detection using 
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chemiluminescence. This method was chosen due to safety issues, costing and superior 
sensitivity over radioactivity; however despite many attempts and altering various 
parameters suggested by the kit manufacturer, probing failed due mainly to procedural 
difficulties in either the probe construction or the detection stages (data not shown). A 
major disadvantage of separating mRNA using polyacrylamide is the limited band 
resolution achieved compared to using formaldehyde/agarose gels, which is why the 
approach described above was attempted in the first instance. The secondary objective of 
determining the transcript size of T21 remained unanswered, however on the findings 
presented here, there is evidence that the T21 transcript exists.    
 
 Further study to conclude the regulatory mechanisms for this splicing event occurring 
could be of interest and allow for a more complete molecular characterisation of T21. 
Previous experiments revealed incomplete 5’ terminal end extension of the mRNA; further 
to this, PCR amplification of T21 from the unique region upstream to exon 1 of CEP290 
demonstrated that T21 may extend to the start of CEP290 and additional sequencing 
analysis of this product revealed an additional adenine residue present in CEP290 which 
was previously omitted from the published T21 sequence. The consequence of this 
nucleotide addition draws questions as to the initiation signal of T21 protein; however this 
study failed to fully confirm the extended upstream sequence from the CEP290 ATG to 
the unique region and therefore unable to determine protein start ATG in order to identify 
the transcriptional start.  
 
Cancer progression has been long associated with genetic alterations which consequently 
result in aberrantly expressed proteins (detailed in chapter 1). These cancer-associated 
alterations can occur at various stages of transcription as a consequence of altered pre-
mRNAs and the use of alternative promoters and splicing events which alter coding 
regions ultimately impacting on protein functionality. For this reason, further insight into 
the regulatory mechanisms of T21 mRNA production is essential to understanding its 
biological significance in cells. Despite CEP290 being a well characterised gene, the 
promotor region remains unknown. Further experimental investigation involving specific 
promotor silencing could determine whether T21 and CEP290 share the same promotor or 
are indeed independently regulated. With this considered, RACE PCR using T21-specific 
forward and reverse primers were employed in an attempt to translate upstream of T21 to 
obtain full length cDNA but despite several attempts, 5’ terminal translation could not be 
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achieved. This is not surprising as RACE PCR of the 5’ end can be technically problematic 
due to the presence of fragment RNA, premature termination of cDNA due to formation of 
secondary structures and amplification bias favouring both highly abundant and short 
amplicons during PCR.        
 
As previously mentioned CEP290 is so named because of its role in centrosome and cilia 
development. The centrosome is the primary microtubule-organising centre (MTOC) 
found in cells, consisting of a pair of centrioles surrounded by an amorphous protein 
lattice collectively termed the pericentriolar material (PCM) component, which is 
responsible for nucleation and anchoring microtubules forming mitotic spindles during 
cell division (Bettencourt-Dias & Glover, 2007). Ontological evaluation of the CEP290 
gene reveals protein and microtubule binding properties that not only localise to the 
centrosomes but also extend to the formation of microtubule basal bodies and connecting 
cilia of photoreceptor, hence the association of CEP290 deregulation seen in many cilia-
related diseases. Moreover, CEP290 was found to be associated with G2/M transition of 
the mitotic cycle through co-operation with ciliary GTPase Rab8A, a member of the RAS 
oncogene family (Tsang et al., 2008). The protein alignment from the cDNA sequence 
suggests that T21 would theoretically retain conserved regions of activity from CEP290 
protein, but contextually, the whole of T21 transcriptional sequence remains unknown 
therefore it would be counter-intuitive to begin bioinformatics-based prediction analysis of 
its potential function. However, focus on CEP290 and the unique region revealed 
sustained evolutionary conservation of the CEP290 gene, as demonstrated in higher 
mammals and (relevant for the latter phase of this study) revealed 87% similarity between 
murine CEP290 and human CEP290 proteins with no sequence similarity to the T21 
unique region. Conservation of the T21 unique region intron sequence was evident in 
primate species such as chimpanzee, gorilla and monkey, however no inclusion into 
putative proteins were observed. Due to there being no significant protein encoding 
sequence similarity of the T21 unique region to any other organism in the Ensembl and 
NCBI databases, from this it could be concluded that this variation is unique to humans.  
 
Previous protein investigations were performed using a polyclonal anti-CEP290/T21 
antibody. Once again the unique region offered the perfect opportunity to target T21 
specifically for transcript-to-protein verification. Following the production of a mono-
specific polyclonal anti-T21 antibody recognising epitopes within the unique region (anti-
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T21u antibody), western blot analysis performed on various cancer and normal cell line 
lysates identified two distinct bands at approximately 90 kDa and 70 kDa, both of which 
were specific to the peptide used to raise the antibody. Critically, immunoprecipitation 
followed by western blotting using anti-T21 antibody revealed a single 90 kDa band from 
which it can be inferred that only this protein holds the correct conformational structure to 
bind the antibody of interest. Future usage of this antibody demonstrated its suitability for 
both linear and native protein analysis applications. However, this study fell short of 
positively identifying T21 using 1D SDS PAGE peptide profiling coupled with mass 
spectrometry and by cross immunoprecipitation with anti-T21 antibody.   
 
As a consequence of these findings, previous investigation into the validity of T21 as a 
potential prostate cancer biomarker and/or an immunotherapeutic target now remain 
unresolved. A new study to investigate the expression of T21 in normal and cancer tissue 
would therefore demonstrate whether T21 holds potential for clinical applications. 
Additionally, investigations into T21 as a biomarker of disease could be aided by 
analysing mRNA and protein expression profiles in comparison to CEP290 in order to 
elucidate its function and involvement, if any, in cancer. In summary, the discovery of the 
unique T21 sequence and its translation into protein holds the possibility of a potential 
prostate cancer biomarker and further study as to its immunogenicity could present a 
viable immunotherapeutic target and may suggest its incorporation into a cancer vaccine. 
 
 
 
 
 
  
   
 
 
 
CHAPTER 4  
 
EXPRESSION OF T21 IN TISSUES AND ITS ROLE IN 
TUMOUR PROGRESSION  
 
4.1 Introduction  
 
The molecular composition of T21 and its origins as a variant of CEP290 have been 
discussed in the previous chapter. To date little is known in regards to the function of T21 
although previous investigations have hypothesised that due to the shared protein 
similarity to CEP290, T21 may play a role in centrosomal function and cilia development. 
The deregulation of the cells centrosomes has long been proposed as a contributing factor 
towards genomic instability and tumourogenesis (Boveri, 1914 (translated by Harris, 
2008)) and so the function and interactions of CEP290 should be further examined.   
 
The centrosomal localisation of CEP290 has been found to be dynamically expressed 
throughout the cell cycle (Sayer et al., 2006) with redistribution to the cytoplasm prior to 
prometaphase. During the interphase, CEP290 localises in two or four centrosomal bodies 
observed in the G1 and G2 phases of the cell cycle. In the G0 phase, CEP290 is present at 
the mother and daughter centrioles sites, the former acting as the basal body from which 
primary cilia is assembled (Tsang et al., 2008). Using various co-immunoprecipitation 
techniques, a number of groups have identified several centrosomal and ciliary-related 
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proteins which interact with CEP290. In 2006, Sayer and colleagues identified an 
interaction between CEP290 (exons 2-21) and activation transcription factor 4 protein 
(ATF4), which regulates the expression of genes involved in oxidative stress, cell 
differentiation, metastasis angiogenesis and drug resistance. It is induced by tumour 
microenvironmental factors in responses to cell stress signals in processes related to 
tumourogenesis (Ameri & Harris, 2008; Horiguchi et al., 2012). Other co-
immunoprecipitation studies revealed associations with several microtubule-based 
transport proteins including centrin, dynactin subunits p150, γ-tubulin, kinase family 
member 3A (KIF3A), kinesin-associated protein 3 (KAP3), ninenin, pericentriolar 
material 1 (PCM1), centrosomal protein 110 (CP110), pericentrin, RPGR and RPGR-
interacting protein 1 (RPGRIP1) and Rab8 (Chang et al., 2006; McEwen et al., 2007; Kim 
et al., 2008). Furthermore, CEP290 gene silencing studies in human retinal pigment 
epithelial cells resulted in the disorganisation of the cytoplasmic microtubule network and 
alterations in the formation of primary cilia through Rab8a, a small GTPase required for 
ciliary membrane elongation at the centrosomes. Knockdown of CEP290 also resulted in 
the disruption in the migration of mother centrioles to the cell cortex. However both 
studies noted that ablation of CEP290 did not impede centrosomal formation or cell cycle 
progression (Kim et al., 2008; Tsang et al., 2008).  
 
Tsang and colleagues also identified regions of CEP290 that are necessary for sufficient 
binding to its interacting proteins; for CP110: amino acids 1-336, 221-366 and 362-822. 
For Rab8a: amino acids 1208-1695, (Tsang et al., 2008) which are beyond the C terminal 
of T21 (at amino acid position 602-1103 of CEP290), however the sequence could 
hypothetically extend further upstream. In silico searches using the NCBI conserved 
Domain Database (http://www.ncbi.nlm.nih.gov/Structure/cdd/cdd.shtml) shows that 
CEP290 consists of two SMC (structural maintenance of chromosome) regions one 
upstream of the known T21 sequence, and one called SMC_prok_B within T21 which is 
structurally associated with the organisation and segregation of partitioning chromosomes 
during cell division (Marchler-Bauer et al., 2011).  
 
To date, investigation of T21 expression in normal and tumour tissue and studies into the 
possible role in cancer progression was carried out without prior knowledge of the unique 
region and the similarity shared between T21 and CEP290. As a consequence, 
experiments designed using the anti-T21/CEP290 antibody, PCR primers and interfering 
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RNA oligonucleotides which have now been confirmed to be common to both T21 and 
CEP290, do not reveal whether T21 is indeed a potential biomarker for cancer or a target 
for immunotherapy. Therefore the primary objective of this study was to assess the 
expression profile of T21 using healthy normal tissues following which cancer samples 
derived from tumour tissues and cancer cell lines were analysed to determine whether T21 
may have potential as a tumour restricted immunotherapeutic target. Expression at the 
mRNA level was determined using both qPCR and RT-Q-PCR and protein expression and 
localisation were determined using immunoblotting and immunostaining techniques 
respectively. The second objective involved conducting a series of experiments using 
immunofluorescence and gene silencing techniques designed to determine whether T21 
and CEP290 share functional characteristics and provide an insight into their relationship 
and T21 involvement in cancer progression.  
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4.2 Results 
 
4.2.1 Expression analysis of T21 mRNA in normal and cancer tissues  
 
Earlier studies of mRNA expression of T21 reported its expression to be restricted to testis 
and to various tumour types confirming its application as a potential biomarker of disease 
and as a possible target of immunotherapy. More recently, sequence similarity to CEP290 
and the newly identified unique region have drawn these findings into question. To 
address this, T21 and CEP290 mRNA expression was assessed using RNA from a panel of 
pooled normal human tissues (purchased from Clontech, USA). Briefly, 2 µg of total RNA 
was reverse transcribed to generate cDNA after which newly designed primers flanking 
the T21 unique region (Figure 3.5B) were used to perform semi-quantitative RT-PCR 
using the conditions described in chapter 2 in comparison to the expression of β-actin 
(house keeping control). In contrast to previous findings, T21 expression was observed in 
brain, placenta, prostate and testis tissue (Figure 4.1a). In addition, the ubiquitous 
expression of CEP290 throughout all normal tissues indicated that there is no shared 
expression profile or association in relation with T21 expression.  
 
In order to assess mRNA T21 expression alone, a more sensitive approach was adopted to 
quantify mRNA using real time quantitative RT-Q-PCR. Primers designed within the 
unique region were used to specifically amplify T21 (Figure 3.5A). In accordance with 
standardised guidelines in the literature (Bustin et al., 2009), primers were optimised to 
achieve maximal efficiency and the relative abundance value of specific gene expression 
was determined by dividing with the value derived by that of averaged housekeeping 
genes (Pfaffl, 2001). Here, two different housekeeping genes were used, hypoxanthine 
guanine phosphoribosyl transferase 1 (HPRT-1) and TATA-box binding protein (TBP), as 
they both displayed low variability across samples and were therefore used for calculating 
relative gene expressions in all subsequent analyses. In this experiment the relative 
expression of T21 was detectable at considerably higher levels in normal prostate, stomach 
and spinal cord when compared to testis, which was set to an arbitrary value of one 
(Figure 4.1b). Similar experiments were performed following extraction of mRNA from a 
panel of cell lines derived from prostate, breast, melanoma and head and neck cancers. 
Care was taken to avoid DNA contamination (and possible amplification of intronic 
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CEP290) of the RNA extracted from cell lines, therefore as a precaution, RNA spin 
columns were used instead of routine acid guanidinium thiocyanate-phenol-chloroform 
extraction using STAT-60. T21 mRNA expression was detected in prostate cancer cell 
lines LNCaP, DU145 and PC3 (all derived from disseminated tumour cells at metastatic 
secondary sites). In comparison, a lower level of expression was observed in cell lines 
from normal immortalised prostate cells (PNT1α and PNT2), and also in OPCT-1, a cell 
line derived from primary prostate tumour (Figure 4.2a). Of the other cancer cell lines 
assessed, T21 was highly expressed in breast (T47D and MCF-7), metastatic melanoma 
(MM27) and head and neck (A253) (Figure 4.2b). Further experiments were attempted 
using samples from prostate cancer patients used in previous studies, however the poor 
quality of the mRNA meant they were unsuitable for any further analysis (results not 
shown).   
 
 
Figure 4.1a – PCR gel images for T21 mRNA expression in normal human tissue. Semi-
quantitative PCR of β-actin loading control (116bp) and T21(287bp)/CEP290(194bp) mRNA 
expression in commercially acquired normal human tissue total RNA panel. Lanes represent - 
Adrenal gland (1), Colon (2), Brain, cerebellum (3), Brain (4), Foetal brain (5), Foetal liver (6), 
Heart (7), Kidney (8), Liver (9), Lung (10), Placenta (11), Prostate (12), Salivary gland (13), 
Skeletal muscle (14), Spleen (15), Testis (16), Thymus (17), Uterus (18), Ovary (19), Mammary 
gland (20), Retina (21), Spinal cord (22), Stomach (23) Negative control (24) (representative of 
two experiments). 
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Figure 4.1b – Quantitative RT-PCR for T21 mRNA expression in normal human tissue. Real 
time PCR expression of T21 mRNA in commercially acquired normal human tissue panel. 
Experiment was carried out three times in duplicate (n=3 technical repeat experiments) 
represented with standard error of mean with data expressed as relative fold change to the 
normalised expression of testis mRNA expression given as an arbitrarily value of 1. Statistical 
significance according to expression in testis indicated (*p<0.05) (**p<0.01) (***p<0.001) as 
determined by student’s t test. Samples derived from different lot panel to those analysed and 
shown in Figure 4.1a.   
 
 
 
 
 
 
 
Figure 4.2a – PCR gel images showing T21 mRNA expression in normal prostate and 
prostate and breast cancer cell lines using qPCR. Semi-quantitative PCR of β-actin loading 
control (116bp) and T21(287bp)/CEP290(194bp) mRNA expression using prostate and prostate 
cancer derived cell lines. Lanes represent – Commercially available normal prostate (1), 
Normal prostate cell lines PNT1α (2) and PNT2 (3), Prostate cancer origin cell line OPCT-1(4), 
Prostate cancer cell lines derived from secondary metastasis DU145 (5), LNCaP (6), PC3 (7), 
Breast cancer origin T47D (8) (n=2). 
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Figure 4.2b – Quantitative RT-PCR for T21 mRNA expression in human cancer cell lines. 
Real time PCR expression of T21 mRNA in various cancer cell lines (PNT1α and PNT2 derived 
from normal prostate) derived from prostate, breast, melanoma and head and neck origin. 
Experiment was carried out three times in duplicate (n=3) represented with standard error of 
mean with data calculated by d^ct and represented as relative gene expression. 
 
 
4.2.2 Expression analysis of T21 protein in normal and cancer tissues  
 
Despite being a useful tool, mRNA expression analysis is not always predictive of protein 
abundance (Guo et al., 2008) nor does it give insight into cellular localisation of proteins. 
Commercially available tissue microarrays were immunohistochemically stained for T21 
protein expression using the anti-T21u antibody. Protein expression was determined by 
staining intensity designated using a scoring ranging from 0 = no staining, 1 = mild 
staining, 2 = moderate staining to 3 = strong staining. In normal tissues cores (purchased 
from US Biomax), staining intensities were limited to no or mild expression with kidney, 
prostate and testis showing moderate expression in some cases. Representative images for 
each normal tissue type are illustrated in Figures 4.3a and b and are fully detailed in Table 
4.1. It is of particular note that T21 protein could not be clearly detected in the thymus 
suggesting the T21-specific T cells may not be subjected to central tolerance mechanisms 
and will be discussed further in the next chapter.  
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Figure 4.3a – Images immunohistochemical staining for T21 protein expression in normal 
tissue microarrays. Cerebral cortex (A), Bone (B), Skin (C), Tonsil (D), Lymph node (E), 
Thymus (F), Lung (G), Thyroid (H), Adrenal gland (I), Kidney (J), Liver (K) and Pancreas (L). 
Representative images at objective magnification x20. 
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Figure 4.3b – Images immunohistochemical staining for T21 protein expression in normal 
tissue microarrays. Stomach (A), Colon (B), Bladder (C), Urethra (D), Heart (E), Stratified 
muscle (F), Breast (G), Uterus (H), Ovary (I), Fallopian tube (J), Testis (K) and Prostate (L). 
Representative images at objective magnification x20. 
 
In addition to examining the expression of T21 protein in normal tissues, further 
assessment was performed using tissues derived from various malignancies (purchased 
from US Biomax) summarised in Table 4.1A alongside normal tissues. An increase of 
expression was observed in malignant tissues derived from colon, lung, bone, prostate and 
uterus compared to their corresponding normal tissues. The overall staining distribution 
indicated that of the normal tissues scored, 94% had no staining/mild staining with the 
remaining 6% having moderate staining. In comparison, collective malignant tissues 
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scored 78% no staining/mild and 23% moderate to strong staining. Taken together, the 
data suggests that T21 may be present at increased levels in some tumours namely in colon, 
uterus, lung and prostate, indicating that further analysis into these tumour types is 
necessary to determine whether T21 expression is indeed associated with disease 
progression.  
 
 A 
  
Anti-T21u Ab   
 B 
  
 CEP290 (The Human Protein Atlas) 
Normal tissue Malignant tissue   Normal tissue Malignant tissue 
staining intensity  staining intensity   staining intensity staining intensity 
Tissue type # 0 1 2 3 # 0 1 2 3 
 
Tissue type # 0 1 2 3 # 0 1 2 3 
Adrenal 1 1 
   
- 
    
  Adrenal 1 
   
1 - 
    
Bladder 1 
 
1 
  
3 3 
   
  Bladder 1 
  
1 
 
- 
    
Bone 1 
 
1 
  
6 2 3 1 
 
  Bone - 
    
- 
    
Breast 4 4 
   
2 2 
   
  Breast 4 1 
 
2 1 12 
 
2 8 2 
Cerebral 7 7 
   
7 7 
   
  Cerebral 3 2 1 
  
- 
    
Colon 9 7 2 
  
3 1 
 
2 
 
  Colon 2 
  
2 
 
12 
 
1 8 3 
Fallopian 1 
 
1 
  
- 
    
  Fallopian 2 
  
2 
 
- 
    
Heart 3 3 
   
- 
    
  Heart 1 1 
   
- 
    
Kidney 3 1 1 1 
 
3 3 
   
  Kidney 2 
  
1 1 11 10 1 
  
Liver 3 
 
3 
  
3 2 1 
  
  Liver 2 2 
   
12 6 3 3 
 
Lung 3 1 2 
  
6 
 
3 2 1   Lung 2 1 1 
  
11 1 8 2 
 
Lymph node 1 1 
   
4 3 1 
  
  Lymph node 1 1 
   
12 10 2 
  
Muscle 1 1 
   
- 
    
  Muscle 1 1 
   
- 
    
Ovary 3 3 
   
3 1 2 
  
  Ovary 2 1 1 
  
11 
 
1 8 2 
Pancreas 3 1 2 
  
3 3 
   
  Pancreas 2 1 
 
1 
 
11 
 
3 8 
 
Parathyroid 1 1 
   
- 
    
  Parathyroid 1 
 
1 
  
- 
    
Pituitary 1 
 
1 
  
- 
    
  Pituitary - 
    
- 
    
Placenta 1 1 
   
- 
    
  Placenta 2 
 
1 
 
1 - 
    
Prostate 3 2 
 
1 
 
3 
  
3 
 
  Prostate 1 
   
1 12 
 
1 10 1 
Skin 3 1 2 
  
3 2 
 
1 
 
  Skin 3 1 1 1 
 
12 4 2 6 
 
Small Int. 1 1 
   
3 2 1 
  
  Small Int. 1 
  
1 
 
- 
    
Spinal 1 1 
   
- 
    
  Spinal - 
    
- 
    
Spleen 1 1 
   
3 2 
 
1 
 
  Spleen 2 1 1 
  
- 
    
Stomach 1 
 
1 
  
3 3 
   
  Stomach 2 
   
2 9 5 1 3 
 
Testis 3 
 
1 2 
 
3 
 
2 1 
 
  Testis 2 
  
1 1 11 5 3 3 
 
Thymus 1 1 
   
- 
    
  Thymus - 
    
- 
    
Thyroid 3 3 
   
2 1 
 
1 
 
  Thyroid 1 
  
1 
 
4 
 
2 1 1 
Tonsil 3 2 1 
  
- 
    
  Tonsil 1 
  
1 
 
- 
    
Umbilical 1 1 
   
- 
    
  Umbilical - 
    
- 
    
Urethra 1 
 
1 
  
- 
    
  Urethra - 
    
11 4 4 3 
 
Uterus 4 2 2 
  
3 1 
 
2 
 
  Uterus 4 
 
2 2 
 
- 
    
 
Table 4.1 – Score summary of immunohistochemistry tissue sections for T21 protein 
expression. Table representing staining intensities observed in normal and cancer tissues using 
purchased TMAs from US Biomax (Cat. MNO341, MNO381 and ME241) (A). As a comparison, 
tissue staining data published by The Human Protein Atlas project (http://www.proteinatlas.org) 
using an anti-CEP290 antibody (purchased from Abbott laboratories)(B). A numerical scoring 
method assigning 0=no staining, 1=mild staining, 2=moderate staining and 3=strong staining 
used. Numbers in cells represent number of tissues scored and shaded areas represent no 
matching cancer tissue available. 
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Previous staining of normal tissues using custom anti-T21/CEP290 antibody (purchased 
from Pacific Immunology) demonstrated that protein expression was restricted to stomach, 
ovary, breast and prostate tissues (Miles et al., 2012). Moreover, data published online by 
The Human Protein Atlas project (http://www.proteinatlas.org) showing protein expression 
profiles for CEP290 in normal human tissues and various cancer types demonstrated 
important staining differences between T21 (using anti-T21u antibody) and CEP290. The 
staining distribution from The Human Protein Atlas project indicated that of the normal 
tissues scored, (22/46) 48% no staining/mild, 35% (16/46) moderate and the remaining 
(8/46) 17% having strong staining. Of these normal tissues, adrenal, breast, kidney, 
placenta, prostate, stomach and testis demonstrated strong staining. In comparison, cancer 
tissues scored (79/151) 52% no staining/mild, (63/151) 42% moderate and (9/151) 6% 
strong staining. Within cancer tissues, breast, colon, ovary, prostate and thyroid tissues 
demonstrated strong staining, equally moderate to strong staining was demonstrated in 
almost all cancer derived cell lines (data available at http://www.proteinatlas.org). Despite 
high levels of CEP290 distributed throughout normal tissues (Figure 4.1B), anti-CEP290 
auto-antibodies have been reported in patients with cancer (Eichmuller et al., 2001; Chen 
& Shou, 2001), which may indicate that CEP290 related immune tolerance mechanisms 
have been overcome in order to generate an immune response. These expression profiles 
patterns vary between the two proteins; however both are upregulated in some cancers. 
 
Following these observations, further investigation of the expression of T21 in prostate 
cancer patients was undertaken in collaboration with Dr Desmond Powe (Department of 
Histopathology, Queens Medical Centre, Nottingham University Hospitals NHS Trust, 
Nottingham, UK). Before commencing the study, the anti-T21u antibody was optimised 
together with assay conditions (buffers and incubation times) on tissue core off-cuts taken 
from the same patient cohort in formalin fixed paraffin embedded (FFPE) tissue 
microarray (TMA) blocks. Optimal concentration conditions were determined to be 1:50 
dilution of a 0.4 mg/ml stock solution left overnight at 4°C. The patient cohort comprised 
of ten TMA FFPE blocks constructed of benign prostatic hyperplasia (BPH) and clinically 
confirmed cancer patients tissue cores collected between 1998 and 2000 as a wider study 
by the Nottingham Prostate Research Group. Ethical approval for generic consent for 
prospective collections and for the use of pathology archival material has been granted by 
the Greater Manchester National Research Ethics Service, 2010. For this study, patient 
cohorts consisted of 79 histopathologically confirmed prostate cancer and 57 benign cases 
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(mean age = 70.8, median age = 71). Semi-quantitative scoring intensity scale ranging 
from 0 for no staining, 1 for weak, 2 for moderate and 3 for strong staining observed was 
applied to determine the degree of IHC staining (Figure 4.4). The association between T21 
and clinical variables were statistically modelled using Kaplan-Meier plots and Cox 
regression hazards risk model (SPSS software version 20.0 from SPSS Inc. USA) 
calculated using univariate chi-square analysis, a statistical significance considered as 
p≤0.05 was applied to the data.   
 
 
 
Figure 4.4 – Immunohistochemical staining for T21 protein expression in prostate tissue. 
Images illustrating scoring method used for prostate tissue. Representative images at objective 
magnification x20 and x40 inset. 
 
In line with previous observations, T21 staining was detected mostly in the cytoplasm and 
for some samples in the nuclei and membrane of prostate glands. No clear centrosomal 
localisation was observed. Within is cohort of TMA samples, 88.9% of patients showed 
positive staining for T21 of which 58.7% were prostate cancer patients (Table 4.2A). 
However, no clear distinction could be determined between benign and prostate cancer 
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patients when assessing the presence or absence of T21. Further examination of disease 
comparative positive staining distribution revealed that the majority of benign patients had 
mild staining, whereas prostate cancer patients had mild/moderate staining intensity. In 
fact, of all of the moderately stained tissues, 71% were of prostate cancer origin (Table 
4.2B). Next, statistical analysis was performed using only the cancer cohort. To summarise, 
no statistical associations were observed between intensity of T21 protein expression and 
age and survival from diagnosis (Table 4.3 and Figure 4.5). Further examination of high 
and low expression of T21 between variables was performed by grouping (0+1 intensities 
= low expression) and (2+3 intensities = high expression). Once again, no significant 
association was seen between T21 expression and survival from initial diagnosis (Figure 
4.6), the time taken to develop of distant metastasis from initial diagnosis (Figure 4.7), 
between low and high Gleason grade, PSA, the presence or absence of vascular invasion, 
tumour percentage, metastasis, androgen deprivation therapy (ADT), or prostate cancer 
related death (Table 4.3).  
A – Presence and 
absence of staining 
Negative Positive 
Total 
0 
All 
intensities 
Benign 
Freq. 7 50 57 
Percent 46.6 41.3 41.9 
Malignant 
Freq. 8 71 79 
Percent 67.4 58.7 58.1 
Total Freq. 15 121 136 
 
 
B – Positive staining 
intensity distribution  
Positive intensities 
Total 
1 2 3 
Benign 
Freq. 33 13 4 50 
Percent 48.5 28.3 57.1 41.3 
Malignant 
Freq. 35 33 3 71 
Percent 51.5 71.7 42.9 58.7 
Total Freq. 68 46 7 121 
 
 
Table 4.2 – Scoring of immunohistochemistry prostate sections for T21 protein. Table 
outlining benign and malignant disease cases stained and scored for T21 expression showing 
absence of expression (negative) and expression observed at any score intensity (positive) (A). 
A numerical scoring method assigning 0=no staining, 1=mild staining, 2=moderate staining 
and 3=strong staining used (illustrated in Figure 4.4) showing the distribution of staining 
among positive intensities (B).  
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Variables Freq. 
Negative Positive intensities 
p-value 
0 1 2 3 
Age 
<49 
79 
0 1 0 0 
0.763 
50-64 1 6 6 0 
65-74 3 12 18 2 
>75 4 16 9 1 
Survival Months 53 7 22 22 2 0.280 
Survival Months  53 29 24 0.436 
Distant Mets Months  27 12 15 0.444 
Gleason 
grade 
1 – 6 
96 
20 21 
0.240 
7 – 10 32 23 
PSA 
< 5ng 
69 
16 14 
0.530 
> 5ng 20 19 
Vascular 
invasion 
Neg.  
68 
30 26 
0.535 
Pos. 6 6 
Cancer Percent 67 36 31 0.231 
Metastasis Months  96 52 44 0.358 
ADT 
w/o 
65 
5 4 
0.639 
With 31 25 
Death 
CaP related  
57 
13 9 
0.469 
Unrelated 19 16 
 
Table 4.3 – Association between T21 expression and other clinicopathological variables.  
 
 
 
 
Figure 4.5 – Kaplan-Meier survival time analysis using all intensities. Survival analysis 
representing clinically confirmed prostate cancer cohort. A numerical scoring method assigning 
0.00=no staining, 1.00=mild staining, 2.00=moderate staining and 3.00=strong staining is 
given. Results indicate no statistical significance. 
n = 33 
n = 8 
n = 35 n = 3 
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Figure 4.6 – Kaplan-Meier survival time analysis using high and low intensities. Survival 
analysis representing clinically confirmed prostate cancer cohort between 0 to 170 months (A) 
and between 60 to 150 months. A numerical scoring method assigning 0.00=no/mild staining 
and 1.00=moderate/strong staining is given. Results indicate no statistical significance.  
  
 
 
Figure 4.7 – Kaplan-Meier survival analysis from diagnosis to time to form metastasis using 
high and low intensities. Survival analysis representing clinically confirmed prostate cancer 
cohort between 0 to 140 months from initial diagnosis to forming distant metastasis. A 
numerical scoring method assigning 0.00=no/mild staining and 1.00=moderate/strong staining 
is given. Results indicate no statistical significance. 
 
 
 
A B 
n = 36 
n = 43 
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4.2.3 Expression analysis of T21 protein in cancer cell lines  
 
As mentioned previously, T21 had been identified from immunogenic screening using sera 
taken from patients with advanced prostate cancer therefore further investigation of this 
antigen was performed using cell lines derived from prostate cancer. The initial expression 
profile of the cancer cell line panel (Figure 4.2b) demonstrated that two breast cancer cell 
lines (T47D and MCF-7) in particular demonstrated extremely high levels of T21 
compared to prostate cell lines therefore it was decided to screen all available prostate and 
breast cancer cell lines further for T21 and CEP290 protein expression. Following 
optimisation of immunoblotting procedures (detailed in chapter 2) cell line derived lysates 
were subjected to western blot analysis using the anti-T21u antibody. Previous 
investigation revealed a T21 specific band at approximately 90 kDa (refer to section 3.2.3). 
The results demonstrated T21 to be detectable when loading 50 µg of total protein lysates 
in prostate cancer cell lines PC3, LNCaP and faintly observed in DU145 (Figure 4.8A). 
The T21 specific band was not detected in PNT1α, PNT2 (normal immortalised prostate 
cell lines) and OPCT-1 (primary prostate cancer). Examination of the breast cancer cell 
lines showed little expression in SkBr3 and MDA468 and -231, however MCF-7 and 
T47D did demonstrate protein expression of T21 (Figure 4.8B). These findings were also 
confirmed when performing ELISA (data not shown).  
 
The expression of CEP290 was also assessed in both prostate and breast cancer cell lines 
using an anti-CEP290 antibody (Everest Biotech) (Figure 3.15). As with other 
commercially available anti-CEP290 antibodies assessed during this investigation (data 
not shown) multiple bands were detected when performing western blotting using this 
antibody. Bands were observed at 250, 200, 150 and 75 kDa making it difficult to 
determine CEP290 expression. The results suggest that CEP290 is expressed in all cell 
lines at varying levels (Figure 4.9), which supports the observations of the mRNA 
expression profiles described earlier. Significantly, no band was detected at 90 kDa which 
would be suggestive of T21 expression, since the anti-CEP290 antibody (Everest Biotech) 
used may “theoretically” detect T21 (Figure 3.15). Attempts were made to isolate a 
CEP290 specific band using immunoprecipitation and magnetic bead separation followed 
by detection of peptide fragments using mass spectrometry; however these experiments 
proved unsuccessful (data not shown).  
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Figure 4.8 – Western blot analysis of T21 protein expression in cancer cell lines. Protein 
expression of various prostate derived cell lines (A) and breast cancer derived cell lines (B) 
showing 2 bands (90 kDa and 70 kDa) performed using western blotting and using β-actin (45 
kDa) as representative protein loading control (n=2). 
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Figure 4.9 – Western blot analysis of CEP290 protein expression in cancer cell lines. Protein 
expression of various prostate derived cell lines (A) and breast cancer derived cell lines (B) 
showing several discreet bands (90 kDa and 70 kDa) performed using western blotting and 
using β-actin (45 kDa) as representative protein loading control (n=2). 
 
 
 
 
In addition to western blotting, T21 cellular localisation was investigated using 
immunofluorescence detection. Antibody staining was optimised, cells were fixed and 
incubated with anti-T21u antibody and subsequently with fluorescently labelled secondary 
Alexafluor antibodies and assessed by fluorescence microscope (Olympus BX51) (detailed 
in section 2.2.5.1). Each assay was performed using the appropriate controls (see appendix 
Figure IIIa). The results demonstrated overall low levels of cytoplasmic expression in 
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PNT1α, PNT2, DU145 and OPCT with higher expression observed in LNCaP, PC3 and 
T47D cells corroborating the expression patterns observed in mRNA and in western 
blotting (Figures 4.10 and 11). However, it was observed that in some seemingly low 
expressing cell lines such as PNT1α, PNT2 and MDA468 cells undergoing division 
demonstrated more intense staining suggesting that T21 may be expressed during the cell 
cycle (Figures 4.10 and 11). During the course of this investigation, prostate cell lines 
were assessed using the previously designed custom anti-T21/CEP290 antibody (Figure 
3.15). It was observed that the expression was present throughout the cytoplasm and also 
strongly localised to the centrosomal bodies during each active stage of the cell cycle (see 
appendix Figure IIIb). As dual-staining of both of these antibodies was not possible (both 
raised using the same species), parallel co-expression experiments using either anti-T21u 
or anti-T21/CEP290 antibodies together with antibodies known to associate with cell 
proliferation, CEP290 and the cell centrosomes was undertaken. Based on the collective 
findings of the cell line mRNA and protein expression profiles, it was decided that 
progress with in vitro investigation of T21 using the prostate cancer cell line PC3.  
 
Thus, T21 expression was observed alongside the cell cycle marker Ki67, which is present 
during all active phases of the cell cycle (Figure 4.12). Immunofluorescence analysis 
demonstrated that the expression of T21/CEP290 (anti-T21/CEP290 antibody) was 
strongly associated with cells undergoing cell proliferation (anti-Ki67 antibody) whereas 
intense staining of T21 using anti-T21u appeared not to co-localise to proliferating cells in 
the same manner (Figure 4.12B). In order to compare T21 and CEP290 expression, cells 
were dual stained with the previously described anti-CEP290 antibody in parallel with 
anti-T21/CEP290 antibody (Figure 4.13A) or anti-T21u antibody (Figure 4.13B). As 
expected the anti-T21/CEP290 antibody strongly co-localised to the CEP290 protein (anti-
CEP290 antibody) whereas no strong localisation was detected using T21 (anti-T21u 
antibody). Centrosomal localisation was validated by staining for the centrosome-specific 
protein pericentrin, a component of the pericentriolar material expressed in the 
centrosomes (Figure 4.14A). Dual staining with anti-pericentrin antibody also confirmed 
that T21 (anti-T21u antibody) did not localise to the centrosomes (Figure 4.14B). From 
these results it can be inferred that T21 does not share a functional role similar to that of 
CEP290 at the centrosomal sites during cell proliferation. 
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Figure 4.10 – Immunofluorescence analysis showing protein expression of T21 in prostate 
derived cell lines. Cells derived from prostate cell lines labelled using custom anti-T21u 
antibody (green) and secondary stained using anti-rabbit Alexafluor 488 antibody and with 
nuclear staining using DAPI (blue). Representative images using magnification x20 (n=2). 
DAPI       T21           Merge 
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PNT2 
 
 
 
DU145 
 
 
 
LNCaP 
 
 
 
PC3 
 
 
 
OPCT1 
 
 
  
Chapter 4: Expression of T21 in tissues and its role in tumour progression 4.2 
 
149 
 
 
 
 
 
Figure 4.11 – Immunofluorescence analysis showing protein expression of T21 in breast 
cancer cell lines. Cells derived from breast cancer lines labelled using anti-T21u antibody 
(green) and secondary staining as described previously and with nuclear staining using DAPI 
(blue). Representative images using objective magnification x20 (n=2).  
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Figure 4.12 – Immunofluorescence composites comparing T21u and T21/CEP290 antibody 
localised with Ki67 in PC3 cell line. Cells derived from PC3 cells were dual stained with anti-
Ki67 antibody (red) and using either anti-T21/CEP290 antibody (A) or anti-T21u antibody (B) 
shown in green and nuclear staining using achieved using DAPI (blue). Cell localisation was 
observed in using anti-CEP290/T21 antibody and to a lesser degree using T21u antibody (white 
arrows). Representative images using objective magnification x40 (n=3).  
 
A1 (DAPI)  A2 (anti-T21/CEP290) 
 
 
 
 
A3 (anti-Ki67)  A4 (merge) 
B1 (DAPI)  B2 (anti-T21u) 
 
 
 
 
B3 (anti-Ki67)  B4 (merge) 
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Figure 4.13 – Immunofluorescence composites comparing T21u and T21/CEP290 antibody 
localised with CEP290 in PC3 cell line. Cells derived from PC3 cells were dual stained with 
anti-CEP290 antibody (red) and using either anti-T21/CEP290 antibody (A) or anti-T21u 
antibody (B) shown in green and nuclear staining using achieved using DAPI (blue). 
Centrosomal localisation was observed in using anti-CEP290/T21 antibody (white arrows) but 
was absent when using T21u antibody. Representative images using objective magnification x20 
(n=3).  
A1 (DAPI)  A2 (anti-T21/CEP290)  
 
 
 
 
A3 (anti/CEP290)  A4 (merge) 
B1 (DAPI)  B2 (anti-T21u) 
 
 
 
 
B3 (anti-CEP290)  B4 (merge) 
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Figure 4.14 – Immunofluorescence composites comparing T21u and T21/CEP290 antibody 
localised with pericentrin in PC3 cell line. Cells derived from PC3 cells were dual stained with 
anti-Pericentrin antibody (red) and using either anti-T21/CEP290 antibody (A) or anti-T21u 
antibody (B) shown in green and nuclear staining using achieved using DAPI (blue). No 
centrosomal co-localisation was detected when using anti-T21u antibody (white arrows). 
Centrosomal co-localisation was observed using CEP290/T21 antibody (white arrows). 
Representative images using objective magnification x100 oil emulsion (n=3).  
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4.2.4 The role of T21 in tumourogenesis 
 
4.2.4.1 Transient gene silencing of T21 using small interfering RNA  
 
In order to understand further the role of T21 has in cells, experiments were designed to 
silence gene expression using RNA interference in PC3 cells. Briefly, three gene specific 
siRNA molecules were designed within the unique region of T21. PC3 cells were then 
cultured in the presence of either control siRNA (ineffective scrambled cassette) or T21-
specific siRNA along with Interferin, a non-liposomal amphiphile transfection reagent. 
Total RNA was extracted from cells using RNA spin columns after 24, 48 and 72 hours 
post transfection to assess T21 silencing at the mRNA level by RT-Q-PCR using T21 
specific primers. The data showed siRNA T21-3 to be the most effective in silencing T21 
(81% inhibition) after 24 hours with the remaining two siRNA molecules achieving 58% 
and 56% knockdown. Moreover, CEP290 expression assessed using gene specific primers 
designed within exon 34 of CEP290 revealed no significant knockdown occurring in any 
of the T21-siRNA treated cells (Figure 4.15A). Maximal knockdown was achieved using 
T21-3 siRNA after 24 hours followed by a gradual return of T21 expression (Figure 
4.15B). Interestingly, knockdown was also observed using primers specific to CEP290 
within exon 2 (upstream of the known T21 start sequence) although failing to reach 
statistical significant (data not shown). This further supports the premise that the T21 
mRNA sequence may indeed extend further upstream then previously demonstrated. 
Furthermore, transfection of PC3 cells with siRNA molecules designed within exon 2 of 
CEP290 has also independently demonstrated T21 specific knockdown (performed by Mr 
B. Alshehri: personal communication).  
 
The transfected cells were observed by microscopy and for changes in cell behaviour and 
morphology during in vitro culture documented. In summary, cells treated with T21 
siRNA did not exhibited any noticeable changes when compared with control siRNA or 
Interferin treatment other than a seemingly reduced capability to proliferate. Following 
this observation, experiments assessing cell proliferation were performed using 3Thy 
incorporation parallel to assessing mRNA T21 knockdown using siRNA T21-3. The data 
demonstrates a significant reduction of the proliferation observed in cells transfected with 
T21 siRNA compared to control siRNA over a period of seven days (Figure 4.16).   
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To confirm that a reduction in T21 mRNA leads to a decrease in T21 protein production, 
T21 knockdown was performed on a larger scale in order to yield sufficient protein to 
perform western blotting using the anti-T21u antibody. Although a comparable decrease in 
T21 protein expression between control siRNA and T21 siRNA was demonstrated after 72 
hours, earlier differences remained inconclusive due to the poor yield of T21 protein 
(Figure 4.17). The large quantities of siRNA required for this approached proved to be a 
limiting factor for repeat experiments. Therefore immunofluorescence was used to assess 
the level of knockdown which revealed a decrease in T21 protein production following 
cell transfection with T21 siRNA (Figure 4.18). Further experiments are required beyond 
the 72 hour timeframe in order to observe if/when T21 protein production is restored. 
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Figure 4.15 – T21 silencing of a T21 positive prostate cancer cell line following T21 specific 
siRNA transfection. (A) Real time PCR analysis showing percentage of T21 and CEP290 
mRNA knockdown following transfection of PC3 cell line with 3 T21 specific siRNA. (B) Time 
course performed by real time PCR showing T21-3 siRNA silencing over time. Experiments 
were carried out three times in duplicate (n=3) represented with standard error of mean with 
data expressed as percentage change to the negative control siRNA.  
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Figure 4.16 – Cell proliferation assay following T21 specific siRNA transfection. Time course 
carried out using 3H-Thy incorporation assay demonstrating reduced PC3 cell proliferation 
observed following T21-3 siRNA silencing over time. Experiments were carried out three times 
on triplicate wells (n=3) represented with standard error of mean. Statistical significance 
indicated (*p<0.05) (**p<0.01) (***p<0.001) as determined by Student’s t test. 
 
 
Figure 4.17 – Western blot analysis of T21 protein expression following T21 specific siRNA 
transfection. Above, protein expression showing 2 bands (90 kDa and 70 kDa) taken during a 
time course of 3 days following siRNA transfection using PC3 cell line. Below, β-actin (45 kDa) 
as representative protein loading control (n=1). 
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Figure 4.18 – Immunofluorescence analysis showing protein expression of T21 protein 
expression following T21 specific siRNA transfection. PC3 cells taken during a time course of 
3 days following siRNA transfection were labelled using anti-T21u antibody (green), secondary 
stained as described previously and with nuclear staining using DAPI (blue). Representative 
images (n=2) using magnification x20.  
 
 
Gene silencing through transfection of interfering RNA by siRNA duplexes or through 
transcriptionally expressed shRNA can lead to the inadvertent stimulation of interferon 
response-pathways (Bridge et al., 2003). The level of mRNA expression of interferon-
response genes, signal transduced and activator of transcription 1 (STAT1) and 
oligoadenylate synthase 1 (OAS1) were assessed and demonstrated no statistical changes 
between control and siRNA knockdown. This confirmed that the effects observed were 
T21-specific (data not shown).  
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Collectively, these findings indicated that T21 may not function in the same context as 
CEP290 within the centrosomes, however the associated reduced proliferative capacity of 
cells following transient silencing of T21 indicate a role in driving cell growth. Therefore 
it was hypothesised that T21 activity may be important during the cell cycle. To assess this 
further, PC3 cells were once again subjected to siRNA treatment for 24, 48 and 72 hours. 
During the final two hours of incubation, cells were washed and incubated with 5-ethynyl-
2´-deoxyuridine (EdU) and carefully harvested using trypsin/versene and fixed before 
proceeding to fluorescent staining for EdU (Click-iT EdU cell proliferation assay) and live 
cells (LIVE/DEAD cell stain) (both purchased from Invitrogen, UK). Cell fluorescence 
was determined using a Gallios flow cytometer and data obtained analysed using the 
Kaluza Flow Analysis Software (Beckman Coulter). The results summarised in Table 4.4 
showed that in cells treated with T21 siRNA there was a consistent reduction in cells 
undergoing G phase of the cell cycle and an increase in G2/M phase transition compared to 
the equivalent control siRNA with little percentage variation observed during S phase 
between the T21 siRNA and control siRNA treated cells. Due to time and reagent 
constraints this experiment was performed once. Therefore, the results presented here are 
preliminary and would require further repetition to gain more conclusive insights.   
 
 Cell cycle phases (% cells) 
G phase S phase G2/M phase 
+24 hours 
siRNA control 63 11 26 
siRNA T21 56 14 30 
+48 hours 
siRNA control 63 8 29 
siRNA T21 60 9 31 
+72 hours 
siRNA control 68 6 26 
siRNA T21 60 7 33 
 
Table 4.4 – Cell cycle analysis following T21 specific siRNA transfection. Time course 
experiment carried out over 72 hours following siRNA transfection of PC3 cells using T21 
specific siRNA and control siRNA (n=1). Cell cycle phases of live transfected cells detected 
using LIVE/DEAD Cell Stain (Invitrogen) coupled with Click-iT EdU cell proliferation assay 
(Invitrogen).  
 
The opportunity arose to study whole genome expression in response to knockdown of T21 
using Next Generation Sequencing (NGS). Briefly, cells treated with either control or T21 
siRNA were lysed directly using RNA STAT-60 and total RNA was extracted using 
isopropanol precipitation (described in section 2.2.2.1). The RNA quality was assessed 
using a RNA 6000 pico chip kit (Agilent) and an Agilent 2100 Bioanalyzer (Agilent) 
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following the manufacturer’s instructions. RNA samples with RNA integrity number (RIN) 
values between 8 and 10 were stored until analysis by NGS. RNA samples with RIN 
values below 8 were discarded. Next generation sequencing of total RNA samples were 
outsourced to Source Bioscience, UK. Briefly, libraries were created by producing a series 
of randomly fragmented RNA to which two adapters were linked. These libraries were 
then denatured to single molecules and randomly hybridised to the surface of a flow cell to 
form clusters. Once the clusters were formed, the flow cell was sequenced on the Illumina 
Genome Analyser IIx platform using 38bp single end reads. Alignment of the reads against 
the human genome was performed by the Bioinformatics Service from Source Bioscience 
UK. Technical repeats were merged and logarithmic (fold-change) values and p values 
were calculated to determine significant differences. Threshold cut off of values above (up 
regulated expression) and below (down regulated expression) 1.5 fold-change were applied 
to determine significant gene regulation changes. Functions of genes undergoing 
significant changes of expression were then obtained using online databases such as 
OMIM (http://www.ncbi.nlm.nih.gov/omim/), Uniprot (http://www.uniprot.org/), and 
GeneCards (http://www.genecards.org/). Although a complete bioinformatics analysis and 
experimental validation of gene expression is currently still ongoing, genes that were either 
significantly up regulated (448 genes) or down regulated (434 genes) following T21 siRNA 
knockdown was complied. Following a more focused examination of gene functions and 
literature searches, a more refined shortlist of 20 genes that had roles in the processes 
involved cancer were chosen to most suitability illustrate the general changes in mRNA 
expression (Table 4.5).  
 
The absence of genes that are known to interact with CEP290 from the data provides 
further evidence that T21 may not share a common centrosomal function. The data 
indicated the up regulation of genes that are involved in the promotion of tumourogenesis 
through cell proliferation and cell cycle control (MAPK6, PKIA, UHMK1, CDKN2B), 
overriding DNA damage pathways and promoting cell survival (HIPK2, MDM2, RBBP8), 
and genes that modulate immune responses (CISH, PLAU, IL6R). The up regulation of 
genes such as SYCP3, CALM3, MFAP2 and RAB3IP may be indicative of a more specific 
role T21 plays in centrosomal and structural rearrangement during mitosis. Conversely, 
genes that were suppressed played regulatory roles involved in tumour progression through 
regulation of Ras family (DOK1 and 3 RAB6B, FRS3), cell stress/DNA repair pathways 
(PPM1E, CHD8, XRCC3) or the PI3K-Akt pathway (PI3KIP1).  
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Genes up regulated when T21 is expressed: 
Gene Pathway / function FC 
MFAP2 Structural Interaction with notch-1 inducing signalling 50 
CYP2D6 
Metabolism 
Drug metabolism, alterations/polymorphisms associated with cancer 30 
IDI2 Interaction with BCL 6 15.9 
HYAL1 Concentration dependent inhibitor or promoter of tumour growth 5.1 
CISH 
JAK/STAT 
pathway 
Negative regulator of cytokine signalling through STAT5 and implicated in immune 
regulation of T and NK cells 
3.4 
SPAG17 Unknown Sperm-associated antigen 17 –CT antigen and potential immunotheraputic target 2.9 
PLAU 
Pro-tumour 
activity 
Involved in degradation of the ECM and possibly involved in tumour cell migration and 
proliferation. Inferred association with Treg suppression 
2.2 
MAPK6 
Promotes cell 
cycle  
Ser/Thr protein kinase linked to promotion of entry in the cell cycle 2.1 
CALM3 Regulates the centrosome cycle and progression through cytokinesis 2.1 
PKIA Inhibitor of cAMP-dependent protein kinase activity 2.1 
HIPK2 DNA damage Inhibits cell growth and promotes apoptosis through p53 target genes 2 
IL6R Cell growth Regulates cell growth and differentiation with a role in the immune response 2 
RAP2A Ras pathway RAP2, member of RAS oncogene family 1.9 
SYCP3 
Promotes cell 
cycle  
Synapsis, recombination and segregation of meiotic chromosomes 1.9 
UHMK1 Promotes cell cycle progression in G1 phase 1.9 
CEP290 Activates ATF4-mediated transcription 1.9 
CDKN2B Cell growth regulator involved in controlling cell cycle G1 progression 1.8 
MDM2 p53 pathway Leads to inactivation of p53, diminishing its tumour suppressor function 1.8 
RBBP8 DNA damage  May itself be a tumour suppressor acting in the same pathway as BRCA1 1.8 
RAB3IP Structural Modulates actin organisation 1.8 
 
Genes down regulated when T21 is expressed:  
Gene Pathway / function FC 
SPATA21 
Unknown  
Involved in the differentiation of haploid spermatids  -19 
CRB2 May play a role in polarized cells morphogenesis associated with cancer -5.2 
BST1 
Immuno-
modulatory 
Involved in pre-B-cell growth 
-3.4 
DOK3 Ras pathway Docking protein 3 - negative regulator of Ras  -3.4 
BCL2L12 Apoptosis BCL family act as anti- or pro-apoptotic regulators -2.7 
DOK1 Ras pathway Docking protein 1 - negative regulator of Ras and TLR4 -2.6 
PDZD2 Immune 
activation / 
pro–tumour 
activity 
Upregulated in primary Pr tumours, possible role in the early stages of Pr tumourogenesis -2.3 
FGF1 
Involved in the regulation of cell survival, division, angiogenesis, differentiation and 
migration 
-2.1 
RAB6B 
Ras pathway 
RAB6B, member RAS oncogene family -2 
FRS3 Function in linking FGF receptor stimulation to activators of Ras -1.9 
PIK3IP1 
PI3K-Akt 
pathway 
A negative regulator of PI3K which promotes cell proliferation and survival 
-1.9 
OAS2 Apoptosis 
Roles in mediating resistance to virus infection, control of cell growth, differentiation, and 
apoptosis 
-1.9 
PPM1E Cell 
proliferation 
Negative regulators of cell stress response pathways -1.9 
CHD8 Suppresses p53 - mediated apoptosis, inhibitor of Wnt signalling pathway -1.8 
XRCC3 DNA repair 
 Involved in the homologous recombination repair (HRR), thought to repair chromosomal 
fragmentation, translocations and deletions 
-1.8 
GGT7 Metabolic  Possibly involved in lung carcinogenesis -1.8 
ZBTB7A Cell cycle Specifically represses the transcription of the CDKN2A gene -1.8 
TRIM2 Cell survival Blocks apoptosis response to ischemia by degrading BIM -1.8 
TUBA3D 
Structural 
Involved in motility and spindle formation -1.8 
SH3GL1 Overexpression may play a role in leukemogenesis -1.8 
 
Table 4.5 – Select list of genes following siRNA transfection. A representative list of 20 up- 
and 20 down-regulated genes following Next Generation Sequencing analysis following 24 hour 
transient siRNA transfection of PC3 cells. Gene selection was based on a minimal 1.8 fold-
change (FC) of expression to control and published literature indicating the role of the gene 
specific to cancer or its involvement in processes known to be altered in cancerous cells.    
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4.2.4.2 Stable gene silencing of T21 using short hairpin RNA  
 
While it is useful to examine the effects of transient suppression of T21 using siRNA 
interference, it is necessary to study what effects long term silencing could have. One 
approach is to use short hairpin RNA interference to stably transfect cells to endogenously 
suppress gene expression. Hence, the siRNA sequence that induced the most significant 
knockdown (T21-3) was chosen to form a custom pGFP-B-RS mammalian expression 
vector containing the T21-specific sequence (purchased from Origene Technologies) along 
with a scramble cassette control vector. Next, PC3 cells were transfected with either T21-
specific shRNA or control vector as detailed in section 2.2.6.2. Transfected cells were 
grown in media supplemented with Blastcidin (selective antibiotic) over one passage 
before single colonies were achieved through limiting dilution assays. Once cells were 
sufficient in number, mRNA was extracted and reverse transcribed to generate cDNA in 
order to assess for the expression of T21 using RT-Q-PCR (Figure 4.19). Next, expanded 
colonies that demonstrated the most stable significant knockdown compared to control 
cells were sorted for GFP+ expressing cells using a MoFlo XDP High-Speed Cell Sorter 
(Beckman Coulter) and returned to culture prior to confirming T21 mRNA expression 
(Figure 4.19). As found in earlier studies using transient transfection, stably transfected 
cells exhibited a reduced proliferative capacity following knockdown of T21 in 
comparison to cells transfected with control vector (Figure 4.20). Finally, the expression 
of T21 protein in transfected cells was assessed using anti-T21u antibody by both western 
blotting (Figure 4.21) and using immunofluorescence (Figure 4.23). Together these 
experiments concluded that T21 protein expression was indeed decreased after shRNA 
transfection, however the effects of the silencing where short-lived returning T21 
expression to that of the control expression after a number of passages. This may require 
further refinement of the antibiotic concentration, timing of fresh antibiotic supplements to 
the media and further cell sorting to establish a more stably transfected cell line (ongoing 
work).  
 
As an interesting side note, retrospective western blot analysis performed using the anti-
T21/CEP290 antibody on PC3 cells transfected with T21 shRNA demonstrated the 
reduction of protein detected in a band at approximately 90 kDa when compared to 
control. This further would appear to confirm reduced T21 protein expression as a result of 
T21 specific knockdown. Therefore, this antibody could also be used to detect T21 protein 
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expression using western blotting technique in addition to the anti-T21u antibody (Figure 
4.22).   
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Figure 4.19 –T21 stable knockdown of PC3 prostate cancer cell line following T21 specific 
shRNA transfection. Following shRNA transfection, cells underwent clonal expansion via 
limiting dilution. One clone was selected for further sorting of GFP-positive cells. Real time 
PCR analysis showing percentage of T21 knockdown following transfection of PC3 cell line 
with pGFP-B-RS vector containing T21 shRNA showing T21 silencing over time. Experiments 
were carried out twice in duplicate (n=2) represented with standard error of mean with data 
expressed as percentage change to the control shRNA.  
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Figure 4.20 – Cell proliferation assay following T21 specific shRNA transfection. Time 
course carried out using a 3H incorporation cell proliferation assay demonstrating reduced 
PC3 cell proliferation observed following T21 shRNA silencing (A) and after cell sorting (B). 
Experiments were carried out three times on triplicate wells (n=3) represented with standard 
error of mean. Statistical significance indicated (**p<0.01) and (***p<0.001) as determined by 
Student’s t test. 
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Figure 4.21 – Western blot analysis of T21 protein expression following T21 specific shRNA 
transfection. Protein expression following 72 hours post-T21 shRNA transfection of PC3 cell 
line compared to control cells. Below, β-actin (45 kDa) as representative protein loading 
control (n=2). 
 
 
 
Figure 4.22 – Western blot analysis of T21/CEP290 protein expression following T21 specific 
shRNA transfection. Protein expression observed at 90 kDa following 48 hours post T21 
shRNA transfection of PC3 cell line compared to control cells. Below, β-actin (45 kDa) as 
representative protein loading control (n=2). 
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Figure 4.23 – Immunofluorescence images illustrating T21 protein expression after shRNA 
silencing of PC3 cells. Immunofluorescence image composites of PC3 cells showing absence of 
co-expression of T21 protein and GFP following 5 days after T21 specific shRNA transfection 
(C) when compared to control shRNA transfection (B) performed using anti-T21 antibody (red). 
Transfection of constructs observed via expression of GFP (green). The absence of T21 staining 
was observed using isotype control (A3).  
B1 (DAPI) B2 (GFP+) 
B3 (anti-T21u) B4 (merge) 
C1 (DAPI) C2 (GFP+) 
C3 (anti-T21u) C4 (merge) 
A1 (DAPI) A2 (GFP+) A3 (Isotype control) A4 (merge) 
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4.3 Discussion 
 
4.3.1  Molecular expression profiles of T21 using human tissues 
 
After previous investigations into T21 protein failed to reveal the true extent of expression 
in normal and cancer tissue, it has until now remained unclear whether T21 holds potential 
as a biomarker of disease or has any viability as an immunotherapeutic target. As a 
consequence, little is known as to what function, if any, T21 may have that could 
contribute to tumourogenesis. The identification of the unique region within T21 presents 
the opportunity to study T21 expression without detecting CEP290. Carefully designed 
T21 specific oligonucleotides in addition to the anti-T21u antibody within the unique 
region allowed re-examination of T21 in human cancer tissues and cell lines to be 
performed. Initially, T21 mRNA expression was assessed in normal healthy tissues using 
both semi-quantitative and quantitative PCR. Experiments demonstrated that T21 mRNA 
expression was not limited to testis tissue; in fact many tissues demonstrated 
comparatively high levels of mRNA expression compared to testis, for example normal 
prostate, stomach and spinal cord tissue. Moreover, protein expression measured in normal 
healthy individual tissue TMA demonstrated an overall absence or mild expression with 
except to some tissues (kidney, prostate and testis) showing moderate levels of expression. 
None of the normal tissues stained for anti-T21u antibody demonstrated strong expression 
of T21. These results demonstrated that the expression of T21 at the RNA level was not 
always consistent to the protein expression observed and that RNA and protein from the 
same patient tissue would be necessary to confirm these findings. What was apparent from 
these results was that although T21 was seemingly distributed throughout many normal 
tissues, the level of expression remained low with exception of normal prostate. This 
suggests that T21 could be tentatively categorised as a tissue-specific unique TAAs.  
 
As T21 was first identified and verified as a novel TAA by immunological probing of 
patient sera taken from advanced prostate cancer, the opportunity to study its expression 
pattern in prostate cancer progression represented an obvious study. Tissue sections taken 
from benign prostatic hyperplasia (BPH) and clinically confirmed prostate cancer patients 
were stained using the anti-T21u antibody. As observed with IHC analysis described 
above, T21 protein was localised largely throughout the cytoplasm and in some instances 
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to the nuclei and cell membrane. Careful observation confirmed no pattern of centrosomal 
localisation with T21 as would be expected with CEP290 staining. This TMA series 
demonstrated no statistical significance in the expression of T21 protein between benign 
(41.3%) and malignant disease (58.7%). Although the staining intensity distribution did 
not show differences among the strong staining, there were differences in staining 
distribution between mild and moderately staining intensities; 48.5% of malignant tissues 
were categorised as moderately positive compared to 28% of benign tissues. The 
differences between mild and moderate staining which was observed suggests a subtle 
increase in T21 expression in malignant tissues compared to benign. Further statistical 
analysis of the prostate cancer TMA series concluded that there are no significance 
difference with age, survival, PSA, death and Gleason grade. The limited number of 
patients within groups made it difficult to conduct a full statistical analysis, therefore 
intensities were grouped and categorised into high and low expression. Perhaps as a 
consequence, the subtle observations between mild and moderate staining intensities in 
prostate cancer patients were missed. Further expansion of the TMA series to include 
more patients should be performed, in addition to cell localisation analysis and in parallel 
with prostate specific disease marker expression (PSA, PAP, PSMA and alpha-methyl-
CoA-Racemase), loss of tumour suppressor expression (p53, p63, PTEN, BRCA genes), 
overexpression of oncogenic proteins (TMPRESS2:EGFR fusion, PI3K), growth factors 
and their receptors (TGFβ1 and EGFR) and mitotic markers (Ki67 and PCNA) (Velonas et 
al., 2013).   
 
The opportunity to screen for mRNA expression derived from various cancer cell lines 
showed that many cancer cell lines from breast, melanoma and head and neck 
demonstrated, to varying degrees, T21 expression. Interestingly, normal (immortalised) 
prostate cell lines (PNTα and PNT2) although positive for T21, showed lower expression 
compared to prostate cancer derived cell lines (PC3, DU145 and LNCaP). As the latter are 
derived from secondary tumour sites, a primary prostate cancer cell line (OPCT-1) was 
also assessed, revealing expression levels similar to that of the normal prostate cell lines. 
This suggests that T21 expression may preferentially be associated with metastatic disease 
although further experimental studies would be required to support this hypothesis, for 
example associating with in vitro migration and the drug resistance.  
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An important question that until now has remained unanswered was the nature of the 
relationship between T21 and CEP290. Evidence at the mRNA level failed to distinguish 
any associations in expression and so far western blot analysis concluded a seemingly 
lower expression of T21 compared to CEP290 in prostate and breast cancer cell lines. A 
consequence of this finding suggests that previous T21 protein analysis using the anti-
T21/CEP290 antibody may have been more likely to show the detection of CEP290 and its 
other molecule weight variants, overshadowing the rather more modest expression of T21. 
In order to distinguish the two proteins T21 was further analysed using the T21 positive 
prostate cancer derived cell line, PC3 by dual immunofluorescence staining. Interestingly, 
staining with anti-T21u antibody and anti-CEP290 antibody (Everest Biotech) revealed 
that T21 does not share a localised pattern of cellular expression, moreover no 
centrosomal localisation with CEP290 was observed. This observation was further 
corroborated using pericentrin, a centrosomal protein confirming that T21 does not share a 
functional role with CEP290 at the centrosomal bodies during cell division.  
 
4.3.2  Functional investigation of T21 
 
The second objective involved conducting a series of experiments using 
immunofluorescence protein detection and gene silencing techniques designed to 
determine whether T21 and CEP290 share functional characteristics and attempted to give 
an insight into their relationship and T21 involvement in cancer progression. Firstly, three 
siRNA oligonucleotides designed within the unique region of T21 were synthesised and 
transfected into PC3. All three siRNA led to the knockdown of T21 with T21-3 achieving 
the most significant knockdown in expression of both mRNA and protein between 24 hour 
and 72 hours post-transfection. Transfection using RNA interference can be subject to off-
target stimulation of interferon response-genes (Bridge et al., 2003), therefore mRNA 
levels of two interferon-response genes (OAS1 and STAT1) were measured to ensure the 
responses observed were in fact gene-specific, which proved to be the case (data not 
shown). No noticeable changes occurred in cell morphology; however cells treated with 
T21 siRNA were seemingly hindered in their capacity to proliferate. Further proliferation 
assays confirmed this observation. Later, siRNA transfection experiments coupled with 
cell cycle analysis revealed that although cells do not seem to be inhibited at S phase, a 
larger percentage of cells were arrested at the G2/M phase transition compared to the 
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equivalent control cells. These findings go some way to explain why PC3 cells stained 
with anti-T21u antibody and Ki67 failed to selectively co-express during cell division or 
the centrosome cycle. As with CEP290, Ki67 is expressed throughout all active stages of 
the cell cycle whereas T21 may in fact only be highly expressed and/or activated during a 
short phase of the cycle. Further experiments using cell cycle markers for G1/S phase 
(cyclins A and D) and G2/M phase (cdc2-cyclin B and phosphohistone H3) transitions 
would be needed to further elucidate the role that T21 may play in cell proliferation. In 
addition to knockdown experiments, a cell line which expresses little or no T21 (such as 
PCI30) would be important in order to demonstrate the role of T21 in proliferation. 
Reverse experiments in which transfection of a T21 cDNA into cells should theoretically 
lead to an increase in cell proliferation. Meanwhile, further knockdown experiments were 
performed using T21 specific shRNA transfection, which could be employed to study what 
long term effects arise from silencing of T21 expression. Stable silencing of T21 in cells 
treated with shRNA do however require further refinement of cell line procedure to 
achieve a stable knockdown over several passages (work ongoing).  
  
The analysis of selected genes that are either up or down regulated in the presence of T21 
provided yet further evidence that T21 may not share common protein functions with 
CEP290. The results did however indicate an up regulation of genes that promote 
tumourogenesis through various molecular networks, including cell proliferation and 
survival, centrosome and structural rearrangement and cell cycle control. In addition to the 
up regulation of those genes that would inhibit the response to DNA damage and those that 
modulate immune responses. Conversely, genes involved in regulatory pathways were 
suppressed in the presence of T21 and included RAS family members, cell stress/DNA 
repair pathways the PI3K-Akt pathway. Although a full and through analysis is essential to 
elucidate pathways that may involve T21 activity (work ongoing), the data presented here 
indicate that T21 appears to be involved in promoting tumourogenesis and therefore could 
represent an attractive target for therapy.  
 
 
 
 
 
 
 
CHAPTER 5  
  
INVESTIGATING THE IMMUNOLOGICAL POTENTIAL 
OF T21  
 
5.1 Introduction  
 
Since the 18th century, vaccines have been successfully utilised to protect against 
otherwise lethal diseases and have been responsible for the eradication of small pox 
reported by Fenner et al., 1988 and more recently, WHO initiatives have reduced annual 
cases of polio to just over 200 as well as countering other infectious diseases. The 
application of vaccines against viruses known to be involved in certain cancer have also 
proved extremely successful, however vaccines used to treat established tumours have 
remained incurable in this manner. This is partly due to their lack of immunogenic potency 
of the antigen used or suppression mechanisms elicited by the tumour. Since the first 
reported human tumour associated-antigen (TAA) (van der Bruggen et al., 1991) coupled 
with the knowledge that T cells respond through recognition of short peptide sequences 
bound to MHC molecules, various strategies have been developed to identify further 
TAAs and assess peptides for their immunogenic potential for their ultimate inclusion in 
therapeutic vaccines against cancer. Some reported antigen-based vaccination targets such 
as MAGE-A3, gp100, tyrosinase, carcino-embryonic antigen, NY-ESO and HER2/neu 
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have been shown to elicit antigen-specific immune responses with encouraging clinical 
outcomes (as outlined in Chapter 1).  
  
Current techniques used to identify immunogenic TAA-derived epitopes can be broadly 
classified as belonging to either “direct” or “reverse” immunological approaches. 
Techniques that rely on isolating epitopes directly using genetic or biochemical 
approaches are termed direct immunology procedures. An early example, involved 
transfection of DNA or cDNA libraries derived from patient tumour cells into cell lines 
expressing matching MHC molecules and isolating reactive CTL clones generated 
following in vitro screening using patient TILs. The technique was used by Boon and 
colleagues to identify MAGE-1 (van der Bruggen et al., 1991). The second subgroup of 
direct techniques relies on acid elution of antigenic peptides either from whole cellular 
extracts or from those bound to MHC class I complexes on tumour cells. Subsequent 
tumour derived peptides are purified and fractionated using reverse phase chromatography 
and assessed for CTL reactivity. Those conferring tumour lysis are sequenced using mass 
spectrometric techniques (van Bleek & Nathenson, 1990; Falk et al., 1991). Although 
successful in the discovery of a number of epitopes, these direct immunology approaches 
could not compensate for the techniques being time consuming and the cellular resources 
required were too demanding to be considered suitable to employ on a routine basis.  
 
In contrast to the direct approaches, reverse immunology attempts to streamline epitope 
discovery by screening peptide sequences taken from TAAs identified using either 
bioinformatics based data mining, serological expression in cancer patients or restricted 
protein expression in solid tumours. Briefly, candidate proteins are identified as TAAs and 
proposed as suitable targets for immunotherapy. Then, using predictive in silico computer-
based algorithms, putative antigenic peptides are selected based on scoring of their high 
affinity binding to predefined MHC alleles. Following predictive modelling, candidate 
sequences can be validated for immunological responses experimentally using synthetic 
peptides. This can include in vitro peptide stimulation of PBMCs from tumour patients or 
healthy donors of the appropriate MHC haplotype in order to expand reactive T cell clones 
that are capable of recognition and lysis of tumour cells (Viatte et al., 2006). A number of 
methods for in vitro expansion of specific T cells have been employed including multiple 
simulation of whole PBMC populations using peptide and cytokines, used to ensure 
survival and proliferation of reactive T cells (Montes et al., 2005) or using peptide-pulsed 
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PBMC subpopulations (such as APCs) cultured together with either/both CD8+ and CD4+ 
T cells (Salio et al., 2001) and finally towards overcome the issue of limited patient 
material, PBMCs can be stimulated with artificial APCs (Dupont et al., 2005). A major 
disadvantage concerning in vitro stimulation of PBMCs cultures, is that in the majority 
cases, T cells are non responsive or elicit extremely weak responses to tumour antigens 
most likely due to many antigens identified as belonging to self and are unable to 
overcome tolerance mechanisms. In addition, difficulties in expanding reactive T cells to 
the numbers required for assessment and the availability of patient material when 
screening for multiple peptides can also hinder epitope identification.   
 
An alternative approach which utilises in vivo models can be used by engineering mice to 
express human MHC class I and/or II molecules either with or without “knockout” of their 
own corresponding MHC molecules. These “humanised” transgenic mice models have 
demonstrated a capacity to identify both class I and II human HLA restricted viral peptides 
(Mann et al., 1995; Ressing et al., 1995) and human TAAs (Visseren et al., 1997; Rojas et 
al., 2005) however, differences in HLA restricted T cell repertoires between human and 
HLA transgenic mice have been reported (Wentworth et al., 1996) and therefore it should 
not be simply assume that conserved antigen processing and presentation between the two 
species always exists (Street et al., 2002). For this reason, newly identified peptide 
epitopes should be extensively assessed using human T cells from healthy and diseased 
donors prior to advancing to human trials. Due to the reported high global population 
frequency of the HLA.A2 (up to 54.5%) and DR1 (up to 24%, depending on ethnic 
background) (Gonzalez-Galarza et al., 2011), these alleles have been most frequently 
selected for double transgenic study (Pajot et al., 2004).  
 
The advancement of in silico epitope prediction tools combined with both in vitro and in 
vivo approaches to determine the immunogenicity of peptide epitopes have been used to 
identify both MHC class I and II defined peptides from numerous TAAs such as TRP2, 
gp100, HER2/neu and p53 (Parkhurst et al., 1998; Tsai et al., 1997; Kawashima et al., 
1998; Rojas et al., 2005). Despite the continued refinement of predictive algorithm 
programs, high affinity binding scores do not necessarily translate into highly 
immunogenic peptides. Another consideration is that T cells with TCRs displaying high 
affinity binding toward self antigens may indeed have been deleted during early T cell 
selection to avoid autoimmunity. Furthermore, identifying peptides that have high affinity 
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binding may not guarantee high avidity T cell responses (Zhong et al., 2013). There is the 
possibility that prediction models may exclude low-moderate affinity binding epitopes 
which may provide suitable targets to generate anti-tumour responses.  
 
Self antigens must overcome several immune safeguard mechanisms in order to maximise 
their desired effect and owing to the majority of TAAs being derived from inherently 
expressed normal cellular proteins, inducing unwanted immune tolerance can be 
problematic. Identification and targeting of single epitopes could lead to specific MHC 
down regulation and the opportunity of immune escape. Exogenous peptides may also 
bind directly to MHC on non-professional APCs leading to the induction of tolerance 
mechanisms. Peptide vaccines can be disadvantageous in that MHC class I restriction 
limits peptides to particular HLA haplotypes and not all HLA matched patients will 
therefore have the same degree of relevance to a particular epitope, however strategies to 
incorporate multiple peptides could circumvent these restriction issues (Salazar et al., 
2003).  
 
Refining the reverse immunology approach to integrate the use of synthetic overlapping 
long peptides (OLPs) taken from TAAs (ranging from over 12 – 50 amino acids in length) 
which could incorporate multiple epitopes capable of priming both CD8+ and CD4+ T cells 
may address the issues raised above. In more recent times, long peptides and OLPs have 
been assessed in a number of cancer trials demonstrating long-lived detection of reactive T 
cell responses and evidence of prolonged overall survival using peptides derived from 
HPV in cervical cancer patients (Welters et al., 2008), p53 in ovarian and metastatic 
colorectal cancer (Leffers et al., 2009; Speetjens et al., 2009), Her2/neu in multiple cancer 
types (Disis et al., 2002) and Muc-1 in lung cancer (Sangha & Butts, 2007). Unlike short 8 
- 10mer peptides, OLPs are not able to bind directly to cell surface MHC receptors and 
therefore their presentation for specific cell uptake requires correct processing and 
presentation to MHC by professional APCs which is perhaps why prolonged responses 
have been observed and not short lived responses which lead it functional deletion of 
antigen-specific CTL (Toes et al., 1996a) and so avoid the induction of T cell tolerance 
(Toes et al., 1996b). The delayed clearance of OLPs from the inflamed lymph nodes 
draining the vaccination site may also lead to increased epitope presentation and clonal 
expansion of IFNγ producing effector T cells (Bijker et al., 2008; Perez et al., 2010a). 
Moreover, long peptides that interact with multiple HLA alleles compared to short peptides 
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have broader T cell responses against multiple epitopes, particularly immunodominant, 
high avidity T cell inducing epitopes which would assist in reducing opportunities of 
tumour escape. In addition, the presence of multiple epitopes on the surface of the same 
APCs may indeed further potentiate antigen presentation and support greater activation of 
CD4+ and CD8+ T cell responses as observed in vaccinations using viral antigens (Shirai et 
al., 1994; Hiranuma et al., 1999).  
 
In the present study, the use of OLPs to identify endogenously processed immunogenic 
peptides using both in vitro and in vivo stimulation was considered the most appropriate 
approach for the purpose of this investigation. A peptide library consisting of OLPs was 
synthesised and screened in pools using HLA.A2/DR1 double transgenic mice assessing 
for generation of immune responses following a series of in vitro restimulation procedures 
involving cell proliferation and IFNγ release (Figure 5.1). Further importance was placed 
on the newly identified unique region sequence within T21 and prospective peptides were 
analysed for their endogenous processing using T21 cDNA immunisation. Finally PBMCs 
derived from prostate cancer patients were chosen to validate T21 specific T cell reactivity 
to unique region OLPs. 
 
 
Figure 5.1 – Overview of T cell activation cascade following antigen presentation. Upon TCR 
activation, cells initiate signalling pathways resulting in, among other events, clonal expansion 
of T cells and cytokine secretion which can be measured as T cell proliferation and cytokine 
release upon in vitro restimulation of T cells using antigen. (MØ=Macrophage, 
EOS=Eosinophil, NK=Natural Killer cell, CTL=Cytotoxic T Lymphocyte, DC=Dendritic Cell, 
Th=T helper cells).   
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5.2 Results 
 
5.2.1  Identification of immunogenic epitopes from T21 derived peptide library 
using HLA.A2/DR1 transgenic mice 
 
5.2.1.1 Evaluation of T21 derived peptide immunogenicity using HLA.A2/DR1 
transgenic mice   
 
In order to investigate peptide immunogenicity, overlapping long peptides (OLPs) derived 
from the whole T21/CEP290 protein sequence consisting of 246 peptides, 15mer in amino 
acid length and overlapping by 10 amino acids were synthesised (Purchased from 
ProImmune Inc, Florida, USA) and segregated into six groups. The first group (43 peptides) 
were prioritised for screening for two reasons; primarily, this region was first identified in 
the discovery of T21 using SEREX (Dr A Miles, PhD Thesis) to elicit IgG antibody 
responses toward prostate cancer patient sera suggesting that this region would be 
considered immunoreactive. Secondly, this group of peptides consists of the entire T21 
unique region including a CEP290 overlap and therefore provides a logical starting point if 
the immunogenicity of T21 only were to be investigated (Figure 3.2). These 43 OLPs were 
randomised and grouped into four pools consisting of 10-11 OLPs (Table 5.1), each group 
was then separately used to immunise HLA.A2/DR1 double transgenic mice 
subcutaneously at the base of the tail with a subsequent second round of immunisation with 
fresh peptide/IFA emulsion after 7 days. A further seven days after the final boost, mice 
were euthanised and splenocytes harvested and assessed using their corresponding OLP 
pool for T cell function and cell proliferation.  
 
Following vaccination a number of stimulation assays using ex vivo T cells have been 
utilised to assess T cell mediated cytotoxicity and other immunological responses. The 
most widely used assay for analysing CTL mediated lysis of is the radioactive chromium 
(51Cr) release assay developed by Brunner et al., 1968 and has been long since been 
considered the “gold standard” in measuring CTL mediated killing. More recently, 
enzyme-linked immunospot assay (EliSpot assay) used to measure secreted cytokines has 
emerged as a valuable technique of evaluating both CTL frequency and functional 
responses (Scheibenbogen et al., 2000). The EliSpot assay also has the added benefit over 
51Cr release assay of requiring less effector cells whilst delivering higher sensitivity and 
specificity. These techniques have allowed for the efficient screening of several peptides at 
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once for their ability to generate peptide specific T cell responses using pre-clinical animal 
models. Further modifications of current in vitro restimulation methodologies would be 
required when using longer peptides (>10mer). If for instance the internal antigen epitope 
is unknown, it can become problematic to restimulate target cells using long peptides to 
assess direct CTL mediated killing. Hence for the purpose of this study, three methods of 
in vitro restimulation were employed to generate T cell responses measured by way of T 
cell production of cytokine (IFNγ release EliSpot assay) and corresponding T cell 
proliferation (3H-thymidine incorporation assay) in each instance.   
 
Method 1 - Ex vivo restimulation: Following harvesting of splenocytes from immunised 
animals, cells were dispensed directly at a density of either 1x106 or 5x105 into 
nitrocellulose bottomed 96-well plates pre-coated with IFNγ capture antibody. T cells were 
directly stimulated using 1 µg/ml of peptide(s) and incubated for 48 hours before addition 
of IFNγ detection antibody and proceeding to spot development. Culture plates for 3H 
proliferation assay were prepared in parallel under the same conditions with the exception 
of assay specific growth media. This method allowed for very minimal in vitro T cell 
manipulation relying on inherent APCs present at the time of harvest from the splenic pulp 
(Swirski et al., 2009).        
 
Method 2 – Peptide-pulsed LPS blast mediated restimulation: Naive syngenic splenocytes 
were harvested and cultured in the presence of lipopolysaccharide (LPS) to induce LPS 
blast cells. These cells were then subject to gamma radiation and pulsed with 1 µg/ml 
peptides for 1 hour to act as stimulators of primed effector T cells when co-cultured 
alongside splenocytes harvested from immunised animals. Following 6 to 7 days of culture, 
cells were harvested and dispensed into assay plates at either 1x105 or 5x104 along with 
cultured DCs pulsed with relevant peptide(s) at a T cell:DC ratio of 10:1. After 24 hour 
incubation cells were assessed for specific IFNγ release and cell proliferation as described 
above.    
 
Method 3 – Peptide restimulation: Immunised splenocytes were harvested and cultured 
alongside peptide(s) at 1 µg/ml and in the presence of IL-2 for two weeks to stimulate T 
cell expansion and activation before being seeded at either 1x104 or 5x103 into assay plates 
alongside cultured DCs pulsed with relevant peptide(s) at a T cell:DC ratio of 10:1. Then, 
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cells were subjected to assay development after 24 hour incubation as described previously 
to detect peptide-specific T cell function and cell proliferation. 
 
Each IFNγ release assay experiment was performed in triplicate wells and along with 
media containing T cells and Staphylococcal Entotoxin B (SEB) super-antigen, a potent 
stimulator of T cell activation which was used as an assay positive control.  
 
 
   
 
Table 5.1 – Overlapping long peptide pool table used in animal immunisations. Table 
showing 43 overlapping 15mer peptides derived from the T21 sequence randomly assigned to 
pools (A - D) and used in animal studies. Peptides 1 -7 lay within the unique region of T21 
highlighted in red.    
 
Peptide pool A:  Peptide pool B: 
Peptide No. Peptide Sequence  Peptide No. Peptide Sequence 
29 H-RNEELRQELRESRKE-OH  31 H-ESRKEAINYSQQLAK-OH 
11 H-RDLERSRTVIAKFQN-OH  28 H-DQLTGRNEELRQELR-OH 
12 H-SRTVIAKFQNKLKEL-OH  6 H-DIELEHHRSQAEQNE-OH 
17 H-MKEILQAIKEMQKDP-OH  7 H-HHRSQAEQNEFLSRE-OH 
21 H-ETSLIIPSLERLVNA-OH  20 H-DVKGGETSLIIPSLE-OH 
8 H-AEQNEFLSRELIEKE-OH  40 H-PDGIAPSSASIINSQ-OH 
42 H-IINSQNEYLIHLLQE-OH  25 H-AEGIFDASLHLKAQV-OH 
33 H-QQLAKANLKIDHLEK-OH  43 H-NEYLIHLLQELENKE-OH 
32 H-AINYSQQLAKANLKI-OH  26 H-DASLHLKAQVDQLTG-OH 
41 H-PSSASIINSQNEYLI-OH  24 H-IESKNAEGIFDASLH-OH 
34 H-ANLKIDHLEKETSLL-OH  18 H-QAIKEMQKDPDVKGG-OH 
     
Peptide pool C:  Peptide pool D: 
Peptide No. Peptide Sequence  Peptide No. Peptide sequence 
14 H-KLKELVEENKQLEEG-OH  16 H-QLEEGMKEILQAIKE-OH 
13 H-AKFQNKLKELVEENK-OH  4 H-LIKEAECRNADIELE-OH 
5 H-ECRNADIELEHHRSQ-OH  2 H-SKNEIIAQEFLIKEA-OH 
35 H-DHLEKETSLLRQSEG-OH  30 H-RQELRESRKEAINYS-OH 
3 H-IAQEFLIKEAECRNA-OH  36 H-ETSLLRQSEGSNVVF-OH 
1 H-MSEAQSKNEIIAQEF-OH  38 H-SNVVFKGIDLPDGIA-OH 
10 H-LIEKERDLERSRTVI-OH  39 H-KGIDLPDGIAPSSAS-OH 
19 H-MQKDPDVKGGETSLI-OH  37 H-RQSEGSNVVFKGIDL-OH 
9 H-FLSRELIEKERDLER-OH  27 H-LKAQVDQLTGRNEEL-OH 
15 H-VEENKQLEEGMKEIL-OH  22 H-IPSLERLVNAIESKN-OH 
23 H-RLVNAIESKNAEGIF-OH    
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Positive responses were determined between peptide pool restimulated and non-
restimulated cells using Student’s t-test. The data demonstrated that statistically, peptide 
pool C generated a 100% positive response score. Pools A and D overall generated positive 
responses across 67% of assays and peptide pool B generated 58% positive T cell function 
and cell proliferation responses (Figures 5.2 - 5.4). Taken together the results revealed that 
all peptide pools generated varying levels of immune responses with peptide pool C 
triggered T cell responses that were significant in all three restimulation methods (Figures 
5.2 – 5.4). It can therefore be theorised that peptide pool C may contain either, single or 
multiple immunogenic epitopes, which clearly demonstrated the ability to elicit an immune 
T cell response in 2/2 animals in all three methods used compared to non-restimulated T 
cells. Moreover, this pool was able to induce T cell proliferation in response to peptide 
restimulation with results consistent with IFNγ release (Figures 5.2 – 5.4). The remaining 
peptide pools were also able to generate responses in both IFNγ release and in cell 
proliferation; however this occurred at reduced significance and with less consistency 
between mice replicates, restimulation methods and between assays.  
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Figure 5.2 – IFNγ release assays and proliferation assays by method 1 using T cells 
generated from HLA.A2/DR1 transgenic mice immunised with peptide pools A to D (method 
1). Mice were immunised as previously described and splenocytes harvested for assessment of 
T cell response to peptide restimulation using IFNγ release EliSpot assay (x-axis) and 3H 
incorporation cell proliferation assay (right y-axis). Assessments were performed following 
method 1 of in vitro restimulation of splenocytes using peptide pools with direct restimulation. 
Experiments were performed once in triplicate represented with standard error of mean 
between T cells either with or without stimulation using peptide pool, with statistical 
significance indicated as (*p<0.05 and **p<0.01) as determined by Student’s t test. 
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Figure 5.3 – IFNγ release assays and proliferation assays by method 2 using T cells 
generated from HLA.A2/DR1 transgenic mice immunised with peptide pools A to D (method 
2). Mice were immunised as previously described and splenocytes harvested for assessment of 
T cell response to peptide restimulation using IFNγ release EliSpot assay (x-axis) and 3H 
incorporation cell proliferation assay (right y-axis). Assessments were performed following 
method 2 of in vitro restimulation of splenocytes using irradiated LPS blast and pulsed DCs. 
Experiments were performed once in triplicate represented with standard error of mean 
between T cells either with or without stimulation using peptide pool, with statistical 
significance indicated as (*p<0.05 and **p<0.01) as determined by Student’s t test. 
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 Figure 5.4 – IFNγ release assays and proliferation assays by method 3 using T cells 
generated from HLA.A2/DR1 transgenic mice immunised with peptide pools A to D (method 
3). Mice were immunised as previously described and splenocytes harvested for assessment of 
T cell response to peptide restimulation using IFNγ release EliSpot assay (x-axis) and 3H 
incorporation cell proliferation assay (right y-axis). Assessments were performed following 
method 3 of in vitro restimulation of splenocytes using peptide pools followed by presentation 
using pulsed DCs. Experiments were performed once in triplicate represented with standard 
error of mean between T cells either with or without stimulation using peptide pool, with 
statistical significance indicated as (*p<0.05, **p<0.01, ***p<0.001) as determined by 
Student’s t test. 
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Based on the conclusion of these data, the decision was taken to interrogate peptide pool C 
further. To this end, peptides derived from pool C were randomly assigned into three 
subgroups and again assessed for their immunogenicity in HLA.A2/DR1 transgenic mice 
(n=2) using the three restimulation methods, however this time, using individual peptides 
to restimulate splenocytes using in vitro assays. In these experiments, a 15mer peptide was 
employed as a control (irrelevant peptide 1 - Seq: SWEKQWYGKAMERAF) to assess 
positive peptide responses (Table 5.2). To ensure the responses observed were specific to 
the peptide restimulation, a threshold of 20 spots above the non-restimulated T cells was 
applied and significance was obtained using Student’s t-test measuring T cell responses 
between pool C specific peptide restimulation and irrelevant peptide 1. Several peptides 
showed significant responses, elicited using methods two (Figure 5.5A) and three (Figure 
5.5B) in the two immunised mice with the strongest and most consistent responses arising 
from peptide 19 in subgroup C1, peptides 3, 15 and 23 in group C3 and peptide 5 in 
subgroup C2. On this occasion however, no responses were observed following ex vivo 
restimulation (method one). Further examination of the data by applying a threshold of 
greater then 2-fold spot change from the control (irrelevant peptide 1) revealed peptides 3, 
5, 15, 19, and 23 to generate significant responses to peptide restimulation (Figure 5.6) 
distinguishing these peptides as being capable of eliciting the most potent responses of all 
peptides assessed. Positive responses, shown to be statistically significant and 
demonstrating greater then 2-fold difference over peptide control, are presented in Table 
5.2.  
 
It is of particular note that both peptides 3 and 5 are present within the unique region and if 
determined to be strongly immunogenic, could potentially provide an opportunity as T21-
specific targets in immunotherapy (Figure 5.5). The pooled peptide based approach for 
screening OLPs has demonstrated that T21 specific T cell responses are generated in a 
HLA.A2.1/DR1 transgenic mouse model. Further confirmation of the immunogenicity of 
the identified peptides derived from T21 by immunising individual OLPs would be 
required, however due to animal and time constraints this could not be achieved during the 
course of this investigation.     
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Figure 5.5 – IFNγ release assays and proliferation assays performed using T cells generated 
from HLA.A2/DR1 transgenic mice immunised with peptide pool C1, 2 and 3 subgroups. 
Mice were immunised with one of pool C derived subgroup peptide pools and splenocytes 
harvested for assessment of T cell response to peptide restimulation using IFNγ release EliSpot 
assay. Assessments were performed following three methods of in vitro restimulation of 
splenocytes using individual peptides derived from the immunising pool. Graphs represent 
(method 2) irradiated LPS blast and pulsed DCs (A), and (method 3) restimulation using 
peptide followed by presentation using pulsed DCs (B). Experiments were performed in two 
mice in triplicate represented with standard error of mean between T cells either with relevant 
or irrelevant peptide 1, with statistical significance indicated as (*p<0.05 and **p<0.01) as 
determined by Student’s t test. 
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Figure 5.6 – Significant fold-change differences with peptide pool C1, 2 and 3 subgroups. 
Mice were immunised with one of pool C derived subgroup peptide pools and splenocytes 
harvested for assessment of T cell response to peptide restimulation using IFNγ release EliSpot 
assay. Assessments were performed following three methods of in vitro restimulation of 
splenocytes using individual peptides derived from the immunising pool. Experiments were 
performed in two mice in triplicate between T cells either with relevant or irrelevant peptide 1, 
with statistical significance determined as a minimal 2-fold change difference to irrelevant 
peptide 1.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7 – Diagram illustrating location of immunogenic peptides identified in pool C on a 
section of the T21 protein sequence. Peptides from pool C identified to have the most 
immunogenic potential following immunised T cell restimulation with individual peptides 
highlighted in red with the unique region bold, underlined.   
 
 
MSEAQSKNEIIAQEFLIKEAECRNADIELEHHRSQAEQNEFLSR 
ELIEKERDLERSRTVIAKFQNKLKELVEENKQLEEGMKEIL 
QAIKEMQKDPDVKGGETSLIIPSLERLVNAIESKNAEGIFDASLHL 
KAQVDQLTGRNEELRQELRESRKEAINYSQQLAKANLKIDHLEK 
ETSLLRQSEGSNVVFKGIDLPDGIAPSSASIINSQNEYLIHLLQELENKE 
5 
3 15 
23 19 
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Pool No. 
Peptide 
assessed  
IFNγ release (≥ 2 fold change) 
(Positive responses / total mice) 
Method 1 Method 2 Method 3 
Pool C1 
OLP:1 (0/2) (0/2) (0/2) 
OLP:9 (0/2) (0/2) (0/2) 
OLP:14 (0/2) (0/2) (0/2) 
OLP:19 (0/2) (0/2) (1/2) 
Pool C2 
OLP:3 (0/2) (0/2) (1/2) 
OLP:10 (0/2) (0/2) (0/2) 
OLP:15 (0/2) (1/2) (0/2) 
OLP:23 (0/2) (0/2) (1/2) 
Pool C3 
OLP:5 (0/2) (1/2) (0/2) 
OLP:13 (0/2) (0/2) (0/2) 
OLP:35 (0/2) (0/2) (0/2) 
 
 
Table 5.2 – Immunogenic peptides derived from dissection of peptide pool C. Tabulation of 
responses determined as minimal 2-fold change compared to irrelevant control peptide 1. 
Assays were performed on T cells generated from 3 groups of 2 mice immunised with peptide 
pool C1, 2, or 3 harvested and restimulated in vitro using individual peptides and assessed for 
T cell function using three methods (described previously). Experiments were performed twice 
in triplicate between T cells either with relevant or irrelevant peptide 1. (n=a/b) with ‘a’ being 
the number of mice that responded to the peptide immunisation and ‘b’ being the total number 
of immunised mice. 
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5.2.2  Identification of candidate immunotherapeutic targets within the T21 
unique region  
 
5.2.2.1 Determination of endogenously processed T21 unique region peptides   
 
One important advantage of studying the immunogenicity of this protein sequence lies in 
the inclusion of the region unique to T21. To determine whether this 31 amino acid 
sequence within the protein comprises of immunogenic epitopes would allow for T21 
specific vaccination avoiding unwanted targeting against to CEP290 and its associated 
protein variants. With this considered a closer examination of the unique sequence to 
establish whether natural endogenously processed epitopes display immunogenic 
capability would be needed.   
 
To achieve this, previously described T21 cDNA (Figure 3.2) inserted into pBudCE4.1 
expression vector was utilised for gene gun immunisation using HLA.A2/DR1 transgenic 
mice. This procedure would confirm proteins to be endogenously processed by the 
proteasome, presented within an MHC context and result in specific priming of T 
lymphocytes against T21-specific epitopes. Following 7 days subsequent to the final boost, 
T cells from immunised mice were harvested and assessed by restimulation directly with 
peptides or through APC presentation of peptide, a positive T cell recognition would elicit 
IFNγ response. In order to gauge the most effective positive response of T cells activated 
via peptide stimulation, immunised T cells were assessed in vitro using all three procedures 
as described previously.  
 
Due to the quantity of peptides now required for this study, peptides from the unique 
region and a 15mer control peptide (irrelevant peptide 2 – Seq: DESFRKYTAFTIPSM) 
were produced in-house applying a standard solid phase peptide synthesis protocol using a 
CEM Discover microwave with peptides being synthesised onto a polystyrene resin. The 
peptides were dissolved in HPLC grade water, HPLC Grade Acetonitrile 99% with 1% 
TFA and quality assured using mass spectrometry analysis (Dr V Mundell, School of 
Science and Technology, Nottingham Trent University, UK) (Table 5.3). Positive T cell 
responses were once again determined by applying a greater then 2-fold difference 
between the T21 derived peptide to the irrelevant peptide 2. The resulting T cell responses 
observed across the seven peptides analysed are summarised in Table 5.4 (see appendix VI) 
with significant responses observed with peptides 1, 4 and 5. Peptide region 3, 4, and 5 
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once more showed significant responses inviting further investigation of these three 
peptides as they may share a common immunogenic epitope that is also endogenously 
processed.  
 
Designated 
name 
Protein origin Sequence 
Top sequence  
similarity score 
Homo 
sapiens 
Mus 
musculus 
OLP:1 
T21, prostate cancer 
antigen T21, 
(AAT01278) 
MSEAQSKNEIIAQEF 
CEP290 
(93%) 
CEP290 
(57%) 
OLP:2 SKNEIIAQEFLIKEA ---- ---- 
OLP:3 IAQEFLIKEAECRNA ---- ---- 
OLP:4 LIKEAECRNADIELE ---- ---- 
OLP:5 ECRNADIELEHHRSQ ---- ---- 
OLP:6 DIELEHHRSQAEQNE ---- ---- 
OLP:7 HHRSQAEQNEFLSRE ---- ---- 
Irrelevant 
peptide 1  
(Irr 1) 
hCG25653, isoform 
CRA_b (EAW85903) 
SWEKQWYGKAMERAF 
hCG25653 
(100%) 
---- 
Irrelevant 
peptide 2  
(Irr 2) 
Pol protein, Human 
immunodeficiency 
virus 1 (ADY92492) 
DESFRKYTAFTIPSM HIV (100%) ---- 
(----) = No significant matches using online alignment tools (NCBI and Ensembl) 
 
Table 5.3 – A summary of T21 overlapping peptide alignment. Table summarising the 
overlapping peptide sequences spanning the unique region and the irrelevant peptides used 
during this study and their alignments to the human and murine proteomes. 
 
Peptide assessed 
IFNγ release (≥ 2 fold change) 
(positive responses / total mice) 
Method 1 Method 2 Method 3 
OLP:1 (0/6)  (1/6) (3/6) 
OLP:2 (0/6)  (1/6) (2/6) 
OLP:3 (0/6) (1/6) (2/6) 
OLP:4 (1/6) (1/6) (2/6) 
OLP:5 (1/6) (1/6) (2/6) 
OLP:6 (0/6) (1/6) (2/6) 
OLP:7 (0/6) (0/6) (2/6) 
 
Table 5.4 – Immunogenic responses of T21 unique region derived peptides. Tabulation of 
positive responses determined as minimal 2-fold change compared to irrelevant control peptide 
2. Assays were performed on T cells generated from 2 groups of 3 mice immunised with T21 
cDNA using gene gun immunisation (previously described) harvested and restimulated in vitro 
using individual peptides and assessed for T cell function using three restimulation methods 
(described previously). Experiments were performed between T cells either with relevant or 
irrelevant peptide 2. (n=a/b) with ‘a’ being the number of mice that responded to the peptide 
immunisation and ‘b’ being the total number of immunised mice.  
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5.2.3  Assessment of T21 derived peptide in prostate cancer patient PBMCs 
 
5.2.3.1 Identification of immunogenic T21 specific peptide in patients  
 
Experiments involving murine models to identify antigen derived immunogenic epitope 
regions remains a valuable and practical tool however, as alluded to previously, a cautious 
view must be applied when drawing conclusions from novel epitopes identified using pre-
clinical models. Natural differences in the cellular processing of endogenous proteins 
through the proteasome and TAP transport have been reported between the human and 
mice (Wentworth et al., 1996; Sesma et al., 2003). In regard to T21, the seven unique 
region peptides evaluated for endogenous processing share no equivalent mouse 
homologue; therefore it is not surprising that T cell responses were observed. As T21 is a 
“self-antigen” in humans there is a limitation in assessment of its peptides in mice as there 
is no need to overcome self tolerance in order to generate immune responses. Hence 
careful verification of novel epitopes must be sought using in vitro culture of healthy 
donor and cancer patient PBMCs.  
 
The most important question that requires addressing is whether, or if any, inherent T cell 
mediated immune response can be mounted against the peptide region of interest in 
patients with cancer. Initial identification of tumour antigen T21 had been derived from 
immunogenic screening for sera taken from patients with prostate cancer using SEREX 
technology which relies on high levels of IgG antibody titre in the patient serum towards 
the reactive cancer antigen. It can therefore be inferred that the production of antibody is 
supported by both B cells and Th1/Th2 cells which implies the presence of a CD4
+ T cell 
response against T21.  
 
In collaboration with Nottingham City Hospital, Urology Centre, prostate cancer patient 
PBMCs from four patients were assessed for T cell reactivity specific to the seven OLPs 
derived from the T21 unique region. In this pilot study, confirmed prostate cancer patients 
were selected with a view to identify any immunogenic peptides, optimise protocol and 
later to expand screening of identified peptides to a larger study of both cancer and BPH 
patient cohorts.   
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Patients selected for this study comprised of, patient-A, a 78 year old man presenting with 
elevated PSA and diagnosed with prostate cancer with biopsy confirming Gleason 7 (4+3) 
and metastatic disease. Patient-B, -C and –D all presenting with above age range PSA and 
diagnosed with localised prostate cancer with biopsy confirming Gleason 7 (3+4) and 
categorised as intermediate risk. All patients underwent radical prostatectomy and were 
monitored for disease recurrence. No tumour was available for T21 expression analysis. 
Patient blood analysis confirmed validity of the experiments (Table 5.5).   
 
 
Normal 
Range 
Patient-A Patient-B Patient-C Patient-D 
Age 
 
78 58 63 57 
Gleason grade 
 
7 (4+3) 7 (3+4) 7 (3+4) 7 (3+4) 
PSA (aged >70)*      (µg/L) 0 – 5 42.1 4.3 10.5 4.6 
Lymphocyte          (x109/L) 1.0 – 4.0 2.9 2.5 2.8 1.9 
Monocytes             (x109/L) 0.1 – 1.5 0.7 0.5 0.7 0.7 
Neutrophils           (x109/L) 2.0 – 7.5 3.6 2.6 3.2 3 
Basophils              (%WBC) 0 – 0.15 0 0.1 0 0.1 
 
Table 5.5 – Blood analysis of prostate cancer patients. Table showing patient age, Gleason 
grade, PSA level and blood differentials at the time of radical prostatectomy. (*)Elevated PSA 
range determined as (age +50=PSA over 3.0) (age +60=PSA over 4.0) and (age +70=PSA 
over 5.0) 
 
Due to the limited number of PBMCs retrieved after defrosting, it was decided to adopt a 
longer stimulation approach that would expand peptide specific reactive T cell populations 
within the cells.  
 
PBMCs from patients were thawed and pulsed with a pool of seven OLPs originating from 
the unique region or control peptide (irrelevant peptide 2). This was performed using a 
relatively low level peptide stimulation (1.4 ng per peptide) equating to a total of            10 
ng/µl of total peptide pool per stimulation. After 7 days, wells were again stimulated with 
the peptide pool and IL-2 and following a further 6 days, cells were gently washed using a 
centrifuge and seeded into wells with the addition of 1 µg/ml of individual peptides or 
control added to the appropriate wells. Using this extended stimulation method, no 
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responses were observed in patient-B, -C and –D (data not shown), however peptide 4 was 
able to induce a positive IFNγ response in patient-A compared to a healthy donor 
(p=<0.001) (Figure 5.8A). This is perhaps due to this patient having a more aggressive 
Gleason grading with metastatic disease and considerably elevated PSA levels compared to 
the other three patients. Despite a positive T cell response demonstrated in one patient, it is 
premature to suggest that peptide 4 contains a HLA restricted naturally expressed epitope; 
unfortunately, clinical information in this instance does not extend to assessing patient 
haplotype.  
 
Although the extended stimulation method provided considerably more reactive T cells to 
specific peptides, there is a risk of potentially skewing the response due to long term 
exposure of T cells to an immunostimulative environment following the addition of 
supplementary cytokines. With this considered, a more representative response was sought 
using PBMCs from patient-A that underwent immediate stimulation with either peptide 
pool, peptide 4 or control peptide and underwent assessment after 48 hours of culture, thus 
avoiding much of the response distortion which may be attributed to long term in vitro 
culturing of T cells.  
 
The resulting experiment confirmed a strong response to stimulation with peptide 4 
compared to control peptide or the response of a healthy donor, suggesting that the 
responses observed previously were indeed genuine and that restimulation in this way can 
generate reactive T cell responses in patients (Figure 5.8B). Interestingly, on comparison 
of the responses generated across the two stimulation methods, a stronger T cell response 
to peptide was observed following extended stimulation, perhaps as a consequence of the 
immunostimulative phenomenon described above. Indeed the lack of T cell response 
generated by the direct stimulation method using healthy donor PBMCs in both control and 
T21 peptide specific wells supports this notion.  
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Figure 5.8 – IFNγ release assay evaluation of a prostate cancer patient PBMCs response to 
peptide 4. Prostate cancer patient-A PBMCs were stimulated with unique region peptides and 
assessed using IFNγ release EliSpot assay. Data shown here represent PBMC response to 
peptide 4 versus control (Irr pep 2) with low levels observed in healthy donor compared to 
elevated levels in Patient-A (A) Further assessment was performed with either peptide 4 
stimulation or unique region pooled peptides (B). Experiments were performed once in 
triplicate represented with standard error of mean with statistical significance indicated as 
(**p<0.01 and ***p<0.001) as determined by Student’s t test.  
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5.2.3.2 T21 specific T cell reactivity in vaccine trial patients  
 
During the course of this study, and through collaboration with Professor Gustav 
Gaudernack (Oslo University Hospital, Norway), an opportunity arose to investigate 
clinical samples from a Phase I/II Norwegian vaccine trial using tumour derived mRNA-
transfected autologous dendritic cells to treat metastatic, androgen resistant prostate cancer 
patients, the findings were later published by Mu et al., (2005). Patient samples collected 
during the trial offered the chance to assess prostate cancer patient PBMCs for T cell 
reactive responses specific to T21 derived peptide prior to DC treatment and following 
completion of the treatment. Crucially, the therapeutic approach centred on immunogenic 
polyvalent prostate cancer antigen generated from three classical prostate cancer cell lines, 
LNCaP, DU145 and PC3. As previously confirmed in chapter 4, these cell lines express 
T21 mRNA and it is perhaps reasonable to consider that the therapeutic strategy used may 
indeed lead to the expression of T21 derived epitopes in the context of MHC on patient 
DCs (Figure 5.9).  
 
Briefly, the trial employed a vaccination method using DC’s transfected with mRNA from 
allogeneic prostate cancer cell lines with each patient receiving a minimum of four weekly 
injections administered either intranodally or intradermally, with 20x106 transfected DCs. 
In the procedure, PBMCs were obtained by leukopheresis and enriched for monocytes by 
magnetic depletion of B cells and T cells. Immature DCs were generated following 5 days 
of culture in serum free media containing GM-CSF and IL-4 (Mu et al., 2003). 
Subsequently, bulk tumour mRNA extracted from DU145, LNCaP and PC3 cells (equating 
to 50x106 of each cell line per vaccine) was prepared and mixed prior to transfection of 
immature DCs using a square-wave electroporation procedure. At 48 hours post-
transfection, cells underwent maturation in media containing IL-1β, IL-6 and TNF-α and 
PGE2. Mature DCs were then stored frozen and thawed as required.  
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Figure 5.9 – Diagram illustrating trial experimental procedure, vaccination schedule and 
acquisition of PBMCs used in this study. Monocytes isolated and cultured in vitro from the 
patient undergo transfection of mRNA isolated from allogenic prostate cell lines and re-
transfused into the patient.  
 
 
For entry into the trial, patients were required to have a verified adenocarcinoma of the 
prostate with evidence of disease progression considered as increasing PSA levels in three 
subsequent analyses. Patients also had an above minimal white blood, neutrophils and 
platelets with adequate haematological renal and hepatic function. In all, 20 patients were 
selected and of which four patients were diagnosed at stage T2 disease and the remaining 
15 patients at stage T3 (one patient did not complete the study). 
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Patients were monitored and evaluated for clinical signs of disease progression defined as 
the appearance of new lesions of malignant disease, or development of symptoms 
consistent with metastatic disease. In addition, PSA levels in serum were assessed before 
therapy (baseline) at week 5 and 3 months after the first round of vaccination. Disease 
status was defined as partial PSA response (50% ≤ than baseline), stable response (>50% 
reduction or <50% increase to baseline) and progressive disease (50% ≥ than baseline).  
 
To evaluate the immune response generated peripheral blood monocytes (PBMCs) were 
taken pre-vaccination (and used a baseline), at 5 weeks and after the final round of therapy 
at 3 months (post-vaccination). First, responses of T cells derived from the PBMCs were 
assessed after 5 days of co-culture with tumour mRNA-transfected stimulator cells using 
3H-thymidine incorporation assay and IFNγ EliSpot assay. T cells from PBMCs that 
demonstrated proliferative cell responses were co-cultured with irradiated allogeneic 
PBMCs and IL-2 and tested for the generation of T cell clones using cell proliferation and 
for CTL specific killing of target tumour mRNA-transfected cells and prostate cell lines 
(where appropriate) using 51Cr release assay.  
 
The trial concluded that clinical outcome was significantly related to immune response 
with 9 out of 11 patients with stable disease demonstrating both a positive immune 
response and decreasing PSA. Conversely, of the 9 patients that showed progressive 
disease, 44% demonstrated no immune response and no improvement in PSA. 
 
In the current study, cryo-preserved PBMCs that had been collected at two time points 
from 12 patients who all underwent therapy, referred to as before therapy (pre-vaccination) 
and 12 weeks after the first vaccination (post-vaccination) as indicated on Figure 5.9. To 
begin this investigation, PBMCs from one patient were rapidly thawed and underwent 
analysis using flow cytometry using combinations of CD markers to confirm that leukocyte 
populations had viable phenotypes compared to healthy levels (Table 5.6).  
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 Normal 
Range 
Pre- 
vaccination 
Post-
vaccination 
Class and (associated CD markers)  % % % 
Lymphocyte    (CD45+, CD3+) 20 – 60 58.33 53.64 
CD8+ T cell      (CD45+, CD3+, CD8+)  10 – 32 9.67 8.29 
CD4+ T cell      (CD45+, CD3+, CD4+)  28 – 59 45.91 42.51 
Monocyte        (CD45+, CD14+) 7 – 10 12.53 9.57 
 
Table 5.6 – Phenotypic analysis of therapy trial patient. Normal ranges of healthy white blood 
cells (%) and assessment of one representative patient pre- and post-vaccination PBMCs from 
frozen using flow cytometry. CD8+ and CD4+ T cell populations derived from gated lymphocyte 
population. Monocyte population derived from whole cell population.     
 
Patient PBMCs were thawed and incubated at 37°C to stabilise cell recovery and to reduce 
non-specific background during the assay. After 30 minutes incubation and gentle washing, 
cells were pulsed with either T21 peptide 4 or irrelevant control peptide 2 and seeded onto 
EliSpot plates pre-coated for with IFNγ capture-antibody. After 48 hours of incubation, 
cells were removed and EliSpot detection was performed and spots counted.  
 
During the trial, after completion of the course of vaccinations, patients were grouped into 
either “responder patients” described as those who demonstrated T cell responses to in 
vitro restimulation to mRNA loaded DCs and had stable or improved PSA levels following 
therapy or those that did not respond to therapy showing no improvement throughout the 
course, referred to as “non-responder” patients. Using this information, the results here 
demonstrated that 6 out of 8 responder patients were able to generate positive responses 
following peptide 4 stimulation when compared to control. It is also important to note that 
four out of eight patients demonstrated responses to peptide 4 in pre-vaccination PBMCs 
with four out of eight patients showing response after therapy (Figure 5.10 A1 and A2) 
which may perhaps point toward the existence of an intrinsic T21 peptide 4 specific T cell 
response. Interestingly, responder patients p12, p15 and p19 all exhibited stable disease 
following treatment and not only generated significant vaccination responses to T21 
peptide compared to control, but also showed significantly increased T cell responses 
between pre- and post-vaccination (Figure 5.10).       
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Figure 5.10 –IFNγ release assay performed on prostate cancer patient derived PBMCs. 
Patient PBMCs were stimulated with either peptide 4 or control (irrelevant peptide 2) and 
incubated for 24 hours before being assessed for T cell IFNγ release. 8 patients represented in 
(A1+A2) were classed as T cell responders to therapy whereas 4 patients (B) showed no T cell 
response to therapy. The experiment was performed once in triplicate wells represented with 
standard error of mean with statistical significance indicated as (*p<0.05, **p<0.01, 
***p<0.001) as determined by Student’s t test.  
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Figure 5.11 – IFNγ spot count distribution in T cell responder and non-responder patient 
groups. Graph (A) showing 8 therapy responder patients pre- and post-vaccination spot count 
distribution when stimulated with either peptide 4 or control (irrelevant peptide 2). Post-
vaccination responses are statistically elevated when compared with control (*p<0.05) and 
when compared to pre-vaccination levels (**p<0.01). Graph (B) representing 4 non-responder 
patients determining statistical significance by paired Student’s t test.  
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In contrast, none of the four non-responder patients generated any significant responses 
post-vaccination. Within this non-responder cohort, three out of the four patients showed T 
cell responses in pre-vaccination PBMCs which seemly induced very strong responses 
compared to the pre-vaccination responses observed in the responders (Figure 5.10B), 
however strong T cell responses were also observed in the control wells (both in non-
stimulated and using control peptide) indicating that the responses were not a consequence 
of peptide stimulation. In addition to this observation, the post-vaccination stimulation in 
non-responders failed to generate similar responses to their respective pre-vaccination 
responses. Overall, no significant differences were observed in this group (Figure 5.11).   
  
It was also possible to differentiate between these groups by depicting the response fold-
change from the responder and non-responder groups as the latter consistently failed to 
generate post-vaccination responses that were stronger than the pre-vaccination responses 
(Figure 5.12A). Collectively, these data show that a fold-change between pre- and post-
vaccination IFNγ responses following stimulation using peptide 4 significantly 
discriminates between responder and non-responder patients (p<0.00195) (Figure 5.12B).  
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Figure 5.12 – Fold change in T cell responder and non-responder patient groups. Graph (A) 
showing responder and non-responder fold change of post-vaccination PBMCs with peptide 4 
using pre-vaccination level response to peptide 4 as baseline (0) Graph (B) representing 
responder and non-responder fold change distribution significance determined at (**p<0.01) 
by Student’s t test.  
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5.3 Discussion 
 
The discovery of T21 using the SEREX approach and importantly, the identification of the 
uniquely encoded region in chapter 3, has led to the opportunity to trigger tumour-killing 
mediated by T21 primed T cells. Once identified, immunogenic peptide sequences could 
have a number of immunotherapeutic applications in cancer. Previous investigation using 
anti-T21/CEP290 antibody demonstrated restricted expression in normal tissues (Miles et 
al., 2007). During the current investigation it has been established that the antibody used 
for previous studies would potentially identify both T21 and CEP290 proteins. The 
published study also demonstrated T21 reactivity in 5 out of 10 prostate cancer patient sera 
with no reactivity observed in normal donor sera (0 out of 10). Taken together, it could be 
concluded from these findings that the mRNA sequence identified using SEREX i) holds 
the ability to evoke pre-existing and detectable humoral immune response suggesting there 
may be an epitope(s) target which can be exploited for immunotherapy ii) the response 
observed is specific to tumour regardless of it being T21 or CEP290 positive and finally iii) 
the tissue-restricted expression of CEP290 would avoid the induction of an unwanted 
autoimmune response against healthy normal cells if triggered during immunotherapy. On 
this premise, the current study of T21 sought to identify immunogenic peptide sequences 
which were capable of generating immune responses using an in vivo double transgenic 
mouse model (HLA.A2/DR1) and in vitro studies using human PBMCs derived from 
prostate cancer patients.  
 
To begin, peptides were screened for their immunogenic reactivity using a library of OLPs 
synthesised from the T21 sequence focusing specifically on 43 OLPs derived from the 
translated mRNA sequence initially identified using SEREX. It was decided that pooling 
OLPs into four groups and immunisation using HLA.A2/DR1 transgenic mice would be 
most suitable to determine the presence of immunogenic peptides. The most reactive pool 
(pool C) was further segregated into sub-pools with three to four OLPs in each which were 
then individually used to restimulate immunised splenocytes in vitro. Interestingly, T21 
unique region specific OLPs 3 and 5 generated consistent and statistically significant 
responses over two of the IFNγ restimulation methods used.  
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In the light of these results and due to the inclusion of the unique region in T21 and not 
CEP290, further evidence of endogenous processing of the unique region epitopes was 
sought. Resulting gene gun assisted T21 cDNA immunisations demonstrated significant 
responses with 1, 4 and 5 OLPs. The conclusion from these early studies of 
immunogenicity in transgenic mice highlighted OLP region 3, 4, and 5 as three peptides 
which may potentially share common immunogenic epitope(s) and may also be 
endogenously processed. One major limiting factor experienced throughout this 
investigation was the availability of transgenic mice due to unforeseen events, therefore 
confirmation of these findings would be required in repeat experiments giving more 
thorough statistical analysis before commencing further studies. 
 
As T21 is a “self-antigen” in humans, it could be argued that assessment of the true 
immunogenicity of T21 derived peptides in mice is compromised as the absence of the 
unique region in mice suggest that there is no need to overcome self tolerance in order to 
generate immune responses. Therefore verification of peptides were sought using in vitro 
culture of healthy donors and prostate cancer patient PBMCs. In the first of two 
independent studies, prostate cancer patient PBMCs were compared against healthy 
controls using restimulation with OLPs derived from the unique region of T21. Results 
demonstrated little responses in healthy normal PBMCs however peptide 4: 
(LIKEAECRNADIELE) demonstrated strong IFNγ release responses indicating that this 
candidate peptide may indeed merit further investigation for immunotherapy. A second 
study involving a shorter in vitro restimulation procedure confirmed these findings. It is of 
note that following in vitro assessment of splenocytes immunised using pools of 10-11 
peptides, pool D which demonstrated consistent responses contained OLP 4. From this it 
could be hypothesised that pool C containing OLPs 3 and 5 (which span the length of 
peptide 4) may have together been responsible for generating the most consistently 
significant responses compared to the other three pools.  
 
Evidence of an immunological response generated following stimulation using peptide 4 
in a prostate cancer patient (confirmed Gleason 7 (4+3)), prompted the study of this 
peptide in a prostate cancer patient cohort. An in vitro peptide 4 stimulation procedure was 
first optimised and performed on PBMCs derived from patients prior to, and proceeding 
an adoptive cell transfer therapy using autologous DCs pulsed with allogenic mRNA 
derived from three classical prostate cell lines (PC3, LNCaP and DU145); all of which 
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express T21 mRNA (chapter 4). The PBMCs used during this study formed part of a larger 
phase I/II clinical trial in which patients with metastatic, castrate resistant prostate cancer 
underwent four doses of DC-therapy (Mu et al., 2005). The trial resulted in 13 out of 19 
treated patients demonstrating decreased rate of PSA which was enhanced further with 
booster vaccinations. Furthermore, PSA reduction and development of specific immune 
responses were also observed and appeared to share a correlation (12 out of 19 treated 
patients). The trial established that the vaccine was well tolerated with no toxicity 
observed and that the clinical outcome is significantly related to T cell response. Since 
then, two more phase I/II trials using autologous instead of allogenic tumour-mRNA in 
prostate (ClinicalTrials.gov Identifier: NCT01197625/completion 2021) and in advanced 
metastatic malignant melanoma (Kyte et al., 2006) have been conducted by the same 
group. 
 
During the current investigation, the patient cohort used consisted of eight patients 
responders to therapy and four non-responders to therapy. An association between 
treatment responses and in vitro stimulation with T21 peptide 4 was observed in all 
clinical responders that were able to generate higher post vaccination responses following 
stimulation, four out of eight of responder patients generated significant levels of IFNγ 
post treatment. It is of note that responder patient’s p12, p15 and p19 all demonstrated 
stable disease following treatment and all showed a significantly increased T cell response 
to stimulation with peptide 4. Conversely, the four clinical non-responder patients seemly 
generated responses pre-vaccination but failed to generate responses post-vaccination. In 
this way simulation using T21 peptide 4 allowed for significant discrimination between 
these two subgroups (p<0.00195). Although limited in the patient numbers in each 
subgroup, stimulation using peptide 4 suggests the following; firstly, human T cells may 
evoke a pre-existing response to T21 peptide 4 therefore breaking immune tolerance may 
be less difficult than first considered. Secondly, a clear discrimination between the 
subgroups following stimulation suggests T21 may contribute in some way to an anti-
tumour response against prostate cancer. Therein, targeting T21 peptide 4 could 
potentially generate immunoreactive responses offering potential in a vaccine setting. 
 
In drawing parallels between the in vivo transgenic studies and the in vitro PBMC studies, 
the evidence suggests that the focus of future immunogenic studies with T21 for 
translation into immunotherapy may lie in examining the immunogenic properties of 
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peptide 4. Investigations must first determine the immunoreactivity of peptide 4 that exists 
in cancer patients. Furthermore, patients who demonstrate reactive responses to peptide 4 
may benefit from T21 directed therapy. 
 
Although mice lack natural expression of the T21 unique region further evaluation of T21 
peptide 4 using pre-clinical models would be useful in demonstrating whether T21 would 
generate T21 specific CTL activity. One approach would be to develop a tumour model 
using murine tumour cell lines transfected to express T21 which could be used to assess 
prophylactic and therapeutic peptide and DNA vaccination strategies. Initial attempts 
using a murine lymphoma cell line (ALC) transfected with both human HLA.A2 and T21 
containing constructs and subsequently injected subcutaneously into the right side flank of 
six HLA.A2/DR1 transgenic mice and monitored for tumour growth. Four out of the six 
mice had measureable tumours after 22 days, the remaining two mice failed to generate 
any tumour during the course of the experiment (data not shown). An alternative to 
transfection would be to use a HLA.A2+ human cell line that naturally expresses T21 such 
as the prostate cancer cell line, LNCaP or breast cancer cells MCF-7 and MDA-231. T21 
expression studies detailed in chapter 4 indicate that LNCaP and MCF-7 may be useful for 
adoptive transfer of T cells derived from HLA.A2/DR1 transgenic mice immunised with 
T21 specific peptide into immunocompromised mice bearing human tumours to assert 
direct tumour killing and determine whether either/both CD8+ and CD4+ T cell recognition 
occurs during anti-tumour responses.  
 
Entry of T21 protein sequence into the in silico prediction algorithm 
(http://www.syfpeithi.de/) using either HLA.A*0201 or HLA.DRB1*0101 MHC types 
failed to rank any unique region peptide over a score of 20 suggesting that they may be 
considered low-moderate affinity binding peptides (data not shown). One explanation of 
the apparent immunogenicity of peptide 4 may be due to specific CTL, T helper or B cell 
activity or to a combination of two or all of these responses at a low level supported by the 
presence of auto-antibodies (indicative of a humoral response) during initial serological 
identification of T21 (Jäger et al., 2000). If indeed a T21 peptide directed anti-tumour 
response occurs in vivo in man, this may be due to an underling low level self 
autoimmunity response to the T21 unique region. The appeal of targeting intron retention 
sequences of self antigens such as the unique region of T21 is that TCR’s recognising 
native sequences, in this instance CEP290, may be preferentially selected over T21 for 
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deletion during thymic and peripheral selection due to high affinity TCRs recognising self-
antigen (CEP290) leaving low affinity (T21 unique specific) TCRs to avoid termination. 
Other investigators have reported the presence of anti-CEP290 antibodies in the sera of 
patients from various cancers (Eichmuller et al., 2001; Chen & Shou, 2001) which may 
suggest functional tolerance and loss of high avidity immunodominant antigen-recognising 
CTL’s whilst retaining those with lower antigen binding affinity which may achieve only 
weak immune responses (Theobald et al., 1997). Functional characteristics of these low-
moderate affinity T cells are still not clearly understood. A recent study in mice 
demonstrated the fully functional capability of auto-reactive low avidity T cells to self-
antigen during infection (Enouz et al., 2012). Therein, the potential of targeting T21 and 
avoiding CEP290 may indeed be viable. 
 
In some cases cancer-specific alternative transcripts have been functionally attributed 
toward tumorogenesis and represent neo-antigens that could be utilised for immunotherapy 
(Kalnina et al., 2005). In mice, targeting of a CD44 variant using DNA encoded 
vaccination demonstrated a reduction in mammary tumour progression (Wallach-Dayan et 
al., 2008). In humans, a number of retained intron sequences have been identified such as 
melanoma ubiquitous mutated-1 (Coulie et al., 1995), GnT-V (Guilloux et al., 1996), TRP-
2-INT2 (Lupetti et al., 1998) and gp100-in4 (Robbins et al., 1997), all of which are 
capable of in vitro HLA-restricted tumour cell killing. In human trials a phase I peptide-
based study in advanced oral cancer using survivin-2B, found to contain partial retention of 
intron 2 as a cryptic exon (Mahotka et al., 1999), has so far demonstrated increased 
peptide-specific CTL in six out of eight patients with no adverse toxicity observed 
(Miyazaki et al., 2011). The study however failed to prevent patients developing 
progressive disease, a failure on the part of vaccination strategy rather than the antigen 
used, which recent studies demonstrated an improved clinical response following peptide 
vaccination combination of incomplete Freund’s adjuvant (IFA) and IFNα (Kameshima et 
al., 2013).  
 
Although monitoring T cell proliferation kinetics and the secretion of IFNγ captures a 
broad overview of an immunological response following antigenic stimulation, they are 
considerably limited in determining the specific T cell population(s) responsible for such 
responses; hence the experiments presented should be considered preliminary. Employing 
three distinct in vitro peptide restimulation procedures during the animal studies attempted 
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to determine which assay was most suited to assessing OLPs. Direct restimulation (method 
1) failed to generate responses comparable to the other two extended culture methods, 
possibly as a consequence of inadequate antigen presentation to immunised splenocytes by 
resident APCs or that the responses generated were weak, amplified only when using 
extended restimulation procedures. Empirically determined optimal peptide doses for in 
vitro restimulation is important in determining the efficiency of T cell responses. Whilst 
low levels of peptide may not result in adequate T cell activation, high concentrations may 
result in overstimulation and T cell apoptosis. Further optimisation of the minimal peptide 
dosage required for T cell responses would therefore be critical in both human and animal 
studies.  
 
By extension, considerations of in vivo peptide vaccination strategies to activate rather 
than tolerise T cells should also include i) Optimisation of peptide vaccine dosage: to 
avoid unwanted tolerising effects induced by high levels of peptide at the site of injection 
ii) Administration route and inclusion of co-stimulatory modulators: aiding the recruitment 
of APCs and correct stimulation of the vaccine-site microenvironment to promote TAA 
processing and presentation iii) The use of immunological adjuvants: as TAA peptides are 
poorly immunogenic, adjuvants serve to induce inflammatory infiltrates such as T cells 
and APCs (Schaed et al., 2002: Dredge et al., 2002). For example, the use of water in oil 
emulsions such as Montanide or IFA in short peptide vaccines can elicit CD8+ T cell 
responses, but not necessarily anti-tumour responses in melanoma patients (Rosenberg et 
al., 1998; Smith et al., 2003; Walker et al., 2004). This may be due to the dysfunction and 
deletion of CD8+ T cells at the administration site (Salerno et al., 2013), although 
surprisingly T cell dysfunction is not observed using longer peptides/IFA vaccinations 
(Bijker et al., 2007; Hailemichael et al., 2013) observed in clinical studies with HPV 
peptide/Montanide vaccine (Kenter et al., 2009) and p53 peptide/Montanide 
administration in ovarian cancer patients (Leffers et al., 2009). This demonstrates the need 
to thoroughly investigate how vaccine-site microenvironments could be modified to 
potentiate peptide-based vaccines, not just by the use of adjuvants (such as IFA/ 
Monotanide/CpG-ODN/Poly-IC), but also immunomodulatory compounds (GM-CSF/IL-
2/IFNs), targeting co-stimulatory receptors (OX40/4-1BB), counteracting suppressive 
immunity by blockade (CTLA-4/PD-1) or depletion (Treg/MDSC) therapy and 
synergising peptide-based immunotherapy with chemotherapy (Arens et al., 2013).  
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In conclusion, the presence of a novel immunogenic and naturally processed peptide target 
in the form of a T21 unique peptide sequence (peptide 4) has been described. Further 
investigation into the immunogenicity of T21 should now focus primarily on providing 
evidence of peptide-specific tumour killing using this peptide sequence. 
 
 
 
 
 
 
 
CHAPTER 6 
 
DISCUSSION 
 
6.1 Introduction 
 
There are now many lines of evidence that support the idea first put forward by Burnet and 
Thomas in 1957 and expanded on by Dunn et al., 2004 that the immune system plays a 
crucial role in tumour elimination and escape from containment to a state of malignancy. 
Taking advantage of immune recognition and the targeted destruction of tumours, cancer 
immunotherapies attempt to harness components of the immune system in order to 
generate long lasting, anti-tumour responses. The appeal of pursuing immune driven 
approaches includes the avoidance of debilitating and sometimes life-threatening side 
effects associated with conventional therapies as well as destruction of tumour cells 
responsible for refractory disease and fatal metastasis. This said, immunotherapy presents 
its own specific challenges that must be addressed when developing strategies in order to 
avoid similar shortcomings associated with conventional therapies. Since the identification 
of the first tumour antigen (MAGE-1), attempts to evoke tumour-specific cell mediation 
killing through CTLs in cancer patients. Although clinical trials have demonstrated 
clinical efficacy for sub-groups of patients, generating responses for all has proved 
difficult (Rosenberg et al., 1998; Schwartzentruber et al., 2011; Kantoff et al., 2010; 
Leffers et al., 2009). Issues of tumour immune evasion such as down regulation of MHC 
class I molecules, induction of T cell anergy and regulation, tolerance, immune 
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suppression attributed to TME factors and so forth have helped us to conclude that direct 
tumour targeting with CTL alone is insufficient. The role of CD4+ T helper cells in 
contributing to the orchestration of immune response have been shown to be pivotal in 
activating immune cells (DCs, T and B cells) that lend support to CTL and effector cells 
mediating  innate immunity (NK cells and macrophages) to eliminate tumours (Ossendorp 
et al., 1998). Therefore the use of TAAs that are capable of engaging both CTL and T 
helper responses may result in generating more potent and long lasting immune responses. 
Indeed some of the more promising TAAs identified have demonstrated that CD4+ and 
CD8+ T cells and B cells form an integrate immune response against tumour and have 
been defined using serological analysis of cDNA expression (SEREX) (Sahin et al., 1997). 
In principle, the screening of antibody libraries relies on the specificity of B cell responses 
whereby the induction of high-titre IgG antibody is dependent on cognate CD4+ T cell 
help which suggests a capability of evoking both the adaptive and humoral responses.  
 
6.1.1 T21 and the centrosomal protein CEP290 
 
In the early 2000’s, T21 (testis clone 21) was identified as a candidate TAA as a result of 
modified SEREX screening of a normal testicular cDNA library expressed in E.coli and 
probed with allogeneic prostate cancer patient serum (Miles et al., 2007). Subsequent 
studies of T21 mRNA and protein expression indicated towards its restriction to normal 
testis and cancer tissues, making its application as a biomarker of disease and potential 
immunotherapeutic target a tangible prospect. Protein expression had been extensively 
studied in prostate cancer reporting significant over expression of T21 in prostate cancer 
glands compared with those derived from benign tissue. Additionally, expression was 
positively associated with pathological stage of tumours and suggested a correlation with 
increasing Gleason grade and PSA recurrence (Miles et al., 2012). However later in silico 
analysis revealed that T21 shared significant sequence similarity with a centrosomal 
protein called CEP290, present in the centrosomes of dividing cells and shown to play a 
role in tissue specific cillogenesis (Coppieters et al., 2010). To date, mutations of CEP290 
have mostly been studied in the context of cilia related disorders. In 2001, two separate 
studies identified CEP290 as a potential TAA, the first study used SEREX by probing a 
testicular cDNA library with sera taken from CTCL patients (termed Se2.2) (Eichmuller et 
al., 2001), the other used an anti-CEP290 mAb (3H11Ag) to probe a cDNA library 
derived from patients with gastric cancer (Chen & Shou, 2001).      
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6.2 Identification of a region unique to T21 and its implications 
 
Since the finding that T21 shared sequence similarly with CEP290, it was paramount to 
establish the extent of this similarly and determine whether T21 was in fact CEP290, a 
variant of CEP290 or a separate gene within its own right. It was quickly established that 
T21 PCR primers designed and the custom anti-T21 Ab (referred to throughout this project 
as anti-T21/CEP290 Ab) used in earlier studies would have been common to both T21 and 
CEP290 suggesting that either or both could be detected in PCR and protein-based studies.  
 
Chapter 3 details how working with the sequences submitted to NCBI, T21 mRNA 
(Accession No. AY590151.1) and CEP290 gene (Gene ID: 80184) were scrutinised in 
order to determine the similarity between the two. CEP290 alignment to the T21 mRNA 
transcript confirmed a 31% alignment coverage similarity between T21 with CEP290 of 
which 96.5% similarity between T21 and CEP290 mRNA was observed. Two conclusions 
were drawn from this initial alignment. The first identified that the T21 mRNA transcript 
begins 835bp downstream of the CEP290 ATG start sequence (within exon 10 of CEP290) 
with the coding sequence commencing at position 1802bp (within exon 10 of CEP290) up 
to position 3401bp (ending at exon 28 of CEP290). Further, the 96.7% similarity between 
T21 and CEP290 protein sequences demonstrated that T21 shares in-frame nucleotide-to-
protein translation with CEP290, suggesting that the Ab used in previous investigations 
would indeed recognise peptide binding sites of both CEP290 and T21. The second 
observation revealed a 3.5% sequence discrepancy between T21 and CEP290. Further 
analysis of this region on T21 uncovered a 93bp insertion proceeding exon 18 of CEP290 
from CEP290 intron 18/19. This subsequently encodes for the incorporation of a 31 amino 
acid sequence which is specific to T21 and not to CEP290 and was thereafter referred to as 
“unique region” as it was an exclusive protein encoding region of T21. Furthermore, no 
significant homology of the T21 unique region to any other organism in the Ensembl and 
NCBI databases was observed. It can therefore be considered that T21 is a transcript of the 
CEP290 gene located on chromosome 12q21.32 and also T21 protein prematurely 
terminates after exon 28 of CEP290. This was determined to be a consequence of an 
alternative splicing event occurring after exon 28 of CEP290 resulting in the uninterrupted 
transcription into the intronic sequence. As a consequence, an immediate sequence 
termination signal gives rise to a truncated T21 protein sequence. These findings were 
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confirmed experimentally using PCR and northern blotting, giving evidence of a novel, 
previously unreported CEP290 protein variant containing an alternatively spliced exon. As 
mentioned, previous reports of disease-related CEP290 mutations deal primarily with 
cilliopathies and of the other two studies purporting CEP290 as a TAA (Eichmuller et al., 
2001; Chen and Shou, 2001), both instances were shown to be independent of T21, either 
due to the location of the identified antigen (Se2-2) or the exclusion of the unique 93bp 
sequence indicating an alternative variant being identified and assessed (3H11Ag).           
 
Although these findings confirmed that previous studies conducted did not discriminate 
between CEP290 and T21, the identification of the unique region and termination sequence 
now allowed both transcripts to be analysed independently from each other. These 
sequence differences allowed the identification of an additional adenine residue present in 
CEP290 which was previously omitted from the published T21 sequence via PCR and 
sequencing data. Consequently, this bp addition into T21 drew questions as to the validity 
of the initiation signal of the encoding region first identified. Evidence suggested that the 
T21 sequence started at the ATG start of CEP290, indicating a possible shared promotor 
region. This study failed to fully confirm the upstream sequence using 5’ RACE PCR. The 
intention was to insert cDNA obtained from PCR experiments into a cloning vector to 
enable DNA sequencing in order to elucidate the entire sequence of T21 and determine the 
encoding start sequence. Despite CEP290 being a well characterised gene, the promotor 
region remains unknown. Further experimental investigation involving specific promotor 
silencing is necessary to determine whether T21 and CEP290 share the same promotor or 
are indeed independently regulated. 
 
Using a custom mono-specific polyclonal anti-T21u antibody specific to T21 (targeting 
the unique sequence), western blot analysis performed on various cancer and normal cell 
line lysates identified two distinct bands at approximately 90 kDa and 70 kDa. The former 
was identified to possess the correct conformational structure to bind the antibody and was 
confirmed to be specific to T21 by both gene silencing and immunoprecipitation of cell 
lysates followed by western blotting analysis. Attempts to verify the protein sequence of 
T21 using mass spectrometry was not achieved during this study, however pursuing this 
line of investigation further would help to confirm the sequence of T21 and provide 
insight into its interactions with other proteins and reveal any functional roles. 
Chapter 6: Discussion  6.3 
 
209 
 
6.3 The emerging role of T21 in tumourogenesis and candidacy as an 
immunotherapeutic target 
 
Due to the inadvertent inclusion of CEP290 during studies of T21, the functional 
processes of T21 protein had yet to be clearly determined. As the CEP290 protein had 
been found to be involved in structural and centrosomal functions, it could naturally be 
concluded that its presence would be in some way linked to cell proliferation. 
Uncontrolled cell proliferation is a defining feature of tumours and has been reflected in 
previous findings using the anti-T21/CEP290 antibody and oligonucleotides. Chapter 4 
outlines the specific targeting of T21 during tumourogenesis experiments performed in 
order to gain insight as to its activity and degree of protein expression for possible 
application as a target for immunotherapy.  
 
In vitro studies using transient and stable gene silencing of T21 in a T21+ prostate cancer 
cell line demonstrated a significant decrease in cell proliferation. Furthermore, cells 
treated with interfering agents were also assessed using immunofluorescence and cell 
cycle analysis revealed a role in promoting cell division, despite showing no strong 
centrosome localisation during any phase of the cell cycle. Otherwise the expression of 
T21 protein seemed to be dispersed largely throughout the cytoplasm. These observations 
require confirming along with additional experiments using cell cycle markers and other 
cell lines. Further “knock-in” experiments using cell lines that express little or no T21 
would also provide can give further evidence of the effect of T21 on cell proliferation and 
possibly reveal the mechanism(s) behind this observation.   
 
Following successful knockdown (gene silencing) of T21, gene expression profiling, by 
Next Generation Sequencing (NGS), made it possible to analyse the genome of human 
prostate cancer cells treated with interfering RNA. Genes that were either up or down 
regulated in the presence of T21 provided evidence that T21 may not share functional 
activity with CEP290. The up regulation of genes that would promote tumourogenesis 
through signalling pathways involved in cell proliferation and cell cycle control (MAPK6, 
PKIA, UHMK1, CDKN2B) and survival (HIPK2, MDM2, RBBP8), centrosome and 
structural rearrangement (SYCP3, CALM3, MFAP2 and RAB3IP) and immune modulation 
(CISH, PLAU, IL6R) were upregulated in the presence of T21. In contrast, genes involved 
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in the regulation of these signalling pathways were suppressed in the presence of T21 
through Ras family (DOK1 and 3 RAB6B, FRS3), cell stress/DNA repair pathways 
(PPM1E, CHD8, XRCC3) or the PI3K-Akt pathway (PI3KIP1). In this investigation, it 
was not possible to conduct an exhaustive post-analysis that would be required to uncover 
the extent of pathways potentially involved in T21 function. However, the data indicated 
that T21 activity is independent of CEP290 activity and may have a role in promoting 
tumourogenesis, thus making it an attractive target for therapy.  
 
To demonstrate T21 as a viable marker of disease and a possible immunological target, 
mRNA and protein expression was assessed in normal healthy and cancer tissues using 
T21-specfic primers for PCR and by IHC staining using anti-T21u antibody. It was 
demonstrated that T21 mRNA expression was high in normal testis, prostate, stomach and 
spinal cord tissues. In addition, protein expression in normal healthy tissues demonstrated 
an overall absence or relatively low expression with except to some tissues (kidney, 
prostate and testis). Expression using commercially available TMAs using malignant 
tissues demonstrated an overall increase in expression of T21 compared to normal healthy 
tissues. Further assessment of T21 was performed using a prostate cancer patient TMA 
series. However, this study failed to demonstrate a significant correlation of T21 protein 
expression with malignant disease or other clinicopathological variables assessed. One 
criticism of this study is the limited number of patients available within variable subgroups 
making it difficult to conduct a full statistical analysis. Expansion of the current TMA or 
staining of larger numbers of tissue samples may enable further evaluation of T21 
expression and its relation to cancer can be determined.   
 
Altered self-antigens are a result of point mutations and chromosomal rearrangement, 
differential expression and in the case of T21, alternative splicing events leading to intron 
retentions are a somewhat undervalued source of potential antigens. The advantages of 
targeting self tumour antigens for immunotherapy are that they may be expressed in many 
patients and be common to many malignancies. Alternatively, self antigens may only 
generate low level anti-tumour responses due to censorship during T cell selection 
(Theobald et al., 1997). Altered self tumour antigens that are recognised by T cells may 
avoid such selection in the thymus (Houghton, 1994; Nickleson & Kuchroo, 1997).   
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6.4 Identification of immunogenic T21 specific peptides 
 
The premise of screening T21 for immunogenic peptides was based on a number of factors 
that indicated T21 to be a good prospective candidate tumour antigen. First, T21 was 
discovered using SEREX screening implying a pre-existing existing humoral response 
which could be exploited to evoke an adaptive T cell mediated immune response. Second, 
the identification of a 31 amino acid residue sequence that is unique to T21 arising from a 
partial intron sequence and the identification of this region in particular during its 
discovery indicated the potential immune reactivity towards this region. Finally, prior to 
this project, T21 was indicated to have a restricted protein expression in normal testis and 
cancer tissues using the anti-T21/CEP290 Ab (Miles et al., 2007). Tissue restricted 
expression of T21/CEP290 would avoid trigging auto-immunity against healthy normal 
cells during immunotherapy. Although re-evaluation of T21 protein expression using anti-
T21u antibody (detailed in chapter 4) indicated mild to little expression in normal tissues 
with elevated expression in only some cancer tissues, work was completed following of 
immunological studies presented here. Interestingly, CEP290 expression has been shown 
to be ubiquitously expressed throughout normal tissues however auto-antibodies in cancer 
patients have been detected (Eichmuller et al., 2001).  
 
Here, the immunogenicity of T21 derived peptides sequences were assessed using a 
synthetic library of 15mer peptides which overlapped by 10 amino acid residues. Peptide 
responses were generated using an in vivo double transgenic mouse model (HLA.A2/DR1) 
and in vitro studies using human PBMCs derived from prostate cancer patients. Emphasis 
was placed on the peptides that spanned the unique region in order to identify 
endogenously processed “immune” sequences capable of generating T21 T cell specific 
responses. The conclusion from these early studies of immunogenicity in mice highlighted 
significant responses in OLP 3, 4 and 5, which potentially share common immunogenic 
endogenously processed epitope(s). As these peptides share sequence similarity, it could be 
presumed that they represent single/multiple common immunogenic epitopes.  
 
Upon critical assessment of the transgenic studies it is clear from the limited number of 
repeat experiments performed render these findings preliminary, and further confirmation 
studies in animals should be undertaken. When assessing T cell reactivity against the panel 
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of peptides, the number of cells available from in vitro culture proved to be a limiting 
factor. The release of IFNγ to assess responses following peptide stimulation captured an 
overall immune “snap-shot” of anti-tumour immune activation and differentiation 
(Schoenborn & Wilson, 2007). Further assessment of other cytokines such as IL-2 and 
TNFα, T cell activation markers (Caruso et al., 1997) and cytotoxicity assays would 
strengthen the existing data and confirm which sub-populations of cells respond to T21 
peptides. Given that the T21 unique region is not naturally presented and processed in 
mice, a T cell response against peptides of this region may not reflect the challenges of 
breaking tolerance, which is associated with other tumour antigens in the human host. 
Assessment of peptides of the unique region using human PBMCs identified OLP 4 as a 
potentially immunogenic peptide. In a study using peptide 4 a strong immunogenic 
response in patients responding to DC vaccine therapy (phase I/II trial) was found (Mu et 
al., 2005). The vaccine itself consisted of autologous DCs transfected with allogeneic 
mRNA derived from three prostate cancer cell lines. The cell lines used during this trial 
were shown to express T21 mRNA therefore it could be inferred that patients may have 
been exposed to T21 derived antigens during vaccination and respond to T21.   
 
Interestingly, the peptide 4 generated a T cell response was demonstrated in patients that 
responded (no new lesions of malignant disease, or development of symptoms consistent 
with metastatic disease in addition to decrease or stable PSA over baseline) to DC therapy 
during the trial. However, the patient HLA type was not available during this trial to 
confirm whether the peptide 4 response was HLA-restricted. One of the major advantages 
of using long peptides, were epitopes would require processing and editing by the host 
immunoproteasome, is the potential to induce long-lived T cell responses and extend 
overall patient survival (Welters et al., 2008; Leffers et al., 2009; Speetjens et al., 2009). 
As alluded to in chapter 1.4, once identified tumour specific epitopes capable of directing 
CTL and T helper responses can be employed in many immunotherapeutic scenarios, 
including  peptide vaccines, peptide stimulated cellular therapies and in TCR engineering 
approaches among others (Bijker et al., 2008; Murphy et al., 1999; Powell et al., 2006). 
The limited, yet encouraging results, demonstrated here may suggest that human T cells 
are able to evoke T21 specific immune responses. The studies presented here using 
HLA.A2/DR1 transgenic mouse model together with in vitro re-stimulation of patient 
PBMCs, provides preliminary evidence for the focus of future immunogenic study of T21, 
suggesting a route to transitional clinical immunotherapy.  
Chapter 6: Discussion  6.5 
 
213 
 
6.5 Conclusion and future work 
 
Immunotherapy represents a promising means for targeting cancer. The identification and 
assessment of candidate tumour associated antigens are crucial in forming the basis for 
such targeted therapies. The evaluation of T21 as a tumour antigen and as a potential 
immunotherapeutic target has been performed and presented here.  
 
From the data, there is strong evidence to suggest that T21 is in fact a transcript variant of 
the centrosomal gene CEP290. Detailed, in silico analysis and experimental confirmation 
suggests that T21 contains an alternative splicing event resulting in the retention of a 93bp 
sequence derived from CEP290 intronic region which gives rise to protein, thus making 
this sequence unique to T21 in humans. Northern blotting analysis suggests that the T21 
termination region is the same as identified previously, however during this investigation 
it was demonstrated that the T21 mRNA sequence may extend further upstream than 
previously reported. Full confirmation of this will be achieved through T21 product 
amplification and sequencing.  
 
Using this T21 “unique region” sequence, T21 mRNA and protein was shown to be 
expressed in some normal tissues including prostate, stomach and spinal cord when 
compared to testis therefore T21 cannot be considered as a cancer testis antigen as 
previously suggested. The high level of expression of T21 in normal prostate tissues at 
both the mRNA and protein level suggests that T21 could instead be classified as a tissue 
specific antigen. However a histological investigation of T21 protein expression failed to 
demonstrate significant discrimination between benign and prostate cancer patients or 
association with other clinicopathological variables. This was a limited study and further 
investigations using a more extensive TMA series are currently being undertaken, 
therefore re-analysis of T21 expression in the future may shed new light on its potential as 
a cancer marker of disease status. 
 
There is also evidence to suggest that T21 activity is independent of that of CEP290. Data 
collected using immunofluorescence indicated that T21 was not localised to the 
centrosome, in addition the expression profiling data obtained from Next Generation 
Sequencing suggest no interactions occur between any known partners of CEP290. 
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Assessment of cell proliferation following T21 gene silencing indicated an association 
between T21 and increased tumour cell proliferation, although further verification is 
required in order to determine the pathways that are associated with this process. Future 
analysis and experimental verification of the NGS data described here will be required in 
order to validate for conclusions relating to T21 activity. The data presented suggests a 
role in cell proliferation and survival, modulation of immune responses and suppression of 
regulatory processes involved in tumourogenesis.   
 
Finally, this study identified a novel immunogenic and naturally processed peptide target 
using a transgenic murine model and further verified this peptide sequence to be of 
significance using human protein cancer patient PBMCs. Future screening of healthy and 
confirmed prostate patient PBMCs may validate T21 derived peptides as candidate targets 
for immunotherapy. In parallel, further experimental investigations are required to 
determine the nature of the immune response and T cell subsets stimulated by T21 derived 
peptides and whether these can be used to induce tumour killing in vivo. 
 
In summary, this study set out to characterise SEREX-defined antigen T21 in order to 
ascertain its value as a diagnostic marker through molecular expression analysis and 
functional studies. A final objective was to determine its candidacy as an immunological 
target for immunotherapy. The results presented here indicate that T21 is associated with 
tumour and may therefore be classified as a differential tumour antigen and that 
immunogenic peptide regions specific to T21 identified here can be taken forward for 
potential study for the incorporation into a cancer vaccine. 
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Appendix I 
 
 
 
T21 unique region shRNA - Top strand sequence (5’ – 3’)  (sense, loop and antisense) 
5'-GCACAGGAATTCTTGATCA TCAAGAG TGATCAAGAATTCCTGTGC-3' 
 
 
Figure Ia - pGFP-B-RS mammalian expression vector (Origene Technologies). Vector 
contains a Blastacidin resistance gene used to select following cell transfection. A non-effective 
29mer scrambled shRNA cassette in pGFP-B-RS vector also purchased from Origene 
Technologies as a negative control.  
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Figure Ib - pBudCE4.1 mammalian expression vector (Invitrogen). Insertion of T21 CDS was 
performed previously by double digestion using HindIII and Xba1 restriction enzymes and 
ligation using T4 DNA ligase (Promega). Vector contains a Zeocin resistance gene for 
antibiotic selection following cell transfection. 
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Appendix II 
 
 
 
 
Figure II – Custom recombinant protein SDS PAGE (purchased from GTP Technology). 
Accompanying datasheet showing coomassie blue stained T21 elution (lane 7) and western 
blotting analysis using anti-His (lane 9). Apparent molecular weight between 68.58 - 59.87 kDa. 
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Appendix III 
 
 
Figure IIIa – Immunofluorescence images showing assay control wells. PC3 cells were 
stained using primary anti-T21Ab only (A), primary anti-IgG Rabbit antibody + secondary 
antibody (B) or secondary antibody alone (C) to ensure fluorescence observed was antibody 
specific. On each occasion, appropriate control experiments such as these were performed 
alongside all antibody staining with each cell line. Images acquired using fluorescence 
microscope (Olympus) - magnification x10. 
 
Figure IIIb – Immunofluorescence analysis showing localisation of T21/CEP290 in OPCT-1 
cell line. OPCT-1 cells were stained using anti-T21/CEP290 antibody (green) in order to 
confirm its protein localisation to the centrosomes using anti-pericentrin antibody (red) and 
nuclear staining using DAPI (blue). Images acquired using fluorescence microscope (Olympus) 
Magnification x20 and x40 respectively (n=3). 
A                              B                            C 
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Figure VI – Immunogenic responses of T21 unique region peptides. Positive responses 
determined as minimal 2-fold change compared to irrelevant 2 used as baseline. Assays were 
performed on T cells generated from 6 animals immunised with T21 cDNA using gene gun 
immunisation (previously described) harvested and restimulated in vitro using individual 
peptides and assessed for T cell function using 3 restimulation methods (described previously). 
Graphs annotated to represent individual animal responses to peptides represented as mouse 1 
(m1), mouse 2 (m2) and so on to mouse 6 (m6).  
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